
<html lang="en"     class="pb-page"  data-request-id="35100c2e-b4b8-49fd-aa98-188c9023b99e"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";requestedJournal:journal:jmcmar;journal:journal:jmcmar;page:string:Article/Chapter View;ctype:string:Journal Content;wgroup:string:ACHS website Group;website:website:acspubs;issue:issue:10.1021/jmcmar.2016.59.issue-16;pageGroup:string:Publication Pages;subPage:string:Full Text;article:article:10.1021/acs.jmedchem.6b00509"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="dc.Title" content="Developing Anticancer Ferric Prodrugs Based on the N-Donor Residues of Human Serum Albumin Carrier IIA Subdomain" /></meta><meta name="dc.Creator" content="Jinxu  Qi" /></meta><meta name="dc.Creator" content="Yi  Gou" /></meta><meta name="dc.Creator" content="Yao  Zhang" /></meta><meta name="dc.Creator" content="Kun  Yang" /></meta><meta name="dc.Creator" content="Shifang  Chen" /></meta><meta name="dc.Creator" content="Li  Liu" /></meta><meta name="dc.Creator" content="Xiaoyang  Wu" /></meta><meta name="dc.Creator" content="Tao  Wang" /></meta><meta name="dc.Creator" content="Wei  Zhang" /></meta><meta name="dc.Creator" content="Feng  Yang" /></meta><meta name="dc.Description" content="To improve the selectivity, delivery, and activity of ferric (Fe) anticancer agents, we design prodrugs based on N-donor residues of the human serum albumin (HSA) carrier IIA subdomain. We synthesi..." /></meta><meta name="Description" content="To improve the selectivity, delivery, and activity of ferric (Fe) anticancer agents, we design prodrugs based on N-donor residues of the human serum albumin (HSA) carrier IIA subdomain. We synthesi..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="August 8, 2016" /></meta><meta name="dc.Type" content="research-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/acs.jmedchem.6b00509" /></meta><meta name="dc.Language" content="EN" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="© 2016 American Chemical Society" /></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Facs.jmedchem.6b00509" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Facs.jmedchem.6b00509" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Facs.jmedchem.6b00509" /></link>
        
    
    

<title>Developing Anticancer Ferric Prodrugs Based on the N-Donor Residues of Human Serum Albumin Carrier IIA Subdomain | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/acs.jmedchem.6b00509" /></meta><meta property="og:title" content="Developing Anticancer Ferric Prodrugs Based on the N-Donor Residues of Human Serum Albumin Carrier IIA Subdomain" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-16/acs.jmedchem.6b00509/20160819/images/large/jm-2016-00509b_0013.jpeg" /></meta><meta property="og:description" content="To improve the selectivity, delivery, and activity of ferric (Fe) anticancer agents, we design prodrugs based on N-donor residues of the human serum albumin (HSA) carrier IIA subdomain. We synthesized six Fe(III) compounds derived from 2-hydroxy-1-naphthaldehyde thiosemicarbazone (7–12). HSA complex structure revealed that Fe compound binds to the hydrophobic cavity in the HSA IIA subdomain. Lys199 and His242 of HSA replace the two Cl atoms of Fe compound, coordinating with Fe3+. In vivo data revealed that compound 12 and HSA-12 complex inhibit the growth of the liver tumor and that the HSA-12 complex has stronger targeting ability and therapeutic efficacy than compound 12 alone. In addition, our results have shown that compound 12 and HSA-12 complex induce Bel-7402 cell death possible by several mechanisms." /></meta><meta property="og:type" content="Article" /></meta><meta property="og:site_name" content="ACS Publications" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta>
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/acs.jmedchem.6b00509"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/kfa7~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-f32cfd249ff7cb4cf9c7.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/acs.jmedchem.6b00509">
            
        




























    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=”true”></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=”true”></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-15/achre4.2021.54.issue-15/20210803/achre4.2021.54.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-7/amrcda.2021.2.issue-7/20210723/amrcda.2021.2.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-7/aabmcb.2021.4.issue-7/20210719/aabmcb.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-7/aaembp.2021.3.issue-7/20210727/aaembp.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-7/aaemcq.2021.4.issue-7/20210726/aaemcq.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-30/aamick.2021.13.issue-30/20210804/aamick.2021.13.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-7/aanmf6.2021.4.issue-7/20210723/aanmf6.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-7/aapmcd.2021.3.issue-7/20210709/aapmcd.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-7/abseba.2021.7.issue-7/20210712/abseba.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-14/accacs.2021.11.issue-14/20210716/accacs.2021.11.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-7/acscii.2021.7.issue-7/20210728/acscii.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-7/acbcct.2021.16.issue-7/20210716/acbcct.2021.16.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-4/achsc5.2021.28.issue-4/20210726/achsc5.2021.28.issue-4.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-15/acncdm.2021.12.issue-15/20210804/acncdm.2021.12.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-7/aesccq.2021.5.issue-7/20210715/aesccq.2021.5.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-7/aelccp.2021.6.issue-7/20210709/aelccp.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-7/aeecco.2021.1.issue-7/20210709/aeecco.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-7/aewcaa.2021.1.issue-7/20210709/aewcaa.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-6/afsthl.2021.1.issue-6/20210716/afsthl.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-7/aidcbc.2021.7.issue-7/20210709/aidcbc.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-7/amlccd.2021.10.issue-7/20210720/amlccd.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-8/amlcef.2021.3.issue-8/20210802/amlcef.2021.3.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-7/amclct.2021.12.issue-7/20210708/amclct.2021.12.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-7/ancac3.2021.15.issue-7/20210727/ancac3.2021.15.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-30/acsodf.2021.6.issue-30/20210803/acsodf.2021.6.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-7/apchd5.2021.8.issue-7/20210721/apchd5.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-7/ascefj.2021.6.issue-7/20210723/ascefj.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-30/ascecg.2021.9.issue-30/20210802/ascecg.2021.9.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-7/asbcd6.2021.10.issue-7/20210716/asbcd6.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-30/ancham.2021.93.issue-30/20210803/ancham.2021.93.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-30/bichaw.2021.60.issue-30/20210803/bichaw.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-7/bcches.2021.32.issue-7/20210721/bcches.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-7/bomaf6.2021.22.issue-7/20210712/bomaf6.2021.22.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-28/cgeabj.2021.99.issue-28/20210802/cgeabj.2021.99.issue-28.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-7/crtoec.2021.34.issue-7/20210719/crtoec.2021.34.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-14/chreay.2021.121.issue-14/20210728/chreay.2021.121.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-14/cmatex.2021.33.issue-14/20210727/cmatex.2021.33.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-8/cgdefu.2021.21.issue-8/20210804/cgdefu.2021.21.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-14/enfuem.2021.35.issue-14/20210715/enfuem.2021.35.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-15/esthag.2021.55.issue-15/20210803/esthag.2021.55.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-7/estlcu.2021.8.issue-7/20210713/estlcu.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-30/iecred.2021.60.issue-30/20210804/iecred.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-15/inocaj.2021.60.issue-15/20210802/inocaj.2021.60.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-7/jaaucr.2021.1.issue-7/20210726/jaaucr.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-30/jafcau.2021.69.issue-30/20210804/jafcau.2021.69.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-7/jceaax.2021.66.issue-7/20210708/jceaax.2021.66.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-7/jceda8.2021.98.issue-7/20210713/jceda8.2021.98.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-7/jcisd8.2021.61.issue-7/20210726/jcisd8.2021.61.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-7/jctcce.2021.17.issue-7/20210713/jctcce.2021.17.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/jmcmar.2021.64.issue-14/20210722/jmcmar.2021.64.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-7/jnprdf.2021.84.issue-7/20210723/jnprdf.2021.84.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-14/joceah.2021.86.issue-14/20210716/joceah.2021.86.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-29/jpcafh.2021.125.issue-29/20210729/jpcafh.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-29/jpcbfk.2021.125.issue-29/20210729/jpcbfk.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-29/jpccck.2021.125.issue-29/20210729/jpccck.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-29/jpclcd.2021.12.issue-29/20210729/jpclcd.2021.12.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-7/jprobs.2021.20.issue-7/20210702/jprobs.2021.20.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-30/jacsat.2021.143.issue-30/20210804/jacsat.2021.143.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-8/jamsef.2021.32.issue-8/20210804/jamsef.2021.32.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-30/langd5.2021.37.issue-30/20210803/langd5.2021.37.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-14/mamobx.2021.54.issue-14/20210727/mamobx.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-8/mpohbp.2021.18.issue-8/20210802/mpohbp.2021.18.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-14/nalefd.2021.21.issue-14/20210728/nalefd.2021.21.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-14/orlef7.2021.23.issue-14/20210716/orlef7.2021.23.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-7/oprdfk.2021.25.issue-7/20210716/oprdfk.2021.25.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-14/orgnd7.2021.40.issue-14/20210726/orgnd7.2021.40.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Facs.jmedchem.6b00509&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Facs.jmedchem.6b00509&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/acs.jmedchem.6b00509&amp;href=/doi/10.1021/acs.jmedchem.6b00509" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2016</span><span class="cit-fg-volume">, 59</span><span class="cit-fg-issue">, 16</span><span class="cit-fg-pageRange">, 7497-7511</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/59/16" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/acs.jmedchem.6b00487" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Article</span><a href="/doi/10.1021/acs.jmedchem.6b00566" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">Developing Anticancer Ferric Prodrugs Based on the N-Donor Residues of Human Serum Albumin Carrier IIA Subdomain</span></h1><ul class="loa non-jats-loa"><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Jinxu++Qi">Jinxu Qi</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Yi++Gou">Yi Gou</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Yao++Zhang">Yao Zhang</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Kun++Yang">Kun Yang</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Shifang++Chen">Shifang Chen</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Li++Liu">Li Liu</a></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Xiaoyang++Wu">Xiaoyang Wu</a></span><span class="author-xref-symbol author-aff-symbol"><sup>§</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Tao++Wang">Tao Wang</a></span><span class="author-xref-symbol "><sup>*</sup></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Wei++Zhang">Wei Zhang</a></span><span class="author-xref-symbol "><sup>*</sup></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, and </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Feng++Yang">Feng Yang</a></span><span class="author-xref-symbol "><sup>*</sup></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator"></span></ul><div class="affiliations"><div class="view-affs"><span class="title">View Author Information</span><i class="caret-icon icon-angle-down"></i></div><div class="all-aff-infos hlFld-Affiliation"><div class="aff-info" id="aff1"><span class="aff-symbol">†</span> <span class="aff-text">School of Pharmacy, Nantong University, Nantong, Jiangsu 226019, China</span></div><div class="aff-info" id="aff2"><span class="aff-symbol">‡</span> <span class="aff-text">Department of Biology, Southern University of Science and Technology, Shenzhen, Guangdong 518055, China</span></div><div class="aff-info" id="aff3"><span class="aff-symbol">§</span> <span class="aff-text">Ben May Department for Cancer Research, University of Chicago, Chicago, Illinois 60637, United States</span></div><div class="corresp-info"><strong>*</strong>E-mail: <a href="/cdn-cgi/l/email-protection#790e18171e0d1816390a0c0a0d1a571c1d0c571a17"><span class="__cf_email__" data-cfemail="99eef8f7feedf8f6d9eaeceaedfab7fcfdecb7faf7">[email protected]</span></a></div><div class="corresp-info"><strong>*</strong>E-mail: <a href="/cdn-cgi/l/email-protection#c0baa8a1aea7b780aeb4b5eea5a4b5eea3ae"><span class="__cf_email__" data-cfemail="afd5c7cec1c8d8efc1dbda81cacbda81ccc1">[email protected]</span></a></div><div class="corresp-info"><strong>*</strong>E-mail: <a href="/cdn-cgi/l/email-protection#412738202f26012c20282d232e396f26392f346f2425346f222f"><span class="__cf_email__" data-cfemail="197f6078777e59747870757b7661377e61776c377c7d6c377a77">[email protected]</span></a>. Phone/Fax: 86-773-584-8836.</div></div></div><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.6b00509&amp;href=/doi/10.1021%2Facs.jmedchem.6b00509" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2016</span></span><span class="cit-volume">, 59</span><span class="cit-issue">, 16</span><span class="cit-pageRange">, 7497–7511</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">July 21, 2016</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>5 April 2016</li><li><span class="item_label"><b>Published</b> online</span>8 August 2016</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 25 August 2016</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/acs.jmedchem.6b00509" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.6b00509</a></div><div class="article_header-article-copyright"><strong>Copyright © 2016 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D7497%26pageCount%3D15%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DJinxu%2BQi%252C%2BYi%2BGou%252C%2BYao%2BZhang%252C%2Bet%2Bal%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D59%26issueNum%3D16%26contentID%3Dacs.jmedchem.6b00509%26title%3DDeveloping%2BAnticancer%2BFerric%2BProdrugs%2BBased%2Bon%2Bthe%2BN-Donor%2BResidues%2Bof%2BHuman%2BSerum%2BAlbumin%2BCarrier%2BIIA%2BSubdomain%26numPages%3D15%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D7511%26publicationDate%3DAugust%2B2016">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/acs.jmedchem.6b00509"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">1280</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val"><a href="#citeThis" class="internalNav">41</a></div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/acs.jmedchem.6b00509" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;Developing Anticancer Ferric Prodrugs Based on the N-Donor Residues of Human Serum Albumin Carrier IIA Subdomain&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Jinxu&quot;,&quot;last_name&quot;:&quot;Qi&quot;},{&quot;first_name&quot;:&quot;Yi&quot;,&quot;last_name&quot;:&quot;Gou&quot;},{&quot;first_name&quot;:&quot;Yao&quot;,&quot;last_name&quot;:&quot;Zhang&quot;},{&quot;first_name&quot;:&quot;Kun&quot;,&quot;last_name&quot;:&quot;Yang&quot;},{&quot;first_name&quot;:&quot;Shifang&quot;,&quot;last_name&quot;:&quot;Chen&quot;},{&quot;first_name&quot;:&quot;Li&quot;,&quot;last_name&quot;:&quot;Liu&quot;},{&quot;first_name&quot;:&quot;Xiaoyang&quot;,&quot;last_name&quot;:&quot;Wu&quot;},{&quot;first_name&quot;:&quot;Tao&quot;,&quot;last_name&quot;:&quot;Wang&quot;},{&quot;first_name&quot;:&quot;Wei&quot;,&quot;last_name&quot;:&quot;Zhang&quot;},{&quot;first_name&quot;:&quot;Feng&quot;,&quot;last_name&quot;:&quot;Yang&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2016&quot;,&quot;month&quot;:&quot;08&quot;,&quot;day&quot;:&quot;08&quot;,&quot;issue&quot;:&quot;16&quot;,&quot;volume&quot;:&quot;59&quot;,&quot;pages&quot;:&quot;7497-7511&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/acs.jmedchem.6b00509&quot;},&quot;abstract&quot;:&quot;To improve the selectivity, delivery, and activity of ferric (Fe) anticancer agents, we design prodrugs based on N-donor residues of the human serum albumin (HSA) carrier IIA subdomain. We synthesized six Fe(III) compounds derived from 2-hydroxy-1-naphthaldehyde thiosemicarbazone (7–12). HSA complex structure revealed that Fe compound binds to the hydrophobic cavity in the HSA IIA subdomain. Lys199 and His242 of HSA replace the two Cl atoms of Fe compound, coordinating with Fe3+. In vivo data revealed that compound 12 and HSA-12 complex inhibit the growth of the liver tumor and that the HSA-12 complex has stronger targeting ability and therapeutic efficacy than compound 12 alone. In addition, our results have shown that compound 12 and HSA-12 complex induce Bel-7402 cell death possible by several mechanisms.&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.6b00509&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.6b00509" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.6b00509&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.6b00509" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.6b00509&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.6b00509" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.6b00509&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.6b00509&amp;href=/doi/10.1021/acs.jmedchem.6b00509" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/acs.jmedchem.6b00509" /></input><a href="/doi/pdf/10.1021/acs.jmedchem.6b00509" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (10 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.6b00509&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Facs.jmedchem.6b00509%26sid%3Dliteratum%253Aachs%26pmid%3D27441502%26genre%3Darticle%26aulast%3DQi%26date%3D2016%26atitle%3DDeveloping%2BAnticancer%2BFerric%2BProdrugs%2BBased%2Bon%2Bthe%2BN-Donor%2BResidues%2Bof%2BHuman%2BSerum%2BAlbumin%2BCarrier%2BIIA%2BSubdomain%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D59%26issue%3D16%26spage%3D7497%26epage%3D7511%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div><div class="article_header-suppInfo pull-left"><i class="icon-supporting-info"></i><span class="article_header-suppInfo-text">Supporting Info (2)</span><span class="article_header-suppInfo-arrow">»</span><a href="#" data-slide-target=".tab__pane-suppInfo" title="Supporting Information" class="article_header-suppInfo-link-mobile hidden-sm hidden-md hidden-lg w-slide__btn">Supporting Information
                </a><a href="#article_content-right" title="Supporting Information" data-scrollDuration="1000" class="article_header-suppInfo-link internalNav hidden-xs">Supporting Information
                </a></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=292366" title="Ligands">Ligands</a>,</li><li><a href="/action/doSearch?ConceptID=292464" title="Rodent models">Rodent models</a>,</li><li><a href="/action/doSearch?ConceptID=290896" title="Cells">Cells</a>,</li><li><a href="/action/doSearch?ConceptID=291070" title="Pharmaceuticals">Pharmaceuticals</a>,</li><li><a href="/action/doSearch?ConceptID=292153" title="Tumors">Tumors</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/59/16" title="Go to Journal of Medicinal Chemistry "><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-16/jmcmar.2016.59.issue-16/20160825/jmcmar.2016.59.issue-16.largecover.jpg" alt="Go to Journal of Medicinal Chemistry "/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="f_tgr1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-16/acs.jmedchem.6b00509/20160819/images/medium/jm-2016-00509b_0013.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-16/acs.jmedchem.6b00509/20160819/images/large/jm-2016-00509b_0013.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00509&amp;id=f_tgr1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">To improve the selectivity, delivery, and activity of ferric (Fe) anticancer agents, we design prodrugs based on N-donor residues of the human serum albumin (HSA) carrier IIA subdomain. We synthesized six Fe(III) compounds derived from 2-hydroxy-1-naphthaldehyde thiosemicarbazone (<b>7</b>–<b>12</b>). HSA complex structure revealed that Fe compound binds to the hydrophobic cavity in the HSA IIA subdomain. Lys199 and His242 of HSA replace the two Cl atoms of Fe compound, coordinating with Fe<sup>3+</sup>. <i>In vivo</i> data revealed that compound <b>12</b> and HSA-<b>12</b> complex inhibit the growth of the liver tumor and that the HSA-<b>12</b> complex has stronger targeting ability and therapeutic efficacy than compound <b>12</b> alone. In addition, our results have shown that compound <b>12</b> and HSA-<b>12</b> complex induce Bel-7402 cell death possible by several mechanisms.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li><li><i class="icon-supporting-info"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i1">Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_54186" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_54186" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Many studies have shown that metal compounds have a biological and chemical diversity that organic drugs simply do not.<a onclick="showRef(event, 'ref1 ref2'); return false;" href="javascript:void(0);" class="ref ref1 ref2">(1, 2)</a> Certain metal–organic ligand complexes have increased biological activity over ligands alone, especially in antitumor activity.<a onclick="showRef(event, 'ref3 ref4'); return false;" href="javascript:void(0);" class="ref ref3 ref4">(3, 4)</a> Therefore, a different strategy for developing anticancer drugs would be to design and synthesize metal complexes derived from organic ligands.<a onclick="showRef(event, 'ref5 ref6 ref7'); return false;" href="javascript:void(0);" class="ref ref5 ref6 ref7">(5-7)</a></div><div class="NLM_p">Current studies reveal that Fe and Cu chelators are promising novel anticancer agents, as cancer cells can absorb more Fe and Cu than the normal cells.<a onclick="showRef(event, 'ref8 ref9'); return false;" href="javascript:void(0);" class="ref ref8 ref9">(8, 9)</a> For example, both desferrioxamine (DFO) (through <i>in vitro</i> and <i>in vivo</i> studies) and 2-hydroxy-1-naphthylaldehyde isonicotinoyl have limited tumor activity.<a onclick="showRef(event, 'ref10 ref11 ref12'); return false;" href="javascript:void(0);" class="ref ref10 ref11 ref12">(10-12)</a> In fact, 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP) has reached clinical trials as an anticancer therapeutic.<a onclick="showRef(event, 'ref12'); return false;" href="javascript:void(0);" class="ref ref12">(12)</a> In addition, a series of novel chelators, such as thiosemicarbazones, have pronounced anticancer activity and selectivity, and overcome resistance to established chemotherapeutics <i>in vivo</i>.<a onclick="showRef(event, 'ref8 ref9'); return false;" href="javascript:void(0);" class="ref ref8 ref9">(8, 9)</a> However, these chelators may produce low antitumor activity; in addition, dose-limiting side effects, including methemoglobinemia and hypoxia, have limited their potential in the clinic.<a onclick="showRef(event, 'ref12 ref13 ref14'); return false;" href="javascript:void(0);" class="ref ref12 ref13 ref14">(12-14)</a> Richardson et al. have investigated the effects of Cu(II) complexes with thiosemicarbazones and determined that they have the potential for antipoliferative activity along with redox in an accessible range for natural reductants.<a onclick="showRef(event, 'ref3 ref12'); return false;" href="javascript:void(0);" class="ref ref3 ref12">(3, 12)</a> These pioneering studies have shown novel anticancer metal agents, derived from thiosemicarbazone ligands, can be developed.<a onclick="showRef(event, 'ref2'); return false;" href="javascript:void(0);" class="ref ref2">(2)</a> Currently, metal compounds derived with a great variety of ligands are under extensive investigation as anticancer agents.<a onclick="showRef(event, 'ref15 ref16'); return false;" href="javascript:void(0);" class="ref ref15 ref16">(15, 16)</a></div><div class="NLM_p">Although a large number of metal compounds have been evaluated <i>in vitro</i> and <i>in vivo</i> and some have even reached clinical trials, researchers still need to determine how to increase targeting success and decrease <i>in vivo</i> side effects;<a onclick="showRef(event, 'ref2'); return false;" href="javascript:void(0);" class="ref ref2">(2)</a> the use of prodrugs and drug carriers may help to tackle these issues.<a onclick="showRef(event, 'ref17 ref18'); return false;" href="javascript:void(0);" class="ref ref17 ref18">(17, 18)</a> Human serum albumin (HSA) is a promising nontoxic, nonantigenic, biocompatible, and biodegradable endogenous protein drug delivery system that lacks immunogenicity.<a onclick="showRef(event, 'ref19'); return false;" href="javascript:void(0);" class="ref ref19">(19)</a> HSA, the most abundant protein in plasma with many active residues, can bind to a diverse group of exogenous compounds.<a onclick="showRef(event, 'ref20 ref21 ref22 ref23 ref24 ref25 ref26'); return false;" href="javascript:void(0);" class="ref ref20 ref21 ref22 ref23 ref24 ref25 ref26">(20-26)</a> Therefore, to improve the targeting of anticancer agents, these properties can be utilized to design novel anticancer prodrugs.<a onclick="showRef(event, 'ref27 ref28 ref29 ref30'); return false;" href="javascript:void(0);" class="ref ref27 ref28 ref29 ref30">(27-30)</a> There are two major ways to design prodrugs based on HSA: through chemically coupling the metal prodrug to the residues of HSA; or through direct complexation of the prodrug with HSA.<a onclick="showRef(event, 'ref30 ref31'); return false;" href="javascript:void(0);" class="ref ref30 ref31">(30, 31)</a> Unfortunately, there can be problems with the release of a drug when metal compounds are delivered to cancer cells using complexed HSA carriers <i>in vivo</i> due to the strength of the binding between HSA and the prodrug.<a onclick="showRef(event, 'ref30'); return false;" href="javascript:void(0);" class="ref ref30">(30)</a> For example, the metal prodrug can be released from HSA prematurely if it is not bound strongly or it may not be released at all if the bond is too tight. To address these issues, Yang et al. proposed the use of a metal prodrug whose design is based on the natural HSA IIA subdomain and the known cancer cell.<a onclick="showRef(event, 'ref30 ref32 ref33 ref34'); return false;" href="javascript:void(0);" class="ref ref30 ref32 ref33 ref34">(30, 32-34)</a> The metal prodrug can contain potential leaving group(s) with no anticancer activity that are then displaced by Lys199 and/or His242 residue(s) of HSA. This is outlined below.</div><div class="NLM_p">Among the next generation of metal-based anticancer compounds, Fe anticancer compounds may be promising.<a onclick="showRef(event, 'ref1'); return false;" href="javascript:void(0);" class="ref ref1">(1)</a> In humans, Fe is an essential bioactive element with an oxidative nature. HSA has active N-donor residues (Lys199 and His242).<a onclick="showRef(event, 'ref30'); return false;" href="javascript:void(0);" class="ref ref30">(30)</a> These residues, which can substitute for metal compound ligands that bind to the HSA IIA subdomain, can converge to the metal center.<a onclick="showRef(event, 'ref33 ref34'); return false;" href="javascript:void(0);" class="ref ref33 ref34">(33, 34)</a> Therefore, to enhance the delivery efficiency, selectivity, and anticancer activity of the Fe agent, Fe anticancer prodrug with two leaving groups that initially binds to the HSA IIA subdomain was created. It then binds to Lys199 and His242 of HSA, displacing the Fe prodrug’s leaving groups. Subsequently, Lys199 and His242 of HSA are protonated in the cancer cell’s lysosomal acidic environment, which decreases its coordination ability with Fe ion. This allows the Fe agent to be released from the HSA carrier (<a class="ref internalNav" href="#fig1" aria-label="Figure 1">Figure 1</a>). Furthermore, liver cancer, which has become very common across the globe, is responsible for a large number of cancer deaths.<a onclick="showRef(event, 'ref35'); return false;" href="javascript:void(0);" class="ref ref35">(35)</a> Taking into consideration the above factors, a model was created using Fe agents derived from thiosemicarbazones and liver cancer (Bel-7402) cells to design anticancer Fe prodrugs based on the N-donor residues (Lys199 and His242) of HSA. The following studies were carried out: (1) design and synthesis of six 2-hydroxy-1-naphthaldehyde-thiosemicarbazone Fe(III)-Schiff base anticancer compounds (<b>7</b>–<b>12</b>) (<a class="ref internalNav" href="#fig2" aria-label="Figure 2">Figure 2</a>), followed by investigation of their structure–activity relationships on Bel-7402 cells; (2) provided feasibility evidence of developing Fe prodrugs based on N-donor residues of the HSA carrier IIA subdomain; (3) compared <i>in vivo</i> targeting ability, therapeutic efficacy, and side effects of the HSA complex to the Fe compound; (4) investigated the release behavior of the Fe compound from HSA and the possible mechanism for HSA complex penetrating cancer cells; (5) determined the potential anticancer mechanism of the Fe compound/HSA complex.</div><figure id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-16/acs.jmedchem.6b00509/20160819/images/medium/jm-2016-00509b_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-16/acs.jmedchem.6b00509/20160819/images/large/jm-2016-00509b_0002.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Hypothesis of developing Fe prodrug based on the N-donor residues of HSA IIA subdomain.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-16/acs.jmedchem.6b00509/20160819/images/large/jm-2016-00509b_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00509&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-16/acs.jmedchem.6b00509/20160819/images/medium/jm-2016-00509b_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-16/acs.jmedchem.6b00509/20160819/images/large/jm-2016-00509b_0003.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Structure of ligands and Fe compounds.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-16/acs.jmedchem.6b00509/20160819/images/large/jm-2016-00509b_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00509&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i2">Results</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_25310" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_25310" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">This study focuses on Fe compounds containing the tridentate 2-hydroxy-1-naphthaldehyde thiosemicarbazone Schiff-base ligands (TsS) for the following reasons: (1) TsS ligands themselves are promising anticancer agents;<a onclick="showRef(event, 'ref36'); return false;" href="javascript:void(0);" class="ref ref36">(36)</a> (2) hydrophobic properties of the benzyl and alkyl components can facilitate targeting of the hydrophobic binding sites of the HSA IIA subdomain by the Fe compound. Therefore, the TsS ligand was designed to complex with the Fe compounds (pharmacophore) and to then allow for the two Cl atoms to be potential leaving groups (<a class="ref internalNav" href="#fig2" aria-label="Figure 2">Figure 2</a>).</div><div id="sec2_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i3" class="anchor-spacer"></div><h3 class="article-section__title" id="_i3"> Design and Structure of Fe Compounds</h3><div class="NLM_p">It was determined by Richardson et al. that modification at the N4 position of a thiosemicarbazone can effectively increase lipophilicity and produce superior antiproliferative activity.<a onclick="showRef(event, 'ref12'); return false;" href="javascript:void(0);" class="ref ref12">(12)</a> Thus, we performed this modification with alkyl or phenyl groups to investigate the structure–activity relationships of Fe (III) compounds (<a class="ref internalNav" href="#fig2" aria-label="Figure 2">Figure 2</a>). The following six Fe (III) compounds were synthesized according to the same method. The single crystals of compounds (compounds <b>7</b>–<b>12</b>), suitable for X-ray diffraction were obtained.</div><div class="NLM_p last">Single-crystal structure analysis showed that all compounds are isomorphous. They all have the same skeleton (1 tridentate Schiff base ligand, 1 Fe(III) center, and two coordinated Cl atoms) and differ only in the modified group of the Schiff base ligand. As shown in <a class="ref internalNav" href="#fig2" aria-label="Figure 2">Figure 2</a>, the coordination polyhedron around all of the Fe(III) centers forms a distorted square pyramid (τ = 0.43 for compound <b>7</b>, 0.27 for compound <b>8</b>, 0.34 for compound <b>9</b>, 0.11 for compound <b>10</b>, 0.12 for compound <b>11</b>, and 0.38 for compound <b>12</b>). The metal was displaced from the O1/N1/S1/Cl1 basal plane, and the Cl<sub>2</sub> appears at the apex. The ligand and metal ion complex forms a five- and a six-membered closed loop ring, this coordination can enhance the stability of complexes. We examined the antitumor activity and considered the probability of its involvement in the thiosemicarbazone activity to determine the crystal structure of each Fe complex.</div></div><div id="sec2_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i4" class="anchor-spacer"></div><h3 class="article-section__title" id="_i4"> Feasibility of Developing Fe Prodrug Based on the N-Donor Residues of HSA IIA Subdomain</h3><div class="NLM_p">HSA fluorescence (∼347 nm) was gradually suppressed with the increase of compound <b>12</b> concentrations, at pH 4.7 and 7.4 (<a class="ref internalNav" href="#notes-1" aria-label="Figure S1A,B">Figure S1A,B</a>). This indicates that the Fe compounds bind close to the HSA IIA subdomain. The MALDI-TOF-MS spectrum shows an increase of 366 Da for the HSA complexes, relative to pure HSA. This is equivalent to the molecular weight of ca. one compound <b>12</b> (<a class="ref internalNav" href="#notes-1" aria-label="Figure S1C">Figure S1C</a>). Furthermore, the electrospray ionization mass spectrometry (ESI-MS) of products released from the HSA-<b>12</b> complex at pH 4.7, showed an intense signal at <i>m</i>/<i>z</i> = 368.04 (<a class="ref internalNav" href="#notes-1" aria-label="Figure S2">Figure S2</a>). This was identified with isotopic envelopes corresponding to [compound <b>12</b>]<sup>2+</sup> (fit: 368.05), implying that two Cl atoms are lost from compound <b>12</b>.</div><div class="NLM_p">We needed to resolve the structure of the HSA-PA-<b>12</b> complex in order to gather feasibility evidence for developing Fe prodrugs based on Lys199 and His242 residues of the HSA IIA subdomain. Electron density maps of the compound <b>12</b> complexed with HSA reveal the presence of one compound <b>12</b> molecule at the IIA subdomain (<a class="ref internalNav" href="#fig3" aria-label="Figure 3">Figure 3</a>A). The compound <b>12</b> bound to the HSA-PA complex is heart-shaped (<a class="ref internalNav" href="#fig3" aria-label="Figure 3">Figure 3</a>B), and in the HSA IIA subdomain, the Fe compound binds to a large hydrophobic pocket, which is surrounded by residues, including Arg218, Arg222, Lys199, Trp214, Leu219, Phe223, Leu238, His242, Arg257, Leu260, Ile264, Ser287, Ile290, and Ala291 (<a class="ref internalNav" href="#fig3" aria-label="Figure 3">Figure 3</a>C). Lys199 and His242 replaced two Cl atoms of compound <b>12</b>, within the HSA-PA-<b>12</b> complex structure, and they coordinate with Fe<sup>3+</sup> (<a class="ref internalNav" href="#fig3" aria-label="Figure 3">Figure 3</a>A,C). Comparing binding site and binding mode of compound <b>12</b> to HSA with cisplatin and [RuCl<sub>5</sub>(ind)]<sup>2–</sup>, we found that they bind to HSA by residue(s) of HSA displacing the ligand(s) in metal compounds, coordinated to metal.<a onclick="showRef(event, 'ref32 ref37'); return false;" href="javascript:void(0);" class="ref ref32 ref37">(32, 37)</a> Interestingly, cisplatin can not bind to IIA subdomain, but [RuCl<sub>5</sub>(ind)]<sup>2–</sup> and compound <b>12</b> could bind to IIA subdomain. Obviously, the molecular structure and geometry of metal compounds play an important role in their binding site and binding mode in HSA.</div><figure id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-16/acs.jmedchem.6b00509/20160819/images/medium/jm-2016-00509b_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-16/acs.jmedchem.6b00509/20160819/images/large/jm-2016-00509b_0004.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. (A) Experimental sigmaA weighted 2Fo–Fc electron density map of compound <b>12</b> at IIA subdomain. (B) Overall structure of the HSA complex. (C) Structural binding environment of compound <b>12</b> to IIA subdomain of HSA. Amino acid chains that are close to the drug molecules are shown as sticks.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-16/acs.jmedchem.6b00509/20160819/images/large/jm-2016-00509b_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00509&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i5" class="anchor-spacer"></div><h3 class="article-section__title" id="_i5"> Structure–Activity Relationships of Anticancer Fe Compounds <i>in Vitro</i></h3><div class="NLM_p last">Fe compounds have higher cytotoxicity against Bel-7402 cells than the ligands and Fe<sup>3+</sup> alone (<a class="ref internalNav" href="#tbl2" aria-label="Table 2">Table 2</a>), implying that the chelation of Fe<sup>3+</sup> to ligands is the reason that the Fe compounds have such high cytotoxicity. The cytotoxicity of Fe compounds against Bel-7402 cells (≤13.36 ± 1.35 μM) is slightly higher than that of cisplatin (14.54 ± 0.85 μM). Among the six Fe compounds studied, compound <b>7</b> has the lowest cytotoxic activity against Bel-7402 cells (13.36 ± 1.35 μM). When, compared to compound <b>7</b>, where one H atom attached to the N4 of thiosemicarbazone is replaced by a methyl or aryl group, as in compound <b>8</b> and compound <b>9</b>, the cytotoxic activity is enhanced (11.87 or 2.22 μM). The Fe compounds derived from thiosemicarbazone where both of the H atoms at the N4 position are altered, i.e., in (compounds <b>10</b>, <b>11</b>, and <b>12</b>), even higher cytotoxicity is observed (0.86–0.65 μM) (<a class="ref internalNav" href="#tbl2" aria-label="Table 2">Table 2</a>). The Fe compounds in complexation with HSA increase their cytotoxicity in Bel-7402 cells by approximately 2–6-fold, relative to the Fe compounds alone; however, in normal cells [immortalized human hepatocyte cells (HL7702)], they do not raise cytotoxicity levels (<a class="ref internalNav" href="#tbl2" aria-label="Table 2">Table 2</a>). As compound <b>12</b> and HSA-<b>12</b> complex have high cytotoxic activity on Bel-7402 cells, relative to other Fe compounds <i>in vitro</i>, these were selected for further investigation.</div></div><div id="sec2_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i6" class="anchor-spacer"></div><h3 class="article-section__title" id="_i6"> <i>In Vivo</i> Animal Studies of Compound <b>12</b> and HSA-<b>12</b> Complex</h3><div class="NLM_p last">To further evaluate combining the HSA carrier with prodrug strategies for the therapeutic efficacy of Fe compound <i>in vivo</i>, the liver cancer Bel-7402 xenograft mouse model was established.</div></div><div id="sec2_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i7" class="anchor-spacer"></div><h3 class="article-section__title" id="_i7"> Acute Toxicity of Compound <b>12</b> and HSA-<b>12</b> Complex <i>in Vivo</i></h3><div class="NLM_p last">We measured levels of creatine kinase (CK), blood urea nitrogen (BUN), aspartate aminotransferase (AST), and alkaline phosphatase (ALT) 3 days after intravenous injection of the drugs in order to assess acute toxicity of compound <b>12</b> and HSA-<b>12</b> complex in the heart, kidney, and liver of normal mice. Levels of CK in compound <b>12</b>-treated mice were greater than levels in the control (NaCl) group. However, the levels of CK in the HSA-<b>12</b> complex-treated mice were similar to those of the control. This indicates that HSA-<b>12</b> complex has low cardiotoxicity. High BUN levels correspond to higher toxicity in the kidney. Compound <b>12</b> caused significant nephrotoxicity, as evidenced by a higher level of BUN than that observed in the control group. In contrast, BUN levels significantly decreased in the HSA-<b>12</b> complex-treated groups, indicating lower nephrotoxicity. Serum AST and ALT levels were significantly elevated in the group treated with compound <b>12</b>; however, the levels induced by HSA-<b>12</b> complex were almost the same as the control group, which indicates lower levels of liver damage in those treated with HSA-<b>12</b> complex.</div></div><div id="sec2_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i8" class="anchor-spacer"></div><h3 class="article-section__title" id="_i8"> Antitumor Activity of Compound <b>12</b> and HSA-<b>12</b> Complex <i>in Vivo</i></h3><div class="NLM_p">Bel-7402 tumor-bearing mice were injected with compound <b>12</b> and HSA-<b>12</b> complex, and saline was injected as a control to evaluate therapeutic efficacy. Tumor-bearing mice had their body weight and tumor volume monitored every 2 days for 28 days. At the end of the experiment, the tumor volumes in the HSA-<b>12</b> complex-treated mice were much smaller than those in saline-treated and compound <b>12</b>-treated mice (<a class="ref internalNav" href="#fig4" aria-label="Figure 4">Figure 4</a>A). Compared to the control group, the tumor volume after 28 days of treatment was 53.2 ± 4.5% for the compound <b>12</b> group and 24.6 ± 2.8% for the HSA-<b>12</b> complex group, demonstrating that HSA-<b>12</b> complex resulted in greater tumor growth inhibitory efficacy than compound <b>12</b>. Compared to the NaCl group, the tumor inhibition rate (TIR) of HSA-<b>12</b> complex was 75.6% (<i>P</i> < 0.001), which was significantly higher than that of compound <b>12</b> (46.8%, <i>P</i> < 0.01).</div><figure id="fig4" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-16/acs.jmedchem.6b00509/20160819/images/medium/jm-2016-00509b_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-16/acs.jmedchem.6b00509/20160819/images/large/jm-2016-00509b_0005.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. (A) Net tumor volume as a function of time on Bel-7402 xenografts after IV administration (tail vein) of vehicle control, compound <b>12</b>, and HSA-<b>12</b> complex. (B) Tumor weight (wet weight) (A) after killing the mice on Day 28. (C) Tumors were removed from the mice after 28 days of treatment and stained with the TUNEL assay (400×). Results are mean ± SD (<i>n</i> = 6–7 mice/condition). Results are mean ± SD (<i>n</i> = 6–7): (*) <i>p</i> < 0.05, (**) <i>p</i> < 0.01, (***) <i>p</i> < 0.001.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-16/acs.jmedchem.6b00509/20160819/images/large/jm-2016-00509b_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00509&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">To further evaluate the antitumor effects of compound <b>12</b> and HSA-<b>12</b> complex in animals, the tumor tissues were excised for pathology. The TUNEL stained tissue sections indicate obvious differences in tumor tissue morphology between treated groups and the NaCl group (<a class="ref internalNav" href="#fig4" aria-label="Figure 4">Figure 4</a>B). As shown in <a class="ref internalNav" href="#fig4" aria-label="Figure 4">Figure 4</a>B, tumor samples from animals treated with compound <b>12</b> and HSA-<b>12</b> complex showed increased apoptosis compared with tumor samples from the control mice. In particular, HSA-<b>12</b> complex was more effective in promoting cell necrosis, relative to compound <b>12</b>.</div></div><div id="sec2_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i9" class="anchor-spacer"></div><h3 class="article-section__title" id="_i9"> Comparison of the Side Effects of Compound <b>12</b> and HSA-<b>12</b> Complex <i>in Vivo</i></h3><div class="NLM_p">To evaluate the toxicology of compound <b>12</b> and HSA-<b>12</b> complex in mice, mouse body weight was monitored throughout the intravenous treatment. At the end of the study, specific organs were collected and weighed (<a class="ref internalNav" href="#notes-1" aria-label="Table S3">Table S3</a>). When compared with the control mice, those intravenously treated with HSA-<b>12</b> complex did not show significant weight loss (<i>p</i> > 0.05). In contrast, mice treated with compound <b>12</b> lost approximately 10% of their body weight (<a class="ref internalNav" href="#fig5" aria-label="Figure 5">Figure 5</a>A). The weight of the liver and heart of mice treated with compound <b>12</b> altered slightly, but no change was observed in mice treated with HSA-<b>12</b> complex (<a class="ref internalNav" href="#notes-1" aria-label="Table S3">Table S3</a>), and there was not a significant difference in the weight of the other organs when comparing the HSA-<b>12</b> complex-treated and the control groups (<a class="ref internalNav" href="#notes-1" aria-label="Table S3">Table S3</a>). Pathological sections stained with Hematoxylin and Eosin (H&E) revealed drug-related side effects to major organs (<a class="ref internalNav" href="#fig5" aria-label="Figure 5">Figure 5</a>B). Serious damage to the heart (vacuolation), liver (vacuolation), and kidneys (focal abnormalities) was observed in mice treated with compound <b>12</b>. This damage was significantly decreased in mice treated with the HSA-<b>12</b> complex. Therefore, increased liver and heart weights are likely attributed to increased vacuolation.</div><figure id="fig5" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-16/acs.jmedchem.6b00509/20160819/images/medium/jm-2016-00509b_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-16/acs.jmedchem.6b00509/20160819/images/large/jm-2016-00509b_0006.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. (A) Average body weight of treated nude mice was measured and recorded for 28 days. (B) After 28 days of treatment, the major organs (heart, liver, and kidney) were harvested from mice and then stained with H&E (400×).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-16/acs.jmedchem.6b00509/20160819/images/large/jm-2016-00509b_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00509&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_8" class="NLM_sec NLM_sec_level_2"><div id="ac_i10" class="anchor-spacer"></div><h3 class="article-section__title" id="_i10"> Selectivity of HSA Complex <i>in Vivo</i></h3><div class="NLM_p">To evaluate whether the HSA complex selectively accumulates in the Bel-7402 tumor <i>in vivo</i>, the Fe content in tumors of mice treated with compound <b>12</b> and HSA-<b>12</b> complex was measured. Using inductively coupled plasma atomic emission spectrometry (ICP-AES), the iron content in tumors treated with HSA-<b>12</b> complex is significantly (<i>p</i> < 0.05) higher compared to those treated with compound <b>12</b>. This data suggests that the HSA complex selectively accumulates in tumors. Furthermore, the data also indicates that the HSA complex decreased Fe compound accumulation in the liver and kidney (<a class="ref internalNav" href="#fig6" aria-label="Figure 6">Figure 6</a>A).</div><figure id="fig6" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-16/acs.jmedchem.6b00509/20160819/images/medium/jm-2016-00509b_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-16/acs.jmedchem.6b00509/20160819/images/large/jm-2016-00509b_0007.jpeg" id="gr6" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. (A) Fe content in tumor of mice treated with compound <b>12</b> and HSA-<b>12</b> complex after 28 days. (B) Fe content released from HSA complex in pH 4.7 and pH 7.4 buffers, 0–48 h, respectively.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-16/acs.jmedchem.6b00509/20160819/images/large/jm-2016-00509b_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00509&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_9" class="NLM_sec NLM_sec_level_2"><div id="ac_i11" class="anchor-spacer"></div><h3 class="article-section__title" id="_i11"> Fe Prodrug Release from HSA</h3><div class="NLM_p last">To examine the release behavior of Fe from HSA in different environments, the environment inside the cancer cell was stimulated, and the compound <b>12</b> released from the HSA carrier was measured in buffers of pH 4.7 and pH 7.4. Approximately 5% of the Fe compound was released from the HSA complex within 48 h in pH 7.4 buffer, whereas up to 80% of Fe compound was released from HSA in pH 4.7 buffer (<a class="ref internalNav" href="#fig6" aria-label="Figure 6">Figure 6</a>B). In addition, the binding affinity of Fe compound to HSA in pH 7.4 buffer [<i>K</i> = 6.88 (±0.08) × 10<sup>6</sup> M<sup>–1</sup>] was significantly greater than that of HSA to Fe compound in pH 4.7 buffer [<i>K</i> = 4.75 (±0.05) × 10<sup>4</sup> M<sup>–1</sup>]. These results indicate that Fe compound bind weakly to, and are more easily released from, HSA in an acidic environment.</div></div><div id="sec2_10" class="NLM_sec NLM_sec_level_2"><div id="ac_i12" class="anchor-spacer"></div><h3 class="article-section__title" id="_i12"> Possible Mechanism of HSA-<b>12</b> Complex Absorbed by Cancer Cells</h3><div class="NLM_p">It was determined by Desai et al. that, after interacting with SPARC (Secreted Protein, Acid, and Rich in Cysteine) on tumor cell surfaces, HSA penetrates the cell membrane by the process of caveolae protein mediated endocytosis.<a onclick="showRef(event, 'ref38 ref39'); return false;" href="javascript:void(0);" class="ref ref38 ref39">(38, 39)</a> To determine if a similar mechanism for HSA-<b>12</b> complex penetration into Bel-7402 cells is observed here, the organization of caveolae was disturbed by treating Bel-7402 cells with methyl-β-cyclodextrin, a known endocytosis inhibitor.<a onclick="showRef(event, 'ref40'); return false;" href="javascript:void(0);" class="ref ref40">(40)</a> The HSA and Fe permeability were then measured. Compared with the control (0 mM of methyl-β-cyclodextrin), the amount of intracellular HSA and Fe in cells incubated with methyl-β-cyclodextrin was reduced (<a class="ref internalNav" href="#fig7" aria-label="Figure 7">Figure 7</a>). In addition, the amount of intracellular HSA and Fe in cells incubated with l mM methyl-β-cyclodextrin is more than that of cells incubated with 2 mM methyl-β-cyclodextrin (<a class="ref internalNav" href="#fig7" aria-label="Figure 7">Figure 7</a>). These results affirm that the Fe cell content is explicitly proportional to the HSA cell content. This indicates that methyl-β-cyclodextrin prevents the albumin-induced increase in transendothelial HSA and Fe permeability, which results in reduction of the amount of HSA and Fe in cells. In turn, this suggests that the HSA-<b>12</b> complex possibly penetrates Bel-7402 cells by endocytosis.</div><figure id="fig7" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-16/acs.jmedchem.6b00509/20160819/images/medium/jm-2016-00509b_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-16/acs.jmedchem.6b00509/20160819/images/large/jm-2016-00509b_0008.jpeg" id="gr7" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. (A) Western blot analysis of HSA in Bel-7402 cells treated with HSA-<b>12</b> complex; β-actin was used as the internal control. (B) Percentage levels of HSA; the values are relative to 0 mM of methyl-β-cyclodextrin-incubated. (C) Intracellular Fe concentration in Bel-7402 cells treated with HSA-<b>12</b> complex relative to 0 mM of methyl-β-cyclodextrin-incubated.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-16/acs.jmedchem.6b00509/20160819/images/large/jm-2016-00509b_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00509&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_11" class="NLM_sec NLM_sec_level_2"><div id="ac_i13" class="anchor-spacer"></div><h3 class="article-section__title" id="_i13"> Potential Anticancer Mechanism of Compound <b>12</b>/HSA-<b>12</b> Complex</h3><div class="NLM_p">DNA transcription and replication require separation of the supercoiled DNA double-helix. Topo-Iiα is responsible for unlinking DNA during replication, which then allows DNA relaxation during transcription and supports chromatin remodeling.<a onclick="showRef(event, 'ref41'); return false;" href="javascript:void(0);" class="ref ref41">(41)</a> Disruption of Topo-IIα leads to double-strand DNA breaks, ultimately causing cell death. This has led to the identification of Topo-IIα as one of the most important clinical targets for modern cancer chemotherapy, and its inhibitors are the central components of many therapeutic regimens.<a onclick="showRef(event, 'ref42'); return false;" href="javascript:void(0);" class="ref ref42">(42)</a> Recently, many reports have acknowledged that thiosemicarbazone derivatives likely target Topo-IIα,<a onclick="showRef(event, 'ref42 ref43 ref44 ref45'); return false;" href="javascript:void(0);" class="ref ref42 ref43 ref44 ref45">(42-45)</a> so we decided to evaluate the use of human Topo-IIα-mediated pBR322 relaxation and kDNA decatenation assays to determine if the compound <b>12</b> can indeed inhibit Topo-Iiα. The results show that the compound <b>12</b> significantly inhibits Topo-IIα activity, suggesting compound <b>12</b> is a potent Topo-IIα inhibitor (<a class="ref internalNav" href="#fig8" aria-label="Figure 8">Figure 8</a>A).</div><figure id="fig8" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-16/acs.jmedchem.6b00509/20160819/images/medium/jm-2016-00509b_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-16/acs.jmedchem.6b00509/20160819/images/large/jm-2016-00509b_0009.jpeg" id="gr8" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. (A) Agarose gel assay for Topo-IIα inhibition by compound <b>12</b>. (B) Effect of the cell cycle of Bel-7402 treated with compound <b>12</b> and HSA-<b>12</b> complex for 24 h compared with untreated cells. (C) Western blot analysis of E2F-1, Cyc A, Cyc E, and Cdk 2 in Bel-7402 cells treated with compound <b>12</b> and HSA-<b>12</b> complex for 24 h; β-actin was used as the internal control. (D) Expression levels of (C) shown as percentages. The values are relative to the control.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-16/acs.jmedchem.6b00509/20160819/images/large/jm-2016-00509b_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00509&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Topo-IIα inhibition is thought to affect cell cycle.<a onclick="showRef(event, 'ref41'); return false;" href="javascript:void(0);" class="ref ref41">(41)</a> Thus, we investigated the influence of compound <b>12</b> and HSA-<b>12</b> complex on the cell cycle distribution in human liver cancer cells using flow cytometric DNA content analysis. We noted that in the S phase, when treated with compound <b>12</b>, the percentage of cells increased from 27.78% to 42.10%, not when treated with HSA-<b>12</b> complex. The control cells, with no drug treatment, had 19.99% of cells in the same phase (<a class="ref internalNav" href="#fig8" aria-label="Figure 8">Figure 8</a>B). The Fe(III) compound and HSA complex may cause cell accumulation in the S phase of the cell cycle by either delaying or inhibiting progression to the next phase. Cell cycle regulatory protein expression, including that of cyclins and cyclin-dependent kinases, was investigated to elucidate the molecular mechanism underlying the S phase arrest induced by Fe(III) compound and HSA complex in Bel-7402 cells. Compound <b>12</b> increased the expression of cyclins E and A (<a class="ref internalNav" href="#fig8" aria-label="Figure 8">Figure 8</a>D), which associate with Cdk2; the resulting complexes, cyclin E/Cdk2 and cyclin A/Cdk2, regulate the initiation and progression of the S phase, respectively.<a onclick="showRef(event, 'ref46 ref47'); return false;" href="javascript:void(0);" class="ref ref46 ref47">(46, 47)</a> The expression of cyclin E and cyclin A was high after 24 h, which suggests that compound <b>12</b> persevered in enhanced S phase progression and thaat compound <b>12</b> caused increased E2F-1 expression (which promotes cyclins E and A transcription) at 24 h (<a class="ref internalNav" href="#fig8" aria-label="Figure 8">Figure 8</a>D).<a onclick="showRef(event, 'ref48'); return false;" href="javascript:void(0);" class="ref ref48">(48)</a> The enhanced expression of cyclins E and A and E2F-1 appear to be directly responsible for the compound <b>12</b>-induced S phase arrest.</div><div class="NLM_p">Many studies have affirmed that metal compounds can introduce reactive oxygen species (ROS) into cancer cells.<a onclick="showRef(event, 'ref49'); return false;" href="javascript:void(0);" class="ref ref49">(49)</a> Increased ROS can damage macromolecules and alter cell function or induce apoptosis.<a onclick="showRef(event, 'ref50'); return false;" href="javascript:void(0);" class="ref ref50">(50)</a> To investigate if compound <b>12</b> and HSA-<b>12</b> complex can produce ROS in Bel-7402 cells, a fluorescent DCF probe and flow cytometry were utilized. The cells treated with compound <b>6</b> and compound <b>12</b> or HSA-<b>12</b> complex have greater DCF fluorescence intensity and a right shifted peak relative to control cells (<a class="ref internalNav" href="#fig9" aria-label="Figure 9">Figure 9</a>A). Compound <b>6</b> does not obviously increase ROS compared to control cells after 24 h. However, compound <b>12</b> significantly (<i>p</i> < 0.001) increased H<sub>2</sub>DCF oxidation 223 ± 20% after 24 h incubation. Thus, compound <b>12</b> produces significantly (<i>p</i> < 0.001) more ROS than compound <b>6</b> (105 ± 20%), but did not produce as much as HSA-<b>12</b> complex (355 ± 20%). Prior studies have confirmed that Fe compounds introduce reactive oxygen species via redox-cycling. In their reduced (Fe<sup>II</sup>) form, these complexes can react with molecular oxygen; the resulting ferric complexes may subsequently interact with cellular reductants. Voltammograms were recorded to determine if compound <b>12</b> can generate reactive oxygen species through the reduction of Fe<sup>III</sup> to Fe<sup>II</sup> (<a class="ref internalNav" href="#fig9" aria-label="Figure 9">Figure 9</a>B). Redox potentials of compound <b>12</b> are relatively high, suggesting that the Fe<sup>III</sup> compound can be easily reduced and then able to take part in redox cycling and ROS generation.</div><figure id="fig9" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 9</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-16/acs.jmedchem.6b00509/20160819/images/medium/jm-2016-00509b_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-16/acs.jmedchem.6b00509/20160819/images/large/jm-2016-00509b_0010.jpeg" id="gr9" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 9. (A) Intracellular production of reactive oxygen species by FeCl<sub>3</sub>, compound <b>6</b>, compound <b>12</b>, and HSA-<b>12</b> complex following a 24 h incubation determined by flow cytotometric. (B) Cyclic voltammograms of 1 mM solutions of compound <b>12</b> show the impact of a halogen atom on the Fe<sup>III/II</sup> redox potential. (C) The percentage of green fluorescence cells treated with FeCl<sub>3</sub>, compound <b>6</b>, compound <b>12</b>, and HSA-<b>12</b> complex for 24 h and control determined by flow cytometry.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-16/acs.jmedchem.6b00509/20160819/images/large/jm-2016-00509b_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00509&amp;id=fig9"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Increased ROS and mitochondrial dysfunction are related apoptosis events.<a onclick="showRef(event, 'ref50 ref51'); return false;" href="javascript:void(0);" class="ref ref50 ref51">(50, 51)</a> The apoptosis process is mediated by the mitochondrial/apoptotic cascade and is often linked with mitochondrial membrane changes caused by the leakage of pro-apoptotic factors.<a onclick="showRef(event, 'ref52'); return false;" href="javascript:void(0);" class="ref ref52">(52)</a> The lipophilic fluorescent probe JC-1 (5, 5, 6, 6′-tetrachloro-1, 1′, 3, 3′-tetraethyl-imidacarbocyanine iodide) was used to measure mitochondrial membrane potential changes (Δψm). JC-1 staining indicates decreased Δψ<i>m</i>, as evidenced by less red fluorescence (JC-1 aggregates) and increased green fluorescence (JC-1 monomers).<a onclick="showRef(event, 'ref49'); return false;" href="javascript:void(0);" class="ref ref49">(49)</a> Bel-7402 cells were then treated with 1 μM of FeCl<sub>3</sub>, compound <b>6</b>, compound <b>12</b>, or HSA-<b>12</b> complex for 24 h, and Δψ<i>m</i> was decreased (<a class="ref internalNav" href="#fig9" aria-label="Figure 9">Figure 9</a>C). Mitochondrial-mediated apoptosis activation was confirmed, and each compound’s ability to decrease Δψ<i>m</i> was consistent with <i>in vitro</i> cytotoxicity. BeL-7402 was incubated with FeCl<sub>3</sub> and compound <b>6</b> for 24 h, which decreased Δψ<i>m</i> (3.46% and 5.52%, respectively) (<i>p</i> < 0.05), and a significant (<i>p</i> < 0.001) decrease in Δψ<i>m</i> was observed after incubation with compound <b>12</b> (12.0%) or HSA-<b>12</b> complex (22.2%) (<a class="ref internalNav" href="#fig9" aria-label="Figure 9">Figure 9</a>C).</div><div class="NLM_p">Topo-IIα inhibition could potentially lead to an attack on components of DNA, DNA strand breaks, DNA intrastrand adducts, and DNA–protein cross-links.<a onclick="showRef(event, 'ref41'); return false;" href="javascript:void(0);" class="ref ref41">(41)</a> Transcription factor p53 is another major player in apoptosis or cell cycle arrest response of cells to DNA damage. Western blotting was used to detect changes of p53 to determine if compound <b>12</b> and HSA-<b>12</b> complex had caused DNA damage. Pretreatment with HSA-<b>12</b> complex enhanced radiation-induced DNA damage more than compound <b>12</b>, as evidenced by increased p53 phosphorylation levels as shown in <a class="ref internalNav" href="#fig10" aria-label="Figure 10">Figure 10</a>. The Bcl-2 protein family are thought to be key regulators of Δψ<i>m</i>.<a onclick="showRef(event, 'ref53 ref54'); return false;" href="javascript:void(0);" class="ref ref53 ref54">(53, 54)</a> Thus, Western blotting was used to determine if compound <b>12</b> or HSA-<b>12</b> complex significantly (<i>p</i> < 0.001) upregulated Bax expression (pro-apoptotic Bcl-2 protein family) and suppressed expression of Bcl-2 and Bcl-xl (pro-survival Bcl-2 family proteins). We determined that the ratio of Bcl-2/Bax was decreased, which indicates that Bcl-2 proteins regulated the loss of Δψ<i>m</i>. HSA-<b>12</b> complex significantly upregulated the expression of Bax and suppressed Bcl-2 and Bcl-xl expression in BEL-7402 cells in comparison to compound <b>12</b> (<i>p</i> < 0.001). In addition, Western blotting revealed that cytochrome c (Cyt C) and the caspase protein family (caspase-3 and -9) were greatly upregulated (<i>p</i> < 0.001), suggesting that Cyt C was the cause of caspase-3 and -9 activation. Results show that HSA-<b>12</b> complex is significantly (<i>p</i> < 0.001) more effective in up-regulating caspase family protein expression and Cyt C in Bel-7402 cells, compared to compound <b>12</b>.</div><figure id="fig10" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Figure 10</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-16/acs.jmedchem.6b00509/20160819/images/medium/jm-2016-00509b_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-16/acs.jmedchem.6b00509/20160819/images/large/jm-2016-00509b_0011.jpeg" id="gr10" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 10. (A) Western blot analysis of p53, Bcl-2, Bcl-xl, Bax, Cyt C, caspase-3, and caspase-9 in Bel-7402 cells treated with compound <b>12</b> and HSA-<b>12</b> complex for 24 h; β-actin was used as the internal control. (B) Expression levels of p53, Bcl-2, Bcl-xl, Bax, Cyt C, caspase-3, and caspase-9 shown as percentages; the values are relative to the control. (C) The effect of cell apoptosis from Bel-7402 treated with compound <b>12</b> and HSA-<b>12</b> complex for 12 h compared with the untreated cells.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-16/acs.jmedchem.6b00509/20160819/images/large/jm-2016-00509b_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00509&amp;id=fig10"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">We used Annexin V-FITC/PI staining to further validate compound <b>12</b>’s and HSA-<b>12</b> complex’s abilities to bolster cell apoptosis; the data showed Bel-7402 cell apoptosis of 10.3% for compound <b>12</b> and 20.9% for HSA-<b>12</b> complex (<a class="ref internalNav" href="#fig10" aria-label="Figure 10">Figure 10</a>C). Results show that HSA-<b>12</b> complex is significantly (<i>p</i> < 0.001) more effective at promoting Bel-7402 cell apoptosis compared to compound <b>12</b>.</div></div></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i14">Discussion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_01880" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_01880" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">The study demonstrated that the anticancer activity of ligands may be enhanced by coordinating with complexes containing Fe(III). The nature of the Fe-bound ligand directly affected the anticancer properties of the Fe compound, and lipophilic groups attached to the ligand also played an important role in increasing the anticancer activity of the potential Fe therapeutic. When we replaced the H atom in the N4 location of the ligand with a more lipophilic functional moiety, such as an alkyl or aryl group, the other five Fe(III) compounds we investigated showed a one- to 20-fold increase in anticancer activity relative to compound <b>7</b> (<a class="ref internalNav" href="#tbl1" aria-label="Table 1">Table 1</a>), and the Fe(III) compound is proportional to the degree of lipophilicity of the ligand. With the basic pharmacophore of the ligand attached to Fe(III) left intact, lipophilic groups of the ligand could be modified in an attempt to regulate the anticancer activity of the Fe(III) compound.</div><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. IC<sub>50</sub> Values of Compounds and HSA Complexes toward Cell Lines for 48 h</div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" rowspan="2" align="center"> </th><th class="rowsep1 colsep0" colspan="2" align="center">IC<sub>50</sub> (μM)</th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">Bel-7402</th><th class="colsep0 rowsep0" align="center">HL-7702</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">compound <b>1</b></td><td class="colsep0 rowsep0" align="left">>40</td><td class="colsep0 rowsep0" align="left">>40</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">compound <b>2</b></td><td class="colsep0 rowsep0" align="left">>40</td><td class="colsep0 rowsep0" align="left">>40</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">compound <b>3</b></td><td class="colsep0 rowsep0" align="left">>40</td><td class="colsep0 rowsep0" align="left">>40</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">compound <b>4</b></td><td class="colsep0 rowsep0" align="left">>40</td><td class="colsep0 rowsep0" align="left">>40</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">compound <b>5</b></td><td class="colsep0 rowsep0" align="left">>40</td><td class="colsep0 rowsep0" align="left">>40</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">compound <b>6</b></td><td class="colsep0 rowsep0" align="left">>40</td><td class="colsep0 rowsep0" align="left">>40</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">compound <b>7</b></td><td class="colsep0 rowsep0" align="left">13.36 ± 1.35</td><td class="colsep0 rowsep0" align="left">15.32 ± 0.85</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">compound <b>8</b></td><td class="colsep0 rowsep0" align="left">11.87 ± 1.25</td><td class="colsep0 rowsep0" align="left">11.24 ± 0.65</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">compound <b>9</b></td><td class="colsep0 rowsep0" align="left">2.22 ± 0.66</td><td class="colsep0 rowsep0" align="left">3.33 ± 0.39</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">compound <b>10</b></td><td class="colsep0 rowsep0" align="left">0.86 ± 0.23</td><td class="colsep0 rowsep0" align="left">0.95 ± 0.28</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">compound <b>11</b></td><td class="colsep0 rowsep0" align="left">0.92 ± 0.37</td><td class="colsep0 rowsep0" align="left">0.99 ± 0.31</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">compound <b>12</b></td><td class="colsep0 rowsep0" align="left">0.65 ± 0.25</td><td class="colsep0 rowsep0" align="left">0.78 ± 0.15</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">HSA-<b>7</b> complex</td><td class="colsep0 rowsep0" align="left">8.37 ± 1.56</td><td class="colsep0 rowsep0" align="left">17.33 ± 1.66</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">HSA-<b>8</b> complex</td><td class="colsep0 rowsep0" align="left">5.21 ± 0.55</td><td class="colsep0 rowsep0" align="left">16.35 ± 1.12</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">HSA-<b>9</b> complex</td><td class="colsep0 rowsep0" align="left">0.96 ± 0.11</td><td class="colsep0 rowsep0" align="left">4.25 ± 0.85</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">HSA-<b>10</b> complex</td><td class="colsep0 rowsep0" align="left">0.34 ± 0.06</td><td class="colsep0 rowsep0" align="left">3.24 ± 0.37</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">HSA-<b>11</b> complex</td><td class="colsep0 rowsep0" align="left">0.37 ± 0.06</td><td class="colsep0 rowsep0" align="left">3.96 ± 0.09</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">HSA-<b>12</b> complex</td><td class="colsep0 rowsep0" align="left">0.11 ± 0.03</td><td class="colsep0 rowsep0" align="left">3.56 ± 0.28</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">cisplatin</td><td class="colsep0 rowsep0" align="left">14.54 ± 0.85</td><td class="colsep0 rowsep0" align="left">15.62 ± 0.63</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">HSA</td><td class="colsep0 rowsep0" align="left">>100</td><td class="colsep0 rowsep0" align="left">>100</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">FeCl<sub>3</sub></td><td class="colsep0 rowsep0" align="left">>60</td><td class="colsep0 rowsep0" align="left">>60</td></tr></tbody></table></div></div><div class="NLM_table-wrap" id="tbl2"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 2. Serological Analysis of Mice Injected with NaCl, Compound <b>12</b>, and HSA-<b>12</b> Complex</div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="char" char="±" /></col><col align="char" char="±" /></col><col align="char" char="±" /></col><col align="char" char="±" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">complex</th><th class="colsep0 rowsep0" align="center" char="±">CK (U/L)</th><th class="colsep0 rowsep0" align="center" char="±">BUN (mmol/L)</th><th class="colsep0 rowsep0" align="center" char="±">ALT (U/L)</th><th class="colsep0 rowsep0" align="center" char="±">AST (U/L)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">NaCl</td><td class="colsep0 rowsep0" align="char" char="±">316 ± 12</td><td class="colsep0 rowsep0" align="char" char="±">8.1 ± 1.2</td><td class="colsep0 rowsep0" align="char" char="±">32.2 ± 8.6</td><td class="colsep0 rowsep0" align="char" char="±">82.5 ± 17</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">compound <b>12</b></td><td class="colsep0 rowsep0" align="char" char="±">352 ± 25</td><td class="colsep0 rowsep0" align="char" char="±">25.0 ± 2.1</td><td class="colsep0 rowsep0" align="char" char="±">55.5 ± 5.9</td><td class="colsep0 rowsep0" align="char" char="±">125 ± 18</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">HSA-<b>12</b> complex</td><td class="colsep0 rowsep0" align="char" char="±">323 ± 26</td><td class="colsep0 rowsep0" align="char" char="±">7.6 ± 1.5</td><td class="colsep0 rowsep0" align="char" char="±">36.6 ± 6.0</td><td class="colsep0 rowsep0" align="char" char="±">90 ± 7.8</td></tr></tbody></table></div></div><div class="NLM_p">There is the potential to increase anticancer activity and metal drug selectivity by altering the carrier; however, efficacy of <i>in vivo</i> drug delivery and the ability to release in cancer cells need to be simultaneously taken into consideration. Yang et al. has proposed a new strategy for designing metal prodrug that is based on the nature of the cancer cells and the HSA IIA subdomain.<a onclick="showRef(event, 'ref32 ref33 ref34'); return false;" href="javascript:void(0);" class="ref ref32 ref33 ref34">(32-34)</a> The results of this study confirm that it is feasible to design an Fe prodrug according to Yang et al.’s proposal. By examining the HSA complex structure, it was determined that Lys199 and His242 replaced two Cl atoms of the Fe compound and coordinated with Fe(III), which enables the Fe compound to forge a strong bond in the hydrophobic cavity of the HSA IIA subdomain. As a result, minimal Fe compound (about 5%) is released from HSA at pH 7.4, whereas approximately 80% of Fe compound are released from HSA in acidic environments (pH 4.7). This is due to a dramatic decrease in the Fe compound binding affinity in these two environments. Based on these release profiles, it is suggested that the HSA complex will be stable in blood during <i>in vivo</i> circulation and that the Fe compound will be released after there is a selective accumulation of acid lysosome in the cancer cells.</div><div class="NLM_p">The therapeutic efficiency of compound <b>12</b>/HSA-<b>12</b> complex <i>in vivo</i> was evaluated by considering three factors: TIR, side effects, and selectivity, in mice. The TIR of the FA-HSA-<b>12</b> complex treated mice almost reached 75.6% and was 1.6 times higher than that of the compound <b>12</b> treated group. FA-HSA-<b>12</b> complex is well tolerated in mice and causes less weight loss relative to compound <b>12</b> alone. H&E staining indicated that HSA-<b>12</b> complex can effectively reduce the heart, liver, and kidney damage induced by free compound <b>12</b>. Furthermore, the ICP-AES results show that HSA-<b>12</b> complex facilitates Fe compound accumulation in the tumor <i>in vivo</i>. The liver cancer xenograft experiments in mice further indicate that HSA complexation is helpful for decreasing side effects, improving antitumor activity and selectivity of Fe compound. Furthermore, the HSA complex has a lower toxicity against normal cells and tissues than the Fe compound. This is due to a more selective accumulation of the HSA complex in tumor cells, enhanced permeability, and the retention (EPR) effect of the macromolecule in tumors (<a class="ref internalNav" href="#fig11" aria-label="Figure 11">Figure 11</a>).<a onclick="showRef(event, 'ref37 ref38 ref39'); return false;" href="javascript:void(0);" class="ref ref37 ref38 ref39">(37-39)</a></div><figure id="fig11" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Figure 11</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-16/acs.jmedchem.6b00509/20160819/images/medium/jm-2016-00509b_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-16/acs.jmedchem.6b00509/20160819/images/large/jm-2016-00509b_0012.jpeg" id="gr11" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 11. Possible delivery and anticancer mechanism of HSA-<b>12</b> complex.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-16/acs.jmedchem.6b00509/20160819/images/large/jm-2016-00509b_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00509&amp;id=fig11"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">These results confirm that the HSA complex has a better therapeutic efficacy and lower systemic toxicity than free compound <b>12</b>. The principle of the classic approach for developing metal anticancer drugs is for them to quickly replicate and speed up the mitotic processes of malignant cells.<a onclick="showRef(event, 'ref5'); return false;" href="javascript:void(0);" class="ref ref5">(5)</a> However, there are still some major drawbacks concerning these metal drugs: they only work with certain types of cancers; some tumors may have acquired or intrinsic resistance; and they often have severe side effects.<a onclick="showRef(event, 'ref7'); return false;" href="javascript:void(0);" class="ref ref7">(7)</a> Therefore, new approaches are needed to develop cancer drugs that circumvent these drawbacks. Among these, developing anticancer drugs that target proteins related to cancer may be promising. Excitingly, the results outlined here show that Fe compounds eradicate cancer cells using multiple anticancer mechanisms, such as regulating the expression of proteins in cancer cells. Furthermore, the anticancer capacity of the Fe compound is improved when complexed with HSA, relative to the Fe compound alone. Therefore, it is necessary to create a multitarget anticancer Fe prodrug based on the HSA carrier that improves delivery efficiency and increases anticancer activity and selectivity while overcoming resistance.</div></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i17">Conclusion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_27157" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_27157" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p last">Due to His242 and Lys199 replacing the groups of Fe prodrug that have left and then coordinating with Fe<sup>3+</sup>, certain aspects of Fe compounds have improved, including delivery efficiency, anticancer activity, and selectivity, since they bind strongly to the IIA subdomain of HSA. Compared to the Fe compound alone, the HSA complex showed better tolerance, higher drug accumulation in tumor tissues, and lower toxicity, indicating that it had superior antitumor activity and was associated with milder side effects. These results suggest that the HSA carrier prodrug strategy for intravenous administration of novel, active thiosemicarbazone containing Fe(III) compounds may be a promising approach for targeted cancer therapy.</div></div><div id="sec5" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i18">Experimental Section</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_18277" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_18277" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec5_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i19" class="anchor-spacer"></div><h3 class="article-section__title" id="_i19"> Chemicals and Reagents</h3><div class="NLM_p last">HSA (fatty acid content <0.05%) was purchased from Sigma-Aldrich (Shanghai, China) and used without requiring further purification. All other chemicals and solvents were of high purity and are available from commercial sources. Distilled water was used in the reactions. Elemental analyses (C, N, H, and S) were carried out on a PerkinElmer 2400 analyzer. We use the X-ray diffraction to determine the compounds structure, and element analysis (C, H, N, S) to determine the purity of compounds is ≥95%.</div></div><div id="sec5_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i20" class="anchor-spacer"></div><h3 class="article-section__title" id="_i20"> Synthesis and Characterization of Ligands</h3><div class="NLM_p">The ligands compound <b>1</b>–<b>6</b> were prepared according to the following procedures.<a onclick="showRef(event, 'ref4 ref36'); return false;" href="javascript:void(0);" class="ref ref4 ref36">(4, 36)</a> In brief, the thiosemicarabazide (10 mmol) and 2-hydroxy-1-naphthaldehyde (10 mmol) were combined in methanol (20 mL) with acetic acid (1–2 drops). While the mixture was boiled, a white or off-white precipitate appeared; after 4 h, it was allowed to cool at room temperature. The mixture was subsequently filtered, washed with cold water, and dried <i>in vacuo</i>.</div><div id="sec5_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i21" class="anchor-spacer"></div><h4 class="article-section__title" id="_i21"> 2-Hydroxy-1-naphthaldehyde-thiosemicarbazide (<b>1</b>)</h4><div class="NLM_p last">Yield: 8.24 mmol (82.4%). Anal. Calcd (%) for C<sub>12</sub>H<sub>10</sub>N<sub>3</sub>OS: C, 59.00; H, 4.13; N, 17.20; O, 6.55; S, 13.13. Found: C, 59.05; H, 4.10; N, 17.21; O, 6.51; S, 13.13. IR, cm<sup>–1</sup>: 3698 (m, OH), 3449 (s, amide), 3256 (s, NH), 3165 (m, aromatic hydrogen), 1607 (s), 1573 (s), 1510 (s), 1471 (s, aromatic), 1394 (s, C═N), 1328 (s, thioamide), 1238 (s), 1118 (s), 880 (m), 819 (m, C–H), 748 (m, C═S), 647 (m). ESI<sup>+</sup><i>m</i>/<i>z</i>: calcd for C<sub>12</sub>H<sub>10</sub>N<sub>3</sub>OS, 244.02 [M – H].</div></div><div id="sec5_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i22" class="anchor-spacer"></div><h4 class="article-section__title" id="_i22"> 2-Hydroxy-1-naphthaldehyde-4-methylthiosemicarbazide (<b>2</b>)</h4><div class="NLM_p last">Yield: 7.96 mmol (79.6%). Anal. Calcd (%) for C<sub>13</sub>H<sub>13</sub>N<sub>3</sub>OS: C, 60.44; H, 4.68; N, 16.27; O, 6.19; S, 12.41. Found: C, 60.40; H, 4.65; N, 16.30; O, 6.16; S, 12.48. IR, cm<sup>–1</sup>: 3702 (m, OH), 3419 (s, amide), 3201 (s, NH), 3007 (m, aromatic hydrogen), 1620 (m), 1596 (s), 1532 (s), 1428 (s, aromatic), 1397 (m, C═N), 1330 (s, thioamide), 947 (s), 888 (s, C–H), 776 (m), 744 (m), 716 (m, C═S), 684 (m). ESI<sup>+</sup><i>m</i>/<i>z</i>: calcd for C<sub>13</sub>H<sub>13</sub>N<sub>3</sub>OS, 258.06 [M – H].</div></div><div id="sec5_5" class="NLM_sec NLM_sec_level_3"><div id="ac_i23" class="anchor-spacer"></div><h4 class="article-section__title" id="_i23"> 2-Hydroxy-1-naphthaldehyde-4-phenylthiosemicarbazide (<b>3</b>)</h4><div class="NLM_p last">Yield: 85.5 mmol (85.5%). Anal. Calcd (%) for C<sub>18</sub>H<sub>15</sub>N<sub>3</sub>OS: C, 67.27; H, 4.70; N, 13.07; O, 4.98; S, 9.98. Found: C, 67.22; H, 4.73; N, 13.03; O, 4.99; S, 10.13. IR, cm<sup>–1</sup>: 3711 (m, OH), 3385 (s, amide), 3151 (s, NH), 3000 (m, aromatic hydrogen), 1621 (m), 1595 (s), 1542 (s), 1442 (m, aromatic), 1415 (m, C═N), 1326 (s, thioamide), 1094 (s), 939 (s, C–H), 902 (m), 856 (m), 766 (m, C═S), 719 (m). ESI<sup>+</sup><i>m</i>/<i>z</i>: calcd for C<sub>18</sub>H<sub>15</sub>N<sub>3</sub>OS, 320.10 [M – H].</div></div><div id="sec5_6" class="NLM_sec NLM_sec_level_3"><div id="ac_i24" class="anchor-spacer"></div><h4 class="article-section__title" id="_i24"> 2-Hydroxy-1-naphthaldehyde-4,4-dimethylthiosemicarbazide (<b>4</b>)</h4><div class="NLM_p last">Yield: 9.01 mmol (90.1%). Anal. Calcd (%) for C<sub>14</sub>H<sub>15</sub>N<sub>3</sub>OS: C, 61.51; H, 5.53; N, 15.37; O, 5.85; S, 11.73. Found: C, 61.51; H, 5.53; N, 15.37; O, 5.85; S, 11.73. IR, cm<sup>–1</sup>: 3739 (m, OH), 3279 (s, amide), 3039 (s, NH), 3000 (m, aromatic hydrogen), 1619 (s), 1548 (m), 1520 (s), 1462 (s, aromatic), 1357 (m, C═N), 1238 (s, thioamide), 1181 (s), 1141 (s), 906 (m), 884 (m, C–H), 650 (m, C═S), 594 (m). ESI<sup>+</sup><i>m</i>/<i>z</i>: calcd for C<sub>14</sub>H<sub>15</sub>N<sub>3</sub>OS, 272.09 [M – H].</div></div><div id="sec5_7" class="NLM_sec NLM_sec_level_3"><div id="ac_i25" class="anchor-spacer"></div><h4 class="article-section__title" id="_i25"> 2-Hydroxy-1-naphthaldehyde-4,4-diethylthiosemicarbazide (<b>5</b>)</h4><div class="NLM_p last">Yield: 7.90 mmol (79.0%). Anal. Calcd (%) for C<sub>16</sub>H<sub>19</sub>N<sub>3</sub>OS: C, 63.76; H, 6.35; N, 13.94; O, 5.31; S, 10.64. Found: C, 63.74; H, 6.36; N, 13.90; O, 5.33; S, 10.67. IR, cm<sup>–1</sup>: 3715 (m, OH), 3293 (s, amide), 2982 (s, NH), 2934 (m, aromatic hydrogen), 1620 (m), 1590 (m), 1538 (s), 1462 (s, aromatic), 1414 (s, C═N), 1356 (s, thioamide), 1271 (m), 1133 (s), 1074 (m), 955 (m, C–H), 803 (m, C═S), 694 (m). ESI<sup>+</sup><i>m</i>/<i>z</i>: calcd for C<sub>16</sub>H<sub>19</sub>N<sub>3</sub>OS, 300.13 [M – H].</div></div><div id="sec5_8" class="NLM_sec NLM_sec_level_3"><div id="ac_i26" class="anchor-spacer"></div><h4 class="article-section__title" id="_i26"> 2-Hydroxy-1-naphthaldehyde-3-piperidinethiosemicarbazide (<b>6</b>)</h4><div class="NLM_p last">Yield: 7.43 mmol (74.3%). Anal. Calcd (%) for C<sub>17</sub>H<sub>19</sub>N<sub>3</sub>OS: C, 65.15; H, 6.11; N, 13.41; O, 5.10; S, 10.23. Found: C, 65.10; H, 6.13; N, 13.42; O, 5.9; S, 10.26. IR, cm<sup>–1</sup>: 3640 (m, OH), 3323 (s, amide), 3204 (s, NH), 2964 (m, aromatic hydrogen), 1620 (s), 1594 (s), 1537 (s), 1465 (s, aromatic), 1403 (s, C═N), 1326 (s, thioamide), 1252 (s), 1180 (s), 1084 (m), 957 (m, C–H), 822 (m, C═S), 746 (m). ESI<sup>+</sup><i>m</i>/<i>z</i>: calcd for C<sub>17</sub>H<sub>19</sub>N<sub>3</sub>OS, 312.13 [M – H].</div></div></div><div id="sec5_9" class="NLM_sec NLM_sec_level_2"><div id="ac_i27" class="anchor-spacer"></div><h3 class="article-section__title" id="_i27"> Synthesis and Characterization of Fe Compounds</h3><div class="NLM_p">The compounds <b>7</b>–<b>12</b> were synthesized as the following methods. The relevant ligands (1 mmol) were dissolved in MeOH (10 mL) over gentle heat and stirred. A solution of FeCl<sub>3</sub> (0.20 g, 1 mmol) in MeOH (10 mL) was added dropwise and stirred, and the ligand solution immediately turned dark brown. Fine dark brown crystals formed upon standing, which were then filtered off and washed with EtOH (5 mL), and diethyl ether (5 mL) was added.</div><div id="sec5_10" class="NLM_sec NLM_sec_level_3"><div id="ac_i28" class="anchor-spacer"></div><h4 class="article-section__title" id="_i28"> 2-Hydroxy-1-naphthaldehyde-thiosemicarbazide-iron(III)-bischlorin (<b>7</b>)</h4><div class="NLM_p last">Yield: 0.65 mmol (65%). CCDC NO. 1442009. Anal. Calcd (%) for C<sub>12</sub>H<sub>9</sub>Cl<sub>2</sub>FeN<sub>3</sub>OS: C, 38.95; H, 2.45; N, 11.36; O, 4.32; S, 8.67. Found: C, 38.98; H, 2.40; N, 11.32; O, 4.36; S, 8.69. IR, cm<sup>–1</sup>: 3246 (s, amide), 3038 (s, NH), 2961 (m, aromatic hydrogen), 1615 (s), 1595 (s), 1573 (s), 1457 (s, aromatic), 1388 (s, C═N), 1337 (s, thioamide), 1196 (s), 1165 (s), 1146 (m), 974 (m, C–H), 821 (m, C═S), 749 (s). ESI<sup>+</sup><i>m</i>/<i>z</i>: calcd for C<sub>12</sub>H<sub>9</sub>Cl<sub>2</sub>FeN<sub>3</sub>OS, 369.03 [M – H].</div></div><div id="sec5_11" class="NLM_sec NLM_sec_level_3"><div id="ac_i29" class="anchor-spacer"></div><h4 class="article-section__title" id="_i29"> 2-Hydroxy-1-naphthaldehyde-4-methylthiosemicarbazide-iron(III)-bischlorin (<b>8</b>)</h4><div class="NLM_p last">Yield: 0.57 mmol (57%). CCDC NO. 1442010. Anal. Calcd (%) for C<sub>13</sub>H<sub>11</sub>Cl<sub>2</sub>FeN<sub>3</sub>OS: C, 40.65; H, 2.89; N, 10.94; O, 4.17; S, 8.35. Found: C, 40.59; H, 2.85; N, 10.96; O, 4.19; S, 8.41. IR, cm<sup>–1</sup>: 3288 (s, amide), 3005 (s, NH), 2974 (m, aromatic hydrogen), 1608 (s), 1534 (s), 1477 (s), 1447 (s, aromatic), 1359 (s, C═N), 1337 (s, thioamide), 1194 (s), 1142 (m), 970 (m, C–H), 823 (m, C═S), 756 (s), 603 (s), 561 (s). ESI<sup>+</sup><i>m</i>/<i>z</i>: calcd for C<sub>13</sub>H<sub>11</sub>Cl<sub>2</sub>FeN<sub>3</sub>OS, 383.06 [M – H].</div></div><div id="sec5_12" class="NLM_sec NLM_sec_level_3"><div id="ac_i30" class="anchor-spacer"></div><h4 class="article-section__title" id="_i30"> 2-Hydroxy-1-naphthaldehyde-4-phenylthiosemicarbazide-iron(III)-bischlorin (<b>9</b>)</h4><div class="NLM_p last">Yield: 0.54 mmol (54%). CCDC NO. 1442011. Anal. Calcd (%) for C<sub>18</sub>H<sub>13</sub>Cl<sub>2</sub>FeN<sub>3</sub>OS: C, 48.46; H, 2.94; N, 9.42; O, 3.59; S, 7.19. Found: C, 48.43; H, 2.95; N, 9.40; O, 3.58; S, 7.24. IR, cm<sup>–1</sup>: 3173 (s, amide), 3014 (s, NH), 2874 (m, aromatic hydrogen), 1595 (s), 1571 (s), 1531 (s), 1456 (m, aromatic), 1389 (s, C═N), 1358 (s, thioamide), 1190 (s), 1139 (s), 1087 (m), 974 (m, C–H), 824 (m, C═S), 747 (s), 699 (s), 651 (m). ESI<sup>+</sup><i>m</i>/<i>z</i>: calcd for C<sub>18</sub>H<sub>13</sub>Cl<sub>2</sub>FeN<sub>3</sub>OS, 444.06 [M – H].</div></div><div id="sec5_13" class="NLM_sec NLM_sec_level_3"><div id="ac_i31" class="anchor-spacer"></div><h4 class="article-section__title" id="_i31"> 2-Hydroxy-1-naphthaldehyde-4,4-dimethylthiosemicarbazide-iron(III)-bischlorin (<b>10</b>)</h4><div class="NLM_p last">Yield: 0.48 mmol (48%). CCDC NO. 1442012. Anal. Calcd (%) for C<sub>14</sub>H<sub>13</sub>Cl<sub>2</sub>FeN<sub>3</sub>OS: C, 42.24; H, 3.29; N, 10.56; O, 4.02; S, 8.05. Found: C, 42.21; H, 3.26; N, 10.59; O, 4.04; S, 8.06. IR, cm<sup>–1</sup>: 3248 (s, amide), 2986 (s), 2934 (m, aromatic hydrogen), 1592 (s), 1536 (s), 1507 (s), 1454 (s, aromatic), 1393 (s, C═N), 1362 (s, thioamide), 1241 (s), 1197 (s), 1165 (m), 976 (m, C–H), 830 (m, C═S), 749 (s). ESI<sup>+</sup><i>m</i>/<i>z</i>: calcd for C<sub>14</sub>H<sub>13</sub>Cl<sub>2</sub>FeN<sub>3</sub>OS, 396.06 [M – H].</div></div><div id="sec5_14" class="NLM_sec NLM_sec_level_3"><div id="ac_i32" class="anchor-spacer"></div><h4 class="article-section__title" id="_i32"> 2-Hydroxy-1-naphthaldehyde-4,4-diethylthiosemicarbazide-iron(III)-bischlorin (<b>11</b>)</h4><div class="NLM_p last">Yield: 0.39 mmol (39%). CCDC NO. 1442013. Anal. Calcd (%) for C<sub>16</sub>H<sub>17</sub>Cl<sub>2</sub>FeN<sub>3</sub>OS: C, 45.10; H, 4.02; N, 9.86; O, 3.75; S, 7.52. Found: C, 45.13; H, 4.04; N, 9.80; O, 3.71; S, 7.57. IR, cm<sup>–1</sup>: 3256 (s, amide), 3055 (s), 2974 (m, aromatic hydrogen), 1570 (s), 1507 (s), 1434 (s, aromatic), 1389 (s, C═N), 1353 (s, thioamide), 1197 (s), 1143 (s), 1086 (m), 975 (m, C–H), 827 (m, C═S), 746 (s). ESI<sup>+</sup><i>m</i>/<i>z</i>: calcd for C<sub>16</sub>H<sub>17</sub>Cl<sub>2</sub>FeN<sub>3</sub>OS, 424.09 [M – H].</div></div><div id="sec5_15" class="NLM_sec NLM_sec_level_3"><div id="ac_i33" class="anchor-spacer"></div><h4 class="article-section__title" id="_i33"> 2-Hydroxy-1-naphthaldehyde-3-piperidinethiosemicarbazide-iron(III)-bischlorin (<b>12</b>)</h4><div class="NLM_p last">Yield: 0.55 mmol (55%). CCDC NO. 1442014. Anal. Calcd (%) for C<sub>17</sub>H<sub>17</sub>Cl<sub>2</sub>FeN<sub>3</sub>OS: C, 46.60; H, 3.91; N, 9.59; O, 3.65; S, 7.32. Found: C, 46.56; H, 3.93; N, 9.57; O, 3.68; S, 7.33. IR, cm<sup>–1</sup>: 2924 (s, amide), 2807 (s), 2758 (m, aromatic hydrogen), 1595 (s), 1576 (s), 1536 (s), 1464 (s, aromatic), 1356 (s, C═N), 1319 (s, thioamide), 1243 (s), 1185 (s), 969 (m, C–H), 826 (m, C═S), 749 (s). ESI<sup>+</sup><i>m</i>/<i>z</i>: calcd for C<sub>17</sub>H<sub>17</sub>Cl<sub>2</sub>FeN<sub>3</sub>OS, 437.14 [M – H].</div></div></div><div id="sec5_16" class="NLM_sec NLM_sec_level_2"><div id="ac_i34" class="anchor-spacer"></div><h3 class="article-section__title" id="_i34"> Crystal Structures Determination of Fe Compounds</h3><div class="NLM_p last">X-ray crystallographic data were collected on a Bruker SMART Apex II CCD diffractometer using graphite-monochromated Mo–Kα (λ = 0.71073 Å) radiation. Empirical adsorption corrections were applied to all data using SADABS. Direct methods were used to solve the structures, and they were then refined against <i>F</i><sup>2</sup> by full-matrix least-squares methods using SHELXTL (version 5.1).<a onclick="showRef(event, 'ref55'); return false;" href="javascript:void(0);" class="ref ref55">(55)</a> All of the non-hydrogen atoms were refined anisotropically, while all of the other hydrogen atoms were placed in ideal geometric positions and constrained to ride on their parent atoms. The crystallographic data for compounds <b>7</b>–<b>12</b> are summarized in <a class="ref internalNav" href="#notes-1" aria-label="Table S1">Table S1</a>, and selected bond lengths and angles are given in <a class="ref internalNav" href="#notes-1" aria-label="Table S2">Table S2</a>. Crystallographic data for the structural analyses were deposited at the Cambridge Crystallographic Data Centre and assigned reference numbers 1442009–1442014. The crystallographic data can be obtained free of charge from the Cambridge Crystallographic Data Centre via <a href="http://www.ccdc.cam.ac.uk/data_request/cif" class="extLink">http://www.ccdc.cam.ac.uk/data_request/cif</a>.</div></div><div id="sec5_17" class="NLM_sec NLM_sec_level_2"><div id="ac_i35" class="anchor-spacer"></div><h3 class="article-section__title" id="_i35"> X-ray Crystallography of HSA Complex</h3><div class="NLM_p">Fatty acid (FA) free HSA was purified by removing HSA dimers and multimers as published.<a onclick="showRef(event, 'ref56'); return false;" href="javascript:void(0);" class="ref ref56">(56)</a> Palmitic acid (PA) was dissolved in alcohol and diluted to 2.5 mM with 20 mM potassium phosphate (pH 7.5). HSA complexes were prepared by mixing 100 μL of HSA (100 mg/mL), 380 μL of PA (2.5 mM), and 90 μL of each Fe compound (5 mM) overnight. Mixtures were then concentrated to 100 mg/mL with a Millipore spin filter (10 000 Da Cut-off). Crystallization was induced using the sitting drop vapor diffusion method at room temperature. An equal volume of the HSA complex was mixed with the reservoir solution, which contained 28–32% (w/v) polyethylene glycol 3350, 50 mM potassium phosphate (pH 7.5), 5% glycerol, and 4% DMSO. Crystals were directly selected from the drop solution and then frozen in liquid nitrogen.</div><div class="NLM_p">X-ray diffraction data were collected under Cryo-conditions (100 K) at BL17U beamline of Shanghai Synchrotron Radiation Facility and then integrated and scaled with HKL2000.<a onclick="showRef(event, 'ref57'); return false;" href="javascript:void(0);" class="ref ref57">(57)</a> The HSA complex structure were solved by molecular replacement using PHASER in PHENIX suites with initial model of HSA-MYR structure (PDB: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=1BJ5">1BJ5</a>), but stripped the ligand as initial searching model, all ligands were built into the model by LigandFit in PHENIX and manually modified and adjusted in COOT.<a onclick="showRef(event, 'ref56 ref58 ref59'); return false;" href="javascript:void(0);" class="ref ref56 ref58 ref59">(56, 58, 59)</a> The HSA structure was refined in PHENIX at resolution of 2.80 Å, with <i>R</i><sub>factor</sub> = 0.209 and <i>R</i><sub>free</sub> = 0.267. All residues located in favored or allowed region and no residues located in outlier region by Ramachandran plot in HSA structure; for the statistics of data collection and refinement, see <a class="ref internalNav" href="#tbl3" aria-label="Table 3">Table 3</a>. Structure superimposition were done by Chimera (<a href="http://www.cgl.ucsf.edu/chimera" class="extLink">http://www.cgl.ucsf.edu/chimera</a>) and all crystallographic figure were drawn by Pymol (<a href="http://www.pymol.org" class="extLink">http://www.pymol.org</a>).<a onclick="showRef(event, 'ref60'); return false;" href="javascript:void(0);" class="ref ref60">(60)</a></div><div class="NLM_table-wrap" id="tbl3"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 3. Data Collection and Refinement Statistics of HSA Complex</div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center">HSA-PA-<b>12</b></th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" colspan="2" align="left">Data Collection</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">space group</td><td class="colsep0 rowsep0" align="left"><i>P</i>1</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">cell dimensions</td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><i>a</i>, <i>b</i>, <i>c</i> (Å)</td><td class="colsep0 rowsep0" align="left">38.47, 94.55, 96.11</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">α, β, γ (deg)</td><td class="colsep0 rowsep0" align="left">104.90, 89.90, 100.86</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">wavelength (Å)</td><td class="colsep0 rowsep0" align="left">1.0</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">resolution (Å)<a class="ref internalNav" href="#t3fn1" aria-label="a">a</a></td><td class="colsep0 rowsep0" align="left">27.13–2.80 (2.90–2.80)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><i>R</i><sub>merge</sub><a class="ref internalNav" href="#t3fn2" aria-label="b">b</a></td><td class="colsep0 rowsep0" align="left">6.9% (24.1%)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><i>I</i>/σ<i>I</i></td><td class="colsep0 rowsep0" align="left">13.6 (4.3)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">completeness (%)</td><td class="colsep0 rowsep0" align="left">96% (96.8%)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">redundancy</td><td class="colsep0 rowsep0" align="left">4.2</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" colspan="2" align="left">Refinement</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">resolution (Å)</td><td class="colsep0 rowsep0" align="left">27.13–2.80</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">no. reflections</td><td class="colsep0 rowsep0" align="left">30491 (2968)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><i>R</i><sub>work</sub>/<i>R</i><sub>free</sub><a class="ref internalNav" href="#t3fn3" aria-label="c">c</a>,<a class="ref internalNav" href="#t3fn4" aria-label="d">d</a></td><td class="colsep0 rowsep0" align="left">0.209/0.267</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">no. of non-H atoms</td><td class="colsep0 rowsep0" align="left">9462</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">protein</td><td class="colsep0 rowsep0" align="left">9212</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">ligand</td><td class="colsep0 rowsep0" align="left">248</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">average <i>B,</i> all atoms (Å<sup>2</sup>)</td><td class="colsep0 rowsep0" align="left">66.41</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">protein</td><td class="colsep0 rowsep0" align="left">66.30</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">ligands</td><td class="colsep0 rowsep0" align="left">70.70</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">r.m.s. deviations</td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">bond lengths (Å)</td><td class="colsep0 rowsep0" align="left">0.019</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">bond angles (deg)</td><td class="colsep0 rowsep0" align="left">1.33</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t3fn1"><div class="footnote" id="t3fn1"><sup>a</sup><p class="last">Values for the outermost resolution shell are given in parentheses.</p></div><div class="footnote" id="t3fn2"><sup>b</sup><p class="last"><i>R</i><sub>merge</sub> = 100 × Σ<sub>h</sub>Σ<sub>j</sub>|I<sub>hj</sub> – I<sub>h</sub>|/Σ<sub>h</sub>Σ<sub>j</sub>I<sub>hj</sub>, where <i>I</i><sub>h</sub> is the weighted mean intensity of the symmetry-related refractions <i>I</i><sub>hj</sub>.</p></div><div class="footnote" id="t3fn3"><sup>c</sup><p class="last"><i>R</i><sub>work</sub> = 100 × Σ<sub>hkl</sub>|F<sub>obs</sub> – <i>F</i><sub>calc</sub>|/Σ<sub>hkl</sub><i>F</i><sub>obs</sub>, where <i>F</i><sub>obs</sub> and <i>F</i><sub>calc</sub> are the observed and calculated structure factors, respectively.</p></div><div class="footnote" id="t3fn4"><sup>d</sup><p class="last"><i>R</i><sub>free</sub> is the <i>R</i><sub>work</sub> calculated using a randomly selected 5% sample of reflection data omitted from the refinement.</p></div></div></div></div><div id="sec5_17_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i37" class="anchor-spacer"></div><h3 class="article-section__title" id="_i37"> <i>In Vitro</i> Anticancer Activity</h3><div id="sec5_18" class="NLM_sec NLM_sec_level_3"><div id="ac_i38" class="anchor-spacer"></div><h4 class="article-section__title" id="_i38"> Cell Culture</h4><div class="NLM_p last">Culture medium DMEM (with <span class="smallcaps smallerCapital">l</span>-glutamin), fetal bovine serum (FBS), phosphate buffered saline (PBS, pH = 7.2), and Antibiotice-Antimycotic came from E.U. Gibco BRL. Human hepatocellular cell line Bel-7402 and normal liver cells HL-7702 were purchased from the American Type Culture Collection and the German Collection of Microorganisms and Cell Cultures and maintained in DMEM supplemented with 10% FBS, 50 U/mL of penicillin, and 50 mg/mL of streptomycin at 37 °C and 5% CO<sub>2</sub>.</div></div><div id="sec5_19" class="NLM_sec NLM_sec_level_3"><div id="ac_i39" class="anchor-spacer"></div><h4 class="article-section__title" id="_i39"> Cytotoxicity Assay (MTT)</h4><div class="NLM_p last">One hundred microliters of cell suspension at a density of 5 × 10<sup>4</sup> cells/mL was seeded in 96-well plates and incubated for 24 h at 37 °C in 5% CO<sub>2</sub>. Complexes at various concentrations were then added to the test well. The resultant cell mixture was incubated at 37 °C in a 5% CO<sub>2</sub> atmosphere for 48 h. An enzyme labeling instrument was used to read absorbance with 570/630 nm double wavelength measurement. Cytotoxicity was determined based on the percentage of cell survival compared with the negative control. The final IC<sub>50</sub> values were calculated by the Bliss method (<i>n</i> = 5). All of the tests were repeated in triplicate.</div></div></div><div id="sec5_19_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i40" class="anchor-spacer"></div><h3 class="article-section__title" id="_i40"> <i>In Vivo</i> Animal Studies</h3><div id="sec5_20" class="NLM_sec NLM_sec_level_3"><div id="ac_i41" class="anchor-spacer"></div><h4 class="article-section__title" id="_i41"> Animal Subject and Tumor Models</h4><div class="NLM_p last">Athymic nude mice were obtained from Beijing HFK Bioscience Co., Ltd., and used in the study at 6 weeks of age. All animal experiments were carried out in compliance with the Animal Management Rules of the People’s Republic of China’s Ministry of Health (document no. 55, 2001) and under the guidelines of the University of Jinan Ethics Committee’s Care and Use of Animals. Athymic nude mice were obtained from Beijing HFK Bioscience Co., Ltd. and used in the study at 6 weeks of age. We dissolved the complexes in DMSO solution as mother liquid mixture (10 mM) and then diluted by NaCl solution to the required concentration in vivo experiments.</div></div><div id="sec5_21" class="NLM_sec NLM_sec_level_3"><div id="ac_i42" class="anchor-spacer"></div><h4 class="article-section__title" id="_i42"> Acute Toxicity Study</h4><div class="NLM_p last">The acute toxicity of compound <b>12</b> and HSA-<b>12</b> complex were assessed on normal mice using the method previously described.<a onclick="showRef(event, 'ref61'); return false;" href="javascript:void(0);" class="ref ref61">(61)</a> Briefly, 32 healthy Kunming mice (aged 3–4 weeks and weighing 18–22 g with an equal number of female and male subjects) were divided into four groups, with eight mice in each group. Compound <b>12</b> and HSA-<b>12</b> complex were administrated into the different groups of mice at doses of 25 μmol Fe/kg body weight. NaCl was injected into the control group. Blood samples from each group of mice were drawn 3 days after intravenous (IV) injection to prepare the serum samples. The serum biochemical parameters of the blood samples were determined: aspartate aminotransferase (AST), alanine aminotransferase (ALT), creatinine kinase (CK), and blood urea nitrogen (BUN). Finally, the major organs heart, liver, and kidney were sectioned for histopathological analysis using hematoxylin and eosin (H&E) staining.</div></div><div id="sec5_22" class="NLM_sec NLM_sec_level_3"><div id="ac_i43" class="anchor-spacer"></div><h4 class="article-section__title" id="_i43"> <i>In Vivo</i> Antitumor Activity Study</h4><div class="NLM_p last">The nude mice were subcutaneously injected in the right flank with 200 μL of cell suspension containing 4 × 10<sup>6</sup> Bel-7402 cells. When the tumor volume was approximately 100 mm<sup>3</sup> for the study, the Bel-7402 tumor-bearing mice were randomly divided into three groups, and mice in different treatment groups were intravenously injected with NaCl, compound <b>12</b><sub>,</sub> and HSA-<b>12</b> complex at doses of 2.5 μmol Fe/kg body weight every 2 days. Each mouse of different group was earmarked and followed individually throughout the whole experiments. The width and length of the tumor and the body weight of mice were measured before every injection until the end of the experiment. Volume was determined using the following equation: tumor volume (<i>V</i>) = 1/2 × length × width<sup>2</sup>. Mice were killed after 28 days of treatment, and tumor tissues and major organs were excised for histopathological analysis with H&E staining.</div></div></div><div id="sec5_23" class="NLM_sec NLM_sec_level_2"><div id="ac_i44" class="anchor-spacer"></div><h3 class="article-section__title" id="_i44"> Hematoxylin and Eosin (H&E) Staining</h3><div class="NLM_p last">Tumor samples were given a routine histopathological examination using standard H&E staining. Small pieces were collected in 4% paraformaldehyde for proper fixation, and they were then processed and embedded in paraffin wax. Sections were cut and stained with hematoxylin and eosin, and samples were then observed under light microscope using an Eclipse E800 Nikon (Nikon, Tokyo, Japan). Representative images were shown. Quantitative analysis of eosin stained areas in treated tumors expressed as relative amount compared to eosin necrotic area of untreated tumors (±SD) were assessed by area counting of three fields for each of five slides per each sample at ×10 magnification by Image–ProPlus software (Immaginie Computer, Milan, Italy).</div></div><div id="sec5_24" class="NLM_sec NLM_sec_level_2"><div id="ac_i45" class="anchor-spacer"></div><h3 class="article-section__title" id="_i45"> Tunel Assay</h3><div class="NLM_p last">The apoptotic cell death was assayed using <i>in situ</i> detection of DNA fragmentation with the terminal deoxynucleotidyl-transferase (TUNEL) assay. Paraffin liver cancer tissue sections (5 μm) were warmed for 30 min (64 °C), deparaffinized, and rehydrated. Terminal transferase mediated dUTP nick end-labeling of nuclei was performed using the APO-BrdU TUNEL Assay kit (A-23210; Molecular Probes, Eugene, OR) following the manufacturer’s protocol. Samples were then observed under fluorescence microscopy using an Eclipse E800 Nikon (Nikon, Tokyo, Japan). Representative images were shown. Quantitative analysis of TUNEL positive areas expressed as relative amount of treated area compared to untreated ones were assessed by area counting of three fields for each of five slides per each sample at ×60 magnification by Image–ProPlus software (Immagini e Computer, Milan, Italy).</div></div><div id="sec5_25" class="NLM_sec NLM_sec_level_2"><div id="ac_i46" class="anchor-spacer"></div><h3 class="article-section__title" id="_i46"> <i>In Vivo</i> Targeting Ability Study</h3><div class="NLM_p last">At the end of the <i>in vivo</i> experiment, the mice tumors were homogenized, and then 0.5 g of the sample was placed in Teflon containers and mineralized in 1 mL of 30% hydrogen peroxide and in 7 mL of concentrated HNO<sub>3</sub> in a microwave apparatus (Milestone MSL 1200) under pressure. The presence of Fe in the mice tumors was determined using inductively coupled plasma atomic emission spectrometry (ICP-AES).</div></div><div id="sec5_26" class="NLM_sec NLM_sec_level_2"><div id="ac_i47" class="anchor-spacer"></div><h3 class="article-section__title" id="_i47"> Fe Prodrug Release from HSA</h3><div class="NLM_p last">The Fe(III) compound release from HSA complex was studied by dialyzing HSA complex at pH 4.7 and pH 7.5 buffers to simulate cell matrix and interstitial space environment, respectively. Briefly, 2 mL of HSA complex in dialysis pocket were dispersed in tube containing 20 mL of pH 4.7 and pH 7.5 buffers, respectively. To investigate release behavior at different time interval, we prepared seven tubes for each pH value. The amount of Fe(III) compound released from the HSA complex was determined by graphite furnace atomic absorption spectrometer (AAS).</div></div><div id="sec5_26_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i48" class="anchor-spacer"></div><h3 class="article-section__title" id="_i48"> Determining the Possible Mechanism of HSA-<b>12</b> Complex Absorbed by Cells</h3><div class="NLM_p last">Bel-7402 cells were cultured in 70 mm culture dishes, grown to 70% confluence, and incubated with 0, 1, or 2 μM methyl-β-cyclodextrin for 1 h at 37 °C, respectively. After 1 h, the cells were treated with 2 μM of HSA-Cu(Bp44 mT) for another 4 h at 37 °C. The cells were then harvested in lysis buffer. After sonication, the samples were centrifuged for 20 min at 13,000<i>g</i>. The protein concentration of the supernatant was determined by BCA (Beyotime Institute of Biotechnology, China) assay. The presence of Fe in the mice tumors was determined using inductively coupled plasma atomic emission spectrometry (ICP-AES). Sodium dodecyl sulfate–polyacrylamide gel electrophoresis was performed by loading equal amount of proteins per lane. Gels were then transferred to poly(vinylidene difluoride) membranes (Millipore) and blocked with 5% nonfat milk in TBST (20 mM Tris-HCl, 150 mM NaCl, and 0.05% Tween 20, pH 8.0) buffer for 1 h. The membranes were incubated with primary antibodies at 1:5000 and diluted in 5% nonfat milk overnight at 4 °C, and after being washed four times with TBST for a total of 30 min, the secondary antibodies were conjugated with horseradish peroxidase at 1:5000 dilution for 1 h at room temperature and washed four times with TBST. The blots were visualized with the Amersham ECL Plus Western blotting detection reagents according to the manufacturer’s instructions. The membranes were stripped to detect the β-actin in order to assess the presence of comparable amount of proteins in each lane.</div></div><div id="sec5_26_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i49" class="anchor-spacer"></div><h3 class="article-section__title" id="_i49"> Determining the Potential Anticancer Mechanistic of Compound <b>12</b>/HSA-<b>12</b> Complex</h3><div id="sec5_27" class="NLM_sec NLM_sec_level_3"><div id="ac_i50" class="anchor-spacer"></div><h4 class="article-section__title" id="_i50"> Topoisomerase IIα Inhibition Assay</h4><div class="NLM_p last">The human Topo IIα kit was purchased from TopoGEN, and Topo IIα activity was measured by the pBR322 DNA relaxation assay following the protocol provided by the manufacturer. Briefly, 20 μL of the reaction mixture was prepared, which contained 0.2 μg (6 μL) of supercoiled pBR322 plasmid DNA, varying amounts of the ferric complex (5 μL), relaxation buffer (4 μL containing 50 mM Tris-HCl (pH 8.0), 150 mM NaCl, 10 mM MgCl<sub>2</sub>, 0.5 mM ATP, and 0.5 mM dithiothreitol), and 1 unit of Topo IIα (5 μL). Reaction mixtures were incubated for 30 min in the kinetic experiments as indicated at 37 °C. The reaction mixtures were quenched by adding the stopping buffer (5% sarkosyl, 0.125% bromophenol blue, and 25% glycerol) and loaded on a 1% agarose gel in TBE buffer (45 mM Tris base, 45 mM boric acid, and 1 mM EDTA) and electrophoresed for 3 h at 80 V. The gel was then stained (1 μg/mL) for 30 min and subsequently destained for 30 min (milli-Q water). The gels were photographed and analyzed using BioRad Gel Doc XR software. The Topo IIα inhibition percentage was obtained from the ratio of supercoiled DNA to the total DNA in each well. Nonhomogeneous backgrounds led to a large error of ±10% of the reported values in quantification.</div></div></div><div id="sec5_28" class="NLM_sec NLM_sec_level_2"><div id="ac_i51" class="anchor-spacer"></div><h3 class="article-section__title" id="_i51"> Cell Cycle Distribution Analysis</h3><div class="NLM_p last">Bel-7402 cells were cultured in 70 mm culture dishes, grown to 70% confluence, and treated with a determined concentration of compound <b>12</b> (1 μM) or HSA-<b>12</b> complex (1 μM). FACS analysis was performed after 24 h of treatment as described. To prepare for cell cycle analysis, the washed cells were fixed with 75% ethanol, washed with PBS, stained with PI, and then analyzed by flow cytometry using a 488 nm laser (FACScan, Becton Dickinson, San Jose, CA). For each sample, 10,000 events were recorded.</div></div><div id="sec5_29" class="NLM_sec NLM_sec_level_2"><div id="ac_i52" class="anchor-spacer"></div><h3 class="article-section__title" id="_i52"> Intracellular Reactive Oxygen Species (ROS) Measurements</h3><div class="NLM_p last">Intracellular ROS generation was determined using 2′,7′-dichlorodihydro-fluorescein diacetate (H<sub>2</sub>DCF-DA) (Beyotime Institute of Biotechnology, Haimen, China). Bel-7402 cells (1 × 10<sup>5</sup> cells/well) were incubated with 1 μM of compound <b>6</b>, compound <b>12</b>, HSA-<b>12</b> complex, or FeCl<sub>3</sub> for 24 h at 37 °C. Cells were then collected for flow cytometric assessment. The fluorescence intensity was monitored with excitation wavelength at 488 nm and emission wavelength at 525 nm.</div></div><div id="sec5_30" class="NLM_sec NLM_sec_level_2"><div id="ac_i53" class="anchor-spacer"></div><h3 class="article-section__title" id="_i53"> Cyclic Voltammetry</h3><div class="NLM_p last">Cyclic voltammetry was performed with a BAS100B/W potentiostat. A glassy carbon working electrode, an aqueous Ag/AgCl reference electrode, and a Pt wire auxiliary electrode were used. All complexes were at ∼1 mMin MeCN/H<sub>2</sub>O (7:3 v/v); this solvent combination was used to ensure the solubility of all compounds. The supporting electrolyte was Et<sub>4</sub>NClO<sub>4</sub> (0.1 M), and the solutions were purged with nitrogen prior to measurement. All potentials are cited versus the normal hydrogen electrode (NHE) by adding 196 mV to the potentials measured relative to the Ag/AgCl reference.</div></div><div id="sec5_31" class="NLM_sec NLM_sec_level_2"><div id="ac_i54" class="anchor-spacer"></div><h3 class="article-section__title" id="_i54"> Change of Mitochondrial Membrane Potential Assay</h3><div class="NLM_p last">Mitochondrial membrane potential was analyzed with a fluorescent dye JC-1 (Beyotime Jiangsu China). Bel-7402 cells were treated with 1 μM compound <b>6</b>, compound <b>12</b>, HSA-<b>12</b> complex, or FeCl<sub>3</sub> in 6-well plates, and PBS was used as a control. Cells were then harvested after 24 h of incubation and stained with 1 mL of JC-1 (10 μg/mL) stock solution. Assays were initiated by incubating BeL-7402 cells with JC-1 for 20 min at 37 °C in the dark, and the fluorescence of separated cells was detected with a flow cytometer (FACScan, Bection Dickinson, San Jose, CA).</div></div><div id="sec5_32" class="NLM_sec NLM_sec_level_2"><div id="ac_i55" class="anchor-spacer"></div><h3 class="article-section__title" id="_i55"> Western Blot Analysis</h3><div class="NLM_p last">BEL-7404 cells were seeded in 10 cm dishes for 24 h and incubated with 5 μM compound <b>12</b> and HSA-<b>12</b> complex in the presence of 10% FBS. Cells were then harvested in lysis buffer. After sonication, the samples were centrifuged for 20 min at 13,000<i>g</i>. The protein concentration of the supernatant was determined by BCA (Beyotime Institute of Biotechnology, China) assay. Sodium dodecyl sulfate–polyacrylamide gel electrophoresis was performed by loading equal amount of proteins per lane. Gels were then transferred to poly(vinylidene difluoride) membranes (Millipore) and blocked with 5% nonfat milk in TBST (20 mM Tris-HCl, 150 mM NaCl, and 0.05% Tween 20, pH 8.0) buffer for 1 h. The membranes were then incubated with primary antibodies at a dilution rate of 1:5000 in 5% nonfat milk overnight at 4 °C. After being washed four times with TBST for a total of 30 min, the secondary antibodies were conjugated with horseradish peroxidase at a dilution rate of 1:5000 for 1 h at room temperature and then washed four times with TBST. The blots were visualized with Amersham’s ECL Plus Western blotting detection reagents according to the manufacturer’s instructions. To determine the presence of comparable amount of proteins in each lane, the membranes were stripped to detect the β-actin.</div></div><div id="sec5_33" class="NLM_sec NLM_sec_level_2"><div id="ac_i56" class="anchor-spacer"></div><h3 class="article-section__title" id="_i56"> Apoptosis by Flow Cytometry</h3><div class="NLM_p last">The apoptotic events induced by compound <b>12</b> (1 μM) or HSA-<b>12</b> complex (1 μM) were determined with annexin V staining and PI according to the manufacturer’s protocol for the Annexin V-FITC Apoptosis Detection Kit (Abcam). For these analyses, we used 1 × 10<sup>5</sup> cells/mL, which were incubated at 5% CO<sub>2</sub> and 37 °C with the compound <b>12</b> (1 μM) or HSA-<b>12</b> complex (1 μM) for 12 h. The BeL-7402 cells were resuspended in 100 μL of 1× annexin V-binding buffer (10 mM Hepes/NaOH, 140 mM NaCl, and 2.5 mM CaCl<sub>2</sub>, pH 7.4), and 5 μL each of annexin V and PI were added to each sample. Next, we incubated the cells for 15 min at room temperature and then subjected them to flow cytometric analysis (FACScan, Bection Dickinson, San Jose, CA). The rate of cell apoptosis was then analyzed.</div></div><div id="sec5_34" class="NLM_sec NLM_sec_level_2"><div id="ac_i57" class="anchor-spacer"></div><h3 class="article-section__title" id="_i57"> Statistical Analysis</h3><div class="NLM_p last">All experiments were repeated between 3 and 5three and five times. Student’s test was applied to evaluate the significance of the differences that were measured. Results are expressed as mean ± SD and considered to be significant when <i>P</i> < 0.05.</div></div></div><div class="NLM_back"><div class="article_supporting-info" id="notes-1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i58"><a href="/doi/suppl/10.1021/acs.jmedchem.6b00509">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_22544" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_22544" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge on the <a href="/" class="ext-link">ACS Publications website</a> at DOI: <a href="/doi/abs/10.1021/acs.jmedchem.6b00509" class="ext-link">10.1021/acs.jmedchem.6b00509</a>.<ul class="NLM_list-list_type-label" id="silist"><li><p class="inline">Determination of binding affinity of HSA for Fe compounds, MALDI-TOF-MS analyses, crystal data for Fe compounds, and selected bond lengths and angles for Fe compounds (<a href="/doi/suppl/10.1021/acs.jmedchem.6b00509/suppl_file/jm6b00509_si_001.pdf" class="ext-link">PDF</a>)</p></li><li><p class="inline">SMILES (<a href="/doi/suppl/10.1021/acs.jmedchem.6b00509/suppl_file/jm6b00509_si_002.csv" class="ext-link">CSV</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.6b00509/suppl_file/jm6b00509_si_001.pdf">jm6b00509_si_001.pdf (360.36 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.6b00509/suppl_file/jm6b00509_si_002.csv">jm6b00509_si_002.csv (0.77 kb)</a></li></ul></div></div></div><span class="author-information-subsection-header">Accession Codes</span><p class="last">PDB code: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5GIX">5GIX</a>, HSA-PA-<b>12</b> complex.</p><div class="testing" data-doi="10.1021/acs.jmedchem.6b00509" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="TermsAndConditionsDropzone3" data-pb-dropzone="TermsAndConditionsDropzone3"><div data-widget-def="UX3HTMLWidget" data-widget-id="85b54935-30e9-4058-a6d2-0b40fb754a85" class="mb-4">
        



        
            <h2 class="">
                Terms & Conditions
            </h2>
        
        <p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system: <a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_42613" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_42613" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Tao Wang</span> - <span class="hlFld-Affiliation affiliation">Department
of Biology, Southern University of Science
and Technology, Shenzhen, Guangdong 518055, China</span>; 
    <span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#0473656a6370656b4477717770672a6160712a676a"><span class="__cf_email__" data-cfemail="bacddbd4ddcedbd5fac9cfc9ced994dfdecf94d9d4">[email protected]</span></a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Wei Zhang</span> - <span class="hlFld-Affiliation affiliation">School
of Pharmacy, Nantong University, Nantong, Jiangsu 226019, China</span>; 
    <span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#4e34262f2029390e203a3b602b2a3b602d20"><span class="__cf_email__" data-cfemail="760c1e171811013618020358131203581518">[email protected]</span></a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Feng Yang</span> - <span class="hlFld-Affiliation affiliation">School
of Pharmacy, Nantong University, Nantong, Jiangsu 226019, China</span>; 
    <span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#d2b4abb3bcb592bfb3bbbeb0bdaafcb5aabca7fcb7b6a7fcb1bc"><span class="__cf_email__" data-cfemail="b8dec1d9d6dff8d5d9d1d4dad7c096dfc0d6cd96dddccd96dbd6">[email protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jinxu Qi</span> - <span class="hlFld-Affiliation affiliation">School
of Pharmacy, Nantong University, Nantong, Jiangsu 226019, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Yi Gou</span> - <span class="hlFld-Affiliation affiliation">School
of Pharmacy, Nantong University, Nantong, Jiangsu 226019, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Yao Zhang</span> - <span class="hlFld-Affiliation affiliation">School
of Pharmacy, Nantong University, Nantong, Jiangsu 226019, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Kun Yang</span> - <span class="hlFld-Affiliation affiliation">School
of Pharmacy, Nantong University, Nantong, Jiangsu 226019, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Shifang Chen</span> - <span class="hlFld-Affiliation affiliation">School
of Pharmacy, Nantong University, Nantong, Jiangsu 226019, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Li Liu</span> - <span class="hlFld-Affiliation affiliation">Department
of Biology, Southern University of Science
and Technology, Shenzhen, Guangdong 518055, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Xiaoyang Wu</span> - <span class="hlFld-Affiliation affiliation">Ben
May Department for Cancer Research, University
of Chicago, Chicago, Illinois 60637, United
States</span></div></li></ul></li><li></li><li></li><li><span class="author-information-subsection-header">Notes</span><div class="authorInformation_notesSection">The authors declare no competing financial interest.<br /></br></div></li></ul></div><div class="ack" id="ACK-d123e3193-autogenerated"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i60">Acknowledgment</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_88205" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_88205" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">We are grateful to staff of Shanghai Synchrotron Radiation Facility for their technical assistance in data collection. This work was supported by the Natural Science Foundation of China (31460232, 31300600), the Natural Science Foundation of Guangxi (2014GXNSFDA118016), the National Key Basic Research Program of China (2013CB911501).</p></div><div id="" class="NLM_sec NLM_sec_level_1"><div id="ac_i61" class="anchor-spacer"></div><h2 class="article-section__title section__title" id="_i61"> </h2><div class="NLM_p last"><table summary="" class="NLM_def-list" id="dl1"><div id="ac_i62" class="anchor-spacer"></div><h2 class="article-section__title section__title" id="_i62"> ABBREVIATIONS USED</h2><tr><td class="NLM_term">BPS</td><td class="NLM_def"><p class="first last">bathophenanthrolinedisulfonate</p></td></tr><tr><td class="NLM_term">DMSO</td><td class="NLM_def"><p class="first last">dimethyl sulfoxide</p></td></tr><tr><td class="NLM_term">DFO</td><td class="NLM_def"><p class="first last">desferrioxamine</p></td></tr><tr><td class="NLM_term">3-AP</td><td class="NLM_def"><p class="first last">3-aminopyridine-2-carboxaldehyde thiosemicarbazone</p></td></tr><tr><td class="NLM_term">311</td><td class="NLM_def"><p class="first last">2-hydroxy-1-naphthaldehyde isoniazid</p></td></tr><tr><td class="NLM_term">SD</td><td class="NLM_def"><p class="first last">standard deviation</p></td></tr><tr><td class="NLM_term">PI</td><td class="NLM_def"><p class="first last">propidium iodide</p></td></tr></table></div></div><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i63">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_18141" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_18141" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 61 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span><span class="NLM_contrib-group">Lainé, A. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Passirani, C.</span><span> </span><span class="NLM_article-title">Novel metal-based anticancer drugs: a new challenge in drug delivery</span> <span class="citation_source-journal">Curr. Opin. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">12</span><span class="NLM_x">, </span> <span class="NLM_fpage">420</span><span class="NLM_x">–</span> <span class="NLM_lpage">426</span><span class="refDoi"> DOI: 10.1016/j.coph.2012.04.006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00509&amp;key=10.1016%2Fj.coph.2012.04.006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00509&amp;key=22609113" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00509&amp;key=1%3ACAS%3A528%3ADC%252BC38XntlSrtLo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2012&pages=420-426&author=A.+L.+Lain%C3%A9author=C.+Passirani&title=Novel+metal-based+anticancer+drugs%3A+a+new+challenge+in+drug+delivery&doi=10.1016%2Fj.coph.2012.04.006"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Novel metal-based anticancer drugs: a new challenge in drug delivery</span></div><div class="casAuthors">Laine, Anne-Laure; Passirani, Catherine</div><div class="citationInfo"><span class="NLM_cas:title">Current Opinion in Pharmacology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">420-426</span>CODEN:
                <span class="NLM_cas:coden">COPUBK</span>;
        ISSN:<span class="NLM_cas:issn">1471-4892</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  Since the serependitous discovery of the cisplatin antiproliferative activity, many efforts have focused on the design of potent metal-based drugs for oncol. therapies.  A large no. of these complexes were evaluated in vitro and in vivo and some have reached clin. trials.  However, while metallodrug chem. has developed to an advanced level, these emerging therapeutics have encountered new hurdles including poor water soly. and pharmacol. deficiencies.  Today, solns. to overcome these issues do not lie in synthesizing new anticancer drugs but in finding suitable drug delivery strategies.  Over the past decades, various delivery systems were developed including prodrug, ligand design and nanocarriers aimed at enhancing the performance profile of these novel metallodrugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo0rPnLyzMlFrVg90H21EOLACvtfcHk0lhuUI6pJPtFDg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XntlSrtLo%253D&md5=6f7b911a7cdf6d20980badfd5aa94c8c</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1016%2Fj.coph.2012.04.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.coph.2012.04.006%26sid%3Dliteratum%253Aachs%26aulast%3DLain%25C3%25A9%26aufirst%3DA.%2BL.%26aulast%3DPassirani%26aufirst%3DC.%26atitle%3DNovel%2520metal-based%2520anticancer%2520drugs%253A%2520a%2520new%2520challenge%2520in%2520drug%2520delivery%26jtitle%3DCurr.%2520Opin.%2520Pharmacol.%26date%3D2012%26volume%3D12%26spage%3D420%26epage%3D426%26doi%3D10.1016%2Fj.coph.2012.04.006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span><span class="NLM_contrib-group">Yang, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liang, H.</span><span> </span><span class="NLM_article-title">HSA IIA subdomain-based developing anticancer metal prodrug: a new and improved approach</span> <span class="citation_source-journal">Future Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">8</span><span class="NLM_x">, </span> <span class="NLM_fpage">89</span><span class="NLM_x">–</span> <span class="NLM_lpage">91</span><span class="refDoi"> DOI: 10.4155/fmc.15.179</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00509&amp;key=10.4155%2Ffmc.15.179" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00509&amp;key=26824398" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00509&amp;key=1%3ACAS%3A528%3ADC%252BC28Xit1Wms7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2016&pages=89-91&author=F.+Yangauthor=H.+Liang&title=HSA+IIA+subdomain-based+developing+anticancer+metal+prodrug%3A+a+new+and+improved+approach&doi=10.4155%2Ffmc.15.179"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">HSA IIA subdomain-based developing anticancer metal prodrug: a new and improved approach</span></div><div class="casAuthors">Yang, Feng; Liang, Hong</div><div class="citationInfo"><span class="NLM_cas:title">Future Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">89-91</span>CODEN:
                <span class="NLM_cas:coden">FMCUA7</span>;
        ISSN:<span class="NLM_cas:issn">1756-8919</span>.
    
            (<span class="NLM_cas:orgname">Future Science Ltd.</span>)
        </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo_zsI4PaxkdbVg90H21EOLACvtfcHk0lhaA86UKieBAA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xit1Wms7g%253D&md5=b36af3e0527593991e3665bdd5fdc128</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.4155%2Ffmc.15.179&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4155%252Ffmc.15.179%26sid%3Dliteratum%253Aachs%26aulast%3DYang%26aufirst%3DF.%26aulast%3DLiang%26aufirst%3DH.%26atitle%3DHSA%2520IIA%2520subdomain-based%2520developing%2520anticancer%2520metal%2520prodrug%253A%2520a%2520new%2520and%2520improved%2520approach%26jtitle%3DFuture%2520Med.%2520Chem.%26date%3D2016%26volume%3D8%26spage%3D89%26epage%3D91%26doi%3D10.4155%2Ffmc.15.179" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group">Jansson, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sharpe, P. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bernhardt, P. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Richardson, D. R.</span><span> </span><span class="NLM_article-title">Novel Thiosemicarbazones of the ApT and DpT series and their copper complexes: identification of pronounced redox activity and characterization of their antitumor activity</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">53</span><span class="NLM_x">, </span> <span class="NLM_fpage">5759</span><span class="NLM_x">–</span> <span class="NLM_lpage">5769</span><span class="refDoi"> DOI: 10.1021/jm100561b</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm100561b" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00509&amp;key=1%3ACAS%3A528%3ADC%252BC3cXotlSnsr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2010&pages=5759-5769&author=P.+J.+Janssonauthor=P.+C.+Sharpeauthor=P.+V.+Bernhardtauthor=D.+R.+Richardson&title=Novel+Thiosemicarbazones+of+the+ApT+and+DpT+series+and+their+copper+complexes%3A+identification+of+pronounced+redox+activity+and+characterization+of+their+antitumor+activity&doi=10.1021%2Fjm100561b"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Novel Thiosemicarbazones of the ApT and DpT Series and Their Copper Complexes: Identification of Pronounced Redox Activity and Characterization of Their Antitumor Activity</span></div><div class="casAuthors">Jansson, Patric J.; Sharpe, Philip C.; Bernhardt, Paul V.; Richardson, Des R.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">5759-5769</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The novel chelators 2-acetylpyridine-4,4-dimethyl-3-thiosemicarbazone (HAp44mT) and di-2-pyridylketone-4,4-dimethyl-3-thiosemicarbazone (HDp44mT) have been examd. to elucidate the structure-activity relationships necessary to form copper (Cu) complexes with pronounced antitumor activity.  Electrochem. studies demonstrated that the Cu complexes of these ligands had lower redox potentials than their iron complexes.  Moreover, the Cu complexes where the ligand/metal ratio was 1:1 rather than 2:1 had significantly higher intracellular oxidative properties and antitumor efficacy.  Interestingly, the 2:1 complex was shown to dissoc. to give significant amts. of the 1:1 complex that could be the major cytotoxic effector.  Both types of Cu complex showed significantly more antiproliferative activity than the ligand alone.  We also demonstrate the importance of the inductive effects of substituents on the carbonyl group of the parent ketone, which influence the CuII/I redox potentials because of their proximity to the metal center.  The structure-activity relationships described are important for the design of potent thiosemicarbazone Cu complexes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqhryQ9dAB5CLVg90H21EOLACvtfcHk0lhaA86UKieBAA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXotlSnsr4%253D&md5=7417f8c18eed7edddd542da369ecb5ab</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1021%2Fjm100561b&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm100561b%26sid%3Dliteratum%253Aachs%26aulast%3DJansson%26aufirst%3DP.%2BJ.%26aulast%3DSharpe%26aufirst%3DP.%2BC.%26aulast%3DBernhardt%26aufirst%3DP.%2BV.%26aulast%3DRichardson%26aufirst%3DD.%2BR.%26atitle%3DNovel%2520Thiosemicarbazones%2520of%2520the%2520ApT%2520and%2520DpT%2520series%2520and%2520their%2520copper%2520complexes%253A%2520identification%2520of%2520pronounced%2520redox%2520activity%2520and%2520characterization%2520of%2520their%2520antitumor%2520activity%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2010%26volume%3D53%26spage%3D5759%26epage%3D5769%26doi%3D10.1021%2Fjm100561b" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group">Qi, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liang, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gou, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhou, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liang, H.</span><span> </span><span class="NLM_article-title">Synthesis of four binuclear copper(II) complexes: structure, anticancer properties and anticancer mechanism</span> <span class="citation_source-journal">Eur. J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">96</span><span class="NLM_x">, </span> <span class="NLM_fpage">360</span><span class="NLM_x">–</span> <span class="NLM_lpage">368</span><span class="refDoi"> DOI: 10.1016/j.ejmech.2015.04.031</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00509&amp;key=10.1016%2Fj.ejmech.2015.04.031" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=96&publication_year=2015&pages=360-368&author=J.+Qiauthor=S.+Liangauthor=Y.+Gouauthor=Z.+Zhangauthor=Z.+Zhouauthor=F.+Yangauthor=H.+Liang&title=Synthesis+of+four+binuclear+copper%28II%29+complexes%3A+structure%2C+anticancer+properties+and+anticancer+mechanism&doi=10.1016%2Fj.ejmech.2015.04.031"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2015.04.031&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2015.04.031%26sid%3Dliteratum%253Aachs%26aulast%3DQi%26aufirst%3DJ.%26aulast%3DLiang%26aufirst%3DS.%26aulast%3DGou%26aufirst%3DY.%26aulast%3DZhang%26aufirst%3DZ.%26aulast%3DZhou%26aufirst%3DZ.%26aulast%3DYang%26aufirst%3DF.%26aulast%3DLiang%26aufirst%3DH.%26atitle%3DSynthesis%2520of%2520four%2520binuclear%2520copper%2528II%2529%2520complexes%253A%2520structure%252C%2520anticancer%2520properties%2520and%2520anticancer%2520mechanism%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2015%26volume%3D96%26spage%3D360%26epage%3D368%26doi%3D10.1016%2Fj.ejmech.2015.04.031" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group">van Rijt, S. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sadler, P. J.</span><span> </span><span class="NLM_article-title">Current applications and future potential for bioinorganic chemistry in the development of anticancer drugs</span> <span class="citation_source-journal">Drug Discovery Today</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">14</span><span class="NLM_x">, </span> <span class="NLM_fpage">1089</span><span class="NLM_x">–</span> <span class="NLM_lpage">1097</span><span class="refDoi"> DOI: 10.1016/j.drudis.2009.09.003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00509&amp;key=10.1016%2Fj.drudis.2009.09.003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00509&amp;key=19782150" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00509&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhsV2murvE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2009&pages=1089-1097&author=S.+H.+van+Rijtauthor=P.+J.+Sadler&title=Current+applications+and+future+potential+for+bioinorganic+chemistry+in+the+development+of+anticancer+drugs&doi=10.1016%2Fj.drudis.2009.09.003"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Current applications and future potential for bioinorganic chemistry in the development of anticancer drugs</span></div><div class="casAuthors">van Rijt, Sabine H.; Sadler, Peter J.</div><div class="citationInfo"><span class="NLM_cas:title">Drug Discovery Today</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">23/24</span>),
    <span class="NLM_cas:pages">1089-1097</span>CODEN:
                <span class="NLM_cas:coden">DDTOFS</span>;
        ISSN:<span class="NLM_cas:issn">1359-6446</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  This review illustrates notable recent progress in the field of medicinal bioinorg. chem. as many new approaches to the design of innovative metal-based anticancer drugs are emerging.  Current research addressing the problems assocd. with platinum drugs has focused on other metal-based therapeutics that have different modes of action and on prodrug and targeting strategies in an effort to diminish the side-effects of cisplatin chemotherapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqojVDzugGUJ7Vg90H21EOLACvtfcHk0lhaA86UKieBAA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhsV2murvE&md5=37e89d98dc15aac0adbd3f9fc0fd0f74</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1016%2Fj.drudis.2009.09.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.drudis.2009.09.003%26sid%3Dliteratum%253Aachs%26aulast%3Dvan%2BRijt%26aufirst%3DS.%2BH.%26aulast%3DSadler%26aufirst%3DP.%2BJ.%26atitle%3DCurrent%2520applications%2520and%2520future%2520potential%2520for%2520bioinorganic%2520chemistry%2520in%2520the%2520development%2520of%2520anticancer%2520drugs%26jtitle%3DDrug%2520Discovery%2520Today%26date%3D2009%26volume%3D14%26spage%3D1089%26epage%3D1097%26doi%3D10.1016%2Fj.drudis.2009.09.003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span><span class="NLM_contrib-group">Kowol, C. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Trondl, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heffeter, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Arion, V. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jakupec, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roller, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Galanski, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Berger, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Keppler, B. K.</span><span> </span><span class="NLM_article-title">Impact of metal coordination on cytotoxicity of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (triapine) and novel insights into terminal dimethylation</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">52</span><span class="NLM_x">, </span> <span class="NLM_fpage">5032</span><span class="NLM_x">–</span> <span class="NLM_lpage">5043</span><span class="refDoi"> DOI: 10.1021/jm900528d</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm900528d" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00509&amp;key=1%3ACAS%3A528%3ADC%252BD1MXptFCht7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2009&pages=5032-5043&author=C.+R.+Kowolauthor=R.+Trondlauthor=P.+Heffeterauthor=V.+B.+Arionauthor=M.+A.+Jakupecauthor=A.+Rollerauthor=M.+Galanskiauthor=W.+Bergerauthor=B.+K.+Keppler&title=Impact+of+metal+coordination+on+cytotoxicity+of+3-aminopyridine-2-carboxaldehyde+thiosemicarbazone+%28triapine%29+and+novel+insights+into+terminal+dimethylation&doi=10.1021%2Fjm900528d"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Impact of Metal Coordination on Cytotoxicity of 3-Aminopyridine-2-carboxaldehyde Thiosemicarbazone (Triapine) and Novel Insights into Terminal Dimethylation</span></div><div class="casAuthors">Kowol, Christian R.; Trondl, Robert; Heffeter, Petra; Arion, Vladimir B.; Jakupec, Michael A.; Roller, Alexander; Galanski, Markus; Berger, Walter; Keppler, Bernhard K.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">52</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">5032-5043</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The 1st metal complexes of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (Triapine) were synthesized.  Triapine was prepd. by a novel three-step procedure in 64% overall yield.  Related ligands, namely, 2-formylpyridine thiosemicarbazone, 2-acetylpyridine thiosemicarbazone, 2-pyridineformamide thiosemicarbazone, and their N4-dimethylated derivs. (including the N4-dimethylated analog of Triapine) were prepd., along with their corresponding Ga(III) and Fe(III) complexes [M(L)2]+, where HL is the resp. thiosemicarbazone.  The compds. were characterized by elemental anal., 1H and 13C NMR, IR and UV-visible spectroscopies, mass spectrometry, and cyclic voltammetry.  Triapine and its Fe(III) and Ga(III) complexes were studied by x-ray crystallog.  All ligands and complexes were tested for their in vitro antiproliferative activity in two human cancer cell lines (41M and SK-BR-3), and structure-activity relations were established.  In general, the coordination to Ga(III) increased the cytotoxicity while the Fe(III) complexes show reduced cytotoxic activity compared to the metal-free thiosemicarbazones.  Selected compds. were studied for the capacity of inhibiting ribonucleotide reductase by incorporation of 3H-cytidine into DNA.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo5oU-NYorlKLVg90H21EOLACvtfcHk0lgnbGDH2KW_ww"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXptFCht7k%253D&md5=7b805ef6e229f3b30eddc9acb0931945</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1021%2Fjm900528d&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm900528d%26sid%3Dliteratum%253Aachs%26aulast%3DKowol%26aufirst%3DC.%2BR.%26aulast%3DTrondl%26aufirst%3DR.%26aulast%3DHeffeter%26aufirst%3DP.%26aulast%3DArion%26aufirst%3DV.%2BB.%26aulast%3DJakupec%26aufirst%3DM.%2BA.%26aulast%3DRoller%26aufirst%3DA.%26aulast%3DGalanski%26aufirst%3DM.%26aulast%3DBerger%26aufirst%3DW.%26aulast%3DKeppler%26aufirst%3DB.%2BK.%26atitle%3DImpact%2520of%2520metal%2520coordination%2520on%2520cytotoxicity%2520of%25203-aminopyridine-2-carboxaldehyde%2520thiosemicarbazone%2520%2528triapine%2529%2520and%2520novel%2520insights%2520into%2520terminal%2520dimethylation%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2009%26volume%3D52%26spage%3D5032%26epage%3D5043%26doi%3D10.1021%2Fjm900528d" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span><span class="NLM_contrib-group">Lainé, A. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Passirani, C.</span><span> </span><span class="NLM_article-title">Novel metal-based anticancer drugs: a new challenge in drug delivery</span> <span class="citation_source-journal">Curr. Opin. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">12</span><span class="NLM_x">, </span> <span class="NLM_fpage">420</span><span class="NLM_x">–</span> <span class="NLM_lpage">426</span><span class="refDoi"> DOI: 10.1016/j.coph.2012.04.006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00509&amp;key=10.1016%2Fj.coph.2012.04.006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00509&amp;key=22609113" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00509&amp;key=1%3ACAS%3A528%3ADC%252BC38XntlSrtLo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2012&pages=420-426&author=A.+L.+Lain%C3%A9author=C.+Passirani&title=Novel+metal-based+anticancer+drugs%3A+a+new+challenge+in+drug+delivery&doi=10.1016%2Fj.coph.2012.04.006"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Novel metal-based anticancer drugs: a new challenge in drug delivery</span></div><div class="casAuthors">Laine, Anne-Laure; Passirani, Catherine</div><div class="citationInfo"><span class="NLM_cas:title">Current Opinion in Pharmacology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">420-426</span>CODEN:
                <span class="NLM_cas:coden">COPUBK</span>;
        ISSN:<span class="NLM_cas:issn">1471-4892</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  Since the serependitous discovery of the cisplatin antiproliferative activity, many efforts have focused on the design of potent metal-based drugs for oncol. therapies.  A large no. of these complexes were evaluated in vitro and in vivo and some have reached clin. trials.  However, while metallodrug chem. has developed to an advanced level, these emerging therapeutics have encountered new hurdles including poor water soly. and pharmacol. deficiencies.  Today, solns. to overcome these issues do not lie in synthesizing new anticancer drugs but in finding suitable drug delivery strategies.  Over the past decades, various delivery systems were developed including prodrug, ligand design and nanocarriers aimed at enhancing the performance profile of these novel metallodrugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo0rPnLyzMlFrVg90H21EOLACvtfcHk0lgnbGDH2KW_ww"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XntlSrtLo%253D&md5=6f7b911a7cdf6d20980badfd5aa94c8c</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1016%2Fj.coph.2012.04.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.coph.2012.04.006%26sid%3Dliteratum%253Aachs%26aulast%3DLain%25C3%25A9%26aufirst%3DA.%2BL.%26aulast%3DPassirani%26aufirst%3DC.%26atitle%3DNovel%2520metal-based%2520anticancer%2520drugs%253A%2520a%2520new%2520challenge%2520in%2520drug%2520delivery%26jtitle%3DCurr.%2520Opin.%2520Pharmacol.%26date%3D2012%26volume%3D12%26spage%3D420%26epage%3D426%26doi%3D10.1016%2Fj.coph.2012.04.006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><span class="NLM_contrib-group">Whitnall, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Howard, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ponka, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Richardson, D. R.</span><span> </span><span class="NLM_article-title">A class of iron chelators with a wide spectrum of potent antitumor activity that overcomes resistance to chemotherapeutics</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U. S. A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">103</span><span class="NLM_x">, </span> <span class="NLM_fpage">14901</span><span class="NLM_x">–</span> <span class="NLM_lpage">14906</span><span class="refDoi"> DOI: 10.1073/pnas.0604979103</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00509&amp;key=10.1073%2Fpnas.0604979103" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=103&publication_year=2006&pages=14901-14906&author=M.+Whitnallauthor=J.+Howardauthor=P.+Ponkaauthor=D.+R.+Richardson&title=A+class+of+iron+chelators+with+a+wide+spectrum+of+potent+antitumor+activity+that+overcomes+resistance+to+chemotherapeutics&doi=10.1073%2Fpnas.0604979103"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1073%2Fpnas.0604979103&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.0604979103%26sid%3Dliteratum%253Aachs%26aulast%3DWhitnall%26aufirst%3DM.%26aulast%3DHoward%26aufirst%3DJ.%26aulast%3DPonka%26aufirst%3DP.%26aulast%3DRichardson%26aufirst%3DD.%2BR.%26atitle%3DA%2520class%2520of%2520iron%2520chelators%2520with%2520a%2520wide%2520spectrum%2520of%2520potent%2520antitumor%2520activity%2520that%2520overcomes%2520resistance%2520to%2520chemotherapeutics%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2006%26volume%3D103%26spage%3D14901%26epage%3D14906%26doi%3D10.1073%2Fpnas.0604979103" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span><span class="NLM_contrib-group">Lovejoy, D. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jansson, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brunk, U. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wong, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ponka, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Richardson, D. R.</span><span> </span><span class="NLM_article-title">Antitumor activity of metal-chelating compound Dp44mT is mediated by formation of a redox-active copper complex that accumulates in lysosomes</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">71</span><span class="NLM_x">, </span> <span class="NLM_fpage">5871</span><span class="NLM_x">–</span> <span class="NLM_lpage">5880</span><span class="refDoi"> DOI: 10.1158/0008-5472.CAN-11-1218</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00509&amp;key=10.1158%2F0008-5472.CAN-11-1218" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00509&amp;key=21750178" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00509&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtFSmtbvL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=71&publication_year=2011&pages=5871-5880&author=D.+B.+Lovejoyauthor=P.+J.+Janssonauthor=U.+T.+Brunkauthor=J.+Wongauthor=P.+Ponkaauthor=D.+R.+Richardson&title=Antitumor+activity+of+metal-chelating+compound+Dp44mT+is+mediated+by+formation+of+a+redox-active+copper+complex+that+accumulates+in+lysosomes&doi=10.1158%2F0008-5472.CAN-11-1218"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Antitumor Activity of Metal-Chelating Compound Dp44mT Is Mediated by Formation of a Redox-Active Copper Complex That Accumulates in Lysosomes</span></div><div class="casAuthors">Lovejoy, David B.; Jansson, Patric J.; Brunk, Ulf T.; Wong, Jacky; Ponka, Prem; Richardson, Des R.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">71</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">5871-5880</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">The metal-chelating compd. Dp44mT is a di-2-pyridylketone thiosemicarbazone (DpT) which displays potent and selective antitumor activity.  This compd. is receiving translational attention, but its mechanism is poorly understood.  Here, we report that Dp44mT targets lysosome integrity through copper binding.  Studies using the lysosomotropic fluorochrome acridine orange established that the copper-Dp44mT complex (Cu[Dp44mT]) disrupted lysosomes.  This targeting was confirmed with pepstatin A-BODIPY FL, which showed redistribution of cathepsin D to the cytosol with ensuing cleavage of the proapoptotic BH3 protein Bid.  Redox activity of Cu[Dp44mT] caused cellular depletion of glutathione, and lysosomal damage was prevented by cotreatment with the glutathione precursor N-acetylcysteine.  Copper binding was essential for the potent antitumor activity of Dp44mT, as coincubation with nontoxic copper chelators markedly attenuated its cytotoxicity.  Taken together, our studies show how the lysosomal apoptotic pathway can be selectively activated in cancer cells by sequestration of redox-active copper.  Our findings define a novel generalized strategy to selectively target lysosome function for chemotherapeutic intervention against cancer.  Cancer Res; 71(17); 5871-80.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqT2ClJjP1OF7Vg90H21EOLACvtfcHk0lgs95fubraslw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtFSmtbvL&md5=e6e8e99034c780e75b410784fd774103</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-11-1218&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-11-1218%26sid%3Dliteratum%253Aachs%26aulast%3DLovejoy%26aufirst%3DD.%2BB.%26aulast%3DJansson%26aufirst%3DP.%2BJ.%26aulast%3DBrunk%26aufirst%3DU.%2BT.%26aulast%3DWong%26aufirst%3DJ.%26aulast%3DPonka%26aufirst%3DP.%26aulast%3DRichardson%26aufirst%3DD.%2BR.%26atitle%3DAntitumor%2520activity%2520of%2520metal-chelating%2520compound%2520Dp44mT%2520is%2520mediated%2520by%2520formation%2520of%2520a%2520redox-active%2520copper%2520complex%2520that%2520accumulates%2520in%2520lysosomes%26jtitle%3DCancer%2520Res.%26date%3D2011%26volume%3D71%26spage%3D5871%26epage%3D5880%26doi%3D10.1158%2F0008-5472.CAN-11-1218" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group">Kalinowski, D. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Richardson, D. R.</span><span> </span><span class="NLM_article-title">The evolution of iron chelators for the treatment of iron overload disease and cancer</span> <span class="citation_source-journal">Pharmacol. Rev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">57</span><span class="NLM_x">, </span> <span class="NLM_fpage">547</span><span class="NLM_x">–</span> <span class="NLM_lpage">583</span><span class="refDoi"> DOI: 10.1124/pr.57.4.2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00509&amp;key=10.1124%2Fpr.57.4.2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00509&amp;key=16382108" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00509&amp;key=1%3ACAS%3A528%3ADC%252BD28XhtFWnsrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2005&pages=547-583&author=D.+S.+Kalinowskiauthor=D.+R.+Richardson&title=The+evolution+of+iron+chelators+for+the+treatment+of+iron+overload+disease+and+cancer&doi=10.1124%2Fpr.57.4.2"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">The evolution of iron chelators for the treatment of iron overload disease and cancer</span></div><div class="casAuthors">Kalinowski, Danuta S.; Richardson, Des. R.</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacological Reviews</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">547-583</span>CODEN:
                <span class="NLM_cas:coden">PAREAQ</span>;
        ISSN:<span class="NLM_cas:issn">0031-6997</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">A review.  The evolution of iron chelators from a range of primordial siderophores and arom. heterocyclic ligands has lead to the formation of a new generation of potent and efficient iron chelators.  For example, various siderophore analogs and synthetic ligands, including ICL670A [4-[3,5-bis-(hydroxyphenyl)-1,2,4-triazol-1-yl]-benzoic acid], 4'-hydroxydesazadesferrithiocin, and Triapine, have been developed from predecessors and illustrate potent iron-mobilizing or antineoplastic activities.  This review focuses on the evolution of iron chelators from initial lead compds. through to the development of novel chelating agents, many of which show great potential to be clin. applied in the treatment of iron overload disease and cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqYJXHJqhQ0U7Vg90H21EOLACvtfcHk0liI6MdDyBkXoQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XhtFWnsrY%253D&md5=2983bf140d7da93242b64c25bd79211d</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1124%2Fpr.57.4.2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fpr.57.4.2%26sid%3Dliteratum%253Aachs%26aulast%3DKalinowski%26aufirst%3DD.%2BS.%26aulast%3DRichardson%26aufirst%3DD.%2BR.%26atitle%3DThe%2520evolution%2520of%2520iron%2520chelators%2520for%2520the%2520treatment%2520of%2520iron%2520overload%2520disease%2520and%2520cancer%26jtitle%3DPharmacol.%2520Rev.%26date%3D2005%26volume%3D57%26spage%3D547%26epage%3D583%26doi%3D10.1124%2Fpr.57.4.2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group">Ma, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goh, B. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tan, E. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lam, K. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Soo, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leong, S. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, L. Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mo, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chan, A. T. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zee, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mok, T.</span><span> </span><span class="NLM_article-title">A multicenter phase II trial of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP, Triapine (R)) and gemcitabine in advanced non-small-cell lung cancer with pharmacokinetic evaluation using peripheral blood mononuclear cells</span> <span class="citation_source-journal">Invest. New Drugs</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">26</span><span class="NLM_x">, </span> <span class="NLM_fpage">169</span><span class="NLM_x">–</span> <span class="NLM_lpage">173</span><span class="refDoi"> DOI: 10.1007/s10637-007-9085-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00509&amp;key=10.1007%2Fs10637-007-9085-0" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2008&pages=169-173&author=B.+Maauthor=B.+C.+Gohauthor=E.+H.+Tanauthor=K.+C.+Lamauthor=R.+Sooauthor=S.+S.+Leongauthor=L.+Z.+Wangauthor=F.+Moauthor=A.+T.+C.+Chanauthor=B.+Zeeauthor=T.+Mok&title=A+multicenter+phase+II+trial+of+3-aminopyridine-2-carboxaldehyde+thiosemicarbazone+%283-AP%2C+Triapine+%28R%29%29+and+gemcitabine+in+advanced+non-small-cell+lung+cancer+with+pharmacokinetic+evaluation+using+peripheral+blood+mononuclear+cells&doi=10.1007%2Fs10637-007-9085-0"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1007%2Fs10637-007-9085-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs10637-007-9085-0%26sid%3Dliteratum%253Aachs%26aulast%3DMa%26aufirst%3DB.%26aulast%3DGoh%26aufirst%3DB.%2BC.%26aulast%3DTan%26aufirst%3DE.%2BH.%26aulast%3DLam%26aufirst%3DK.%2BC.%26aulast%3DSoo%26aufirst%3DR.%26aulast%3DLeong%26aufirst%3DS.%2BS.%26aulast%3DWang%26aufirst%3DL.%2BZ.%26aulast%3DMo%26aufirst%3DF.%26aulast%3DChan%26aufirst%3DA.%2BT.%2BC.%26aulast%3DZee%26aufirst%3DB.%26aulast%3DMok%26aufirst%3DT.%26atitle%3DA%2520multicenter%2520phase%2520II%2520trial%2520of%25203-aminopyridine-2-carboxaldehyde%2520thiosemicarbazone%2520%25283-AP%252C%2520Triapine%2520%2528R%2529%2529%2520and%2520gemcitabine%2520in%2520advanced%2520non-small-cell%2520lung%2520cancer%2520with%2520pharmacokinetic%2520evaluation%2520using%2520peripheral%2520blood%2520mononuclear%2520cells%26jtitle%3DInvest.%2520New%2520Drugs%26date%3D2008%26volume%3D26%26spage%3D169%26epage%3D173%26doi%3D10.1007%2Fs10637-007-9085-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group">Lovejoy, D. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sharp, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Seebacher, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Obeidy, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Prichard, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stefani, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Basha, M. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sharpe, P. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jansson, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kalinowski, D. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bernhardt, P. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Richardson, D. R.</span><span> </span><span class="NLM_article-title">Novel second-generation di-2-pyridylketone thiosemicarbazones show synergism with standard chemotherapeutics and demonstrate potent activity against lung cancer xenografts after oral and intravenous administration in vivo</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">55</span><span class="NLM_x">, </span> <span class="NLM_fpage">7230</span><span class="NLM_x">–</span> <span class="NLM_lpage">7244</span><span class="refDoi"> DOI: 10.1021/jm300768u</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm300768u" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00509&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtFClurbK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=7230-7244&author=D.+B.+Lovejoyauthor=D.+M.+Sharpauthor=N.+Seebacherauthor=P.+Obeidyauthor=T.+Prichardauthor=C.+Stefaniauthor=M.+T.+Bashaauthor=P.+C.+Sharpeauthor=P.+J.+Janssonauthor=D.+S.+Kalinowskiauthor=P.+V.+Bernhardtauthor=D.+R.+Richardson&title=Novel+second-generation+di-2-pyridylketone+thiosemicarbazones+show+synergism+with+standard+chemotherapeutics+and+demonstrate+potent+activity+against+lung+cancer+xenografts+after+oral+and+intravenous+administration+in+vivo&doi=10.1021%2Fjm300768u"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Novel Second-Generation Di-2-Pyridylketone Thiosemicarbazones Show Synergism with Standard Chemotherapeutics and Demonstrate Potent Activity against Lung Cancer Xenografts after Oral and Intravenous Administration in Vivo</span></div><div class="casAuthors">Lovejoy, David B.; Sharp, Danae M.; Seebacher, Nicole; Obeidy, Peyman; Prichard, Thomas; Stefani, Christian; Basha, Maram T.; Sharpe, Philip C.; Jansson, Patric J.; Kalinowski, Danuta S.; Bernhardt, Paul V.; Richardson, Des R.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">7230-7244</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">We developed a series of second-generation di-2-pyridyl ketone thiosemicarbazone (DpT) and 2-benzoylpyridine thiosemicarbazone (BpT) ligands to improve the efficacy and safety profile of these potential antitumor agents.  Two novel DpT analogs, Dp4e4mT and DpC, exhibited pronounced and selective activity against human lung cancer xenografts in vivo via the i.v. and oral routes.  Importantly, these analogs did not induce the cardiotoxicity obsd. at high nonoptimal doses of the first-generation DpT analog, Dp44mT.  The Cu(II) complexes of these ligands exhibited potent antiproliferative activity having redox potentials in a range accessible to biol. reductants.  The activity of the copper complexes of Dp4e4mT and DpC against lung cancer cells was synergistic in combination with gemcitabine or cisplatin.  It was demonstrated by EPR spectroscopy that dimeric copper compds. of the type [CuLCl]2, identified crystallog., dissoc. in soln. to give monomeric 1:1 Cu:ligand complexes.  These monomers represent the biol. active form of the complex.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo75KAO0Ooc6bVg90H21EOLACvtfcHk0lhzh-RxhUbNQA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtFClurbK&md5=ce94f696851fc28cde48fc91bb38d132</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1021%2Fjm300768u&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm300768u%26sid%3Dliteratum%253Aachs%26aulast%3DLovejoy%26aufirst%3DD.%2BB.%26aulast%3DSharp%26aufirst%3DD.%2BM.%26aulast%3DSeebacher%26aufirst%3DN.%26aulast%3DObeidy%26aufirst%3DP.%26aulast%3DPrichard%26aufirst%3DT.%26aulast%3DStefani%26aufirst%3DC.%26aulast%3DBasha%26aufirst%3DM.%2BT.%26aulast%3DSharpe%26aufirst%3DP.%2BC.%26aulast%3DJansson%26aufirst%3DP.%2BJ.%26aulast%3DKalinowski%26aufirst%3DD.%2BS.%26aulast%3DBernhardt%26aufirst%3DP.%2BV.%26aulast%3DRichardson%26aufirst%3DD.%2BR.%26atitle%3DNovel%2520second-generation%2520di-2-pyridylketone%2520thiosemicarbazones%2520show%2520synergism%2520with%2520standard%2520chemotherapeutics%2520and%2520demonstrate%2520potent%2520activity%2520against%2520lung%2520cancer%2520xenografts%2520after%2520oral%2520and%2520intravenous%2520administration%2520in%2520vivo%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26spage%3D7230%26epage%3D7244%26doi%3D10.1021%2Fjm300768u" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13"><span><span class="NLM_contrib-group">Knox, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hotte, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kollmannsberger, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Winquist, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fisher, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eisenhauer, E. A.</span><span> </span><span class="NLM_article-title">Phase II study of triapine in patients with metastatic renal cell carcinoma: a trial of the national cancer institute of Canada clinical trials group (NCIC IND.161)</span> <span class="citation_source-journal">Invest. New Drugs</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">25</span><span class="NLM_x">, </span> <span class="NLM_fpage">471</span><span class="NLM_x">–</span> <span class="NLM_lpage">477</span><span class="refDoi"> DOI: 10.1007/s10637-007-9044-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00509&amp;key=10.1007%2Fs10637-007-9044-9" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2007&pages=471-477&author=J.+J.+Knoxauthor=S.+J.+Hotteauthor=C.+Kollmannsbergerauthor=E.+Winquistauthor=B.+Fisherauthor=E.+A.+Eisenhauer&title=Phase+II+study+of+triapine+in+patients+with+metastatic+renal+cell+carcinoma%3A+a+trial+of+the+national+cancer+institute+of+Canada+clinical+trials+group+%28NCIC+IND.161%29&doi=10.1007%2Fs10637-007-9044-9"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1007%2Fs10637-007-9044-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs10637-007-9044-9%26sid%3Dliteratum%253Aachs%26aulast%3DKnox%26aufirst%3DJ.%2BJ.%26aulast%3DHotte%26aufirst%3DS.%2BJ.%26aulast%3DKollmannsberger%26aufirst%3DC.%26aulast%3DWinquist%26aufirst%3DE.%26aulast%3DFisher%26aufirst%3DB.%26aulast%3DEisenhauer%26aufirst%3DE.%2BA.%26atitle%3DPhase%2520II%2520study%2520of%2520triapine%2520in%2520patients%2520with%2520metastatic%2520renal%2520cell%2520carcinoma%253A%2520a%2520trial%2520of%2520the%2520national%2520cancer%2520institute%2520of%2520Canada%2520clinical%2520trials%2520group%2520%2528NCIC%2520IND.161%2529%26jtitle%3DInvest.%2520New%2520Drugs%26date%3D2007%26volume%3D25%26spage%3D471%26epage%3D477%26doi%3D10.1007%2Fs10637-007-9044-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group">Ma, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goh, B. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tan, E. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lam, K. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Soo, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leong, S. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, L. Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mo, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chan, A. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zee, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mok, T.</span><span> </span><span class="NLM_article-title">A Multicenter phase II trial of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP, Triapine) and gemcitabine in advanced non-small-cell lung cancer with pharmacokinetic evaluation using peripheral blood mononuclear cells</span> <span class="citation_source-journal">Invest. New Drugs</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">26</span><span class="NLM_x">, </span> <span class="NLM_fpage">169</span><span class="NLM_x">–</span> <span class="NLM_lpage">173</span><span class="refDoi"> DOI: 10.1007/s10637-007-9085-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00509&amp;key=10.1007%2Fs10637-007-9085-0" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2008&pages=169-173&author=B.+Maauthor=B.+C.+Gohauthor=E.+H.+Tanauthor=K.+C.+Lamauthor=R.+Sooauthor=S.+S.+Leongauthor=L.+Z.+Wangauthor=F.+Moauthor=A.+T.+Chanauthor=B.+Zeeauthor=T.+Mok&title=A+Multicenter+phase+II+trial+of+3-aminopyridine-2-carboxaldehyde+thiosemicarbazone+%283-AP%2C+Triapine%29+and+gemcitabine+in+advanced+non-small-cell+lung+cancer+with+pharmacokinetic+evaluation+using+peripheral+blood+mononuclear+cells&doi=10.1007%2Fs10637-007-9085-0"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1007%2Fs10637-007-9085-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs10637-007-9085-0%26sid%3Dliteratum%253Aachs%26aulast%3DMa%26aufirst%3DB.%26aulast%3DGoh%26aufirst%3DB.%2BC.%26aulast%3DTan%26aufirst%3DE.%2BH.%26aulast%3DLam%26aufirst%3DK.%2BC.%26aulast%3DSoo%26aufirst%3DR.%26aulast%3DLeong%26aufirst%3DS.%2BS.%26aulast%3DWang%26aufirst%3DL.%2BZ.%26aulast%3DMo%26aufirst%3DF.%26aulast%3DChan%26aufirst%3DA.%2BT.%26aulast%3DZee%26aufirst%3DB.%26aulast%3DMok%26aufirst%3DT.%26atitle%3DA%2520Multicenter%2520phase%2520II%2520trial%2520of%25203-aminopyridine-2-carboxaldehyde%2520thiosemicarbazone%2520%25283-AP%252C%2520Triapine%2529%2520and%2520gemcitabine%2520in%2520advanced%2520non-small-cell%2520lung%2520cancer%2520with%2520pharmacokinetic%2520evaluation%2520using%2520peripheral%2520blood%2520mononuclear%2520cells%26jtitle%3DInvest.%2520New%2520Drugs%26date%3D2008%26volume%3D26%26spage%3D169%26epage%3D173%26doi%3D10.1007%2Fs10637-007-9085-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><span class="NLM_contrib-group">Yu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kalinowski, D. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kovacevic, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Siafakas, A. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jansson, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stefani, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lovejoy, D. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sharpe, P. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bernhardt, P. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Richardson, D. R.</span><span> </span><span class="NLM_article-title">Thiosemicarbazones from the old to new: Iron chelators that are more than just ribonucleotide reductase inhibitors</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">52</span><span class="NLM_x">, </span> <span class="NLM_fpage">5271</span><span class="NLM_x">–</span> <span class="NLM_lpage">5294</span><span class="refDoi"> DOI: 10.1021/jm900552r</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm900552r" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00509&amp;key=1%3ACAS%3A528%3ADC%252BD1MXosVGjs7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2009&pages=5271-5294&author=Y.+Yuauthor=D.+S.+Kalinowskiauthor=Z.+Kovacevicauthor=A.+R.+Siafakasauthor=P.+J.+Janssonauthor=C.+Stefaniauthor=D.+B.+Lovejoyauthor=P.+C.+Sharpeauthor=P.+V.+Bernhardtauthor=D.+R.+Richardson&title=Thiosemicarbazones+from+the+old+to+new%3A+Iron+chelators+that+are+more+than+just+ribonucleotide+reductase+inhibitors&doi=10.1021%2Fjm900552r"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Thiosemicarbazones from the Old to New: Iron Chelators That Are More Than Just Ribonucleotide Reductase Inhibitors</span></div><div class="casAuthors">Yu, Yu; Kalinowski, Danuta S.; Kovacevic, Zaklina; Siafakas, Aritee R.; Jansson, Patric J.; Stefani, Christian; Lovejoy, David B.; Sharpe, Philip C.; Bernhardt, Paul V.; Richardson, Des R.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">52</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">5271-5294</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  The chem. and biol. effects of thiosemicarbazones have received considerable interest from medicinal chemists for many years.  This is attributed to first, their wide pharmacol. utility that includes antineoplastic, antibacterial, antiviral, and antifungal activity, and second, their versatility as ligands that allows them to give rise to a great variety of coordination modes.  The antineoplastic activity of thiosemicarbazones has been continually examd. since the 1950s, where some compds. of this general class were found to have antileukemic activity.  The pronounced anti-neoplastic efficacy of these ligands has been widely attributed to their inhibition of the mammalian enzyme ribonucleotide reductase (RR).  The ability to inhibit RR is of particular importance owing to the role of RR in the de novo synthesis of deoxyribonucleotides required for DNA replication and repair.  Considering this, these compds. have often been described as RR inhibitors without mention of the property that actually leads to this effect, namely, metal chelation.  Apart from the inhibition of RR, it is also known that thiosemicarbazones are typically excellent chelators of transition metals such as iron (Fe), copper (Cu), and zinc (Zn).  Such ability for metal chelation is also an attractive strategy in developing anticancer drugs because of the high requirement of neoplastic cells for essential metals needed in growth and proliferation.  In fact, thiosemicarbazones were the first class of chelators to be comprehensively assessed as antineoplastic agents against cancer cells in vitro and in clin. trials.  This Perspective will focus on understanding the anti-neoplastic activity of thiosemicarbazones from the point of view of chelation.  To do this effectively, introduction to the roles of metals in cellular proliferation is required in addn. to an evaluation of the development of chelators for the treatment of cancer and other diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqx7tH0WVefYrVg90H21EOLACvtfcHk0lhGl1X7_i60HA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXosVGjs7g%253D&md5=f0faee975954e0dfa7fbf5dd83829421</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1021%2Fjm900552r&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm900552r%26sid%3Dliteratum%253Aachs%26aulast%3DYu%26aufirst%3DY.%26aulast%3DKalinowski%26aufirst%3DD.%2BS.%26aulast%3DKovacevic%26aufirst%3DZ.%26aulast%3DSiafakas%26aufirst%3DA.%2BR.%26aulast%3DJansson%26aufirst%3DP.%2BJ.%26aulast%3DStefani%26aufirst%3DC.%26aulast%3DLovejoy%26aufirst%3DD.%2BB.%26aulast%3DSharpe%26aufirst%3DP.%2BC.%26aulast%3DBernhardt%26aufirst%3DP.%2BV.%26aulast%3DRichardson%26aufirst%3DD.%2BR.%26atitle%3DThiosemicarbazones%2520from%2520the%2520old%2520to%2520new%253A%2520Iron%2520chelators%2520that%2520are%2520more%2520than%2520just%2520ribonucleotide%2520reductase%2520inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2009%26volume%3D52%26spage%3D5271%26epage%3D5294%26doi%3D10.1021%2Fjm900552r" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span><span class="NLM_contrib-group">Richardson, D. R.</span><span> </span><span class="NLM_article-title">Molecular mechanisms of iron uptake by cells and the use of iron chelators for the treatment of cancer</span> <span class="citation_source-journal">Curr. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">12</span><span class="NLM_x">, </span> <span class="NLM_fpage">2711</span><span class="NLM_x">–</span> <span class="NLM_lpage">2729</span><span class="refDoi"> DOI: 10.2174/092986705774462996</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00509&amp;key=10.2174%2F092986705774462996" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00509&amp;key=16305467" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00509&amp;key=1%3ACAS%3A528%3ADC%252BD2MXht1ShsrrL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2005&pages=2711-2729&author=D.+R.+Richardson&title=Molecular+mechanisms+of+iron+uptake+by+cells+and+the+use+of+iron+chelators+for+the+treatment+of+cancer&doi=10.2174%2F092986705774462996"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Molecular mechanisms of iron uptake by cells and the use of iron chelators for the treatment of cancer</span></div><div class="casAuthors">Richardson, Des R.</div><div class="citationInfo"><span class="NLM_cas:title">Current Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">2711-2729</span>CODEN:
                <span class="NLM_cas:coden">CMCHE7</span>;
        ISSN:<span class="NLM_cas:issn">0929-8673</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  The field of Fe metab. has been invigorated in the past 10 years with the discovery of a variety of new mols. involved in the homeostatic control of this crit. nutrient.  These proteins include the transferrin receptor 2, Frataxin, Hephaestin, Hepcidin, Hemojuvelin, and others.  Basic understanding of the metab. of Fe in cells is vital in order to develop Fe chelators for the treatment of a variety of disease states.  In addn., examn. of the role of Fe in the regulation of cell cycle progression and angiogenesis has led to investigations of the use of novel Fe chelators as antiproliferative agents.  These studies have resulted in the identification of new ligands that show selective and potent antitumor activity in vitro and in vivo.  Moreover, the ability of these chelators to inhibit growth is not only limited to the inhibition of DNA synthesis.  In fact, there is a range of targets that are affected by Fe depletion, such as mols. involved in cell cycle control, angiogenesis, and metastasis suppression.  These include hypoxia-inducible factor-1α (HIF-1α), vascular endothelial growth factor-1 (VEGF1), p21CIP1/WAF1, cyclin D1, and the protein product of the N-myc downstream regulated gene-1 (Ndrg1).  As such, Fe chelators can now be designed to target mols. to induce specific effects, for instance, angiogenesis or metastasis suppression.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrwOqPiuDevOrVg90H21EOLACvtfcHk0lhGl1X7_i60HA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXht1ShsrrL&md5=434a4239bfa1952f45679d3cc9bf7ccf</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.2174%2F092986705774462996&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F092986705774462996%26sid%3Dliteratum%253Aachs%26aulast%3DRichardson%26aufirst%3DD.%2BR.%26atitle%3DMolecular%2520mechanisms%2520of%2520iron%2520uptake%2520by%2520cells%2520and%2520the%2520use%2520of%2520iron%2520chelators%2520for%2520the%2520treatment%2520of%2520cancer%26jtitle%3DCurr.%2520Med.%2520Chem.%26date%3D2005%26volume%3D12%26spage%3D2711%26epage%3D2729%26doi%3D10.2174%2F092986705774462996" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span><span class="NLM_contrib-group">Liu, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mu, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xing, B.</span><span> </span><span class="NLM_article-title">Recent advances on the development of pharmacotherapeutic agents on the basis of human serum albumin</span> <span class="citation_source-journal">Curr. Pharm. Des.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">21</span><span class="NLM_x">, </span> <span class="NLM_fpage">1866</span><span class="NLM_x">–</span> <span class="NLM_lpage">1888</span><span class="refDoi"> DOI: 10.2174/1381612821666150302115411</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00509&amp;key=10.2174%2F1381612821666150302115411" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00509&amp;key=25732552" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00509&amp;key=1%3ACAS%3A528%3ADC%252BC2MXls1als7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2015&pages=1866-1888&author=F.+Liuauthor=J.+Muauthor=B.+Xing&title=Recent+advances+on+the+development+of+pharmacotherapeutic+agents+on+the+basis+of+human+serum+albumin&doi=10.2174%2F1381612821666150302115411"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Recent Advances on the Development of Pharmacotherapeutic Agents on the Basis of Human Serum Albumin</span></div><div class="casAuthors">Liu, Fang; Mu, Jing; Xing, Bengang</div><div class="citationInfo"><span class="NLM_cas:title">Current Pharmaceutical Design</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">1866-1888</span>CODEN:
                <span class="NLM_cas:coden">CPDEFP</span>;
        ISSN:<span class="NLM_cas:issn">1381-6128</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">Human serum albumin (HSA), a major transport protein component in blood plasma, has been reported recently to play many important roles in pharmacotherapeutics development.  Owing to its promising intrinsic binding capability of drug mols., HSA offers favorable characteristics and can be directly used as its monomeric formula or can be fabricated into protein based nanoparticle platforms to realize the effective delivery of therapeutic mols. into targeted diseases areas.  In addn., HSA can also serve as a protein stabilizer or environment-responsive moieties to hybridize with the functional materials including polymers or inorg. nanoparticles through the covalent reactions or electrostatic interactions, and can thus greatly alter the relevant biol. distribution and pharmacokinetic behavior to improve their therapeutic efficacy.  By right, extensive studies have been conducted to develop HSA-conjugated pharmacotherapeutic agents toward effective in vitro and in vivo diseases diagnosis and treatment.  The current review gives an in-detail account of the latest progresses of HSA-based carriers as functional protein materials, mainly with respect to its conjugation types, formulation aspects, and importantly their promising applications towards enhanced drug delivery and medical diagnosis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrm8KeYtnh2ybVg90H21EOLACvtfcHk0lhGl1X7_i60HA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXls1als7g%253D&md5=ae9fb179bed5d22e48a6cc620f1196a1</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.2174%2F1381612821666150302115411&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F1381612821666150302115411%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DF.%26aulast%3DMu%26aufirst%3DJ.%26aulast%3DXing%26aufirst%3DB.%26atitle%3DRecent%2520advances%2520on%2520the%2520development%2520of%2520pharmacotherapeutic%2520agents%2520on%2520the%2520basis%2520of%2520human%2520serum%2520albumin%26jtitle%3DCurr.%2520Pharm.%2520Des.%26date%3D2015%26volume%3D21%26spage%3D1866%26epage%3D1888%26doi%3D10.2174%2F1381612821666150302115411" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span><span class="NLM_contrib-group">Fanali, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">di Masi, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Trezza, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marino, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fasano, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ascenzi, P.</span><span> </span><span class="NLM_article-title">Human serum albumin: from bench to bedside</span> <span class="citation_source-journal">Mol. Aspects Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">33</span><span class="NLM_x">, </span> <span class="NLM_fpage">209</span><span class="NLM_x">–</span> <span class="NLM_lpage">90</span><span class="refDoi"> DOI: 10.1016/j.mam.2011.12.002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00509&amp;key=10.1016%2Fj.mam.2011.12.002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00509&amp;key=22230555" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00509&amp;key=1%3ACAS%3A528%3ADC%252BC38Xls12hu7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=33&publication_year=2012&pages=209-90&author=G.+Fanaliauthor=A.+di+Masiauthor=V.+Trezzaauthor=M.+Marinoauthor=M.+Fasanoauthor=P.+Ascenzi&title=Human+serum+albumin%3A+from+bench+to+bedside&doi=10.1016%2Fj.mam.2011.12.002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Human serum albumin: From bench to bedside</span></div><div class="casAuthors">Fanali, Gabriella; di Masi, Alessandra; Trezza, Viviana; Marino, Maria; Fasano, Mauro; Ascenzi, Paolo</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Aspects of Medicine</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">33</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">209-290</span>CODEN:
                <span class="NLM_cas:coden">MAMED5</span>;
        ISSN:<span class="NLM_cas:issn">0098-2997</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  Human serum albumin (HSA), the most abundant protein in plasma, is a monomeric multi-domain macromol., representing the main determinant of plasma oncotic pressure and the main modulator of fluid distribution between body compartments.  HSA displays an extraordinary ligand binding capacity, providing a depot and carrier for many endogenous and exogenous compds.  Indeed, HSA represents the main carrier for fatty acids, affects pharmacokinetics of many drugs, provides the metabolic modification of some ligands, renders potential toxins harmless, accounts for most of the anti-oxidant capacity of human plasma, and displays (pseudo-)enzymic properties.  HSA is a valuable biomarker of many diseases, including cancer, rheumatoid arthritis, ischemia, post-menopausal obesity, severe acute graft-vs.-host disease, and diseases that need monitoring of the glycemic control.  Moreover, HSA is widely used clin. to treat several diseases, including hypovolemia, shock, burns, surgical blood loss, trauma, hemorrhage, cardiopulmonary bypass, acute respiratory distress syndrome, hemodialysis, acute liver failure, chronic liver disease, nutrition support, resuscitation, and hypoalbuminemia.  Recently, biotechnol. applications of HSA, including implantable biomaterials, surgical adhesives and sealants, biochromatog., ligand trapping, and fusion proteins, have been reported.  Here, genetic, biochem., biomedical, and biotechnol. aspects of HSA are reviewed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoxjvB_5YQuerVg90H21EOLACvtfcHk0liuppArjltO7Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xls12hu7w%253D&md5=976cbd0c53b93f77bc172f909ba6682a</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1016%2Fj.mam.2011.12.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.mam.2011.12.002%26sid%3Dliteratum%253Aachs%26aulast%3DFanali%26aufirst%3DG.%26aulast%3Ddi%2BMasi%26aufirst%3DA.%26aulast%3DTrezza%26aufirst%3DV.%26aulast%3DMarino%26aufirst%3DM.%26aulast%3DFasano%26aufirst%3DM.%26aulast%3DAscenzi%26aufirst%3DP.%26atitle%3DHuman%2520serum%2520albumin%253A%2520from%2520bench%2520to%2520bedside%26jtitle%3DMol.%2520Aspects%2520Med.%26date%3D2012%26volume%3D33%26spage%3D209%26epage%3D90%26doi%3D10.1016%2Fj.mam.2011.12.002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group">Peters, T.</span> <span class="citation_source-book">All about Albumin: Biochemistry, Genetics, and Medical Applications</span>; <span class="NLM_publisher-name">Academic Press</span>: <span class="NLM_publisher-loc">San Diego</span>,<span class="NLM_x"> </span><span class="NLM_year">1996</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=1996&author=T.+Peters&title=All+about+Albumin%3A+Biochemistry%2C+Genetics%2C+and+Medical+Applications"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26aulast%3DPeters%26aufirst%3DT.%26btitle%3DAll%2520about%2520Albumin%253A%2520Biochemistry%252C%2520Genetics%252C%2520and%2520Medical%2520Applications%26pub%3DAcademic%2520Press%26date%3D1996" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20"><span><span class="NLM_contrib-group">Ghuman, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zunszain, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Petitpas, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bhattacharya, A. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Otagiri, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Curry, S.</span><span> </span><span class="NLM_article-title">Structural basis of the drug-binding specificity of human serum albumin</span> <span class="citation_source-journal">J. Mol. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">353</span><span class="NLM_x">, </span> <span class="NLM_fpage">38</span><span class="NLM_x">–</span> <span class="NLM_lpage">52</span><span class="refDoi"> DOI: 10.1016/j.jmb.2005.07.075</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00509&amp;key=10.1016%2Fj.jmb.2005.07.075" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00509&amp;key=16169013" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00509&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhtVensrbJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=353&publication_year=2005&pages=38-52&author=J.+Ghumanauthor=P.+A.+Zunszainauthor=I.+Petitpasauthor=A.+A.+Bhattacharyaauthor=M.+Otagiriauthor=S.+Curry&title=Structural+basis+of+the+drug-binding+specificity+of+human+serum+albumin&doi=10.1016%2Fj.jmb.2005.07.075"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Structural Basis of the Drug-binding Specificity of Human Serum Albumin</span></div><div class="casAuthors">Ghuman, Jamie; Zunszain, Patricia A.; Petitpas, Isabelle; Bhattacharya, Ananyo A.; Otagiri, Masaki; Curry, Stephen</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Molecular Biology</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">353</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">38-52</span>CODEN:
                <span class="NLM_cas:coden">JMOBAK</span>;
        ISSN:<span class="NLM_cas:issn">0022-2836</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Human serum albumin (HSA) is an abundant plasma protein that binds a remarkably wide range of drugs, thereby restricting their free, active concns.  The problem of overcoming the binding affinity of lead compds. for HSA represents a major challenge in drug development.  Crystallog. anal. of 17 different complexes of HSA with a wide variety of drugs and small-mol. toxins reveals the precise architecture of the two primary drug-binding sites on the protein, identifying residues that are key determinants of binding specificity and illuminating the capacity of both pockets for flexible accommodation.  Numerous secondary binding sites for drugs distributed across the protein have also been identified.  The binding of fatty acids, the primary physiol. ligand for the protein, is shown to alter the polarity and increase the vol. of drug site 1.  These results clarify the interpretation of accumulated drug binding data and provide a valuable template for design efforts to modulate the interaction with HSA.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpyKWUfReJZ-bVg90H21EOLACvtfcHk0liuppArjltO7Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhtVensrbJ&md5=d82105920c360292329bf509667df42f</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1016%2Fj.jmb.2005.07.075&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jmb.2005.07.075%26sid%3Dliteratum%253Aachs%26aulast%3DGhuman%26aufirst%3DJ.%26aulast%3DZunszain%26aufirst%3DP.%2BA.%26aulast%3DPetitpas%26aufirst%3DI.%26aulast%3DBhattacharya%26aufirst%3DA.%2BA.%26aulast%3DOtagiri%26aufirst%3DM.%26aulast%3DCurry%26aufirst%3DS.%26atitle%3DStructural%2520basis%2520of%2520the%2520drug-binding%2520specificity%2520of%2520human%2520serum%2520albumin%26jtitle%3DJ.%2520Mol.%2520Biol.%26date%3D2005%26volume%3D353%26spage%3D38%26epage%3D52%26doi%3D10.1016%2Fj.jmb.2005.07.075" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21"><span><span class="NLM_contrib-group">Zsila, F.</span><span> </span><span class="NLM_article-title">Subdomain IB is the third major drug binding region of human serum albumin: toward the three-sites model</span> <span class="citation_source-journal">Mol. Pharmaceutics</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x">, </span> <span class="NLM_fpage">1668</span><span class="NLM_x">–</span> <span class="NLM_lpage">1682</span><span class="refDoi"> DOI: 10.1021/mp400027q</span> </span><div class="citationLinks">[<a href="/doi/10.1021/mp400027q" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00509&amp;key=1%3ACAS%3A528%3ADC%252BC3sXjslSgurs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2013&pages=1668-1682&author=F.+Zsila&title=Subdomain+IB+is+the+third+major+drug+binding+region+of+human+serum+albumin%3A+toward+the+three-sites+model&doi=10.1021%2Fmp400027q"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Subdomain IB Is the Third Major Drug Binding Region of Human Serum Albumin: Toward the Three-Sites Model</span></div><div class="casAuthors">Zsila, Ferenc</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Pharmaceutics</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1668-1682</span>CODEN:
                <span class="NLM_cas:coden">MPOHBP</span>;
        ISSN:<span class="NLM_cas:issn">1543-8384</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">According to the conventional view, noncovalent assocn. of small mols. with human serum albumin (HSA) occurs principally at the so-called Sudlow's sites located in subdomain IIA and IIIA.  By employing a CD spectroscopic approach, it is shown that biliverdin is the specific CD label of an addnl. drug binding area in subdomain IB.  CD competition expts. disclosed the entrapment of a diverse assortment of acidic, neutral, and basic mols. within subdomain IB including anticancer agents (camptothecin, doxorubicin, daunorubicin, teniposide, suramin, tyrosine kinase inhibitors), anticoagulants (dicoumarol), various steroids (bile acids, carbenoxolone), nonsteroidal antiinflammatory drugs, natural substances (aristolochic acid, glycyrrhetinic acid), and synthetic dyes (methyl orange, azocarmine B).  These finding imply that subdomain IB can be considered as the third major drug binding region of HSA featured with promiscuous ligand recognition ability.  Addnl., subdomain IB is allosterically coupled with the Sudlow's sites, the ligand binding of which is shown to alter the HSA binding mode and affinity of biliverdin and hemin.  Brief case studies are presented to illustrate how the evaluation of spectral changes of tetrapyrrole CD probes gains new insight into the HSA binding properties of endogenous as well as pharmaceutical compds.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGru_3GyTZnyF7Vg90H21EOLACvtfcHk0liuppArjltO7Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXjslSgurs%253D&md5=0244eaa1f7bb00e7d1038b3bffaa10ba</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1021%2Fmp400027q&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fmp400027q%26sid%3Dliteratum%253Aachs%26aulast%3DZsila%26aufirst%3DF.%26atitle%3DSubdomain%2520IB%2520is%2520the%2520third%2520major%2520drug%2520binding%2520region%2520of%2520human%2520serum%2520albumin%253A%2520toward%2520the%2520three-sites%2520model%26jtitle%3DMol.%2520Pharmaceutics%26date%3D2013%26volume%3D10%26spage%3D1668%26epage%3D1682%26doi%3D10.1021%2Fmp400027q" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22"><span><span class="NLM_contrib-group">Lambrinidis, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vallianatou, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsantili-Kakoulidou, A.</span><span> </span><span class="NLM_article-title">In vitro, in silico and integrated strategies for the estimation of plasma protein binding. A review</span> <span class="citation_source-journal">Adv. Drug Delivery Rev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">86</span><span class="NLM_x">, </span> <span class="NLM_fpage">27</span><span class="NLM_x">–</span> <span class="NLM_lpage">45</span><span class="refDoi"> DOI: 10.1016/j.addr.2015.03.011</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00509&amp;key=10.1016%2Fj.addr.2015.03.011" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00509&amp;key=25819487" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00509&amp;key=1%3ACAS%3A528%3ADC%252BC2MXlslCltbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=86&publication_year=2015&pages=27-45&author=G.+Lambrinidisauthor=T.+Vallianatouauthor=A.+Tsantili-Kakoulidou&title=In+vitro%2C+in+silico+and+integrated+strategies+for+the+estimation+of+plasma+protein+binding.+A+review&doi=10.1016%2Fj.addr.2015.03.011"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">In vitro, in silico and integrated strategies for the estimation of plasma protein binding. A review</span></div><div class="casAuthors">Lambrinidis, George; Vallianatou, Theodosia; Tsantili-Kakoulidou, Anna</div><div class="citationInfo"><span class="NLM_cas:title">Advanced Drug Delivery Reviews</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">86</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">27-45</span>CODEN:
                <span class="NLM_cas:coden">ADDREP</span>;
        ISSN:<span class="NLM_cas:issn">0169-409X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Plasma protein binding (PPB) strongly affects drug distribution and pharmacokinetic behavior with consequences in overall pharmacol. action.  Extended plasma protein binding may be assocd. with drug safety issues and several adverse effects, like low clearance, low brain penetration, drug-drug interactions, loss of efficacy, while influencing the fate of enantiomers and diastereoisomers by stereoselective binding within the body.  Therefore in holistic drug design approaches, where ADME(T) properties are considered in parallel with target affinity, considerable efforts are focused in early estn. of PPB mainly in regard to human serum albumin (HSA), which is the most abundant and most important plasma protein.  The second crit. serum protein α1-acid glycoprotein (AGP), although often underscored, plays also an important and complicated role in clin. therapy and thus the last years it has been studied thoroughly too.In the present review, after an overview of the principles of HSA and AGP binding as well as the structure topol. of the proteins, the current trends and perspectives in the field of PPB predictions are presented and discussed considering both HSA and AGP binding.  Since however for the latter protein systematic studies have started only the last years, the review focuses mainly to HSA.  One part of the review highlights the challenge to develop rapid techniques for HSA and AGP binding simulation and their performance in assessment of PPB.  The second part focuses on in silico approaches to predict HSA and AGP binding, analyzing and evaluating structure-based and ligand-based methods, as well as combination of both methods in the aim to exploit the different information and overcome the limitations of each individual approach.  Ligand-based methods use the Quant. Structure-Activity Relationships (QSAR) methodol. to establish quantitate models for the prediction of binding consts. from mol. descriptors, while they provide only indirect information on binding mechanism.  Efforts for the establishment of global models, automated workflows and web-based platforms for PPB predictions are presented and discussed.  Structure-based methods relying on the crystal structures of drug-protein complexes provide detailed information on the underlying mechanism but are usually restricted to specific compds.  They are useful to identify the specific binding site while they may be important in investigating drug-drug interactions, related to PPB.  Moreover, chemometrics or structure-based modeling may be supported by exptl. data a promising integrated alternative strategy for ADME(T) properties optimization.  In the case of PPB the use of mol. modeling combined with bioanal. techniques is frequently used for the investigation of AGP binding.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrO5Jya4dWQ6LVg90H21EOLACvtfcHk0lhFUAxH3UMNxQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXlslCltbo%253D&md5=06b12cb016d725b42c3f59af08919f4e</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1016%2Fj.addr.2015.03.011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.addr.2015.03.011%26sid%3Dliteratum%253Aachs%26aulast%3DLambrinidis%26aufirst%3DG.%26aulast%3DVallianatou%26aufirst%3DT.%26aulast%3DTsantili-Kakoulidou%26aufirst%3DA.%26atitle%3DIn%2520vitro%252C%2520in%2520silico%2520and%2520integrated%2520strategies%2520for%2520the%2520estimation%2520of%2520plasma%2520protein%2520binding.%2520A%2520review%26jtitle%3DAdv.%2520Drug%2520Delivery%2520Rev.%26date%3D2015%26volume%3D86%26spage%3D27%26epage%3D45%26doi%3D10.1016%2Fj.addr.2015.03.011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23"><span><span class="NLM_contrib-group">Kragh-Hansen, U.</span><span> </span><span class="NLM_article-title">Molecular and practical aspects of the enzymatic properties of human serum albumin and of albumin-ligand complexes</span> <span class="citation_source-journal">Biochim. Biophys. Acta, Gen. Subj.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">1830</span><span class="NLM_x">, </span> <span class="NLM_fpage">5535</span><span class="NLM_x">–</span> <span class="NLM_lpage">5544</span><span class="refDoi"> DOI: 10.1016/j.bbagen.2013.03.015</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00509&amp;key=10.1016%2Fj.bbagen.2013.03.015" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00509&amp;key=23528895" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00509&amp;key=1%3ACAS%3A528%3ADC%252BC3sXlvVWgs78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1830&publication_year=2013&pages=5535-5544&author=U.+Kragh-Hansen&title=Molecular+and+practical+aspects+of+the+enzymatic+properties+of+human+serum+albumin+and+of+albumin-ligand+complexes&doi=10.1016%2Fj.bbagen.2013.03.015"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Molecular and practical aspects of the enzymatic properties of human serum albumin and of albumin-ligand complexes</span></div><div class="casAuthors">Kragh-Hansen, Ulrich</div><div class="citationInfo"><span class="NLM_cas:title">Biochimica et Biophysica Acta, General Subjects</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">1830</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">5535-5544</span>CODEN:
                <span class="NLM_cas:coden">BBGSB3</span>;
        ISSN:<span class="NLM_cas:issn">0304-4165</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Human serum albumin (HSA) and some of its ligand complexes possess enzymic properties which are useful both in vivo and in vitro.  Here, the author summarizes present knowledge about mol. aspects, practical applications, and potentials of these properties.  The most pronounced activities of HSA are different types of hydrolysis.  Key examples are esterase-like activities involving Tyr-411 or Lys-199 and the thioesterase activity of Cys-34.  In the 1st case, hydrolysis involves water and both products are released, whereas in the latter cases one of the products is set free, and the other stays covalently bound to the protein.  However, the modified Cys-34 can be converted back to its reduced form by another compd./enzymic system.  Among the other activities are glucuronidase, phosphatase, and amidase as well as isomerase and dehydration properties.  HSA has great impact on the metab. of, e.g., eicosanoids and xenobiotics.  HSA with a metal ion-contg. complex is capable of facilitating reactions involving reactive O and reactive N species.  HSA is useful in detoxification reactions, for activating prodrugs, and for binding and activating drug conjugates.  HSA can be used to construct smart nanotubes with enzymic properties useful for biomedical applications.  The binding of org. compds. with a metal ion often results in metalloenzymes or can be used for nanoparticle formation.  Because any compd. acting as cofactor and/or the protein can be modified, enzymes can be constructed which are not naturally found and therefore can increase, often stereospecifically, the no. of catalytic reactions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrri2FcKt6EX7Vg90H21EOLACvtfcHk0lhFUAxH3UMNxQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXlvVWgs78%253D&md5=226207b69070320146e3fcf70b8af508</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1016%2Fj.bbagen.2013.03.015&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bbagen.2013.03.015%26sid%3Dliteratum%253Aachs%26aulast%3DKragh-Hansen%26aufirst%3DU.%26atitle%3DMolecular%2520and%2520practical%2520aspects%2520of%2520the%2520enzymatic%2520properties%2520of%2520human%2520serum%2520albumin%2520and%2520of%2520albumin-ligand%2520complexes%26jtitle%3DBiochim.%2520Biophys.%2520Acta%252C%2520Gen.%2520Subj.%26date%3D2013%26volume%3D1830%26spage%3D5535%26epage%3D5544%26doi%3D10.1016%2Fj.bbagen.2013.03.015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24"><span><span class="NLM_contrib-group">He, X. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carter, D. C.</span><span> </span><span class="NLM_article-title">Atomic structure and chemistry of human serum albumin</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1992</span><span class="NLM_x">, </span> <span class="NLM_volume">358</span><span class="NLM_x">, </span> <span class="NLM_fpage">209</span><span class="NLM_x">–</span> <span class="NLM_lpage">215</span><span class="refDoi"> DOI: 10.1038/358209a0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00509&amp;key=10.1038%2F358209a0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00509&amp;key=1630489" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00509&amp;key=1%3ACAS%3A528%3ADyaK38XlsVGmurg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=358&publication_year=1992&pages=209-215&author=X.+M.+Heauthor=D.+C.+Carter&title=Atomic+structure+and+chemistry+of+human+serum+albumin&doi=10.1038%2F358209a0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Atomic structure and chemistry of human serum albumin</span></div><div class="casAuthors">He, Xiao Min; Carter, Daniel C.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">1992</span>),
    <span class="NLM_cas:volume">358</span>
        (<span class="NLM_cas:issue">6383</span>),
    <span class="NLM_cas:pages">209-15</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    </div><div class="casAbstract">The three-dimensional structure of human serum albumin has been detd. crystallog. to a resoln. of 2.8 Å.  It comprises three homologous domains that assemble to form a heart-shaped mol.  Each domain is a product of two subdomains that possess common structural motifs.  The principal regions of ligand binding to human serum albumin are located in hydrophobic cavities in subdomains IIA and IIIA, which exhibit similar chem.  The structure explains numerous phys. phenomena and should provide insight into future pharmacokinetic and genetically engineered therapeutic applications of serum albumin.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqxk19HsvWbsbVg90H21EOLACvtfcHk0lhFUAxH3UMNxQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK38XlsVGmurg%253D&md5=19bf8b69b15e16b6cde6486a230431c8</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1038%2F358209a0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252F358209a0%26sid%3Dliteratum%253Aachs%26aulast%3DHe%26aufirst%3DX.%2BM.%26aulast%3DCarter%26aufirst%3DD.%2BC.%26atitle%3DAtomic%2520structure%2520and%2520chemistry%2520of%2520human%2520serum%2520albumin%26jtitle%3DNature%26date%3D1992%26volume%3D358%26spage%3D209%26epage%3D215%26doi%3D10.1038%2F358209a0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit25"><span><span class="NLM_contrib-group">Yang, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ma, Z. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, G. Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Qin, J. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lockridge, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liang, H.</span><span> </span><span class="NLM_article-title">Human serum albumin-based design of a diflunisal prodrug</span> <span class="citation_source-journal">Eur. J. Pharm. Biopharm.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">84</span><span class="NLM_x">, </span> <span class="NLM_fpage">549</span><span class="NLM_x">–</span> <span class="NLM_lpage">554</span><span class="refDoi"> DOI: 10.1016/j.ejpb.2013.01.013</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00509&amp;key=10.1016%2Fj.ejpb.2013.01.013" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00509&amp;key=23416065" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00509&amp;key=1%3ACAS%3A528%3ADC%252BC3sXns1Kgs7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=84&publication_year=2013&pages=549-554&author=F.+Yangauthor=Z.+Y.+Maauthor=Y.+Zhangauthor=G.+Q.+Liauthor=M.+Liauthor=J.+K.+Qinauthor=O.+Lockridgeauthor=H.+Liang&title=Human+serum+albumin-based+design+of+a+diflunisal+prodrug&doi=10.1016%2Fj.ejpb.2013.01.013"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Human serum albumin-based design of a diflunisal prodrug</span></div><div class="casAuthors">Yang, Feng; Ma, Zhi Yuan; Zhang, Yao; Li, Guo Qing; Li, Mei; Qin, Jiang Ke; Lockridge, Oksana; Liang, Hong</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Pharmaceutics and Biopharmaceutics</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">84</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">549-554</span>CODEN:
                <span class="NLM_cas:coden">EJPBEL</span>;
        ISSN:<span class="NLM_cas:issn">0939-6411</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The cyclooxygenase-2 inhibitor, diflunisal, is used in the clinic for its anti-inflammatory activity.  About 99% of a dose of diflunisal is unavailable for reaction with the target enzyme, because diflunisal strongly binds to human serum albumin (HSA).  To reduce the binding affinity of diflunisal to albumin, we designed and synthesized the prodrug acetyldiflunisal.  The crystal structure of HSA complexed with fatty acid and acetyldiflunisal revealed that acetyldiflunisal binds to the IIA subdomain and that upon binding, it acetylates lysine 199.  Mass spectrometry confirmed that acetyldiflunisal acetylates Lys199.  The acetylated albumin had twofold weaker binding affinity for diflunisal as demonstrated by fluorescence quenching.  Reduced binding affinity means that diflunisal is more easily released from acetylated albumin into the circulation.  Therefore, lower doses of acetyldiflunisal compared to diflunisal will be required.  Taken together, our results not only provide a template for design of HSA-based prodrugs, but also pave the way toward more effective use of diflunisal in the clinic.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo_hwUREiEoJLVg90H21EOLACvtfcHk0lirMTTLbDmyNg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXns1Kgs7k%253D&md5=f815912af39a7214fb73944d292c178a</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1016%2Fj.ejpb.2013.01.013&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejpb.2013.01.013%26sid%3Dliteratum%253Aachs%26aulast%3DYang%26aufirst%3DF.%26aulast%3DMa%26aufirst%3DZ.%2BY.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DLi%26aufirst%3DG.%2BQ.%26aulast%3DLi%26aufirst%3DM.%26aulast%3DQin%26aufirst%3DJ.%2BK.%26aulast%3DLockridge%26aufirst%3DO.%26aulast%3DLiang%26aufirst%3DH.%26atitle%3DHuman%2520serum%2520albumin-based%2520design%2520of%2520a%2520diflunisal%2520prodrug%26jtitle%3DEur.%2520J.%2520Pharm.%2520Biopharm.%26date%3D2013%26volume%3D84%26spage%3D549%26epage%3D554%26doi%3D10.1016%2Fj.ejpb.2013.01.013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="NLM_citation" id="cit26"><span><span class="NLM_contrib-group">Yang, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yue, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ma, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ma, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liang, H.</span><span> </span><span class="NLM_article-title">Interactive associations of drug-drug and drug-drug-drug with IIA subdomain of human serum albumin</span> <span class="citation_source-journal">Mol. Pharmaceutics</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x">, </span> <span class="NLM_fpage">3259</span><span class="NLM_x">–</span> <span class="NLM_lpage">3265</span><span class="refDoi"> DOI: 10.1021/mp300322y</span> </span><div class="citationLinks">[<a href="/doi/10.1021/mp300322y" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00509&amp;key=1%3ACAS%3A528%3ADC%252BC38Xhtl2rtrnM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2012&pages=3259-3265&author=F.+Yangauthor=J.+Yueauthor=L.+Maauthor=Z.+Maauthor=M.+Liauthor=X.+Wuauthor=H.+Liang&title=Interactive+associations+of+drug-drug+and+drug-drug-drug+with+IIA+subdomain+of+human+serum+albumin&doi=10.1021%2Fmp300322y"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">Interactive Associations of Drug-Drug and Drug-Drug-Drug with IIA Subdomain of Human Serum Albumin</span></div><div class="casAuthors">Yang, Feng; Yue, Jiping; Ma, Li; Ma, Zhiyuan; Li, Mei; Wu, Xiaoyang; Liang, Hong</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Pharmaceutics</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">3259-3265</span>CODEN:
                <span class="NLM_cas:coden">MPOHBP</span>;
        ISSN:<span class="NLM_cas:issn">1543-8384</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Owing to advantageous biochem. and pharmacol. properties of human serum albumin (HSA), HSA-based drug carrier is playing an increasing role in the clin. setting.  Since the IIA subdomain of HSA is a big hydrophobic cavity, we proposed that HSA delivers multiple drugs simultaneously docking on the IIA subdomain and that drugs may influence each other's binding affinity to albumin when cobinding the HSA IIA subdomain.  Therefore, we studied the interactive assocn. of drugs with the IIA subdomain of HSA by fluorescence spectroscopy and X-ray crystallog., in order to elucidate the mol. mechanism and behavior of drugs cobinding the IIA subdomain of HSA, and develop a universal structure-based model for HSA carrier design.  We solved HSA-fatty acid-cinnamic acid, HSA-fatty acid-cinnamic acid-indomethacin and HSA-fatty acid-cinnamic acid-indomethacin-lamivudine complex structures, resp.  HSA complex structures and fluorescence quenching of HSA revealed that different drugs can regulate binding sites, binding mode and binding affinity of each other.  For example, indomethacin renders cinnamic acid to make reposition, and decreases binding affinity of HSA for cinnamic acid, but increases binding affinity of itself to HSA.  Lamivudine makes cinnamic acid and indomethacin to bind new subsites.  Cinnamic acid-indomethacin enhances binding affinity of lamivudine, and cinnamic acid-lamivudine increases binding affinity of indomethacin, but indomethacin-lamivudine decreases binding affinity of cinnamic acid to HSA.  The study provided a biochem. basis for structure-guided development of HSA delivery system.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqgnqaryPC5-7Vg90H21EOLACvtfcHk0lirMTTLbDmyNg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xhtl2rtrnM&md5=a5e8ae79b334ddaec4ce1041ac771cac</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1021%2Fmp300322y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fmp300322y%26sid%3Dliteratum%253Aachs%26aulast%3DYang%26aufirst%3DF.%26aulast%3DYue%26aufirst%3DJ.%26aulast%3DMa%26aufirst%3DL.%26aulast%3DMa%26aufirst%3DZ.%26aulast%3DLi%26aufirst%3DM.%26aulast%3DWu%26aufirst%3DX.%26aulast%3DLiang%26aufirst%3DH.%26atitle%3DInteractive%2520associations%2520of%2520drug-drug%2520and%2520drug-drug-drug%2520with%2520IIA%2520subdomain%2520of%2520human%2520serum%2520albumin%26jtitle%3DMol.%2520Pharmaceutics%26date%3D2012%26volume%3D9%26spage%3D3259%26epage%3D3265%26doi%3D10.1021%2Fmp300322y" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref27"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref27'); return false;" data-citation="" class="refNumLink">27</a></strong><div class="NLM_citation" id="cit27"><span><span class="NLM_contrib-group">Durante, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Orienti, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Teti, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Salvatore, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Focaroli, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tesei, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pignatta, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Falconi, M.</span><span> </span><span class="NLM_article-title">Anti-tumor activity of fenretinide complexed with human serum albumin in lung cancer xenograft mouse model</span> <span class="citation_source-journal">Oncotarget.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">5</span><span class="NLM_x">, </span> <span class="NLM_fpage">4811</span><span class="NLM_x">–</span> <span class="NLM_lpage">4820</span><span class="refDoi"> DOI: 10.18632/oncotarget.2038</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00509&amp;key=10.18632%2Foncotarget.2038" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00509&amp;key=25015569" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00509&amp;key=1%3ACAS%3A280%3ADC%252BC2cbhsFarug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2014&pages=4811-4820&author=S.+Duranteauthor=I.+Orientiauthor=G.+Tetiauthor=V.+Salvatoreauthor=S.+Focaroliauthor=A.+Teseiauthor=S.+Pignattaauthor=M.+Falconi&title=Anti-tumor+activity+of+fenretinide+complexed+with+human+serum+albumin+in+lung+cancer+xenograft+mouse+model&doi=10.18632%2Foncotarget.2038"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Anti-tumor activity of fenretinide complexed with human serum albumin in lung cancer xenograft mouse model</span></div><div class="casAuthors">Durante Sandra; Falconi Mirella; Orienti Isabella; Teti Gabriella; Salvatore Viviana; Focaroli Stefano; Tesei Anna; Pignatta Sara</div><div class="citationInfo"><span class="NLM_cas:title">Oncotarget</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">4811-20</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Sufficient knowledge regarding cellular and molecular basis of lung cancer progression and metastasis would help in the development of novel and effective strategies for the treatment of lung cancer. 4HPR is a synthetic retinoid with potential anti-tumor activity but is still limited because of its poor bioavailability.  The use of albumin as a complexing agent for a hydrophobic drug is expected to improve the water solubility and consequently their bioavailability.This study investigated the antitumor activity of a novel complex between albumin and 4-HPR in a mouse model of human lung cancer and focuses on role and mechanism of Cav-1 mainly involved in regulating cancer and ACSVL3 mainly connected with tumor growth.  Their expressions were assayed by immunohistochemistry and qRT-PCR, to demonstrate the reduction of the tumor growth following the drug treatment.  Our results showed a high antitumor activity of 4HPR-HSA by reduction of the volume of tumor mass and the presence of a high level of apoptotic cell by TUNEL assay.  The downregulation of Cav-1 and ACSVL3 suggested a reduction of tumor growth.  In conclusion, we demonstrated the great potential of 4HPR-HSA in the treatment of lung cancer.  More data about the mechanism of drug delivery the 4HPR-HSA are necessary.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRQAYuurzxHUeWhZTslLrfffW6udTcc2ebnDuUXAGNVX7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2cbhsFarug%253D%253D&md5=b8179db2db32c1aafd302a7da6fdc5b7</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.18632%2Foncotarget.2038&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.18632%252Foncotarget.2038%26sid%3Dliteratum%253Aachs%26aulast%3DDurante%26aufirst%3DS.%26aulast%3DOrienti%26aufirst%3DI.%26aulast%3DTeti%26aufirst%3DG.%26aulast%3DSalvatore%26aufirst%3DV.%26aulast%3DFocaroli%26aufirst%3DS.%26aulast%3DTesei%26aufirst%3DA.%26aulast%3DPignatta%26aufirst%3DS.%26aulast%3DFalconi%26aufirst%3DM.%26atitle%3DAnti-tumor%2520activity%2520of%2520fenretinide%2520complexed%2520with%2520human%2520serum%2520albumin%2520in%2520lung%2520cancer%2520xenograft%2520mouse%2520model%26jtitle%3DOncotarget.%26date%3D2014%26volume%3D5%26spage%3D4811%26epage%3D4820%26doi%3D10.18632%2Foncotarget.2038" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref28"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref28'); return false;" data-citation="" class="refNumLink">28</a></strong><div class="NLM_citation" id="cit28"><span><span class="NLM_contrib-group">Sasson, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marcus, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lev-Goldman, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rubinraut, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fridkin, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shechter, Y.</span><span> </span><span class="NLM_article-title">Engineering prolonged-acting prodrugs employing an albumin-binding probe that undergoes slow hydrolysis at physiological conditions</span> <span class="citation_source-journal">J. Controlled Release</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">142</span><span class="NLM_x">, </span> <span class="NLM_fpage">214</span><span class="NLM_x">–</span> <span class="NLM_lpage">220</span><span class="refDoi"> DOI: 10.1016/j.jconrel.2009.10.028</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00509&amp;key=10.1016%2Fj.jconrel.2009.10.028" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00509&amp;key=19883707" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00509&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhvFehurk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=142&publication_year=2010&pages=214-220&author=K.+Sassonauthor=Y.+Marcusauthor=V.+Lev-Goldmanauthor=S.+Rubinrautauthor=M.+Fridkinauthor=Y.+Shechter&title=Engineering+prolonged-acting+prodrugs+employing+an+albumin-binding+probe+that+undergoes+slow+hydrolysis+at+physiological+conditions&doi=10.1016%2Fj.jconrel.2009.10.028"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">Engineering prolonged-acting prodrugs employing an albumin-binding probe that undergoes slow hydrolysis at physiological conditions</span></div><div class="casAuthors">Sasson, K.; Marcus, Y.; Lev-Goldman, V.; Rubinraut, S.; Fridkin, M.; Shechter, Y.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Controlled Release</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">142</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">214-220</span>CODEN:
                <span class="NLM_cas:coden">JCREEC</span>;
        ISSN:<span class="NLM_cas:issn">0168-3659</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Here we describe the design and application of OSu-FMS-MAL-S-(CH2)15-COOH, an agent that assocs. with albumin while linked to a peptide or a protein with sufficient affinity (Ka = 2 to 2.6 × 105 M- 1) to protract the action of short- lived peptides and proteins in vivo.  Under physiol. conditions this probe undergoes spontaneous hydrolysis with the concomitant reactivation of inactive conjugates.  I.v. administered 125I-labeled-Insulin-FMS-MAL-S-(CH2)15-COOH to rats shows half-life of 17 ± 2 h, exceeding 5.2 times that obtained with i.v. administered 125I-labeled Insulin.  In mice this deriv. facilitates glucose-lowering effect over a period of 24 h, yielding AUC five times greater than that obtained by a similar dose of insulin-detemir.  Similarly, s.c. administration of Exendin-4-FMS-MAL-S-(CH2)15-COOH into mice facilitated prolonged and stable redn. in glucose level, yielding a t1/2 value of 28 ± 2 h, exceeding the effect of exendin-4 4.7 folds.  The inactive deriv. gentamicin-FMS-MAL-S-(CH2)15-COOH regained its full antibacterial potency upon incubation at physiol. conditions yielding a t1/2 value of 7.1 ± 0.2 h.  In conclusion, the albumin-binding probe we introduced enables to prolong the action of any amino contg. mol. in vivo, without the drawback of inactivation that often occurs upon such derivatization.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGovYJ3iL1DddbVg90H21EOLACvtfcHk0ljqQ4yAudrd0Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhvFehurk%253D&md5=2daf59c742b023abd376af6a4d24487f</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1016%2Fj.jconrel.2009.10.028&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jconrel.2009.10.028%26sid%3Dliteratum%253Aachs%26aulast%3DSasson%26aufirst%3DK.%26aulast%3DMarcus%26aufirst%3DY.%26aulast%3DLev-Goldman%26aufirst%3DV.%26aulast%3DRubinraut%26aufirst%3DS.%26aulast%3DFridkin%26aufirst%3DM.%26aulast%3DShechter%26aufirst%3DY.%26atitle%3DEngineering%2520prolonged-acting%2520prodrugs%2520employing%2520an%2520albumin-binding%2520probe%2520that%2520undergoes%2520slow%2520hydrolysis%2520at%2520physiological%2520conditions%26jtitle%3DJ.%2520Controlled%2520Release%26date%3D2010%26volume%3D142%26spage%3D214%26epage%3D220%26doi%3D10.1016%2Fj.jconrel.2009.10.028" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref29"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref29'); return false;" data-citation="" class="refNumLink">29</a></strong><div class="NLM_citation" id="cit29"><span><span class="NLM_contrib-group">Kratz, F.</span><span> </span><span class="NLM_article-title">Albumin as a drug carrier: design of prodrugs, drug conjugates and nanoparticles</span> <span class="citation_source-journal">J. Controlled Release</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">132</span><span class="NLM_x">, </span> <span class="NLM_fpage">171</span><span class="NLM_x">–</span> <span class="NLM_lpage">183</span><span class="refDoi"> DOI: 10.1016/j.jconrel.2008.05.010</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00509&amp;key=10.1016%2Fj.jconrel.2008.05.010" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00509&amp;key=18582981" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00509&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhsVensLvP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=132&publication_year=2008&pages=171-183&author=F.+Kratz&title=Albumin+as+a+drug+carrier%3A+design+of+prodrugs%2C+drug+conjugates+and+nanoparticles&doi=10.1016%2Fj.jconrel.2008.05.010"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Albumin as a drug carrier: Design of prodrugs, drug conjugates and nanoparticles</span></div><div class="casAuthors">Kratz, Felix</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Controlled Release</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">132</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">171-183</span>CODEN:
                <span class="NLM_cas:coden">JCREEC</span>;
        ISSN:<span class="NLM_cas:issn">0168-3659</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Albumin is playing an increasing role as a drug carrier in the clin. setting.  Principally, three drug delivery technologies can be distinguished: coupling of low-mol. wt. drugs to exogenous or endogenous albumin, conjugation with bioactive proteins and encapsulation of drugs into albumin nanoparticles.  The accumulation of albumin in solid tumors forms the rationale for developing albumin-based drug delivery systems for tumor targeting.  Clin., a methotrexate-albumin conjugate, an albumin-binding prodrug of doxorubicin, i.e. the (6-maleimido)caproylhydrazone deriv. of doxorubicin (DOXO-EMCH), and an albumin paclitaxel nanoparticle (Abraxane) have been evaluated clin.  Abraxane has been approved for treating metastatic breast cancer.  An alternative strategy is to bind a therapeutic peptide or protein covalently or phys. to albumin to enhance its stability and half-life.  This approach has been applied to peptides with antinociceptive, antidiabetes, antitumor or antiviral activity: Levemir, a myristic acid deriv. of insulin that binds to the fatty acid binding sites of circulating albumin, has been approved for the treatment of diabetes.  Furthermore, Albuferon, a fusion protein of albumin and interferon, is currently being assessed in phase III clin. trials for the treatment of hepatitis C and could become an alternative to pegylated interferon.  This review gives an account of the different drug delivery systems which make use of albumin as a drug carrier with a focus on those systems that have reached an advanced stage of preclin. evaluation or that have entered clin. trials.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoPSwOkIFOBr7Vg90H21EOLACvtfcHk0ljqQ4yAudrd0Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhsVensLvP&md5=32729be05d7227de8b6a5c8d8d890e38</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1016%2Fj.jconrel.2008.05.010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jconrel.2008.05.010%26sid%3Dliteratum%253Aachs%26aulast%3DKratz%26aufirst%3DF.%26atitle%3DAlbumin%2520as%2520a%2520drug%2520carrier%253A%2520design%2520of%2520prodrugs%252C%2520drug%2520conjugates%2520and%2520nanoparticles%26jtitle%3DJ.%2520Controlled%2520Release%26date%3D2008%26volume%3D132%26spage%3D171%26epage%3D183%26doi%3D10.1016%2Fj.jconrel.2008.05.010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref30"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref30'); return false;" data-citation="" class="refNumLink">30</a></strong><div class="NLM_citation" id="cit30"><span><span class="NLM_contrib-group">Gou, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liang, H.</span><span> </span><span class="NLM_article-title">Designing prodrugs based on special residues of human serum albumin</span> <span class="citation_source-journal">Curr. Top. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">16</span><span class="NLM_x">, </span> <span class="NLM_fpage">996</span><span class="NLM_x">–</span> <span class="NLM_lpage">1008</span><span class="refDoi"> DOI: 10.2174/1568026615666150825142908</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00509&amp;key=10.2174%2F1568026615666150825142908" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00509&amp;key=26303424" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00509&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhvFGkurjJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2016&pages=996-1008&author=Y.+Gouauthor=F.+Yangauthor=H.+Liang&title=Designing+prodrugs+based+on+special+residues+of+human+serum+albumin&doi=10.2174%2F1568026615666150825142908"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Designing Prodrugs Based on Special Residues of Human Serum Albumin</span></div><div class="casAuthors">Gou, Yi; Yang, Feng; Liang, Hong</div><div class="citationInfo"><span class="NLM_cas:title">Current Topics in Medicinal Chemistry (Sharjah, United Arab Emirates)</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">996-1008</span>CODEN:
                <span class="NLM_cas:coden">CTMCCL</span>;
        ISSN:<span class="NLM_cas:issn">1568-0266</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">Human serum albumin (HSA) is the most abundant protein in the plasma.  HSA plays a central role in drug pharmacokinetics because most drugs bound to HSA are delivered to their target organ/tissues.  The prodrug strategies have shown great promise for improving the activity and selectivity of drugs.  Designing prodrugs based on special HSA residues, such as Cys34 and Lys residues, has been extensively studied.  Therefore, this review provides an overview of the development of nonsteroidal anti-inflammatory and anticancer prodrugs based on these special residues.  In conclusion, this review may guide the rational design and development of new prodrugs for future clin. applications.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrUircGh2an-7Vg90H21EOLACvtfcHk0ljqQ4yAudrd0Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhvFGkurjJ&md5=9a9401879ba2d7ec9e9b2acb12714eed</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.2174%2F1568026615666150825142908&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F1568026615666150825142908%26sid%3Dliteratum%253Aachs%26aulast%3DGou%26aufirst%3DY.%26aulast%3DYang%26aufirst%3DF.%26aulast%3DLiang%26aufirst%3DH.%26atitle%3DDesigning%2520prodrugs%2520based%2520on%2520special%2520residues%2520of%2520human%2520serum%2520albumin%26jtitle%3DCurr.%2520Top.%2520Med.%2520Chem.%26date%3D2016%26volume%3D16%26spage%3D996%26epage%3D1008%26doi%3D10.2174%2F1568026615666150825142908" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref31"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref31'); return false;" data-citation="" class="refNumLink">31</a></strong><div class="NLM_citation" id="cit31"><span><span class="NLM_contrib-group">Elsadek, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kratz, F.</span><span> </span><span class="NLM_article-title">Impact of albumin on drug delivery—New applications on the horizon</span> <span class="citation_source-journal">J. Controlled Release</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">157</span><span class="NLM_x">, </span> <span class="NLM_fpage">4</span><span class="NLM_x">–</span> <span class="NLM_lpage">28</span><span class="refDoi"> DOI: 10.1016/j.jconrel.2011.09.069</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00509&amp;key=10.1016%2Fj.jconrel.2011.09.069" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00509&amp;key=21959118" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00509&amp;key=1%3ACAS%3A528%3ADC%252BC38XntFyguw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=157&publication_year=2012&pages=4-28&author=B.+Elsadekauthor=F.+Kratz&title=Impact+of+albumin+on+drug+delivery%E2%80%94New+applications+on+the+horizon&doi=10.1016%2Fj.jconrel.2011.09.069"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">Impact of albumin on drug delivery - New applications on the horizon</span></div><div class="casAuthors">Elsadek, Bakheet; Kratz, Felix</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Controlled Release</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">157</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">4-28</span>CODEN:
                <span class="NLM_cas:coden">JCREEC</span>;
        ISSN:<span class="NLM_cas:issn">0168-3659</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Over the past decades, albumin has emerged as a versatile carrier for therapeutic and diagnostic agents, primarily for diagnosing and treating diabetes, cancer, rheumatoid arthritis and infectious diseases.  Market approved products include fatty acid derivs. of human insulin or the glucagon-like-1 peptide (Levemir and Victoza) for treating diabetes, the taxol albumin nanoparticle Abraxane for treating metastatic breast cancer which is also under clin. investigation in further tumor indications, and 99mTc-aggregated albumin (Nanocoll and Albures) for diagnosing cancer and rheumatoid arthritis as well as for lymphoscintigraphy.  In addn., an increasing no. of albumin-based or albumin-binding drugs are in clin. trials such as antibody fusion proteins (MM-111) for treating HER2/neu pos. breast cancer (phase I), a camelid albumin-binding nanobody anti-HSA-anti-TNF-α (ATN-103) in phase II studies for treating rheumatoid arthritis, an antidiabetic Exendin-4 analog bound to recombinant human albumin (phase I/II), a fluorescein-labeled albumin conjugate (AFL)-human serum albumin for visualizing the malignant borders of brain tumors for improved surgical resection, and finally an albumin-binding prodrug of doxorubicin (INNO-206) entering phase II studies against sarcoma and gastric cancer.  In the preclin. setting, novel approaches include attaching peptides with high-affinity for albumin to antibody fragments, the exploitation of albumin-binding gadolinium contrast agents for magnetic resonance imaging, and phys. or covalent attachment of antiviral, antibacterial, and anticancer drugs to albumin that are permanently or transiently attached to human serum albumin (HSA) or act as albumin-binding prodrugs.  This review gives an overview of the expanding field of preclin. and clin. drug applications and developments that use albumin as a protein carrier to improve the pharmacokinetic profile of the drug or to target the drug to the pathogenic site addressing diseases with unmet medical needs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq-TUARuO_GX7Vg90H21EOLACvtfcHk0ljkQe14oDhJvw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XntFyguw%253D%253D&md5=04108fb5645788a1d61484df344a47a5</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1016%2Fj.jconrel.2011.09.069&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jconrel.2011.09.069%26sid%3Dliteratum%253Aachs%26aulast%3DElsadek%26aufirst%3DB.%26aulast%3DKratz%26aufirst%3DF.%26atitle%3DImpact%2520of%2520albumin%2520on%2520drug%2520delivery%25E2%2580%2594New%2520applications%2520on%2520the%2520horizon%26jtitle%3DJ.%2520Controlled%2520Release%26date%3D2012%26volume%3D157%26spage%3D4%26epage%3D28%26doi%3D10.1016%2Fj.jconrel.2011.09.069" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref32"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref32'); return false;" data-citation="" class="refNumLink">32</a></strong><div class="NLM_citation" id="cit32"><span><span class="NLM_contrib-group">Zhang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ho, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yue, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kong, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhou, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liang, H.</span><span> </span><span class="NLM_article-title">Structural basis and anticancer properties of ruthenium-based drug complexed with human serum albumin</span> <span class="citation_source-journal">Eur. J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">86</span><span class="NLM_x">, </span> <span class="NLM_fpage">449</span><span class="NLM_x">–</span> <span class="NLM_lpage">455</span><span class="refDoi"> DOI: 10.1016/j.ejmech.2014.08.071</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00509&amp;key=10.1016%2Fj.ejmech.2014.08.071" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00509&amp;key=25200980" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00509&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhsFSjt7vE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=86&publication_year=2014&pages=449-455&author=Y.+Zhangauthor=A.+Hoauthor=J.+Yueauthor=L.+Kongauthor=Z.+Zhouauthor=X.+Wuauthor=F.+Yangauthor=H.+Liang&title=Structural+basis+and+anticancer+properties+of+ruthenium-based+drug+complexed+with+human+serum+albumin&doi=10.1016%2Fj.ejmech.2014.08.071"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">Structural basis and anticancer properties of ruthenium-based drug complexed with human serum albumin</span></div><div class="casAuthors">Zhang, Yao; Ho, Andy; Yue, Jiping; Kong, Linlin; Zhou, Zuping; Wu, Xiaoyang; Yang, Feng; Liang, Hong</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">86</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">449-455</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">Ruthenium-based anticancer complexes have become increasingly popular for study over the last two decades.  Although ruthenium complexes are currently being investigated in clin. trials, there are still some difficulties with their delivery and assocd. side effects.  Human serum albumin (HSA)-based delivery systems are promising for improving anticancer drug targeting and reducing neg. side effects.  However, there have been few studies regarding the HSA delivery system for metal-based anticancer compds. and no mention of its structural mechanism.  Therefore, we studied the structure and anticancer properties of the ruthenium-based compd. [RuCl5(ind)]2- in complex with HSA.  The structure revealed that [RuCl5(ind)]2- has two binding sites in HSA.  In the IB subdomain, [RuCl5(ind)]2- binds to a new sub-site by coordinating with His-146.  In the IIA subdomain, ruthenium (III) of [RuCl5(ind)]2- binds to the hydrophobic cavity and forms coordination bonds by replacing chlorine atoms with the His-242 and Lys-199 residues of HSA.  Interestingly, [RuCl5(ind)]2-, together with HSA, can enhance cytotoxicity by two to five times in cancer cells but has no effect on normal cells in vitro.  Compared with unbound drug, the HSA-[RuCl5(ind)]2- complex promotes MGC-803 cell apoptosis and also has a stronger capacity for cell cycle arrest at the G2 phase in MGC-803.  In conclusion, this study will guide the rational design and development of ruthenium-contg. or ruthenium-centered drugs and an HSA delivery system for ruthenium-based drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoyudavla2evbVg90H21EOLACvtfcHk0ljkQe14oDhJvw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhsFSjt7vE&md5=b2bf15b76c83ea83e8327f626bafc60a</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2014.08.071&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2014.08.071%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DHo%26aufirst%3DA.%26aulast%3DYue%26aufirst%3DJ.%26aulast%3DKong%26aufirst%3DL.%26aulast%3DZhou%26aufirst%3DZ.%26aulast%3DWu%26aufirst%3DX.%26aulast%3DYang%26aufirst%3DF.%26aulast%3DLiang%26aufirst%3DH.%26atitle%3DStructural%2520basis%2520and%2520anticancer%2520properties%2520of%2520ruthenium-based%2520drug%2520complexed%2520with%2520human%2520serum%2520albumin%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2014%26volume%3D86%26spage%3D449%26epage%3D455%26doi%3D10.1016%2Fj.ejmech.2014.08.071" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref33"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref33'); return false;" data-citation="" class="refNumLink">33</a></strong><div class="NLM_citation" id="cit33"><span><span class="NLM_contrib-group">Gou, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Qi, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ajayi, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhou, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liang, H.</span><span> </span><span class="NLM_article-title">Developing anticancer copper(II) prodrugs based on the nature of cancer cells and the human serum albumin carrier IIA subdomain</span> <span class="citation_source-journal">Mol. Pharmaceutics</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">12</span><span class="NLM_x">, </span> <span class="NLM_fpage">3597</span><span class="NLM_x">–</span> <span class="NLM_lpage">3609</span><span class="refDoi"> DOI: 10.1021/acs.molpharmaceut.5b00314</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.molpharmaceut.5b00314" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00509&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhsVOnsrbE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2015&pages=3597-3609&author=Y.+Gouauthor=J.+Qiauthor=J.+P.+Ajayiauthor=Y.+Zhangauthor=Z.+Zhouauthor=F.+Yangauthor=H.+Liang&title=Developing+anticancer+copper%28II%29+prodrugs+based+on+the+nature+of+cancer+cells+and+the+human+serum+albumin+carrier+IIA+subdomain&doi=10.1021%2Facs.molpharmaceut.5b00314"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">Developing Anticancer Copper(II) Pro-drugs Based on the Nature of Cancer Cells and the Human Serum Albumin Carrier IIA Subdomain</span></div><div class="casAuthors">Gou, Yi; Qi, Jinxu; Ajayi, Joshua-Paul; Zhang, Yao; Zhou, Zuping; Wu, Xiaoyang; Yang, Feng; Liang, Hong</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Pharmaceutics</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">3597-3609</span>CODEN:
                <span class="NLM_cas:coden">MPOHBP</span>;
        ISSN:<span class="NLM_cas:issn">1543-8384</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">To synergistically enhance the selectivity and efficiency of anticancer copper drugs, we proposed and built a model to develop anticancer copper pro-drugs based on the nature of human serum albumin (HSA) IIA subdomain and cancer cells.  Three copper(II) compds. of a 2-hydroxy-1-naphthaldehyde benzoyl hydrazone Schiff-base ligand in the presence pyridine, imidazole, or indazole ligands were synthesized (C1-C3).  The structures of three HSA complexes revealed that the Cu compds. bind to the hydrophobic cavity in the HSA IIA subdomain.  Among them, the pyridine and imidazole ligands of C1 and C2 are replaced by Lys199, and His242 directly coordinates with Cu(II).  The indazole and Br ligands of C3 are replaced by Lys199 and His242, resp.  Compared with the Cu(II) compds. alone, the HSA complexes enhance cytotoxicity in MCF-7 cells approx. 3-5-fold, but do not raise cytotoxicity levels in normal cells in vitro through selectively accumulating in cancer cells to some extent.  We find that the HSA complex has a stronger capacity for cell cycle arrest in the G2/M phase of MCF-7 by targeting cyclin-dependent kinase 1 (CDK1) and down-regulating the expression of CDK1 and cyclin B1.  Moreover, the HSA complex promotes MCF-7 cell apoptosis possibly through the intrinsic reactive oxygen species (ROS) mediated mitochondrial pathway, accompanied by the regulation of Bcl-2 family proteins.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoQC67vwTNSRLVg90H21EOLACvtfcHk0ljkQe14oDhJvw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhsVOnsrbE&md5=c1977caff60b0d3a7ca3f47ce443c886</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1021%2Facs.molpharmaceut.5b00314&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.molpharmaceut.5b00314%26sid%3Dliteratum%253Aachs%26aulast%3DGou%26aufirst%3DY.%26aulast%3DQi%26aufirst%3DJ.%26aulast%3DAjayi%26aufirst%3DJ.%2BP.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DZhou%26aufirst%3DZ.%26aulast%3DYang%26aufirst%3DF.%26aulast%3DLiang%26aufirst%3DH.%26atitle%3DDeveloping%2520anticancer%2520copper%2528II%2529%2520prodrugs%2520based%2520on%2520the%2520nature%2520of%2520cancer%2520cells%2520and%2520the%2520human%2520serum%2520albumin%2520carrier%2520IIA%2520subdomain%26jtitle%3DMol.%2520Pharmaceutics%26date%3D2015%26volume%3D12%26spage%3D3597%26epage%3D3609%26doi%3D10.1021%2Facs.molpharmaceut.5b00314" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref34"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref34'); return false;" data-citation="" class="refNumLink">34</a></strong><div class="NLM_citation" id="cit34"><span><span class="NLM_contrib-group">Qi, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gou, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhou, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liang, H.</span><span> </span><span class="NLM_article-title">Developing an anticancer copper(II) prodrug based on the His242 residue of the human serum albumin carrier IIA subdomain</span> <span class="citation_source-journal">Mol. Pharmaceutics</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">13</span><span class="NLM_x">, </span> <span class="NLM_fpage">1501</span><span class="NLM_x">–</span> <span class="NLM_lpage">1507</span><span class="refDoi"> DOI: 10.1021/acs.molpharmaceut.5b00938</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.molpharmaceut.5b00938" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00509&amp;key=1%3ACAS%3A528%3ADC%252BC28XkvVahurg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2016&pages=1501-1507&author=J.+Qiauthor=Y.+Zhangauthor=Y.+Gouauthor=Z.+Zhangauthor=Z.+Zhouauthor=X.+Wuauthor=F.+Yangauthor=H.+Liang&title=Developing+an+anticancer+copper%28II%29+prodrug+based+on+the+His242+residue+of+the+human+serum+albumin+carrier+IIA+subdomain&doi=10.1021%2Facs.molpharmaceut.5b00938"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">Developing an Anticancer Copper(II) Pro-Drug Based on the His242 Residue of the Human Serum Albumin Carrier IIA Subdomain</span></div><div class="casAuthors">Qi, Jinxu; Zhang, Yao; Gou, Yi; Zhang, Zhenlei; Zhou, Zuping; Wu, Xiaoyang; Yang, Feng; Liang, Hong</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Pharmaceutics</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1501-1507</span>CODEN:
                <span class="NLM_cas:coden">MPOHBP</span>;
        ISSN:<span class="NLM_cas:issn">1543-8384</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">To increase delivery efficiency, anticancer activity, and selectivity of anticancer metal agents in vivo, we proposed to develop the anticancer metal pro-drug based on His242 residue of the human serum albumin (HSA) carrier IIA subdomain.  To confirm our hypothesis, we prepd. two Cu(II) compds. [Cu(P4 mT)Cl and Cu(Bp44 mT)Cl] by modifying Cu(II) compd. ligand structure.  Studies with two HSA complex structures revealed that Cu(P4 mT)Cl bound to the HSA subdomain IIA via hydrophobic interactions, but Cu(Bp44 mT)Cl bound to the HSA subdomain IIA via His242 replacement of a Cl atom of Cu(Bp44 mT)Cl, and a coordination to Cu2+.  Furthermore, Cu(II) compds. released from HSA could be regulated at different pHs.  In vivo data revealed that the HSA-Cu(Bp44 mT) complex increased copper's selectivity and capacity of inhibiting tumor growth compared to Cu(Bp44 mT)Cl alone.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqHVA5oWe9GUbVg90H21EOLACvtfcHk0lhF4o5CkZIdig"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XkvVahurg%253D&md5=590fcfb50f0478829e3435277c6e8fd3</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1021%2Facs.molpharmaceut.5b00938&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.molpharmaceut.5b00938%26sid%3Dliteratum%253Aachs%26aulast%3DQi%26aufirst%3DJ.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DGou%26aufirst%3DY.%26aulast%3DZhang%26aufirst%3DZ.%26aulast%3DZhou%26aufirst%3DZ.%26aulast%3DWu%26aufirst%3DX.%26aulast%3DYang%26aufirst%3DF.%26aulast%3DLiang%26aufirst%3DH.%26atitle%3DDeveloping%2520an%2520anticancer%2520copper%2528II%2529%2520prodrug%2520based%2520on%2520the%2520His242%2520residue%2520of%2520the%2520human%2520serum%2520albumin%2520carrier%2520IIA%2520subdomain%26jtitle%3DMol.%2520Pharmaceutics%26date%3D2016%26volume%3D13%26spage%3D1501%26epage%3D1507%26doi%3D10.1021%2Facs.molpharmaceut.5b00938" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref35"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref35'); return false;" data-citation="" class="refNumLink">35</a></strong><div class="NLM_citation" id="cit35"><span><span class="NLM_contrib-group">Torre, L. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bray, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Siegel, R. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ferlay, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lortet-Tieulent, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jemal, A.</span><span> </span><span class="NLM_article-title">Global cancer statistics, 2012</span> <span class="citation_source-journal">Ca-Cancer J. Clin.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">65</span><span class="NLM_x">, </span> <span class="NLM_fpage">87</span><span class="NLM_x">–</span> <span class="NLM_lpage">108</span><span class="refDoi"> DOI: 10.3322/caac.21262</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00509&amp;key=10.3322%2Fcaac.21262" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00509&amp;key=25651787" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00509&amp;key=1%3ACAS%3A280%3ADC%252BC2Mris1Ggsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=65&publication_year=2015&pages=87-108&author=L.+A.+Torreauthor=F.+Brayauthor=R.+L.+Siegelauthor=J.+Ferlayauthor=J.+Lortet-Tieulentauthor=A.+Jemal&title=Global+cancer+statistics%2C+2012&doi=10.3322%2Fcaac.21262"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">Global cancer statistics, 2012</span></div><div class="casAuthors">Torre Lindsey A; Bray Freddie; Siegel Rebecca L; Ferlay Jacques; Lortet-Tieulent Joannie; Jemal Ahmedin</div><div class="citationInfo"><span class="NLM_cas:title">CA: a cancer journal for clinicians</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">65</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">87-108</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Cancer constitutes an enormous burden on society in more and less economically developed countries alike.  The occurrence of cancer is increasing because of the growth and aging of the population, as well as an increasing prevalence of established risk factors such as smoking, overweight, physical inactivity, and changing reproductive patterns associated with urbanization and economic development.  Based on GLOBOCAN estimates, about 14.1 million new cancer cases and 8.2 million deaths occurred in 2012 worldwide.  Over the years, the burden has shifted to less developed countries, which currently account for about 57% of cases and 65% of cancer deaths worldwide.  Lung cancer is the leading cause of cancer death among males in both more and less developed countries, and has surpassed breast cancer as the leading cause of cancer death among females in more developed countries; breast cancer remains the leading cause of cancer death among females in less developed countries.  Other leading causes of cancer death in more developed countries include colorectal cancer among males and females and prostate cancer among males.  In less developed countries, liver and stomach cancer among males and cervical cancer among females are also leading causes of cancer death.  Although incidence rates for all cancers combined are nearly twice as high in more developed than in less developed countries in both males and females, mortality rates are only 8% to 15% higher in more developed countries.  This disparity reflects regional differences in the mix of cancers, which is affected by risk factors and detection practices, and/or the availability of treatment.  Risk factors associated with the leading causes of cancer death include tobacco use (lung, colorectal, stomach, and liver cancer), overweight/obesity and physical inactivity (breast and colorectal cancer), and infection (liver, stomach, and cervical cancer).  A substantial portion of cancer cases and deaths could be prevented by broadly applying effective prevention measures, such as tobacco control, vaccination, and the use of early detection tests.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcS93OidvnAA79ts4TFFB11gfW6udTcc2eYzw8P_7Nhpjrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2Mris1Ggsg%253D%253D&md5=f008b208320b129e10c7c383193ff772</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.3322%2Fcaac.21262&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3322%252Fcaac.21262%26sid%3Dliteratum%253Aachs%26aulast%3DTorre%26aufirst%3DL.%2BA.%26aulast%3DBray%26aufirst%3DF.%26aulast%3DSiegel%26aufirst%3DR.%2BL.%26aulast%3DFerlay%26aufirst%3DJ.%26aulast%3DLortet-Tieulent%26aufirst%3DJ.%26aulast%3DJemal%26aufirst%3DA.%26atitle%3DGlobal%2520cancer%2520statistics%252C%25202012%26jtitle%3DCa-Cancer%2520J.%2520Clin.%26date%3D2015%26volume%3D65%26spage%3D87%26epage%3D108%26doi%3D10.3322%2Fcaac.21262" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref36"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref36'); return false;" data-citation="" class="refNumLink">36</a></strong><div class="NLM_citation" id="cit36"><span><span class="NLM_contrib-group">Lovejoy, D. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Richardson, D. R.</span><span> </span><span class="NLM_article-title">Novel ″hybrid″ iron chelators derived from aroylhydrazones and thiosemicarbazones demonstrate selective antiproliferative activity against tumor cells</span> <span class="citation_source-journal">Blood</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">100</span><span class="NLM_x">, </span> <span class="NLM_fpage">666</span><span class="NLM_x">–</span> <span class="NLM_lpage">676</span><span class="refDoi"> DOI: 10.1182/blood.V100.2.666</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00509&amp;key=10.1182%2Fblood.V100.2.666" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=100&publication_year=2002&pages=666-676&author=D.+B.+Lovejoyauthor=D.+R.+Richardson&title=Novel+%E2%80%B3hybrid%E2%80%B3+iron+chelators+derived+from+aroylhydrazones+and+thiosemicarbazones+demonstrate+selective+antiproliferative+activity+against+tumor+cells&doi=10.1182%2Fblood.V100.2.666"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1182%2Fblood.V100.2.666&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood.V100.2.666%26sid%3Dliteratum%253Aachs%26aulast%3DLovejoy%26aufirst%3DD.%2BB.%26aulast%3DRichardson%26aufirst%3DD.%2BR.%26atitle%3DNovel%2520%25E2%2580%25B3hybrid%25E2%2580%25B3%2520iron%2520chelators%2520derived%2520from%2520aroylhydrazones%2520and%2520thiosemicarbazones%2520demonstrate%2520selective%2520antiproliferative%2520activity%2520against%2520tumor%2520cells%26jtitle%3DBlood%26date%3D2002%26volume%3D100%26spage%3D666%26epage%3D676%26doi%3D10.1182%2Fblood.V100.2.666" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref37"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref37'); return false;" data-citation="" class="refNumLink">37</a></strong><div class="NLM_citation" id="cit37"><span><span class="NLM_contrib-group">Ferraro, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Massai, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Messori, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Merlino, A.</span><span> </span><span class="NLM_article-title">Cisplatin binding to human serum albumin: a structural study</span> <span class="citation_source-journal">Chem. Commun.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">51</span><span class="NLM_x">, </span> <span class="NLM_fpage">9436</span><span class="NLM_x">–</span> <span class="NLM_lpage">9439</span><span class="refDoi"> DOI: 10.1039/C5CC01751C</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00509&amp;key=10.1039%2FC5CC01751C" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00509&amp;key=25873085" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00509&amp;key=1%3ACAS%3A528%3ADC%252BC2MXmt1WlsL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2015&pages=9436-9439&author=G.+Ferraroauthor=L.+Massaiauthor=L.+Messoriauthor=A.+Merlino&title=Cisplatin+binding+to+human+serum+albumin%3A+a+structural+study&doi=10.1039%2FC5CC01751C"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">Cisplatin binding to human serum albumin: a structural study</span></div><div class="casAuthors">Ferraro, Giarita; Massai, Lara; Messori, Luigi; Merlino, Antonello</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Communications (Cambridge, United Kingdom)</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">51</span>
        (<span class="NLM_cas:issue">46</span>),
    <span class="NLM_cas:pages">9436-9439</span>CODEN:
                <span class="NLM_cas:coden">CHCOFS</span>;
        ISSN:<span class="NLM_cas:issn">1359-7345</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">The reaction between cisplatin and human serum albumin (HSA) was investigated by X-ray crystallog. and crystal structures of the cisplatin/HSA adduct were eventually solved for the first time.  Structural data unambiguously prove that cisplatin mainly binds to His105 and Met329 side chains; addnl. binding sites are detected at His288, Met298, and Met548 and at His535, His67 and His247.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrsyb8t3PkHAbVg90H21EOLACvtfcHk0lhF4o5CkZIdig"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXmt1WlsL8%253D&md5=f33fc82894330a0397afc82c4a45e3d8</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1039%2FC5CC01751C&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252FC5CC01751C%26sid%3Dliteratum%253Aachs%26aulast%3DFerraro%26aufirst%3DG.%26aulast%3DMassai%26aufirst%3DL.%26aulast%3DMessori%26aufirst%3DL.%26aulast%3DMerlino%26aufirst%3DA.%26atitle%3DCisplatin%2520binding%2520to%2520human%2520serum%2520albumin%253A%2520a%2520structural%2520study%26jtitle%3DChem.%2520Commun.%26date%3D2015%26volume%3D51%26spage%3D9436%26epage%3D9439%26doi%3D10.1039%2FC5CC01751C" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref38"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref38'); return false;" data-citation="" class="refNumLink">38</a></strong><div class="NLM_citation" id="cit38"><span><span class="NLM_contrib-group">Desai, N.</span><span> </span><span class="NLM_article-title">Nab Technology: A drug delivery platform utilizing endothelial gp60 receptor-based transport and tumor derived SPARC for targeting</span>.  <span class="citation_source-book">Drug Delivery Report Winter 2007/008</span>,<span class="NLM_x"> </span><span class="NLM_year">2007</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2007&author=N.+Desai&title=Drug+Delivery+Report+Winter+2007%2F008"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26aulast%3DDesai%26aufirst%3DN.%26atitle%3DNab%2520Technology%253A%2520A%2520drug%2520delivery%2520platform%2520utilizing%2520endothelial%2520gp60%2520receptor-based%2520transport%2520and%2520tumor%2520derived%2520SPARC%2520for%2520targeting%26btitle%3DDrug%2520Delivery%2520Report%2520Winter%25202007%252F008%26date%3D2007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref39"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref39'); return false;" data-citation="" class="refNumLink">39</a></strong><div class="NLM_citation" id="cit39"><span><span class="NLM_contrib-group">Atorrasagasti, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Malvicini, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aquino, J. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alaniz, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Garcia, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bolontrade, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rizzo, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Podhajcer, O. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mazzolini, G.</span><span> </span><span class="NLM_article-title">Overexpression of SPARC obliterates the in vivo tumorigenicity of human hepatocellular carcinoma cells</span> <span class="citation_source-journal">Int. J. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">126</span><span class="NLM_x">, </span> <span class="NLM_fpage">2726</span><span class="NLM_x">–</span> <span class="NLM_lpage">2740</span><span class="refDoi"> DOI: 10.1002/ijc.24966</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00509&amp;key=10.1002%2Fijc.24966" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00509&amp;key=19830689" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00509&amp;key=1%3ACAS%3A528%3ADC%252BC3cXjvFKlsb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=126&publication_year=2010&pages=2726-2740&author=C.+Atorrasagastiauthor=M.+Malviciniauthor=J.+B.+Aquinoauthor=L.+Alanizauthor=M.+Garciaauthor=M.+Bolontradeauthor=M.+Rizzoauthor=O.+L.+Podhajcerauthor=G.+Mazzolini&title=Overexpression+of+SPARC+obliterates+the+in+vivo+tumorigenicity+of+human+hepatocellular+carcinoma+cells&doi=10.1002%2Fijc.24966"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">Overexpression of SPARC obliterates the in vivo tumorigenicity of human hepatocellular carcinoma cells</span></div><div class="casAuthors">Atorrasagasti, Catalina; Malvicini, Mariana; Aquino, Jorge B.; Alaniz, Laura; Garcia, Mariana; Bolontrade, Marcela; Rizzo, Manglio; Podhajcer, Osvaldo L.; Mazzolini, Guillermo</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Cancer</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">126</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">2726-2740</span>CODEN:
                <span class="NLM_cas:coden">IJCNAW</span>;
        ISSN:<span class="NLM_cas:issn">0020-7136</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Liss, Inc.</span>)
        </div><div class="casAbstract">Hepatocellular carcinoma (HCC) is the sixth most common cancer and the third leading cause of cancer-related death worldwide.  Current treatments are extremely disappointing.  SPARC (Secreted protein, acidic and rich in cysteine) is a matricellular glycoprotein with differential expression in several tumors, including HCC, which significance remains unclear.  We infected HCC cells (HepG2, Hep3B and Huh7) with an adenovirus expressing SPARC (AdsSPARC) to examine the role of SPARC expression on HCC cells and its effect on tumor aggressiveness.  The in vitro HCC cells substrate-dependent proliferation and cell cycle profile were unaffected; however, SPARC overexpression reduced HCC proliferation when cells were grown in spheroids.  A mild induction of cellular apoptosis was obsd. upon SPARC overexpression.  SPARC overexpression resulted in spheroid growth inhibition in vitro while no effects were found when recombinant SPARC was exogenously applied.  Moreover, the clonogenic and migratory capabilities were largely decreased in SPARC-overexpressing HCC cells, altogether suggesting a less aggressive HCC cell phenotype.  Consistently, AdsSPARC-transduced cells showed increased E-cadherin expression and a concomitant decrease in N-cadherin expression.  Furthermore, SPARC overexpression was found to reduce HCC cell viability in response to 5-FU-based chemotherapy in vitro, partially through induction of apoptosis.  In vivo expts. revealed that SPARC overexpression in HCC cells inhibited their tumorigenic capacity and increased animal survival through a mechanism that partially involves host macrophages.  Our data suggest that SPARC overexpression in HCC cells results in a reduced tumorigenicity partially through the induction of mesenchymal-to-epithelial transition (MET).  These evidences point to SPARC as a novel target for HCC treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqh5waYevKpQLVg90H21EOLACvtfcHk0li6sXG7Ce5BHg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXjvFKlsb0%253D&md5=e4247112eb4f96badc4e0798525bc8ff</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1002%2Fijc.24966&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fijc.24966%26sid%3Dliteratum%253Aachs%26aulast%3DAtorrasagasti%26aufirst%3DC.%26aulast%3DMalvicini%26aufirst%3DM.%26aulast%3DAquino%26aufirst%3DJ.%2BB.%26aulast%3DAlaniz%26aufirst%3DL.%26aulast%3DGarcia%26aufirst%3DM.%26aulast%3DBolontrade%26aufirst%3DM.%26aulast%3DRizzo%26aufirst%3DM.%26aulast%3DPodhajcer%26aufirst%3DO.%2BL.%26aulast%3DMazzolini%26aufirst%3DG.%26atitle%3DOverexpression%2520of%2520SPARC%2520obliterates%2520the%2520in%2520vivo%2520tumorigenicity%2520of%2520human%2520hepatocellular%2520carcinoma%2520cells%26jtitle%3DInt.%2520J.%2520Cancer%26date%3D2010%26volume%3D126%26spage%3D2726%26epage%3D2740%26doi%3D10.1002%2Fijc.24966" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref40"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref40'); return false;" data-citation="" class="refNumLink">40</a></strong><div class="NLM_citation" id="cit40"><span><span class="NLM_contrib-group">Tiruppathi, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Naqvi, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vogel, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Minshall, R. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Malik, A. B.</span><span> </span><span class="NLM_article-title">Albumin mediates the transcytosis of myeloperoxidase by means of caveolae in endothelial cells</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U. S. A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">101</span><span class="NLM_x">, </span> <span class="NLM_fpage">7699</span><span class="NLM_x">–</span> <span class="NLM_lpage">7704</span><span class="refDoi"> DOI: 10.1073/pnas.0401712101</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00509&amp;key=10.1073%2Fpnas.0401712101" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=101&publication_year=2004&pages=7699-7704&author=C.+Tiruppathiauthor=T.+Naqviauthor=Y.+Wuauthor=S.+M.+Vogelauthor=R.+D.+Minshallauthor=A.+B.+Malik&title=Albumin+mediates+the+transcytosis+of+myeloperoxidase+by+means+of+caveolae+in+endothelial+cells&doi=10.1073%2Fpnas.0401712101"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1073%2Fpnas.0401712101&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.0401712101%26sid%3Dliteratum%253Aachs%26aulast%3DTiruppathi%26aufirst%3DC.%26aulast%3DNaqvi%26aufirst%3DT.%26aulast%3DWu%26aufirst%3DY.%26aulast%3DVogel%26aufirst%3DS.%2BM.%26aulast%3DMinshall%26aufirst%3DR.%2BD.%26aulast%3DMalik%26aufirst%3DA.%2BB.%26atitle%3DAlbumin%2520mediates%2520the%2520transcytosis%2520of%2520myeloperoxidase%2520by%2520means%2520of%2520caveolae%2520in%2520endothelial%2520cells%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2004%26volume%3D101%26spage%3D7699%26epage%3D7704%26doi%3D10.1073%2Fpnas.0401712101" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref41"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref41'); return false;" data-citation="" class="refNumLink">41</a></strong><div class="NLM_citation" id="cit41"><span><span class="NLM_contrib-group">Larsen, A. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Escargueil, A. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Skladanowski, A.</span><span> </span><span class="NLM_article-title">Catalytic topoisomerase II inhibitors in cancer therapy</span> <span class="citation_source-journal">Pharmacol. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">99</span><span class="NLM_x">, </span> <span class="NLM_fpage">167</span><span class="NLM_x">–</span> <span class="NLM_lpage">181</span><span class="refDoi"> DOI: 10.1016/S0163-7258(03)00058-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00509&amp;key=10.1016%2FS0163-7258%2803%2900058-5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00509&amp;key=12888111" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00509&amp;key=1%3ACAS%3A528%3ADC%252BD3sXlvVWhtL0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=99&publication_year=2003&pages=167-181&author=A.+K.+Larsenauthor=A.+E.+Escargueilauthor=A.+Skladanowski&title=Catalytic+topoisomerase+II+inhibitors+in+cancer+therapy&doi=10.1016%2FS0163-7258%2803%2900058-5"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit41R"><div class="casContent"><span class="casTitleNuber">41</span><div class="casTitle"><span class="NLM_cas:atitle">Catalytic topoisomerase II inhibitors in cancer therapy</span></div><div class="casAuthors">Larsen, Annette K.; Escargueil, Alexandre E.; Skladanowski, Andrzej</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacology & Therapeutics</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">99</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">167-181</span>CODEN:
                <span class="NLM_cas:coden">PHTHDT</span>;
        ISSN:<span class="NLM_cas:issn">0163-7258</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science B.V.</span>)
        </div><div class="casAbstract">A review.  The nuclear enzyme DNA topoisomerase II is a major target for antineoplastic agents.  All topoisomerase II-directed agents are able to interfere with at least one step of the catalytic cycle.  Agents able to stabilize the covalent DNA topoisomerase II complex (also known as the cleavable complex) are traditionally called topoisomerase II poisons, while agents acting on any of the other steps in the catalytic cycle are called catalytic inhibitors.  Thus, catalytic topoisomerase II inhibitors are a heterogeneous group of compds. that might interfere with the binding between DNA and topoisomerase II (aclarubicin and suramin), stabilize noncovalent DNA topoisomerase II complexes (merbarone, ICRF-187, and structurally related bisdioxopiperazine derivs.), or inhibit ATP binding (novobiocin).  Some, such as fostriecin, may also have alternative biol. targets.  Whereas topoisomerase II poisons are used solely for their antitumor activities, catalytic inhibitors are utilized for a variety of reasons, including their activity as antineoplastic agents (aclarubicin and MST-16), cardioprotectors (ICRF-187), or modulators in order to increase the efficacy of other agents (suramin and novobiocin).  In this review, the mechanism and biol. activity of different catalytic inhibitors is described, with emphasis on therapeutically used compds.  We will then discuss future development and applications of this interesting class of compds.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGote2bOTWP17bVg90H21EOLACvtfcHk0li6sXG7Ce5BHg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXlvVWhtL0%253D&md5=4207fb899e2b98345f97e91983514913</span></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1016%2FS0163-7258%2803%2900058-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0163-7258%252803%252900058-5%26sid%3Dliteratum%253Aachs%26aulast%3DLarsen%26aufirst%3DA.%2BK.%26aulast%3DEscargueil%26aufirst%3DA.%2BE.%26aulast%3DSkladanowski%26aufirst%3DA.%26atitle%3DCatalytic%2520topoisomerase%2520II%2520inhibitors%2520in%2520cancer%2520therapy%26jtitle%3DPharmacol.%2520Ther.%26date%3D2003%26volume%3D99%26spage%3D167%26epage%3D181%26doi%3D10.1016%2FS0163-7258%2803%2900058-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref42"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref42'); return false;" data-citation="" class="refNumLink">42</a></strong><div class="NLM_citation" id="cit42"><span><span class="NLM_contrib-group">Zeglis, B. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Divilov, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lewis, J. S.</span><span> </span><span class="NLM_article-title">Role of metalation in the topoisomerase IIα inhibition and antiproliferation activity of a series of α-heterocyclic-N4-substituted thiosemicarbazones and their Cu(II) complexes</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">54</span><span class="NLM_x">, </span> <span class="NLM_fpage">2391</span><span class="NLM_x">–</span> <span class="NLM_lpage">2398</span><span class="refDoi"> DOI: 10.1021/jm101532u</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm101532u" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00509&amp;key=1%3ACAS%3A528%3ADC%252BC3MXivFygsLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2011&pages=2391-2398&author=B.+M.+Zeglisauthor=V.+Divilovauthor=J.+S.+Lewis&title=Role+of+metalation+in+the+topoisomerase+II%CE%B1+inhibition+and+antiproliferation+activity+of+a+series+of+%CE%B1-heterocyclic-N4-substituted+thiosemicarbazones+and+their+Cu%28II%29+complexes&doi=10.1021%2Fjm101532u"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit42R"><div class="casContent"><span class="casTitleNuber">42</span><div class="casTitle"><span class="NLM_cas:atitle">Role of metalation in the topoisomerase IIα inhibition and antiproliferation activity of a series of α-heterocyclic-N4-substituted thiosemicarbazones and their Cu(II) complexes</span></div><div class="casAuthors">Zeglis, Brian M.; Divilov, Vadim; Lewis, Jason S.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">2391-2398</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The topoisomerase-IIα inhibition and antiproliferative activity of α-heterocyclic thiosemicarbazones and their corresponding copper(II) complexes have been investigated.  The CuII(thiosemicarbazonato)Cl complexes were shown to catalytically inhibit topoisomerase-IIα at concns. (0.3-7.2 μM) over an order of magnitude lower than their corresponding thiosemicarbazone ligands alone.  The copper complexes were also shown to inhibit the proliferation of breast cancer cells expressing high levels of topoisomerase-IIα (SK-BR-3) at lower concns. than cells expressing lower levels of the enzyme (MCF-7).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo59ej6iFerf7Vg90H21EOLACvtfcHk0li6sXG7Ce5BHg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXivFygsLk%253D&md5=9f6215d0b0fbfd470b24d777122658db</span></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1021%2Fjm101532u&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm101532u%26sid%3Dliteratum%253Aachs%26aulast%3DZeglis%26aufirst%3DB.%2BM.%26aulast%3DDivilov%26aufirst%3DV.%26aulast%3DLewis%26aufirst%3DJ.%2BS.%26atitle%3DRole%2520of%2520metalation%2520in%2520the%2520topoisomerase%2520II%25CE%25B1%2520inhibition%2520and%2520antiproliferation%2520activity%2520of%2520a%2520series%2520of%2520%25CE%25B1-heterocyclic-N4-substituted%2520thiosemicarbazones%2520and%2520their%2520Cu%2528II%2529%2520complexes%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2011%26volume%3D54%26spage%3D2391%26epage%3D2398%26doi%3D10.1021%2Fjm101532u" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref43"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref43'); return false;" data-citation="" class="refNumLink">43</a></strong><div class="NLM_citation" id="cit43"><span><span class="NLM_contrib-group">Miller, M. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bastow, K. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stineman, C. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vance, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Song, S. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">West, D. X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hall, I. H.</span><span> </span><span class="NLM_article-title">The cytotoxicity of 2-formyl and 2-acetyl-(6-picolyl)-4N-substituted thiosemicarbazones and their copper(II) complexes</span> <span class="citation_source-journal">Arch. Pharm.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1998</span><span class="NLM_x">, </span> <span class="NLM_volume">331</span><span class="NLM_x">, </span> <span class="NLM_fpage">121</span><span class="NLM_x">–</span> <span class="NLM_lpage">127</span><span class="refDoi"> DOI: 10.1002/(SICI)1521-4184(199804)331:4<121::AID-ARDP121>3.3.CO;2-K</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00509&amp;key=10.1002%2F%28SICI%291521-4184%28199804%29331%3A4%3C121%3A%3AAID-ARDP121%3E3.3.CO%3B2-K" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00509&amp;key=9648520" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00509&amp;key=1%3ACAS%3A528%3ADyaK1cXjs1Ghtr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=331&publication_year=1998&pages=121-127&author=M.+C.+Millerauthor=K.+F.+Bastowauthor=C.+N.+Stinemanauthor=J.+R.+Vanceauthor=S.+C.+Songauthor=D.+X.+Westauthor=I.+H.+Hall&title=The+cytotoxicity+of+2-formyl+and+2-acetyl-%286-picolyl%29-4N-substituted+thiosemicarbazones+and+their+copper%28II%29+complexes&doi=10.1002%2F%28SICI%291521-4184%28199804%29331%3A4%3C121%3A%3AAID-ARDP121%3E3.3.CO%3B2-K"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit43R"><div class="casContent"><span class="casTitleNuber">43</span><div class="casTitle"><span class="NLM_cas:atitle">The cytotoxicity of 2-formyl and 2-acetyl-(6-picolyl)-4N-substituted thiosemicarbazones and their copper(II) complexes</span></div><div class="casAuthors">Miller, Merrill C.; Bastow, Kenneth F., III; Stineman, Christa N.; Vance, John R.; Song, Sun C.; West, Douglas X.; Hall, Iris H.</div><div class="citationInfo"><span class="NLM_cas:title">Archiv der Pharmazie (Weinheim, Germany)</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">331</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">121-127</span>CODEN:
                <span class="NLM_cas:coden">ARPMAS</span>;
        ISSN:<span class="NLM_cas:issn">0365-6233</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH</span>)
        </div><div class="casAbstract">2-Acetyl-(6-picolyl)-4N-substituted thiosemicarbazones and their Cu(II) complexes were shown to be potent antineoplastic and cytotoxic agents against murine and human cultured cells.  Numerous derivs. were as active against solid tumor growth as clin. useful agents.  The agents inhibited L1210 DNA and RNA syntheses with inhibition of key regulatory enzyme activities of the purine pathway as well as nucleoside kinase activities.  D[NTP] pools were reduced and DNA strand scission occurred.  These agents were DNA topoisomerase II inhibitors with lower IC50 values than that of VP-16.  However, they did not cause L1210 DNA protein linked breaks and actually protected against those breaks afforded by VP-16.  The agents were not synergistic with VP-16 in reducing cell growth or DNA synthesis although they did reduce growth of L1210 cells in agar suspended media.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqnDY-qmYHwS7Vg90H21EOLACvtfcHk0liN47ey55xQAw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXjs1Ghtr0%253D&md5=bbe6bb5147cf27395e83f1d3a8cee20b</span></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.1002%2F%28SICI%291521-4184%28199804%29331%3A4%3C121%3A%3AAID-ARDP121%3E3.3.CO%3B2-K&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252F%2528SICI%25291521-4184%2528199804%2529331%253A4%253C121%253A%253AAID-ARDP121%253E3.3.CO%253B2-K%26sid%3Dliteratum%253Aachs%26aulast%3DMiller%26aufirst%3DM.%2BC.%26aulast%3DBastow%26aufirst%3DK.%2BF.%26aulast%3DStineman%26aufirst%3DC.%2BN.%26aulast%3DVance%26aufirst%3DJ.%2BR.%26aulast%3DSong%26aufirst%3DS.%2BC.%26aulast%3DWest%26aufirst%3DD.%2BX.%26aulast%3DHall%26aufirst%3DI.%2BH.%26atitle%3DThe%2520cytotoxicity%2520of%25202-formyl%2520and%25202-acetyl-%25286-picolyl%2529-4N-substituted%2520thiosemicarbazones%2520and%2520their%2520copper%2528II%2529%2520complexes%26jtitle%3DArch.%2520Pharm.%26date%3D1998%26volume%3D331%26spage%3D121%26epage%3D127%26doi%3D10.1002%2F%28SICI%291521-4184%28199804%29331%3A4%3C121%3A%3AAID-ARDP121%3E3.3.CO%3B2-K" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref44"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref44'); return false;" data-citation="" class="refNumLink">44</a></strong><div class="NLM_citation" id="cit44"><span><span class="NLM_contrib-group">Huang, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ku, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meng, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhu, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jiang, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ding, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, H.</span><span> </span><span class="NLM_article-title">A series of alpha-heterocyclic carboxaldehyde thiosemicarbazones inhibit topoisomerase-II catalytic activity</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">53</span><span class="NLM_x">, </span> <span class="NLM_fpage">3048</span><span class="NLM_x">–</span> <span class="NLM_lpage">3064</span><span class="refDoi"> DOI: 10.1021/jm9014394</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm9014394" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2010&pages=3048-3064&author=H.+Huangauthor=W.+Chenauthor=X.+Kuauthor=L.+Mengauthor=L.+Linauthor=X.+Wangauthor=C.+Zhuauthor=Y.+Wangauthor=Z.+Chenauthor=M.+Liauthor=H.+Jiangauthor=K.+Chenauthor=J.+Dingauthor=H.+Liu&title=A+series+of+alpha-heterocyclic+carboxaldehyde+thiosemicarbazones+inhibit+topoisomerase-II+catalytic+activity&doi=10.1021%2Fjm9014394"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.1021%2Fjm9014394&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm9014394%26sid%3Dliteratum%253Aachs%26aulast%3DHuang%26aufirst%3DH.%26aulast%3DChen%26aufirst%3DW.%26aulast%3DKu%26aufirst%3DX.%26aulast%3DMeng%26aufirst%3DL.%26aulast%3DLin%26aufirst%3DL.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DZhu%26aufirst%3DC.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DChen%26aufirst%3DZ.%26aulast%3DLi%26aufirst%3DM.%26aulast%3DJiang%26aufirst%3DH.%26aulast%3DChen%26aufirst%3DK.%26aulast%3DDing%26aufirst%3DJ.%26aulast%3DLiu%26aufirst%3DH.%26atitle%3DA%2520series%2520of%2520alpha-heterocyclic%2520carboxaldehyde%2520thiosemicarbazones%2520inhibit%2520topoisomerase-II%2520catalytic%2520activity%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2010%26volume%3D53%26spage%3D3048%26epage%3D3064%26doi%3D10.1021%2Fjm9014394" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref45"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref45'); return false;" data-citation="" class="refNumLink">45</a></strong><div class="NLM_citation" id="cit45"><span><span class="NLM_contrib-group">Rao, V. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Klein, S. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Agama, K. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Toyoda, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Adachi, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pommier, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shacter, E. B.</span><span> </span><span class="NLM_article-title">The iron chelator Dp44mT causes DNA damage and selective inhibition of topoisomerase-II in breast cancer cells</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">69</span><span class="NLM_x">, </span> <span class="NLM_fpage">948</span><span class="NLM_x">–</span> <span class="NLM_lpage">957</span><span class="refDoi"> DOI: 10.1158/0008-5472.CAN-08-1437</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00509&amp;key=10.1158%2F0008-5472.CAN-08-1437" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=69&publication_year=2009&pages=948-957&author=V.+A.+Raoauthor=S.+R.+Kleinauthor=K.+K.+Agamaauthor=E.+Toyodaauthor=N.+Adachiauthor=Y.+Pommierauthor=E.+B.+Shacter&title=The+iron+chelator+Dp44mT+causes+DNA+damage+and+selective+inhibition+of+topoisomerase-II+in+breast+cancer+cells&doi=10.1158%2F0008-5472.CAN-08-1437"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-08-1437&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-08-1437%26sid%3Dliteratum%253Aachs%26aulast%3DRao%26aufirst%3DV.%2BA.%26aulast%3DKlein%26aufirst%3DS.%2BR.%26aulast%3DAgama%26aufirst%3DK.%2BK.%26aulast%3DToyoda%26aufirst%3DE.%26aulast%3DAdachi%26aufirst%3DN.%26aulast%3DPommier%26aufirst%3DY.%26aulast%3DShacter%26aufirst%3DE.%2BB.%26atitle%3DThe%2520iron%2520chelator%2520Dp44mT%2520causes%2520DNA%2520damage%2520and%2520selective%2520inhibition%2520of%2520topoisomerase-II%2520in%2520breast%2520cancer%2520cells%26jtitle%3DCancer%2520Res.%26date%3D2009%26volume%3D69%26spage%3D948%26epage%3D957%26doi%3D10.1158%2F0008-5472.CAN-08-1437" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref46"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref46'); return false;" data-citation="" class="refNumLink">46</a></strong><div class="NLM_citation" id="cit46"><span><span class="NLM_contrib-group">Eastman, A.</span><span> </span><span class="NLM_article-title">Cell cycle checkpoints and their impact on anticancer therapeutic strategies</span> <span class="citation_source-journal">J. Cell. Biochem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">91</span><span class="NLM_x">, </span> <span class="NLM_fpage">223</span><span class="NLM_x">–</span> <span class="NLM_lpage">231</span><span class="refDoi"> DOI: 10.1002/jcb.10699</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00509&amp;key=10.1002%2Fjcb.10699" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=91&publication_year=2004&pages=223-231&author=A.+Eastman&title=Cell+cycle+checkpoints+and+their+impact+on+anticancer+therapeutic+strategies&doi=10.1002%2Fjcb.10699"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.1002%2Fjcb.10699&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fjcb.10699%26sid%3Dliteratum%253Aachs%26aulast%3DEastman%26aufirst%3DA.%26atitle%3DCell%2520cycle%2520checkpoints%2520and%2520their%2520impact%2520on%2520anticancer%2520therapeutic%2520strategies%26jtitle%3DJ.%2520Cell.%2520Biochem.%26date%3D2004%26volume%3D91%26spage%3D223%26epage%3D231%26doi%3D10.1002%2Fjcb.10699" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref47"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref47'); return false;" data-citation="" class="refNumLink">47</a></strong><div class="NLM_citation" id="cit47"><span><span class="NLM_contrib-group">Masai, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Matsumoto, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">You, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yoshizawa-Sugata, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oda, M.</span><span> </span><span class="NLM_article-title">Eukaryotic chromosome DNA replication: where, when, and how?</span> <span class="citation_source-journal">Annu. Rev. Biochem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">79</span><span class="NLM_x">, </span> <span class="NLM_fpage">89</span><span class="NLM_x">–</span> <span class="NLM_lpage">130</span><span class="refDoi"> DOI: 10.1146/annurev.biochem.052308.103205</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00509&amp;key=10.1146%2Fannurev.biochem.052308.103205" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00509&amp;key=20373915" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00509&amp;key=1%3ACAS%3A528%3ADC%252BC3cXpslShsbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=79&publication_year=2010&pages=89-130&author=H.+Masaiauthor=S.+Matsumotoauthor=Z.+Youauthor=N.+Yoshizawa-Sugataauthor=M.+Oda&title=Eukaryotic+chromosome+DNA+replication%3A+where%2C+when%2C+and+how%3F&doi=10.1146%2Fannurev.biochem.052308.103205"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit47R"><div class="casContent"><span class="casTitleNuber">47</span><div class="casTitle"><span class="NLM_cas:atitle">Eukaryotic chromosome DNA replication: where, when, and how?</span></div><div class="casAuthors">Masai, Hisao; Matsumoto, Seiji; You, Zhiying; Yoshizawa-Sugata, Naoko; Oda, Masako</div><div class="citationInfo"><span class="NLM_cas:title">Annual Review of Biochemistry</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">79</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">89-130</span>CODEN:
                <span class="NLM_cas:coden">ARBOAW</span>;
        ISSN:<span class="NLM_cas:issn">0066-4154</span>.
    
            (<span class="NLM_cas:orgname">Annual Reviews Inc.</span>)
        </div><div class="casAbstract">A review.  DNA replication is central to cell proliferation.  Studies in the past six decades since the proposal of a semiconservative mode of DNA replication have confirmed the high degree of conservation of the basic machinery of DNA replication from prokaryotes to eukaryotes.  However, the need for replication of a substantially longer segment of DNA in coordination with various internal and external signals in eukaryotic cells has led to more complex and versatile regulatory strategies.  The replication program in higher eukaryotes is under a dynamic and plastic regulation within a single cell, or within the cell population, or during development.  We review here various regulatory mechanisms that control the replication program in eukaryotes and discuss future directions in this dynamic field.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoSQqhVEPZuJLVg90H21EOLACvtfcHk0liN47ey55xQAw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXpslShsbs%253D&md5=c8a0dfe38359a7eb2fe724d0693116b2</span></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=10.1146%2Fannurev.biochem.052308.103205&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1146%252Fannurev.biochem.052308.103205%26sid%3Dliteratum%253Aachs%26aulast%3DMasai%26aufirst%3DH.%26aulast%3DMatsumoto%26aufirst%3DS.%26aulast%3DYou%26aufirst%3DZ.%26aulast%3DYoshizawa-Sugata%26aufirst%3DN.%26aulast%3DOda%26aufirst%3DM.%26atitle%3DEukaryotic%2520chromosome%2520DNA%2520replication%253A%2520where%252C%2520when%252C%2520and%2520how%253F%26jtitle%3DAnnu.%2520Rev.%2520Biochem.%26date%3D2010%26volume%3D79%26spage%3D89%26epage%3D130%26doi%3D10.1146%2Fannurev.biochem.052308.103205" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref48"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref48'); return false;" data-citation="" class="refNumLink">48</a></strong><div class="NLM_citation" id="cit48"><span><span class="NLM_contrib-group">Kang, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nho, C. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, N. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Song, D. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Park, Y. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pan, C. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shin, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oh, S. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oh, H. S.</span><span> </span><span class="NLM_article-title">Daurinol, a catalytic inhibitor of topoisomerase IIα, suppresses SNU-840 ovarian cancer cell proliferation through cell cycle arrest in S phase</span> <span class="citation_source-journal">Int. J. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">45</span><span class="NLM_x">, </span> <span class="NLM_fpage">558</span><span class="NLM_x">–</span> <span class="NLM_lpage">566</span><span class="refDoi"> DOI: 10.3892/ijo.2014.2442</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00509&amp;key=10.3892%2Fijo.2014.2442" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00509&amp;key=24841075" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00509&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhsVShsb7J" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=45&publication_year=2014&pages=558-566&author=K.+Kangauthor=C.+W.+Nhoauthor=N.+D.+Kimauthor=D.+G.+Songauthor=Y.+G.+Parkauthor=M.+Kimauthor=C.+H.+Panauthor=D.+Shinauthor=S.+H.+Ohauthor=H.+S.+Oh&title=Daurinol%2C+a+catalytic+inhibitor+of+topoisomerase+II%CE%B1%2C+suppresses+SNU-840+ovarian+cancer+cell+proliferation+through+cell+cycle+arrest+in+S+phase&doi=10.3892%2Fijo.2014.2442"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit48R"><div class="casContent"><span class="casTitleNuber">48</span><div class="casTitle"><span class="NLM_cas:atitle">Daurinol, a catalytic inhibitor of topoisomerase IIα, suppresses SNU-840 ovarian cancer cell proliferation through cell cycle arrest in S phase</span></div><div class="casAuthors">Kang, Kyungsu; Nho, Chu Won; Kim, Nam Doo; Song, Dae-Geun; Park, Young Gyun; Kim, Minkyun; Pan, Cheol-Ho; Shin, Dongyun; Oh, Seung Hyun; Oh, Ho-Suk</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Oncology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">45</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">558-566</span>CODEN:
                <span class="NLM_cas:coden">IJONES</span>;
        ISSN:<span class="NLM_cas:issn">1019-6439</span>.
    
            (<span class="NLM_cas:orgname">Spandidos Publications Ltd.</span>)
        </div><div class="casAbstract">Daurinol, a lignan from the ethnopharmacol. plant Haplophyllum dauricum, was recently reported to be a novel topoisomerase II inhibitor and an alternative to the clin. anticancer agent etoposide based on a colorectal cancer model.  In the present study, we elucidated the detailed biochem. mechanism underlying the inhibition of human topoisomerase IIα by daurinol based on a mol. docking study and in vitro biochem. expts.  The computational simulation predicted that daurinol binds to the ATP-binding pocket of topoisomerase IIα.  In a biochem. assay, daurinol (10-100 μM) inhibited the catalytic activity of topoisomerase IIα in an ATP concn.-dependent manner and suppressed the ATP hydrolysis activity of the enzyme.  However, daurinol did not inhibit topoisomerase I activity, most likely because topoisomerase I does not contain an ATP-binding domain.  We also evaluated the anti-proliferative activity of daurinol in ovarian, small cell lung and testicular cancer cells, common target cancers treated with etoposide.  Daurinol potently inhibited SNU-840 human ovarian cancer cell proliferation through cell cycle arrest in S phase, while etoposide induced G2/M phase arrest.  Daurinol induced the increased expression of cyclin E, cyclin A and E2F-1, which are important proteins regulating S phase initiation and progression.  Daurinol did not induce abnormal cell and nuclear enlargement in SNU-840 cells, in contrast to etoposide.  Based on these data, we suggest that daurinol is a potential anticancer drug candidate for the treatment of human ovarian cancer with few side effects.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpUi5IaNQeJ3rVg90H21EOLACvtfcHk0lgLGt5d5Cu-5g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhsVShsb7J&md5=553c732910df583645be9a6791ee0244</span></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=10.3892%2Fijo.2014.2442&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3892%252Fijo.2014.2442%26sid%3Dliteratum%253Aachs%26aulast%3DKang%26aufirst%3DK.%26aulast%3DNho%26aufirst%3DC.%2BW.%26aulast%3DKim%26aufirst%3DN.%2BD.%26aulast%3DSong%26aufirst%3DD.%2BG.%26aulast%3DPark%26aufirst%3DY.%2BG.%26aulast%3DKim%26aufirst%3DM.%26aulast%3DPan%26aufirst%3DC.%2BH.%26aulast%3DShin%26aufirst%3DD.%26aulast%3DOh%26aufirst%3DS.%2BH.%26aulast%3DOh%26aufirst%3DH.%2BS.%26atitle%3DDaurinol%252C%2520a%2520catalytic%2520inhibitor%2520of%2520topoisomerase%2520II%25CE%25B1%252C%2520suppresses%2520SNU-840%2520ovarian%2520cancer%2520cell%2520proliferation%2520through%2520cell%2520cycle%2520arrest%2520in%2520S%2520phase%26jtitle%3DInt.%2520J.%2520Oncol.%26date%3D2014%26volume%3D45%26spage%3D558%26epage%3D566%26doi%3D10.3892%2Fijo.2014.2442" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref49"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref49'); return false;" data-citation="" class="refNumLink">49</a></strong><div class="NLM_citation" id="cit49"><span><span class="NLM_contrib-group">Stefani, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jansson, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gutierrez, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bernhardt, P. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Richardson, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kalinowski, D. S.</span><span> </span><span class="NLM_article-title">Alkyl substituted 2′-benzoylpyridine thiosemicarbazone chelators with potent and selective anti-neoplastic activity: novel ligands that limit methemoglobin formation</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">56</span><span class="NLM_x">, </span> <span class="NLM_fpage">357</span><span class="NLM_x">–</span> <span class="NLM_lpage">370</span><span class="refDoi"> DOI: 10.1021/jm301691s</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm301691s" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2013&pages=357-370&author=C.+Stefaniauthor=P.+J.+Janssonauthor=E.+Gutierrezauthor=P.+V.+Bernhardtauthor=D.+R.+Richardsonauthor=D.+S.+Kalinowski&title=Alkyl+substituted+2%E2%80%B2-benzoylpyridine+thiosemicarbazone+chelators+with+potent+and+selective+anti-neoplastic+activity%3A+novel+ligands+that+limit+methemoglobin+formation&doi=10.1021%2Fjm301691s"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=10.1021%2Fjm301691s&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm301691s%26sid%3Dliteratum%253Aachs%26aulast%3DStefani%26aufirst%3DC.%26aulast%3DJansson%26aufirst%3DP.%2BJ.%26aulast%3DGutierrez%26aufirst%3DE.%26aulast%3DBernhardt%26aufirst%3DP.%2BV.%26aulast%3DRichardson%26aufirst%3DD.%2BR.%26aulast%3DKalinowski%26aufirst%3DD.%2BS.%26atitle%3DAlkyl%2520substituted%25202%25E2%2580%25B2-benzoylpyridine%2520thiosemicarbazone%2520chelators%2520with%2520potent%2520and%2520selective%2520anti-neoplastic%2520activity%253A%2520novel%2520ligands%2520that%2520limit%2520methemoglobin%2520formation%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2013%26volume%3D56%26spage%3D357%26epage%3D370%26doi%3D10.1021%2Fjm301691s" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref50"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref50'); return false;" data-citation="" class="refNumLink">50</a></strong><div class="NLM_citation" id="cit50"><span><span class="NLM_contrib-group">Jiang, G. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zheng, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yao, J. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Han, B. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huang, H. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, Y. J.</span><span> </span><span class="NLM_article-title">Ruthenium(II) polypyridyl complexes induce BEL-7402 cell apoptosis by ROS-mediated mitochondrial pathway</span> <span class="citation_source-journal">J. Inorg. Biochem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">141</span><span class="NLM_x">, </span> <span class="NLM_fpage">170</span><span class="NLM_x">–</span> <span class="NLM_lpage">179</span><span class="refDoi"> DOI: 10.1016/j.jinorgbio.2014.09.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00509&amp;key=10.1016%2Fj.jinorgbio.2014.09.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00509&amp;key=25268891" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00509&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhsFOqsL3N" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=141&publication_year=2014&pages=170-179&author=G.+B.+Jiangauthor=X.+Zhengauthor=J.+H.+Yaoauthor=B.+J.+Hanauthor=W.+Liauthor=J.+Wangauthor=H.+L.+Huangauthor=Y.+J.+Liu&title=Ruthenium%28II%29+polypyridyl+complexes+induce+BEL-7402+cell+apoptosis+by+ROS-mediated+mitochondrial+pathway&doi=10.1016%2Fj.jinorgbio.2014.09.001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit50R"><div class="casContent"><span class="casTitleNuber">50</span><div class="casTitle"><span class="NLM_cas:atitle">Ruthenium(II) polypyridyl complexes induce BEL-7402 cell apoptosis by ROS-mediated mitochondrial pathway</span></div><div class="casAuthors">Jiang, Guang-Bin; Zheng, Xiang; Yao, Jun-Hua; Han, Bing-Jie; Li, Wei; Wang, Ji; Huang, Hong-Liang; Liu, Yun-Jun</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Inorganic Biochemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">141</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">170-179</span>CODEN:
                <span class="NLM_cas:coden">JIBIDJ</span>;
        ISSN:<span class="NLM_cas:issn">0162-0134</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">A new ligand dmdppz and its four ruthenium(II) polypyridyl complexes [Ru(dmb)2(dmdppz)](ClO4)2 (1), [Ru(bpy)2(dmdppz)](ClO4)2 (2), [Ru(phen)2(dmdppz)](ClO4)2 (3) and [Ru(dmp)2(dmdppz)](ClO4)2 (4) (where dmb, bpy, phen, dmp and dmdppz stand for 4,4'-dimethyl-2,2'-bipyridine, 2,2'-bipyridine, 1,10-phenanthroline, 2,9-dimethyl-1,10-phenanthroline and 5,8-dimethoxylpyrido[3,2-a:2',3'-c]phenazine, resp.) have been synthesized and characterized.  Their DNA binding behaviors show that the complexes bind to calf thymus DNA by intercalation.  The complexes exhibit efficient photocleavage of pBR322 DNA on irradn.  The cytotoxicity of the ligand and the complexes toward HepG-2, HeLa, MG-63, A549 and BEL-7402 were assayed by MTT ((3-(4,5-dimethylthiazo-2-yl)-2,5-diphenyltetrazolium bromide)) method.  The IC50 values of the complexes 1, 2, 3 and 4 toward BEL-7402 cells are 14.6, 16.8, 18.0 and 16.7 μM, resp.  Dmdppz shows no cytotoxic activity against selected cell lines.  The cellular uptake, apoptosis, comet assay, reactive oxygen species (ROS), mitochondrial membrane potential and western blot anal. were investigated.  These results indicate that complexes 1-4 exert their toxicity through the intrinsic ROS-mediated mitochondrial pathway, which is accompanied by the regulation of Bcl-2 family proteins.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrOidPqyTc7eLVg90H21EOLACvtfcHk0lgLGt5d5Cu-5g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhsFOqsL3N&md5=cf025ba89250d70c28809f92dd04d0c3</span></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=10.1016%2Fj.jinorgbio.2014.09.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jinorgbio.2014.09.001%26sid%3Dliteratum%253Aachs%26aulast%3DJiang%26aufirst%3DG.%2BB.%26aulast%3DZheng%26aufirst%3DX.%26aulast%3DYao%26aufirst%3DJ.%2BH.%26aulast%3DHan%26aufirst%3DB.%2BJ.%26aulast%3DLi%26aufirst%3DW.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DHuang%26aufirst%3DH.%2BL.%26aulast%3DLiu%26aufirst%3DY.%2BJ.%26atitle%3DRuthenium%2528II%2529%2520polypyridyl%2520complexes%2520induce%2520BEL-7402%2520cell%2520apoptosis%2520by%2520ROS-mediated%2520mitochondrial%2520pathway%26jtitle%3DJ.%2520Inorg.%2520Biochem.%26date%3D2014%26volume%3D141%26spage%3D170%26epage%3D179%26doi%3D10.1016%2Fj.jinorgbio.2014.09.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref51"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref51'); return false;" data-citation="" class="refNumLink">51</a></strong><div class="NLM_citation" id="cit51"><span><span class="NLM_contrib-group">Trachootham, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alexandre, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huang, P.</span><span> </span><span class="NLM_article-title">Targeting cancer cells by ROS-mediated mechanisms: a radical therapeutic approach?</span> <span class="citation_source-journal">Nat. Rev. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">8</span><span class="NLM_x">, </span> <span class="NLM_fpage">579</span><span class="NLM_x">–</span> <span class="NLM_lpage">591</span><span class="refDoi"> DOI: 10.1038/nrd2803</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00509&amp;key=10.1038%2Fnrd2803" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00509&amp;key=19478820" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00509&amp;key=1%3ACAS%3A528%3ADC%252BD1MXmsFWqsLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2009&pages=579-591&author=D.+Trachoothamauthor=J.+Alexandreauthor=P.+Huang&title=Targeting+cancer+cells+by+ROS-mediated+mechanisms%3A+a+radical+therapeutic+approach%3F&doi=10.1038%2Fnrd2803"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit51R"><div class="casContent"><span class="casTitleNuber">51</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting cancer cells by ROS-mediated mechanisms: a radical therapeutic approach?</span></div><div class="casAuthors">Trachootham, Dunyaporn; Alexandre, Jerome; Huang, Peng</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">579-591</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Increased generation of reactive oxygen species (ROS) and an altered redox status have long been obsd. in cancer cells, and recent studies suggest that this biochem. property of cancer cells can be exploited for therapeutic benefits.  Cancer cells in advanced stage tumors frequently exhibit multiple genetic alterations and high oxidative stress, suggesting that it might be possible to preferentially eliminate these cells by pharmacol. ROS insults.  However, the upregulation of antioxidant capacity in adaptation to intrinsic oxidative stress in cancer cells can confer drug resistance.  Abrogation of such drug-resistant mechanisms by redox modulation could have significant therapeutic implications.  We argue that modulating the unique redox regulatory mechanisms of cancer cells might be an effective strategy to eliminate these cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGobgIa2fgBPBrVg90H21EOLACvtfcHk0liPN5l_e_yYFw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXmsFWqsLk%253D&md5=d50931b8de8bcab62d376becc768a71c</span></div><a href="/servlet/linkout?suffix=cit51&amp;dbid=16384&amp;doi=10.1038%2Fnrd2803&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd2803%26sid%3Dliteratum%253Aachs%26aulast%3DTrachootham%26aufirst%3DD.%26aulast%3DAlexandre%26aufirst%3DJ.%26aulast%3DHuang%26aufirst%3DP.%26atitle%3DTargeting%2520cancer%2520cells%2520by%2520ROS-mediated%2520mechanisms%253A%2520a%2520radical%2520therapeutic%2520approach%253F%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2009%26volume%3D8%26spage%3D579%26epage%3D591%26doi%3D10.1038%2Fnrd2803" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref52"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref52'); return false;" data-citation="" class="refNumLink">52</a></strong><div class="NLM_citation" id="cit52"><span><span class="NLM_contrib-group">Han, C. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jun do, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, Y. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, J. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, Y. H.</span><span> </span><span class="NLM_article-title">Prometaphase arrest-dependent phosphorylation of Bcl-2 family proteins and activation of mitochondrial apoptotic pathway are associated with 17α-estradiol-induced apoptosis in human Jurkat T cells</span> <span class="citation_source-journal">Biochim. Biophys. Acta, Mol. Cell Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">1833</span><span class="NLM_x">, </span> <span class="NLM_fpage">2220</span><span class="NLM_x">–</span> <span class="NLM_lpage">2232</span><span class="refDoi"> DOI: 10.1016/j.bbamcr.2013.05.016</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00509&amp;key=10.1016%2Fj.bbamcr.2013.05.016" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00509&amp;key=23707954" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00509&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtFSlsL7N" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1833&publication_year=2013&pages=2220-2232&author=C.+R.+Hanauthor=Y.+Jun+doauthor=Y.+H.+Kimauthor=J.+Y.+Leeauthor=Y.+H.+Kim&title=Prometaphase+arrest-dependent+phosphorylation+of+Bcl-2+family+proteins+and+activation+of+mitochondrial+apoptotic+pathway+are+associated+with+17%CE%B1-estradiol-induced+apoptosis+in+human+Jurkat+T+cells&doi=10.1016%2Fj.bbamcr.2013.05.016"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit52R"><div class="casContent"><span class="casTitleNuber">52</span><div class="casTitle"><span class="NLM_cas:atitle">Prometaphase arrest-dependent phosphorylation of Bcl-2 family proteins and activation of mitochondrial apoptotic pathway are associated with 17α-estradiol-induced apoptosis in human Jurkat T cells</span></div><div class="casAuthors">Han, Cho Rong; Jun, Do Youn; Kim, Yoon Hee; Lee, Ji Young; Kim, Young Ho</div><div class="citationInfo"><span class="NLM_cas:title">Biochimica et Biophysica Acta, Molecular Cell Research</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">1833</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">2220-2232</span>CODEN:
                <span class="NLM_cas:coden">BBAMCO</span>;
        ISSN:<span class="NLM_cas:issn">0167-4889</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">In Jurkat T cell clone (JT/Neo), G2/M arrest, apoptotic sub-G1 peak, mitochondrial membrane potential (Δψm) loss, and TUNEL-pos. DNA fragmentation were induced following exposure to 17α-estradiol (17α-E2), whereas none of these events (except for G2/M arrest) were induced in Jurkat cells overexpressing Bcl-2 (JT/Bcl-2).  Under these conditions, phosphorylation at Thr161 and dephosphorylation at Tyr15 of Cdk1, upregulation of cyclin B1 level, histone H1 phosphorylation, Cdc25C phosphorylation at , Bcl-2 phosphorylation at Thr-56 and Ser-70, Mcl-1 phosphorylation, and Bim phosphorylation were detected in the presence of Bcl-2 overexpression.  However, the 17α-E2-induced upregulation of Bak levels, activation of Bak, activation of caspase-3, and PARP degrdn. were abrogated by Bcl-2 overexpression.  In the presence of the G1/S blocking agent hydroxyurea, 17α-E2 failed to induce G2/M arrest and all apoptotic events including Cdk1 activation and phosphorylation of Bcl-2, Mcl-1 and Bim.  The 17α-E2-induced phosphorylation of Bcl-2 family proteins and mitochondrial apoptotic events were suppressed by a Cdk1 inhibitor but not by aurora A and aurora B kinase inhibitors.  Immunofluorescence microscopic anal. showed that an aberrant bipolar microtubule array, incomplete chromosome congression at the metaphase plate, and prometaphase arrest, which was reversible, were the underlying factors for 17α-E2-induced mitotic arrest.  The in vitro microtubule polymn. assay showed that 17α-E2 could directly inhibit microtubule formation.  These results show that the apoptogenic activity of 17α-E2 was due to the impaired mitotic spindle assembly causing prometaphase arrest and prolonged Cdk1 activation, the phosphorylation of Bcl-2, Mcl-1 and Bim, and the activation of Bak and mitochondria-dependent caspase cascade.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoP8jSwpLEnErVg90H21EOLACvtfcHk0liPN5l_e_yYFw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtFSlsL7N&md5=5ea80b538dd35c2fa324ecf26a7e3973</span></div><a href="/servlet/linkout?suffix=cit52&amp;dbid=16384&amp;doi=10.1016%2Fj.bbamcr.2013.05.016&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bbamcr.2013.05.016%26sid%3Dliteratum%253Aachs%26aulast%3DHan%26aufirst%3DC.%2BR.%26aulast%3DJun%2Bdo%26aufirst%3DY.%26aulast%3DKim%26aufirst%3DY.%2BH.%26aulast%3DLee%26aufirst%3DJ.%2BY.%26aulast%3DKim%26aufirst%3DY.%2BH.%26atitle%3DPrometaphase%2520arrest-dependent%2520phosphorylation%2520of%2520Bcl-2%2520family%2520proteins%2520and%2520activation%2520of%2520mitochondrial%2520apoptotic%2520pathway%2520are%2520associated%2520with%252017%25CE%25B1-estradiol-induced%2520apoptosis%2520in%2520human%2520Jurkat%2520T%2520cells%26jtitle%3DBiochim.%2520Biophys.%2520Acta%252C%2520Mol.%2520Cell%2520Res.%26date%3D2013%26volume%3D1833%26spage%3D2220%26epage%3D2232%26doi%3D10.1016%2Fj.bbamcr.2013.05.016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref53"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref53'); return false;" data-citation="" class="refNumLink">53</a></strong><div class="NLM_citation" id="cit53"><span><span class="NLM_contrib-group">He, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liao, S. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tan, C. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ye, R. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, Y. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhao, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ji, L. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mao, Z. W.</span><span> </span><span class="NLM_article-title">Ruthenium-Arene-β-Carboline complexes as potent inhibitors of cyclin-dependent kinase 1: synthesis, characterization and anticancer mechanism studies</span> <span class="citation_source-journal">Chem. - Eur. J.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">19</span><span class="NLM_x">, </span> <span class="NLM_fpage">12152</span><span class="NLM_x">–</span> <span class="NLM_lpage">12160</span><span class="refDoi"> DOI: 10.1002/chem.201301389</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00509&amp;key=10.1002%2Fchem.201301389" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00509&amp;key=23878093" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00509&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtFCjtbnK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2013&pages=12152-12160&author=L.+Heauthor=S.+Y.+Liaoauthor=C.+P.+Tanauthor=R.+R.+Yeauthor=Y.+W.+Xuauthor=M.+Zhaoauthor=L.+N.+Jiauthor=Z.+W.+Mao&title=Ruthenium-Arene-%CE%B2-Carboline+complexes+as+potent+inhibitors+of+cyclin-dependent+kinase+1%3A+synthesis%2C+characterization+and+anticancer+mechanism+studies&doi=10.1002%2Fchem.201301389"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit53R"><div class="casContent"><span class="casTitleNuber">53</span><div class="casTitle"><span class="NLM_cas:atitle">Ruthenium-Arene-β-Carboline Complexes as Potent Inhibitors of Cyclin-Dependent Kinase 1: Synthesis, Characterization and Anticancer Mechanism Studies</span></div><div class="casAuthors">He, Liang; Liao, Si-Yan; Tan, Cai-Ping; Ye, Rui-Rong; Xu, Yu-Wen; Zhao, Meng; Ji, Liang-Nian; Mao, Zong-Wan</div><div class="citationInfo"><span class="NLM_cas:title">Chemistry - A European Journal</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">36</span>),
    <span class="NLM_cas:pages">12152-12160</span>CODEN:
                <span class="NLM_cas:coden">CEUJED</span>;
        ISSN:<span class="NLM_cas:issn">0947-6539</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">Ru(II)-arene complexes, [(η6-arene)Ru(L)Cl]PF6 (1-6, arene = benzene or p-cymene; L = bidentate β-carboline deriv., an indole alkaloid with potential cyclin-dependent kinases (CDKs) inhibitory activities), are prepd. from [(η6-arene)RuCl2]2 and L.  All the complexes were fully characterized by classical anal. methods, and three were characterized by x-ray crystallog.  Hydrolytic studies show that β-carboline ligands play a vital role in their aq. behavior.  These complexes are highly active in vitro, with the most active complex 6 displaying a 3-12-fold higher anticancer activity than cisplatin against several cancer cell lines.  The complexes are able to overcome cross-resistance to cisplatin, and show much lower cytotoxicity against normal cells.  Complexes 1-6 may directly target CDK1, because they can block cells in the G2M phase, down-regulate the expression of CDK1 and cyclin B1, and inhibit CDK1/cyclin B in vitro.  Further mechanism studies show that the complexes can effectively induce apoptosis through mitochondrial-related pathways and intracellular reactive O species (ROS) elevation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo6h10BlYuFK7Vg90H21EOLACvtfcHk0liPN5l_e_yYFw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtFCjtbnK&md5=fb2b63894c4f96209d60c1b4e8266e9a</span></div><a href="/servlet/linkout?suffix=cit53&amp;dbid=16384&amp;doi=10.1002%2Fchem.201301389&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fchem.201301389%26sid%3Dliteratum%253Aachs%26aulast%3DHe%26aufirst%3DL.%26aulast%3DLiao%26aufirst%3DS.%2BY.%26aulast%3DTan%26aufirst%3DC.%2BP.%26aulast%3DYe%26aufirst%3DR.%2BR.%26aulast%3DXu%26aufirst%3DY.%2BW.%26aulast%3DZhao%26aufirst%3DM.%26aulast%3DJi%26aufirst%3DL.%2BN.%26aulast%3DMao%26aufirst%3DZ.%2BW.%26atitle%3DRuthenium-Arene-%25CE%25B2-Carboline%2520complexes%2520as%2520potent%2520inhibitors%2520of%2520cyclin-dependent%2520kinase%25201%253A%2520synthesis%252C%2520characterization%2520and%2520anticancer%2520mechanism%2520studies%26jtitle%3DChem.%2520-%2520Eur.%2520J.%26date%3D2013%26volume%3D19%26spage%3D12152%26epage%3D12160%26doi%3D10.1002%2Fchem.201301389" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref54"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref54'); return false;" data-citation="" class="refNumLink">54</a></strong><div class="NLM_citation" id="cit54"><span><span class="NLM_contrib-group">Marzec, K. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, M. Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martin, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baxter, R. C.</span><span> </span><span class="NLM_article-title">Involvement of p53 in insulin-like growth factor binding protein-3 regulation in the breast cancer cell response to DNA damage</span> <span class="citation_source-journal">Oncotarget.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">26583</span><span class="NLM_x">–</span> <span class="NLM_lpage">26598</span><span class="refDoi"> DOI: 10.18632/oncotarget.5612</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00509&amp;key=10.18632%2Foncotarget.5612" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2015&pages=26583-26598&author=K.+A.+Marzecauthor=M.+Z.+Linauthor=J.+L.+Martinauthor=R.+C.+Baxter&title=Involvement+of+p53+in+insulin-like+growth+factor+binding+protein-3+regulation+in+the+breast+cancer+cell+response+to+DNA+damage&doi=10.18632%2Foncotarget.5612"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit54&amp;dbid=16384&amp;doi=10.18632%2Foncotarget.5612&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.18632%252Foncotarget.5612%26sid%3Dliteratum%253Aachs%26aulast%3DMarzec%26aufirst%3DK.%2BA.%26aulast%3DLin%26aufirst%3DM.%2BZ.%26aulast%3DMartin%26aufirst%3DJ.%2BL.%26aulast%3DBaxter%26aufirst%3DR.%2BC.%26atitle%3DInvolvement%2520of%2520p53%2520in%2520insulin-like%2520growth%2520factor%2520binding%2520protein-3%2520regulation%2520in%2520the%2520breast%2520cancer%2520cell%2520response%2520to%2520DNA%2520damage%26jtitle%3DOncotarget.%26date%3D2015%26volume%3D6%26spage%3D26583%26epage%3D26598%26doi%3D10.18632%2Foncotarget.5612" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref55"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref55'); return false;" data-citation="" class="refNumLink">55</a></strong><div class="NLM_citation" id="cit55"><span><span class="NLM_contrib-group">Sheldrick, G. M.</span> <span class="citation_source-book">SHELXTL</span> V5.1; <span class="NLM_publisher-name">Bruker AXS. Inc.</span>: <span class="NLM_publisher-loc">Madison, WI</span>,<span class="NLM_x"> </span><span class="NLM_year">1997</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=1997&author=G.+M.+Sheldrick&title=SHELXTL"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit55&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26aulast%3DSheldrick%26aufirst%3DG.%2BM.%26btitle%3DSHELXTL%26pub%3DBruker%2520AXS.%2520Inc%26date%3D1997" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref56"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref56'); return false;" data-citation="" class="refNumLink">56</a></strong><div class="NLM_citation" id="cit56"><span><span class="NLM_contrib-group">Curry, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mandelkow, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brick, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Franks, N.</span><span> </span><span class="NLM_article-title">Crystal structure of human serum albumin complexed with fatty acid reveals an asymmetric distribution of binding sites</span> <span class="citation_source-journal">Nat. Struct. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1998</span><span class="NLM_x">, </span> <span class="NLM_volume">5</span><span class="NLM_x">, </span> <span class="NLM_fpage">827</span><span class="NLM_x">–</span> <span class="NLM_lpage">835</span><span class="refDoi"> DOI: 10.1038/1869</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00509&amp;key=10.1038%2F1869" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00509&amp;key=9731778" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00509&amp;key=1%3ACAS%3A528%3ADyaK1cXlvVyhs7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=1998&pages=827-835&author=S.+Curryauthor=H.+Mandelkowauthor=P.+Brickauthor=N.+Franks&title=Crystal+structure+of+human+serum+albumin+complexed+with+fatty+acid+reveals+an+asymmetric+distribution+of+binding+sites&doi=10.1038%2F1869"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit56R"><div class="casContent"><span class="casTitleNuber">56</span><div class="casTitle"><span class="NLM_cas:atitle">Crystal structure of human serum albumin complexed with fatty acid reveals an asymmetric distribution of binding sites</span></div><div class="casAuthors">Curry, Stephen; Mandelkow, Hendrik; Brick, Peter; Franks, Nick</div><div class="citationInfo"><span class="NLM_cas:title">Nature Structural Biology</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">827-835</span>CODEN:
                <span class="NLM_cas:coden">NSBIEW</span>;
        ISSN:<span class="NLM_cas:issn">1072-8368</span>.
    
            (<span class="NLM_cas:orgname">Nature America</span>)
        </div><div class="casAbstract">Human serum albumin (HSA) is the most abundant protein in the circulatory system.  Its principal function is to transport fatty acids, but it is also capable of binding a great variety of metabolites and drugs.  Despite intensive efforts, the detailed structural basis of fatty acid binding to HSA has remained elusive.  Here, the crystal structure of HSA complexed with 5 mols. of myristate at 2.5 Å resoln. is reported.  The fatty acid mols. were found to bind in long, hydrophobic pockets capped by polar side chains, many of which were basic.  These pockets were distributed asym. throughout the HSA mol., despite its sym. repeating domain structure.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrjkf-Ylc5g_7Vg90H21EOLACvtfcHk0lgQtmGubjX2mA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXlvVyhs7w%253D&md5=6df17724b7dac4c5aa99e71bf41f5849</span></div><a href="/servlet/linkout?suffix=cit56&amp;dbid=16384&amp;doi=10.1038%2F1869&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252F1869%26sid%3Dliteratum%253Aachs%26aulast%3DCurry%26aufirst%3DS.%26aulast%3DMandelkow%26aufirst%3DH.%26aulast%3DBrick%26aufirst%3DP.%26aulast%3DFranks%26aufirst%3DN.%26atitle%3DCrystal%2520structure%2520of%2520human%2520serum%2520albumin%2520complexed%2520with%2520fatty%2520acid%2520reveals%2520an%2520asymmetric%2520distribution%2520of%2520binding%2520sites%26jtitle%3DNat.%2520Struct.%2520Biol.%26date%3D1998%26volume%3D5%26spage%3D827%26epage%3D835%26doi%3D10.1038%2F1869" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref57"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref57'); return false;" data-citation="" class="refNumLink">57</a></strong><div class="NLM_citation" id="cit57"><span><span class="NLM_contrib-group">Otwinowski, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Minor, W.</span><span> </span><span class="NLM_article-title">Processing of X-ray diffraction data collected in oscillation mode</span> <span class="citation_source-journal">Methods Enzymol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1997</span><span class="NLM_x">, </span> <span class="NLM_volume">276</span><span class="NLM_x">, </span> <span class="NLM_fpage">307</span><span class="NLM_x">–</span> <span class="NLM_lpage">326</span><span class="refDoi"> DOI: 10.1016/S0076-6879(97)76066-X</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00509&amp;key=10.1016%2FS0076-6879%2897%2976066-X" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00509&amp;key=27754618" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00509&amp;key=1%3ACAS%3A528%3ADyaK2sXivFehsbw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=276&publication_year=1997&pages=307-326&author=Z.+Otwinowskiauthor=W.+Minor&title=Processing+of+X-ray+diffraction+data+collected+in+oscillation+mode&doi=10.1016%2FS0076-6879%2897%2976066-X"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit57R"><div class="casContent"><span class="casTitleNuber">57</span><div class="casTitle"><span class="NLM_cas:atitle">Processing of x-ray diffraction data collected in oscillation mode</span></div><div class="casAuthors">Otwinowski, Zbyszek; Minor, Wladek</div><div class="citationInfo"><span class="NLM_cas:title">Methods in Enzymology</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">276</span>
        (<span class="NLM_cas:issue">Macromolecular Crystallography, Part A</span>),
    <span class="NLM_cas:pages">307-326</span>CODEN:
                <span class="NLM_cas:coden">MENZAU</span>;
        ISSN:<span class="NLM_cas:issn">0076-6879</span>.
    
            (<span class="NLM_cas:orgname">Academic</span>)
        </div><div class="casAbstract">Macromol. crystallog. is an iterative process.  Rarely do the first crystals provide all the necessary data to solve the biol. problem being studied.  Each step benefits from experience learned in previous steps.  To monitor the progress, the HKL package provides 2 tools: (1) statistics, both weighted (χ2) and unweighted (R-merge), are provided, and the Bayesian reasoning and multicomponent error model facilitates obtaining the proper error ests. and (2) visualization of the process plays a double role by helping the operator to confirm that the process of data redn., including the resulting statistics, is correct, and allowing one to evaluate problems for which there are no good statistical criteria.  Visualization also provides confidence that the point of diminishing returns in data collection and redn. has been reached.  At that point, the effort should be directed to solving the structure.  The methods presented here have been applied to solve a large variety of problems, from inorg. mols. with 5 Å unit cell to rotavirus of 700 Å diam. crystd. in 700 × 1000 × 1400 Å cell.  Overall quality of the method was tested by many researchers by successful application of the programs to MAD structure detns.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrA3fvBOHqhhrVg90H21EOLACvtfcHk0lgQtmGubjX2mA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXivFehsbw%253D&md5=c9536971d4e32cc35352c40fb9368131</span></div><a href="/servlet/linkout?suffix=cit57&amp;dbid=16384&amp;doi=10.1016%2FS0076-6879%2897%2976066-X&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0076-6879%252897%252976066-X%26sid%3Dliteratum%253Aachs%26aulast%3DOtwinowski%26aufirst%3DZ.%26aulast%3DMinor%26aufirst%3DW.%26atitle%3DProcessing%2520of%2520X-ray%2520diffraction%2520data%2520collected%2520in%2520oscillation%2520mode%26jtitle%3DMethods%2520Enzymol.%26date%3D1997%26volume%3D276%26spage%3D307%26epage%3D326%26doi%3D10.1016%2FS0076-6879%2897%2976066-X" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref58"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref58'); return false;" data-citation="" class="refNumLink">58</a></strong><div class="NLM_citation" id="cit58"><span><span class="NLM_contrib-group">Adams, P. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Afonine, P. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bunkóczi, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, V. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Davis, I. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Echols, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Headd, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hung, L. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kapral, G. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grosse-Kunstleve, R. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McCoy, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moriarty, N. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oeffner, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Read, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Richardson, D. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Richardson, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Terwilliger, T. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zwart, P. H.</span><span> </span><span class="NLM_article-title">PHENIX: a comprehensive Python-based system for macromolecular structure solution</span> <span class="citation_source-journal">Acta Crystallogr., Sect. D: Biol. Crystallogr.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">66</span><span class="NLM_x">, </span> <span class="NLM_fpage">213</span><span class="NLM_x">–</span> <span class="NLM_lpage">221</span><span class="refDoi"> DOI: 10.1107/S0907444909052925</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00509&amp;key=10.1107%2FS0907444909052925" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00509&amp;key=20124702" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00509&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhs1Sisbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=66&publication_year=2010&pages=213-221&author=P.+D.+Adamsauthor=P.+V.+Afonineauthor=G.+Bunk%C3%B3cziauthor=V.+B.+Chenauthor=I.+W.+Davisauthor=N.+Echolsauthor=J.+J.+Headdauthor=L.+W.+Hungauthor=G.+J.+Kapralauthor=R.+W.+Grosse-Kunstleveauthor=A.+J.+McCoyauthor=N.+W.+Moriartyauthor=R.+Oeffnerauthor=R.+J.+Readauthor=D.+C.+Richardsonauthor=J.+S.+Richardsonauthor=T.+C.+Terwilligerauthor=P.+H.+Zwart&title=PHENIX%3A+a+comprehensive+Python-based+system+for+macromolecular+structure+solution&doi=10.1107%2FS0907444909052925"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit58R"><div class="casContent"><span class="casTitleNuber">58</span><div class="casTitle"><span class="NLM_cas:atitle">PHENIX: a comprehensive Python-based system for macromolecular structure solution</span></div><div class="casAuthors">Adams, Paul D.; Afonine, Pavel V.; Bunkoczi, Gabor; Chen, Vincent B.; Davis, Ian W.; Echols, Nathaniel; Headd, Jeffrey J.; Hung, Li Wei; Kapral, Gary J.; Grosse-Kunstleve, Ralf W.; McCoy, Airlie J.; Moriarty, Nigel W.; Oeffner, Robert; Read, Randy J.; Richardson, David C.; Richardson, Jane S.; Terwilliger, Thomas C.; Zwart, Peter H.</div><div class="citationInfo"><span class="NLM_cas:title">Acta Crystallographica, Section D: Biological Crystallography</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">66</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">213-221</span>CODEN:
                <span class="NLM_cas:coden">ABCRE6</span>;
        ISSN:<span class="NLM_cas:issn">0907-4449</span>.
    
            (<span class="NLM_cas:orgname">International Union of Crystallography</span>)
        </div><div class="casAbstract">A review.  Macromol. X-ray crystallog. is routinely applied to understand biol. processes at a mol. level.  However, significant time and effort are still required to solve and complete many of these structures because of the need for manual interpretation of complex numerical data using many software packages and the repeated use of interactive three-dimensional graphics.  PHENIX has been developed to provide a comprehensive system for macromol. crystallog. structure soln. with an emphasis on the automation of all procedures.  This has relied on the development of algorithms that minimize or eliminate subjective input, the development of algorithms that automate procedures that are traditionally performed by hand and, finally, the development of a framework that allows a tight integration between the algorithms.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpm_HgKRpa-ObVg90H21EOLACvtfcHk0lgQtmGubjX2mA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhs1Sisbc%253D&md5=67b439ff4bd61c659cae37ca4209b7bc</span></div><a href="/servlet/linkout?suffix=cit58&amp;dbid=16384&amp;doi=10.1107%2FS0907444909052925&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1107%252FS0907444909052925%26sid%3Dliteratum%253Aachs%26aulast%3DAdams%26aufirst%3DP.%2BD.%26aulast%3DAfonine%26aufirst%3DP.%2BV.%26aulast%3DBunk%25C3%25B3czi%26aufirst%3DG.%26aulast%3DChen%26aufirst%3DV.%2BB.%26aulast%3DDavis%26aufirst%3DI.%2BW.%26aulast%3DEchols%26aufirst%3DN.%26aulast%3DHeadd%26aufirst%3DJ.%2BJ.%26aulast%3DHung%26aufirst%3DL.%2BW.%26aulast%3DKapral%26aufirst%3DG.%2BJ.%26aulast%3DGrosse-Kunstleve%26aufirst%3DR.%2BW.%26aulast%3DMcCoy%26aufirst%3DA.%2BJ.%26aulast%3DMoriarty%26aufirst%3DN.%2BW.%26aulast%3DOeffner%26aufirst%3DR.%26aulast%3DRead%26aufirst%3DR.%2BJ.%26aulast%3DRichardson%26aufirst%3DD.%2BC.%26aulast%3DRichardson%26aufirst%3DJ.%2BS.%26aulast%3DTerwilliger%26aufirst%3DT.%2BC.%26aulast%3DZwart%26aufirst%3DP.%2BH.%26atitle%3DPHENIX%253A%2520a%2520comprehensive%2520Python-based%2520system%2520for%2520macromolecular%2520structure%2520solution%26jtitle%3DActa%2520Crystallogr.%252C%2520Sect.%2520D%253A%2520Biol.%2520Crystallogr.%26date%3D2010%26volume%3D66%26spage%3D213%26epage%3D221%26doi%3D10.1107%2FS0907444909052925" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref59"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref59'); return false;" data-citation="" class="refNumLink">59</a></strong><div class="NLM_citation" id="cit59"><span><span class="NLM_contrib-group">Emsley, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cowtan, K.</span><span> </span><span class="NLM_article-title">Coot: model-building tools for molecular graphics</span> <span class="citation_source-journal">Acta Crystallogr., Sect. D: Biol. Crystallogr.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">60</span><span class="NLM_x">, </span> <span class="NLM_fpage">2126</span><span class="NLM_x">–</span> <span class="NLM_lpage">2132</span><span class="refDoi"> DOI: 10.1107/S0907444904019158</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00509&amp;key=10.1107%2FS0907444904019158" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00509&amp;key=15572765" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00509&amp;key=1%3ACAS%3A528%3ADC%252BD2cXhtVars73P" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2004&pages=2126-2132&author=P.+Emsleyauthor=K.+Cowtan&title=Coot%3A+model-building+tools+for+molecular+graphics&doi=10.1107%2FS0907444904019158"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit59R"><div class="casContent"><span class="casTitleNuber">59</span><div class="casTitle"><span class="NLM_cas:atitle">Coot: model-building tools for molecular graphics</span></div><div class="casAuthors">Emsley, Paul; Cowtan, Kevin</div><div class="citationInfo"><span class="NLM_cas:title">Acta Crystallographica, Section D: Biological Crystallography</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">D60</span>
        (<span class="NLM_cas:issue">12, Pt. 1</span>),
    <span class="NLM_cas:pages">2126-2132</span>CODEN:
                <span class="NLM_cas:coden">ABCRE6</span>;
        ISSN:<span class="NLM_cas:issn">0907-4449</span>.
    
            (<span class="NLM_cas:orgname">Blackwell Publishing Ltd.</span>)
        </div><div class="casAbstract">CCP4mg is a project that aims to provide a general-purpose tool for structural biologists, providing tools for x-ray structure soln., structure comparison and anal., and publication-quality graphics.  The map-fitting tools are available as a stand-alone package, distributed as 'Coot'.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoMisM42468k7Vg90H21EOLACvtfcHk0ljKzvusjFV3qA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXhtVars73P&md5=1be390f3bb6fd584468499ad0921161e</span></div><a href="/servlet/linkout?suffix=cit59&amp;dbid=16384&amp;doi=10.1107%2FS0907444904019158&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1107%252FS0907444904019158%26sid%3Dliteratum%253Aachs%26aulast%3DEmsley%26aufirst%3DP.%26aulast%3DCowtan%26aufirst%3DK.%26atitle%3DCoot%253A%2520model-building%2520tools%2520for%2520molecular%2520graphics%26jtitle%3DActa%2520Crystallogr.%252C%2520Sect.%2520D%253A%2520Biol.%2520Crystallogr.%26date%3D2004%26volume%3D60%26spage%3D2126%26epage%3D2132%26doi%3D10.1107%2FS0907444904019158" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref60"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref60'); return false;" data-citation="" class="refNumLink">60</a></strong><div class="NLM_citation" id="cit60"><span><span class="NLM_contrib-group">DeLano, W. L.</span> <span class="citation_source-book">The PyMol. Molecular Graphics System</span>; <span class="NLM_publisher-name">DeLano ScientiWc</span>: <span class="NLM_publisher-loc">San Carlos, CA</span>,<span class="NLM_x"> </span><span class="NLM_year">2004</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2004&author=W.+L.+DeLano&title=The+PyMol.+Molecular+Graphics+System"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit60&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26aulast%3DDeLano%26aufirst%3DW.%2BL.%26btitle%3DThe%2520PyMol.%2520Molecular%2520Graphics%2520System%26pub%3DDeLano%2520ScientiWc%26date%3D2004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref61"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref61'); return false;" data-citation="" class="refNumLink">61</a></strong><div class="NLM_citation" id="cit61"><span><span class="NLM_contrib-group">Du, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Deng, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shan, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wan, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cao, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tian, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Achilefu, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gu, Y.</span><span> </span><span class="NLM_article-title">A pH-sensitive doxorubicin prodrug based on folate-conjugated BSA for tumor-targeted drug delivery</span> <span class="citation_source-journal">Biomaterials</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">34</span><span class="NLM_x">, </span> <span class="NLM_fpage">3087</span><span class="NLM_x">–</span> <span class="NLM_lpage">3097</span><span class="refDoi"> DOI: 10.1016/j.biomaterials.2013.01.041</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00509&amp;key=10.1016%2Fj.biomaterials.2013.01.041" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00509&amp;key=23374705" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00509&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhs1Cgtbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=34&publication_year=2013&pages=3087-3097&author=C.+Duauthor=D.+Dengauthor=L.+Shanauthor=S.+Wanauthor=J.+Caoauthor=J.+Tianauthor=S.+Achilefuauthor=Y.+Gu&title=A+pH-sensitive+doxorubicin+prodrug+based+on+folate-conjugated+BSA+for+tumor-targeted+drug+delivery&doi=10.1016%2Fj.biomaterials.2013.01.041"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit61R"><div class="casContent"><span class="casTitleNuber">61</span><div class="casTitle"><span class="NLM_cas:atitle">A pH-sensitive doxorubicin prodrug based on folate-conjugated BSA for tumor-targeted drug delivery</span></div><div class="casAuthors">Du, Changli; Deng, Dawei; Shan, Lingling; Wan, Shunan; Cao, Jie; Tian, Junmei; Achilefu, Samuel; Gu, Yueqing</div><div class="citationInfo"><span class="NLM_cas:title">Biomaterials</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">34</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">3087-3097</span>CODEN:
                <span class="NLM_cas:coden">BIMADU</span>;
        ISSN:<span class="NLM_cas:issn">0142-9612</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Doxorubicin (DOX) is one of the most effective anti-cancer drugs, but its therapeutic efficacy is greatly hampered by its non-specific delivery to the target tissue and the resultant cumulative cardiotoxicity and nephrotoxicity.  In order to overcome this limitation, we prepd. a folate-bovine serum albumin (BSA)-cis-aconitic anhydride-doxorubicin prodrug, denoted by FA-BSA-CAD.  A tumor-targeting agent, folic acid, was linked to BSA to increase the selective targeting ability of the conjugate.  BSA provided a large no. of reactive sites for multivalent coupling of bioactive mols. and improved the water-soly. of the prodrug.  DOX is attached to the BSA via a pH-sensitive linker, cis-aconitic anhydride, which hydrolyzes in the acidic lysosomal environment to allow pH-responsive release of DOX.  The in vitro results demonstrate a pH-responsive drug release under different pH conditions.  Furthermore, the targeting ability and therapeutic efficacy of the prodrug were assessed both in vitro and in vivo.  The results demonstrate that FA-BSA-CAD prodrug selectively targeted tumor cells and tissue, with assocd. redn. in non-specific toxicity to the normal cells.  More importantly, the therapeutic efficacy of the prodrug for FA-pos. tumors increased compared to the non-conjugated DOX.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr-GqVf-n7iAbVg90H21EOLACvtfcHk0ljKzvusjFV3qA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhs1Cgtbk%253D&md5=440dafd9e6542b524cd933567f296f91</span></div><a href="/servlet/linkout?suffix=cit61&amp;dbid=16384&amp;doi=10.1016%2Fj.biomaterials.2013.01.041&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.biomaterials.2013.01.041%26sid%3Dliteratum%253Aachs%26aulast%3DDu%26aufirst%3DC.%26aulast%3DDeng%26aufirst%3DD.%26aulast%3DShan%26aufirst%3DL.%26aulast%3DWan%26aufirst%3DS.%26aulast%3DCao%26aufirst%3DJ.%26aulast%3DTian%26aufirst%3DJ.%26aulast%3DAchilefu%26aufirst%3DS.%26aulast%3DGu%26aufirst%3DY.%26atitle%3DA%2520pH-sensitive%2520doxorubicin%2520prodrug%2520based%2520on%2520folate-conjugated%2520BSA%2520for%2520tumor-targeted%2520drug%2520delivery%26jtitle%3DBiomaterials%26date%3D2013%26volume%3D34%26spage%3D3087%26epage%3D3097%26doi%3D10.1016%2Fj.biomaterials.2013.01.041" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2'],'ref3':['cit3'],'ref4':['cit4'],'ref5':['cit5'],'ref6':['cit6'],'ref7':['cit7'],'ref8':['cit8'],'ref9':['cit9'],'ref10':['cit10'],'ref11':['cit11'],'ref12':['cit12'],'ref13':['cit13'],'ref14':['cit14'],'ref15':['cit15'],'ref16':['cit16'],'ref17':['cit17'],'ref18':['cit18'],'ref19':['cit19'],'ref20':['cit20'],'ref21':['cit21'],'ref22':['cit22'],'ref23':['cit23'],'ref24':['cit24'],'ref25':['cit25'],'ref26':['cit26'],'ref27':['cit27'],'ref28':['cit28'],'ref29':['cit29'],'ref30':['cit30'],'ref31':['cit31'],'ref32':['cit32'],'ref33':['cit33'],'ref34':['cit34'],'ref35':['cit35'],'ref36':['cit36'],'ref37':['cit37'],'ref38':['cit38'],'ref39':['cit39'],'ref40':['cit40'],'ref41':['cit41'],'ref42':['cit42'],'ref43':['cit43'],'ref44':['cit44'],'ref45':['cit45'],'ref46':['cit46'],'ref47':['cit47'],'ref48':['cit48'],'ref49':['cit49'],'ref50':['cit50'],'ref51':['cit51'],'ref52':['cit52'],'ref53':['cit53'],'ref54':['cit54'],'ref55':['cit55'],'ref56':['cit56'],'ref57':['cit57'],'ref58':['cit58'],'ref59':['cit59'],'ref60':['cit60'],'ref61':['cit61']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article is cited by 41 publications.</p><ol class="cited-content_cbyCitation"><li><span class="cited-content_cbyCitation_article-contributors">Juzheng Zhang, Ming Jiang, Shanhe Li, Zhenlei Zhang, Hongbin Sun, Feng Yang, <span class="NLM_string-name hlFld-ContribAuthor">Hong Liang</span>. </span><span class="cited-content_cbyCitation_article-title">Developing a Novel Anticancer Gold(III) Agent to Integrate Chemotherapy and Immunotherapy. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>64 </em>
                                    (10)
                                     , 6777-6791. <a href="https://doi.org/10.1021/acs.jmedchem.1c00050" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.1c00050</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.1c00050&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.1c00050%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDeveloping%252Ba%252BNovel%252BAnticancer%252BGold%252528III%252529%252BAgent%252Bto%252BIntegrate%252BChemotherapy%252Band%252BImmunotherapy%26aulast%3DZhang%26aufirst%3DJuzheng%26date%3D2021%26date%3D2021%26date%3D2021%26date%3D12012021%26date%3D17052021%26volume%3D64%26issue%3D10%26spage%3D6777%26epage%3D6791" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Juzheng Zhang, Zhenlei Zhang, Ming Jiang, Shanhe Li, Haoliang Yuan, Hongbin Sun, Feng Yang, <span class="NLM_string-name hlFld-ContribAuthor">Hong Liang</span>. </span><span class="cited-content_cbyCitation_article-title">Developing a Novel Gold(III) Agent to Treat Glioma Based on the Unique Properties of Apoferritin Nanoparticles: Inducing Lethal Autophagy and Apoptosis. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>63 </em>
                                    (22)
                                     , 13695-13708. <a href="https://doi.org/10.1021/acs.jmedchem.0c01257" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c01257</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c01257&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.0c01257%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDeveloping%252Ba%252BNovel%252BGold%252528III%252529%252BAgent%252Bto%252BTreat%252BGlioma%252BBased%252Bon%252Bthe%252BUnique%252BProperties%252Bof%252BApoferritin%252BNanoparticles%25253A%252BInducing%252BLethal%252BAutophagy%252Band%252BApoptosis%26aulast%3DZhang%26aufirst%3DJuzheng%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D19072020%26date%3D13112020%26volume%3D63%26issue%3D22%26spage%3D13695%26epage%3D13708" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Ryan Shaktah, Laura Vardanyan, Elroma David, Alexis Aleman, Dupre Orr, Lawrence A. Shaktah, Daniel Tamae, <span class="NLM_string-name hlFld-ContribAuthor">Thomas Minehan</span>. </span><span class="cited-content_cbyCitation_article-title">Synthesis and Stereochemical Assignment of Conioidine A: DNA- and HSA-Binding Studies of the Four Diastereomers. </span><span class="cited-content_cbyCitation_journal-name">Journal of Natural Products</span><span> <strong>2020,</strong> <em>83 </em>
                                    (10)
                                     , 3191-3198. <a href="https://doi.org/10.1021/acs.jnatprod.0c00871" title="DOI URL">https://doi.org/10.1021/acs.jnatprod.0c00871</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jnatprod.0c00871&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jnatprod.0c00871%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Natural%2520Products%26atitle%3DSynthesis%252Band%252BStereochemical%252BAssignment%252Bof%252BConioidine%252BA%25253A%252BDNA-%252Band%252BHSA-Binding%252BStudies%252Bof%252Bthe%252BFour%252BDiastereomers%26aulast%3DShaktah%26aufirst%3DRyan%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D04082020%26date%3D09102020%26volume%3D83%26issue%3D10%26spage%3D3191%26epage%3D3198" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Zhenlei Zhang, Juzheng Zhang, Ming Jiang, Lei Zhao, Shanhe Li, Hongbin Sun, Feng Yang, <span class="NLM_string-name hlFld-ContribAuthor">Hong Liang</span>. </span><span class="cited-content_cbyCitation_article-title">Human Serum Albumin-Based Dual-Agent Delivery Systems for Combination Therapy: Acting against Cancer Cells and Inhibiting Neovascularization in the Tumor Microenvironment. </span><span class="cited-content_cbyCitation_journal-name">Molecular Pharmaceutics</span><span> <strong>2020,</strong> <em>17 </em>
                                    (4)
                                     , 1405-1414. <a href="https://doi.org/10.1021/acs.molpharmaceut.0c00133" title="DOI URL">https://doi.org/10.1021/acs.molpharmaceut.0c00133</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.molpharmaceut.0c00133&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.molpharmaceut.0c00133%26sid%3Dliteratum%253Aachs%26jtitle%3DMolecular%2520Pharmaceutics%26atitle%3DHuman%252BSerum%252BAlbumin-Based%252BDual-Agent%252BDelivery%252BSystems%252Bfor%252BCombination%252BTherapy%25253A%252BActing%252Bagainst%252BCancer%252BCells%252Band%252BInhibiting%252BNeovascularization%252Bin%252Bthe%252BTumor%252BMicroenvironment%26aulast%3DZhang%26aufirst%3DZhenlei%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D09022020%26date%3D25022020%26date%3D24022020%26date%3D04032020%26date%3D25022020%26volume%3D17%26issue%3D4%26spage%3D1405%26epage%3D1414" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Zhenlei Zhang, Ping Yu, Yi Gou, Juzheng Zhang, Shanhe Li, Meiling Cai, Hongbin Sun, Feng Yang, <span class="NLM_string-name hlFld-ContribAuthor">Hong Liang</span>. </span><span class="cited-content_cbyCitation_article-title">Novel Brain-Tumor-Inhibiting Copper(II) Compound Based on a Human Serum Albumin (HSA)-Cell Penetrating Peptide Conjugate. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2019,</strong> <em>62 </em>
                                    (23)
                                     , 10630-10644. <a href="https://doi.org/10.1021/acs.jmedchem.9b00939" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.9b00939</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.9b00939&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.9b00939%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DNovel%252BBrain-Tumor-Inhibiting%252BCopper%252528II%252529%252BCompound%252BBased%252Bon%252Ba%252BHuman%252BSerum%252BAlbumin%252B%252528HSA%252529-Cell%252BPenetrating%252BPeptide%252BConjugate%26aulast%3DZhang%26aufirst%3DZhenlei%26date%3D2019%26date%3D2019%26date%3D2019%26date%3D12062019%26date%3D21112019%26date%3D06112019%26volume%3D62%26issue%3D23%26spage%3D10630%26epage%3D10644" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Giuseppe Sciortino, Eugenio Garribba, <span class="NLM_string-name hlFld-ContribAuthor">Jean-Didier Maréchal</span>. </span><span class="cited-content_cbyCitation_article-title">Validation and Applications of Protein–Ligand Docking Approaches Improved for Metalloligands with Multiple Vacant Sites. </span><span class="cited-content_cbyCitation_journal-name">Inorganic Chemistry</span><span> <strong>2019,</strong> <em>58 </em>
                                    (1)
                                     , 294-306. <a href="https://doi.org/10.1021/acs.inorgchem.8b02374" title="DOI URL">https://doi.org/10.1021/acs.inorgchem.8b02374</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.inorgchem.8b02374&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.inorgchem.8b02374%26sid%3Dliteratum%253Aachs%26jtitle%3DInorganic%2520Chemistry%26atitle%3DValidation%252Band%252BApplications%252Bof%252BProtein%2525E2%252580%252593Ligand%252BDocking%252BApproaches%252BImproved%252Bfor%252BMetalloligands%252Bwith%252BMultiple%252BVacant%252BSites%26aulast%3DSciortino%26aufirst%3DGiuseppe%26date%3D2019%26date%3D2018%26date%3D2018%26date%3D22082018%26date%3D26112018%26volume%3D58%26issue%3D1%26spage%3D294%26epage%3D306" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Jun Wang, Yi Gou, Zhenlei Zhang, Ping Yu, Jinxu Qi, Qipin Qin, Hongbin Sun, Xiaoyang Wu, Hong Liang, <span class="NLM_string-name hlFld-ContribAuthor">Feng Yang</span>. </span><span class="cited-content_cbyCitation_article-title">Developing an Anticancer Copper(II) Multitarget Pro-Drug Based on the His146 Residue in the IB Subdomain of Modified Human Serum Albumin. </span><span class="cited-content_cbyCitation_journal-name">Molecular Pharmaceutics</span><span> <strong>2018,</strong> <em>15 </em>
                                    (6)
                                     , 2180-2193. <a href="https://doi.org/10.1021/acs.molpharmaceut.8b00045" title="DOI URL">https://doi.org/10.1021/acs.molpharmaceut.8b00045</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.molpharmaceut.8b00045&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.molpharmaceut.8b00045%26sid%3Dliteratum%253Aachs%26jtitle%3DMolecular%2520Pharmaceutics%26atitle%3DDeveloping%252Ban%252BAnticancer%252BCopper%252528II%252529%252BMultitarget%252BPro-Drug%252BBased%252Bon%252Bthe%252BHis146%252BResidue%252Bin%252Bthe%252BIB%252BSubdomain%252Bof%252BModified%252BHuman%252BSerum%252BAlbumin%26aulast%3DWang%26aufirst%3DJun%26date%3D2018%26date%3D2018%26date%3D2018%26date%3D2018%26date%3D2018%26date%3D15012018%26date%3D03052018%26date%3D30042018%26date%3D10052018%26date%3D03052018%26volume%3D15%26issue%3D6%26spage%3D2180%26epage%3D2193" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Yi  Gou</span>, <span class="hlFld-ContribAuthor ">Yao  Zhang</span>, <span class="hlFld-ContribAuthor ">Zhenlei  Zhang</span>, <span class="hlFld-ContribAuthor ">Jun  Wang</span>, <span class="hlFld-ContribAuthor ">Zuping  Zhou</span>, <span class="hlFld-ContribAuthor ">Hong  Liang</span>, and <span class="hlFld-ContribAuthor ">Feng  Yang</span>  . </span><span class="cited-content_cbyCitation_article-title">Design of an Anticancer Copper(II) Prodrug Based on the Lys199 Residue of the Active Targeting Human Serum Albumin Nanoparticle Carrier. </span><span class="cited-content_cbyCitation_journal-name">Molecular Pharmaceutics</span><span> <strong>2017,</strong> <em>14 </em>
                                    (6)
                                     , 1861-1873. <a href="https://doi.org/10.1021/acs.molpharmaceut.6b01074" title="DOI URL">https://doi.org/10.1021/acs.molpharmaceut.6b01074</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.molpharmaceut.6b01074&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.molpharmaceut.6b01074%26sid%3Dliteratum%253Aachs%26jtitle%3DMolecular%2520Pharmaceutics%26atitle%3DDesign%252Bof%252Ban%252BAnticancer%252BCopper%252528II%252529%252BProdrug%252BBased%252Bon%252Bthe%252BLys199%252BResidue%252Bof%252Bthe%252BActive%252BTargeting%252BHuman%252BSerum%252BAlbumin%252BNanoparticle%252BCarrier%26aulast%3DGou%26aufirst%3DYi%26date%3D2017%26date%3D2017%26date%3D2017%26date%3D2016%26date%3D2017%26date%3D27112016%26date%3D04052017%26date%3D10042017%26date%3D09052017%26date%3D05062017%26date%3D04052017%26volume%3D14%26issue%3D6%26spage%3D1861%26epage%3D1873" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Yi  Gou</span>, <span class="hlFld-ContribAuthor ">GuoJin  Huang</span>, <span class="hlFld-ContribAuthor ">Jinlong  Li</span>, <span class="hlFld-ContribAuthor ">Feng  Yang</span>, <span class="hlFld-ContribAuthor ">Hong  Liang</span>. </span><span class="cited-content_cbyCitation_article-title">Versatile delivery systems for non-platinum metal-based anticancer therapeutic agents. </span><span class="cited-content_cbyCitation_journal-name">Coordination Chemistry Reviews</span><span> <strong>2021,</strong> <em>441 </em>, 213975. <a href="https://doi.org/10.1016/j.ccr.2021.213975" title="DOI URL">https://doi.org/10.1016/j.ccr.2021.213975</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ccr.2021.213975&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ccr.2021.213975%26sid%3Dliteratum%253Aachs%26jtitle%3DCoordination%2520Chemistry%2520Reviews%26atitle%3DVersatile%252Bdelivery%252Bsystems%252Bfor%252Bnon-platinum%252Bmetal-based%252Banticancer%252Btherapeutic%252Bagents%26aulast%3DGou%26aufirst%3DYi%26date%3D2021%26volume%3D441%26spage%3D213975" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">M.  Sennappan</span>, <span class="hlFld-ContribAuthor ">P.  Murali Krishna</span>, <span class="hlFld-ContribAuthor ">Praveen B.  Managutti</span>, <span class="hlFld-ContribAuthor ">Sumitra N.  Mangasuli</span>, <span class="hlFld-ContribAuthor ">S.  Malini</span>. </span><span class="cited-content_cbyCitation_article-title">Nucleic Acid Interaction and Photoluminescent Properties of Acylhydrazone and Its Mn(II), Co(II), Cu(II), Zn(II) and Cd(II) Complexes. </span><span class="cited-content_cbyCitation_journal-name">Chemistry Africa</span><span> <strong>2021,</strong> <em>4 </em>
                                    (2)
                                     , 313-321. <a href="https://doi.org/10.1007/s42250-020-00222-8" title="DOI URL">https://doi.org/10.1007/s42250-020-00222-8</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/s42250-020-00222-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2Fs42250-020-00222-8%26sid%3Dliteratum%253Aachs%26jtitle%3DChemistry%2520Africa%26atitle%3DNucleic%252BAcid%252BInteraction%252Band%252BPhotoluminescent%252BProperties%252Bof%252BAcylhydrazone%252Band%252BIts%252BMn%252528II%252529%25252C%252BCo%252528II%252529%25252C%252BCu%252528II%252529%25252C%252BZn%252528II%252529%252Band%252BCd%252528II%252529%252BComplexes%26aulast%3DSennappan%26aufirst%3DM.%26date%3D2021%26date%3D2021%26volume%3D4%26issue%3D2%26spage%3D313%26epage%3D321" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Sutthida  Wongsuwan</span>, <span class="hlFld-ContribAuthor ">Jaruwan  Chatwichien</span>, <span class="hlFld-ContribAuthor ">Bussaba  Pinchaipat</span>, <span class="hlFld-ContribAuthor ">Sarawut  Kumphune</span>, <span class="hlFld-ContribAuthor ">David J.  Harding</span>, <span class="hlFld-ContribAuthor ">Phimphaka  Harding</span>, <span class="hlFld-ContribAuthor ">Jaursup  Boonmak</span>, <span class="hlFld-ContribAuthor ">Sujittra  Youngme</span>, <span class="hlFld-ContribAuthor ">Ratanon  Chotima</span>. </span><span class="cited-content_cbyCitation_article-title">Synthesis, characterization and anticancer activity of Fe(II) and Fe(III) complexes containing N-(8-quinolyl)salicylaldimine Schiff base ligands. </span><span class="cited-content_cbyCitation_journal-name">JBIC Journal of Biological Inorganic Chemistry</span><span> <strong>2021,</strong> <em>26 </em>
                                    (2-3)
                                     , 327-339. <a href="https://doi.org/10.1007/s00775-021-01857-9" title="DOI URL">https://doi.org/10.1007/s00775-021-01857-9</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/s00775-021-01857-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2Fs00775-021-01857-9%26sid%3Dliteratum%253Aachs%26jtitle%3DJBIC%2520Journal%2520of%2520Biological%2520Inorganic%2520Chemistry%26atitle%3DSynthesis%25252C%252Bcharacterization%252Band%252Banticancer%252Bactivity%252Bof%252BFe%252528II%252529%252Band%252BFe%252528III%252529%252Bcomplexes%252Bcontaining%252BN-%2525288-quinolyl%252529salicylaldimine%252BSchiff%252Bbase%252Bligands%26aulast%3DWongsuwan%26aufirst%3DSutthida%26date%3D2021%26date%3D2021%26volume%3D26%26issue%3D2-3%26spage%3D327%26epage%3D339" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Jinxu  Qi</span>, <span class="hlFld-ContribAuthor ">Wei  Zhao</span>, <span class="hlFld-ContribAuthor ">Yunyun  Zheng</span>, <span class="hlFld-ContribAuthor ">Ruiya  Wang</span>, <span class="hlFld-ContribAuthor ">Qiu  Chen</span>, <span class="hlFld-ContribAuthor ">Fu-An  Wang</span>, <span class="hlFld-ContribAuthor ">Weiwei  Fan</span>, <span class="hlFld-ContribAuthor ">Huashan  Gao</span>, <span class="hlFld-ContribAuthor ">Xichao  Xia</span>. </span><span class="cited-content_cbyCitation_article-title">Single-crystal structure and intracellular localization of Zn(II)-thiosemicarbazone complex targeting mitochondrial apoptosis pathways. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry Letters</span><span> <strong>2020,</strong> <em>30 </em>
                                    (16)
                                     , 127340. <a href="https://doi.org/10.1016/j.bmcl.2020.127340" title="DOI URL">https://doi.org/10.1016/j.bmcl.2020.127340</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmcl.2020.127340&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmcl.2020.127340%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DSingle-crystal%252Bstructure%252Band%252Bintracellular%252Blocalization%252Bof%252BZn%252528II%252529-thiosemicarbazone%252Bcomplex%252Btargeting%252Bmitochondrial%252Bapoptosis%252Bpathways%26aulast%3DQi%26aufirst%3DJinxu%26date%3D2020%26volume%3D30%26issue%3D16%26spage%3D127340" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Uttara  Basu</span>, <span class="hlFld-ContribAuthor ">Mithun  Roy</span>, <span class="hlFld-ContribAuthor ">Akhil R.  Chakravarty</span>. </span><span class="cited-content_cbyCitation_article-title">Recent advances in the chemistry of iron-based chemotherapeutic agents. </span><span class="cited-content_cbyCitation_journal-name">Coordination Chemistry Reviews</span><span> <strong>2020,</strong> <em>417 </em>, 213339. <a href="https://doi.org/10.1016/j.ccr.2020.213339" title="DOI URL">https://doi.org/10.1016/j.ccr.2020.213339</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ccr.2020.213339&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ccr.2020.213339%26sid%3Dliteratum%253Aachs%26jtitle%3DCoordination%2520Chemistry%2520Reviews%26atitle%3DRecent%252Badvances%252Bin%252Bthe%252Bchemistry%252Bof%252Biron-based%252Bchemotherapeutic%252Bagents%26aulast%3DBasu%26aufirst%3DUttara%26date%3D2020%26volume%3D417%26spage%3D213339" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">A.K.  Patel</span>, <span class="hlFld-ContribAuthor ">R.N.  Jadeja</span>, <span class="hlFld-ContribAuthor ">H.  Roy</span>, <span class="hlFld-ContribAuthor ">R.N.  Patel</span>, <span class="hlFld-ContribAuthor ">S.K.  Patel</span>, <span class="hlFld-ContribAuthor ">R.J.  Butcher</span>, <span class="hlFld-ContribAuthor ">M.  Cortijo</span>, <span class="hlFld-ContribAuthor ">S.  Herrero</span>. </span><span class="cited-content_cbyCitation_article-title">Copper(II) hydrazone complexes with different nuclearities and geometries: Synthesis, structural characterization, antioxidant SOD activity and antiproliferative properties. </span><span class="cited-content_cbyCitation_journal-name">Polyhedron</span><span> <strong>2020,</strong> <em>186 </em>, 114624. <a href="https://doi.org/10.1016/j.poly.2020.114624" title="DOI URL">https://doi.org/10.1016/j.poly.2020.114624</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.poly.2020.114624&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.poly.2020.114624%26sid%3Dliteratum%253Aachs%26jtitle%3DPolyhedron%26atitle%3DCopper%252528II%252529%252Bhydrazone%252Bcomplexes%252Bwith%252Bdifferent%252Bnuclearities%252Band%252Bgeometries%25253A%252BSynthesis%25252C%252Bstructural%252Bcharacterization%25252C%252Bantioxidant%252BSOD%252Bactivity%252Band%252Bantiproliferative%252Bproperties%26aulast%3DPatel%26aufirst%3DA.K.%26date%3D2020%26volume%3D186%26spage%3D114624" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Mauro  Carcelli</span>, <span class="hlFld-ContribAuthor ">Matteo  Tegoni</span>, <span class="hlFld-ContribAuthor ">Jennifer  Bartoli</span>, <span class="hlFld-ContribAuthor ">Cristina  Marzano</span>, <span class="hlFld-ContribAuthor ">Giorgio  Pelosi</span>, <span class="hlFld-ContribAuthor ">Marika  Salvalaio</span>, <span class="hlFld-ContribAuthor ">Dominga  Rogolino</span>, <span class="hlFld-ContribAuthor ">Valentina  Gandin</span>. </span><span class="cited-content_cbyCitation_article-title">In vitro and in vivo anticancer activity of tridentate thiosemicarbazone copper complexes: Unravelling an unexplored pharmacological target. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>194 </em>, 112266. <a href="https://doi.org/10.1016/j.ejmech.2020.112266" title="DOI URL">https://doi.org/10.1016/j.ejmech.2020.112266</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2020.112266&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2020.112266%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DIn%2525C2%2525A0vitro%252Band%252Bin%2525C2%2525A0vivo%252Banticancer%252Bactivity%252Bof%252Btridentate%252Bthiosemicarbazone%252Bcopper%252Bcomplexes%25253A%252BUnravelling%252Ban%252Bunexplored%252Bpharmacological%252Btarget%26aulast%3DCarcelli%26aufirst%3DMauro%26date%3D2020%26volume%3D194%26spage%3D112266" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Qian  Zhang</span>, <span class="hlFld-ContribAuthor ">Qiang  Zhang</span>, <span class="hlFld-ContribAuthor ">Zhen-zhen  Li</span>, <span class="hlFld-ContribAuthor ">Hua  Liu</span>, <span class="hlFld-ContribAuthor ">Jia-cheng  Liu</span>. </span><span class="cited-content_cbyCitation_article-title">Copper (II) complexes modified with water-soluble porphyrin and various small molecules ligand for DNA binding and potential selectivity antitumor agents. </span><span class="cited-content_cbyCitation_journal-name">Dyes and Pigments</span><span> <strong>2020,</strong> <em>173 </em>, 107923. <a href="https://doi.org/10.1016/j.dyepig.2019.107923" title="DOI URL">https://doi.org/10.1016/j.dyepig.2019.107923</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.dyepig.2019.107923&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.dyepig.2019.107923%26sid%3Dliteratum%253Aachs%26jtitle%3DDyes%2520and%2520Pigments%26atitle%3DCopper%252B%252528II%252529%252Bcomplexes%252Bmodified%252Bwith%252Bwater-soluble%252Bporphyrin%252Band%252Bvarious%252Bsmall%252Bmolecules%252Bligand%252Bfor%252BDNA%252Bbinding%252Band%252Bpotential%252Bselectivity%252Bantitumor%252Bagents%26aulast%3DZhang%26aufirst%3DQian%26date%3D2020%26volume%3D173%26spage%3D107923" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Shengshi  Jiang</span>, <span class="hlFld-ContribAuthor ">Honghui  Ni</span>, <span class="hlFld-ContribAuthor ">Fen  Liu</span>, <span class="hlFld-ContribAuthor ">Shanshan  Gu</span>, <span class="hlFld-ContribAuthor ">Ping  Yu</span>, <span class="hlFld-ContribAuthor ">Yi  Gou</span>. </span><span class="cited-content_cbyCitation_article-title">Binuclear Schiff base copper(II) complexes: Syntheses, crystal structures, HSA interaction and anti-cancer properties. </span><span class="cited-content_cbyCitation_journal-name">Inorganica Chimica Acta</span><span> <strong>2020,</strong> <em>499 </em>, 119186. <a href="https://doi.org/10.1016/j.ica.2019.119186" title="DOI URL">https://doi.org/10.1016/j.ica.2019.119186</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ica.2019.119186&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ica.2019.119186%26sid%3Dliteratum%253Aachs%26jtitle%3DInorganica%2520Chimica%2520Acta%26atitle%3DBinuclear%252BSchiff%252Bbase%252Bcopper%252528II%252529%252Bcomplexes%25253A%252BSyntheses%25252C%252Bcrystal%252Bstructures%25252C%252BHSA%252Binteraction%252Band%252Banti-cancer%252Bproperties%26aulast%3DJiang%26aufirst%3DShengshi%26date%3D2020%26volume%3D499%26spage%3D119186" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ming  Liu</span>, <span class="hlFld-ContribAuthor ">Xue-Qing  Song</span>, <span class="hlFld-ContribAuthor ">Yuan-Di  Wu</span>, <span class="hlFld-ContribAuthor ">Jing  Qian</span>, <span class="hlFld-ContribAuthor ">Jing-Yuan  Xu</span>. </span><span class="cited-content_cbyCitation_article-title">Cu(
              ii
              )-TACN complexes selectively induce antitumor activity in HepG-2 cells
              via
              DNA damage and mitochondrial-ROS-mediated apoptosis. </span><span class="cited-content_cbyCitation_journal-name">Dalton Transactions</span><span> <strong>2020,</strong> <em>49 </em>
                                    (1)
                                     , 114-123. <a href="https://doi.org/10.1039/C9DT03641E" title="DOI URL">https://doi.org/10.1039/C9DT03641E</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/C9DT03641E&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FC9DT03641E%26sid%3Dliteratum%253Aachs%26jtitle%3DDalton%2520Transactions%26atitle%3DCu%252528%252Bii%252B%252529-TACN%252Bcomplexes%252Bselectively%252Binduce%252Bantitumor%252Bactivity%252Bin%252BHepG-2%252Bcells%252Bvia%252BDNA%252Bdamage%252Band%252Bmitochondrial-ROS-mediated%252Bapoptosis%26aulast%3DLiu%26aufirst%3DMing%26date%3D2020%26date%3D2020%26volume%3D49%26issue%3D1%26spage%3D114%26epage%3D123" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Jungang  Deng</span>, <span class="hlFld-ContribAuthor ">Ping  Yu</span>, <span class="hlFld-ContribAuthor ">Zhenlei  Zhang</span>, <span class="hlFld-ContribAuthor ">Juzheng  Zhang</span>, <span class="hlFld-ContribAuthor ">Sun  Zhewen</span>, <span class="hlFld-ContribAuthor ">Meiling  Cai</span>, <span class="hlFld-ContribAuthor ">Haoliang  Yuan</span>, <span class="hlFld-ContribAuthor ">Hong  Liang</span>, <span class="hlFld-ContribAuthor ">Feng  Yang</span>. </span><span class="cited-content_cbyCitation_article-title">Novel Pt(
              ii
              ) complexes with modified aroyl-hydrazone Schiff-base ligands: synthesis, cytotoxicity and action mechanism. </span><span class="cited-content_cbyCitation_journal-name">Metallomics</span><span> <strong>2019,</strong> <em>11 </em>
                                    (11)
                                     , 1847-1863. <a href="https://doi.org/10.1039/C9MT00193J" title="DOI URL">https://doi.org/10.1039/C9MT00193J</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/C9MT00193J&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FC9MT00193J%26sid%3Dliteratum%253Aachs%26jtitle%3DMetallomics%26atitle%3DNovel%252BPt%252528%252Bii%252B%252529%252Bcomplexes%252Bwith%252Bmodified%252Baroyl-hydrazone%252BSchiff-base%252Bligands%25253A%252Bsynthesis%25252C%252Bcytotoxicity%252Band%252Baction%252Bmechanism%26aulast%3DDeng%26aufirst%3DJungang%26date%3D2019%26date%3D2019%26volume%3D11%26issue%3D11%26spage%3D1847%26epage%3D1863" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Xing  Lu</span>, <span class="hlFld-ContribAuthor ">Yan-Cheng  Liu</span>, <span class="hlFld-ContribAuthor ">Chris  Orvig</span>, <span class="hlFld-ContribAuthor ">Hong  Liang</span>, <span class="hlFld-ContribAuthor ">Zhen-Feng  Chen</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of β-carboline copper(II) complexes as Mcl-1 inhibitor and in vitro and in vivo activity in cancer models. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2019,</strong> <em>181 </em>, 111567. <a href="https://doi.org/10.1016/j.ejmech.2019.111567" title="DOI URL">https://doi.org/10.1016/j.ejmech.2019.111567</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2019.111567&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2019.111567%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Bof%252B%2525CE%2525B2-carboline%252Bcopper%252528II%252529%252Bcomplexes%252Bas%252BMcl-1%252Binhibitor%252Band%252Bin%2525C2%2525A0vitro%252Band%252Bin%2525C2%2525A0vivo%252Bactivity%252Bin%252Bcancer%252Bmodels%26aulast%3DLu%26aufirst%3DXing%26date%3D2019%26volume%3D181%26spage%3D111567" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ping  Yu</span>, <span class="hlFld-ContribAuthor ">Jungang  Deng</span>, <span class="hlFld-ContribAuthor ">Jinhua  Cai</span>, <span class="hlFld-ContribAuthor ">Zhenlei  Zhang</span>, <span class="hlFld-ContribAuthor ">Juzheng  Zhang</span>, <span class="hlFld-ContribAuthor ">Muhammad  Hamid Khan</span>, <span class="hlFld-ContribAuthor ">Hong  Liang</span>, <span class="hlFld-ContribAuthor ">Feng  Yang</span>. </span><span class="cited-content_cbyCitation_article-title">Anticancer and biological properties of a Zn-2,6-diacetylpyridine bis(thiosemicarbazone) complex. </span><span class="cited-content_cbyCitation_journal-name">Metallomics</span><span> <strong>2019,</strong> <em>11 </em>
                                    (8)
                                     , 1372-1386. <a href="https://doi.org/10.1039/C9MT00124G" title="DOI URL">https://doi.org/10.1039/C9MT00124G</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/C9MT00124G&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FC9MT00124G%26sid%3Dliteratum%253Aachs%26jtitle%3DMetallomics%26atitle%3DAnticancer%252Band%252Bbiological%252Bproperties%252Bof%252Ba%252BZn-2%25252C6-diacetylpyridine%252Bbis%252528thiosemicarbazone%252529%252Bcomplex%26aulast%3DYu%26aufirst%3DPing%26date%3D2019%26date%3D2019%26volume%3D11%26issue%3D8%26spage%3D1372%26epage%3D1386" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Qian  Yao</span>, <span class="hlFld-ContribAuthor ">Jinxu  Qi</span>, <span class="hlFld-ContribAuthor ">Yunyun  Zheng</span>, <span class="hlFld-ContribAuthor ">Kun  Qian</span>, <span class="hlFld-ContribAuthor ">Lai  Wei</span>, <span class="hlFld-ContribAuthor ">Mukedasi  Maimaitiyiming</span>, <span class="hlFld-ContribAuthor ">Zhen  Cheng</span>, <span class="hlFld-ContribAuthor ">Yihong  Wang</span>. </span><span class="cited-content_cbyCitation_article-title">Synthesis, anticancer activity and mechanism of iron chelator derived from 2,6-diacetylpyridine bis(acylhydrazones). </span><span class="cited-content_cbyCitation_journal-name">Journal of Inorganic Biochemistry</span><span> <strong>2019,</strong> <em>193 </em>, 1-8. <a href="https://doi.org/10.1016/j.jinorgbio.2019.01.003" title="DOI URL">https://doi.org/10.1016/j.jinorgbio.2019.01.003</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.jinorgbio.2019.01.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.jinorgbio.2019.01.003%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Inorganic%2520Biochemistry%26atitle%3DSynthesis%25252C%252Banticancer%252Bactivity%252Band%252Bmechanism%252Bof%252Biron%252Bchelator%252Bderived%252Bfrom%252B2%25252C6-diacetylpyridine%252Bbis%252528acylhydrazones%252529%26aulast%3DYao%26aufirst%3DQian%26date%3D2019%26volume%3D193%26spage%3D1%26epage%3D8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Wanbao  Cao</span>, <span class="hlFld-ContribAuthor ">Jinxu  Qi</span>, <span class="hlFld-ContribAuthor ">Kun  Qian</span>, <span class="hlFld-ContribAuthor ">Liang  Tian</span>, <span class="hlFld-ContribAuthor ">Zhen  Cheng</span>, <span class="hlFld-ContribAuthor ">Yihong  Wang</span>. </span><span class="cited-content_cbyCitation_article-title">Structure−activity relationships of 2‑quinolinecarboxaldehyde thiosemicarbazone gallium(III) complexes with potent and selective anticancer activity. </span><span class="cited-content_cbyCitation_journal-name">Journal of Inorganic Biochemistry</span><span> <strong>2019,</strong> <em>191 </em>, 174-182. <a href="https://doi.org/10.1016/j.jinorgbio.2018.11.017" title="DOI URL">https://doi.org/10.1016/j.jinorgbio.2018.11.017</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.jinorgbio.2018.11.017&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.jinorgbio.2018.11.017%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Inorganic%2520Biochemistry%26atitle%3DStructure%2525E2%252588%252592activity%252Brelationships%252Bof%252B2%2525E2%252580%252591quinolinecarboxaldehyde%252Bthiosemicarbazone%252Bgallium%252528III%252529%252Bcomplexes%252Bwith%252Bpotent%252Band%252Bselective%252Banticancer%252Bactivity%26aulast%3DCao%26aufirst%3DWanbao%26date%3D2019%26volume%3D191%26spage%3D174%26epage%3D182" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Jungang  Deng</span>, <span class="hlFld-ContribAuthor ">Ping  Yu</span>, <span class="hlFld-ContribAuthor ">Zhenlei  Zhang</span>, <span class="hlFld-ContribAuthor ">Jun  Wang</span>, <span class="hlFld-ContribAuthor ">Jinhua  Cai</span>, <span class="hlFld-ContribAuthor ">Na  Wu</span>, <span class="hlFld-ContribAuthor ">Hongbin  Sun</span>, <span class="hlFld-ContribAuthor ">Hong  Liang</span>, <span class="hlFld-ContribAuthor ">Feng  Yang</span>. </span><span class="cited-content_cbyCitation_article-title">Designing anticancer copper(II) complexes by optimizing 2-pyridine-thiosemicarbazone ligands. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2018,</strong> <em>158 </em>, 442-452. <a href="https://doi.org/10.1016/j.ejmech.2018.09.020" title="DOI URL">https://doi.org/10.1016/j.ejmech.2018.09.020</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2018.09.020&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2018.09.020%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDesigning%252Banticancer%252Bcopper%252528II%252529%252Bcomplexes%252Bby%252Boptimizing%252B2-pyridine-thiosemicarbazone%252Bligands%26aulast%3DDeng%26aufirst%3DJungang%26date%3D2018%26volume%3D158%26spage%3D442%26epage%3D452" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Jinxu  Qi</span>, <span class="hlFld-ContribAuthor ">Qian  Yao</span>, <span class="hlFld-ContribAuthor ">Liang  Tian</span>, <span class="hlFld-ContribAuthor ">Yihong  Wang</span>. </span><span class="cited-content_cbyCitation_article-title">Piperidylthiosemicarbazones Cu(II) complexes with a high anticancer activity by catalyzing hydrogen peroxide to degrade DNA and promote apoptosis. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2018,</strong> <em>158 </em>, 853-862. <a href="https://doi.org/10.1016/j.ejmech.2018.09.034" title="DOI URL">https://doi.org/10.1016/j.ejmech.2018.09.034</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2018.09.034&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2018.09.034%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DPiperidylthiosemicarbazones%252BCu%252528II%252529%252Bcomplexes%252Bwith%252Ba%252Bhigh%252Banticancer%252Bactivity%252Bby%252Bcatalyzing%252Bhydrogen%252Bperoxide%252Bto%252Bdegrade%252BDNA%252Band%252Bpromote%252Bapoptosis%26aulast%3DQi%26aufirst%3DJinxu%26date%3D2018%26volume%3D158%26spage%3D853%26epage%3D862" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Lingxue  Li</span>, <span class="hlFld-ContribAuthor ">Xiaochao  Huang</span>, <span class="hlFld-ContribAuthor ">Rizhen  Huang</span>, <span class="hlFld-ContribAuthor ">Shaohua  Gou</span>, <span class="hlFld-ContribAuthor ">Zhimei  Wang</span>, <span class="hlFld-ContribAuthor ">Hengshan  Wang</span>. </span><span class="cited-content_cbyCitation_article-title">Pt(IV) prodrugs containing microtubule inhibitors displayed potent antitumor activity and ability to overcome cisplatin resistance. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2018,</strong> <em>156 </em>, 666-679. <a href="https://doi.org/10.1016/j.ejmech.2018.07.016" title="DOI URL">https://doi.org/10.1016/j.ejmech.2018.07.016</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2018.07.016&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2018.07.016%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DPt%252528IV%252529%252Bprodrugs%252Bcontaining%252Bmicrotubule%252Binhibitors%252Bdisplayed%252Bpotent%252Bantitumor%252Bactivity%252Band%252Bability%252Bto%252Bovercome%252Bcisplatin%252Bresistance%26aulast%3DLi%26aufirst%3DLingxue%26date%3D2018%26volume%3D156%26spage%3D666%26epage%3D679" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Feng  Yang</span>, <span class="hlFld-ContribAuthor ">Hong  Liang</span>. </span><span class="cited-content_cbyCitation_article-title">Designing anticancer multitarget metal thiosemicarbazone prodrug based on the nature of binding sites of human serum albumin carrier. </span><span class="cited-content_cbyCitation_journal-name">Future Medicinal Chemistry</span><span> <strong>2018,</strong> <em>10 </em>
                                    (16)
                                     , 1881-1883. <a href="https://doi.org/10.4155/fmc-2018-0175" title="DOI URL">https://doi.org/10.4155/fmc-2018-0175</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.4155/fmc-2018-0175&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.4155%2Ffmc-2018-0175%26sid%3Dliteratum%253Aachs%26jtitle%3DFuture%2520Medicinal%2520Chemistry%26atitle%3DDesigning%252Banticancer%252Bmultitarget%252Bmetal%252Bthiosemicarbazone%252Bprodrug%252Bbased%252Bon%252Bthe%252Bnature%252Bof%252Bbinding%252Bsites%252Bof%252Bhuman%252Bserum%252Balbumin%252Bcarrier%26aulast%3DYang%26aufirst%3DFeng%26date%3D2018%26volume%3D10%26issue%3D16%26spage%3D1881%26epage%3D1883" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Jinxu  Qi</span>, <span class="hlFld-ContribAuthor ">Qian  Yao</span>, <span class="hlFld-ContribAuthor ">Kun  Qian</span>, <span class="hlFld-ContribAuthor ">Liang  Tian</span>, <span class="hlFld-ContribAuthor ">Zhen  Cheng</span>, <span class="hlFld-ContribAuthor ">Dongmei  Yang</span>, <span class="hlFld-ContribAuthor ">Yihong  Wang</span>. </span><span class="cited-content_cbyCitation_article-title">Synthesis, antiproliferative activity and mechanism of gallium(III)-thiosemicarbazone complexes as potential anti-breast cancer agents. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2018,</strong> <em>154 </em>, 91-100. <a href="https://doi.org/10.1016/j.ejmech.2018.05.016" title="DOI URL">https://doi.org/10.1016/j.ejmech.2018.05.016</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2018.05.016&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2018.05.016%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DSynthesis%25252C%252Bantiproliferative%252Bactivity%252Band%252Bmechanism%252Bof%252Bgallium%252528III%252529-thiosemicarbazone%252Bcomplexes%252Bas%252Bpotential%252Banti-breast%252Bcancer%252Bagents%26aulast%3DQi%26aufirst%3DJinxu%26date%3D2018%26volume%3D154%26spage%3D91%26epage%3D100" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Xiaochao  Huang</span>, <span class="hlFld-ContribAuthor ">Shixian  Hua</span>, <span class="hlFld-ContribAuthor ">Rizhen  Huang</span>, <span class="hlFld-ContribAuthor ">Zhikun  Liu</span>, <span class="hlFld-ContribAuthor ">Shaohua  Gou</span>, <span class="hlFld-ContribAuthor ">Zhimei  Wang</span>, <span class="hlFld-ContribAuthor ">Zhixin  Liao</span>, <span class="hlFld-ContribAuthor ">Hengshan  Wang</span>. </span><span class="cited-content_cbyCitation_article-title">Dual-targeting antitumor hybrids derived from Pt(IV) species and millepachine analogues. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2018,</strong> <em>148 </em>, 1-25. <a href="https://doi.org/10.1016/j.ejmech.2018.02.012" title="DOI URL">https://doi.org/10.1016/j.ejmech.2018.02.012</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2018.02.012&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2018.02.012%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDual-targeting%252Bantitumor%252Bhybrids%252Bderived%252Bfrom%252BPt%252528IV%252529%252Bspecies%252Band%252Bmillepachine%252Banalogues%26aulast%3DHuang%26aufirst%3DXiaochao%26date%3D2018%26volume%3D148%26spage%3D1%26epage%3D25" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Xiaochao  Huang</span>, <span class="hlFld-ContribAuthor ">Rizhen  Huang</span>, <span class="hlFld-ContribAuthor ">Zhimei  Wang</span>, <span class="hlFld-ContribAuthor ">Lingxue  Li</span>, <span class="hlFld-ContribAuthor ">Shaohua  Gou</span>, <span class="hlFld-ContribAuthor ">Zhixin  Liao</span>, <span class="hlFld-ContribAuthor ">Hengshan  Wang</span>. </span><span class="cited-content_cbyCitation_article-title">Pt(IV) complexes conjugating with chalcone analogue as inhibitors of microtubule polymerization exhibited selective inhibition in human cancer cells. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2018,</strong> <em>146 </em>, 435-450. <a href="https://doi.org/10.1016/j.ejmech.2018.01.075" title="DOI URL">https://doi.org/10.1016/j.ejmech.2018.01.075</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2018.01.075&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2018.01.075%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DPt%252528IV%252529%252Bcomplexes%252Bconjugating%252Bwith%252Bchalcone%252Banalogue%252Bas%252Binhibitors%252Bof%252Bmicrotubule%252Bpolymerization%252Bexhibited%252Bselective%252Binhibition%252Bin%252Bhuman%252Bcancer%252Bcells%26aulast%3DHuang%26aufirst%3DXiaochao%26date%3D2018%26volume%3D146%26spage%3D435%26epage%3D450" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ajaz  Ahmad</span>, <span class="hlFld-ContribAuthor ">Masood  Ahmad</span>. </span><span class="cited-content_cbyCitation_article-title">Understanding the fate of human serum albumin upon interaction with edifenphos: Biophysical and biochemical approaches. </span><span class="cited-content_cbyCitation_journal-name">Pesticide Biochemistry and Physiology</span><span> <strong>2018,</strong> <em>145 </em>, 46-55. <a href="https://doi.org/10.1016/j.pestbp.2018.01.006" title="DOI URL">https://doi.org/10.1016/j.pestbp.2018.01.006</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.pestbp.2018.01.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.pestbp.2018.01.006%26sid%3Dliteratum%253Aachs%26jtitle%3DPesticide%2520Biochemistry%2520and%2520Physiology%26atitle%3DUnderstanding%252Bthe%252Bfate%252Bof%252Bhuman%252Bserum%252Balbumin%252Bupon%252Binteraction%252Bwith%252Bedifenphos%25253A%252BBiophysical%252Band%252Bbiochemical%252Bapproaches%26aulast%3DAhmad%26aufirst%3DAjaz%26date%3D2018%26volume%3D145%26spage%3D46%26epage%3D55" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Jiyong  Hu</span>, <span class="hlFld-ContribAuthor ">Chunli  Liao</span>, <span class="hlFld-ContribAuthor ">Ruina  Mao</span>, <span class="hlFld-ContribAuthor ">Junshuai  Zhang</span>, <span class="hlFld-ContribAuthor ">Jin'an  Zhao</span>, <span class="hlFld-ContribAuthor ">Zhenzhen  Gu</span>. </span><span class="cited-content_cbyCitation_article-title">DNA interactions and
              in vitro
              anticancer evaluations of pyridine-benzimidazole-based Cu complexes. </span><span class="cited-content_cbyCitation_journal-name">MedChemComm</span><span> <strong>2018,</strong> <em>9 </em>
                                    (2)
                                     , 337-343. <a href="https://doi.org/10.1039/C7MD00462A" title="DOI URL">https://doi.org/10.1039/C7MD00462A</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/C7MD00462A&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FC7MD00462A%26sid%3Dliteratum%253Aachs%26jtitle%3DMedChemComm%26atitle%3DDNA%252Binteractions%252Band%252Bin%252Bvitro%252Banticancer%252Bevaluations%252Bof%252Bpyridine-benzimidazole-based%252BCu%252Bcomplexes%26aulast%3DHu%26aufirst%3DJiyong%26date%3D2018%26date%3D2018%26volume%3D9%26issue%3D2%26spage%3D337%26epage%3D343" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Jinxu  Qi</span>, <span class="hlFld-ContribAuthor ">Kun  Qian</span>, <span class="hlFld-ContribAuthor ">Liang  Tian</span>, <span class="hlFld-ContribAuthor ">Zhen  Cheng</span>, <span class="hlFld-ContribAuthor ">Yihong  Wang</span>. </span><span class="cited-content_cbyCitation_article-title">Gallium(
              iii
              )–2-benzoylpyridine-thiosemicarbazone complexes promote apoptosis through Ca
              2+
              signaling and ROS-mediated mitochondrial pathways. </span><span class="cited-content_cbyCitation_journal-name">New Journal of Chemistry</span><span> <strong>2018,</strong> <em>42 </em>
                                    (12)
                                     , 10226-10233. <a href="https://doi.org/10.1039/C8NJ00697K" title="DOI URL">https://doi.org/10.1039/C8NJ00697K</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/C8NJ00697K&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FC8NJ00697K%26sid%3Dliteratum%253Aachs%26jtitle%3DNew%2520Journal%2520of%2520Chemistry%26atitle%3DGallium%252528%252Biii%252B%252529%2525E2%252580%2525932-benzoylpyridine-thiosemicarbazone%252Bcomplexes%252Bpromote%252Bapoptosis%252Bthrough%252BCa%252B2%25252B%252Bsignaling%252Band%252BROS-mediated%252Bmitochondrial%252Bpathways%26aulast%3DQi%26aufirst%3DJinxu%26date%3D2018%26date%3D2018%26volume%3D42%26issue%3D12%26spage%3D10226%26epage%3D10233" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Yi  Gou</span>, <span class="hlFld-ContribAuthor ">Zhenlei  Zhang</span>, <span class="hlFld-ContribAuthor ">Dongyang  Li</span>, <span class="hlFld-ContribAuthor ">Lei  Zhao</span>, <span class="hlFld-ContribAuthor ">Meiling  Cai</span>, <span class="hlFld-ContribAuthor ">Zhewen  Sun</span>, <span class="hlFld-ContribAuthor ">Yongping  Li</span>, <span class="hlFld-ContribAuthor ">Yao  Zhang</span>, <span class="hlFld-ContribAuthor ">Hamid  Khan</span>, <span class="hlFld-ContribAuthor ">Hongbing  Sun</span>, <span class="hlFld-ContribAuthor ">Tao  Wang</span>, <span class="hlFld-ContribAuthor ">Hong  Liang</span>, <span class="hlFld-ContribAuthor ">Feng  Yang</span>. </span><span class="cited-content_cbyCitation_article-title">HSA-based multi-target combination therapy: regulating drugs’ release from HSA and overcoming single drug resistance in a breast cancer model. </span><span class="cited-content_cbyCitation_journal-name">Drug Delivery</span><span> <strong>2018,</strong> <em>25 </em>
                                    (1)
                                     , 321-329. <a href="https://doi.org/10.1080/10717544.2018.1428245" title="DOI URL">https://doi.org/10.1080/10717544.2018.1428245</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1080/10717544.2018.1428245&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1080%2F10717544.2018.1428245%26sid%3Dliteratum%253Aachs%26jtitle%3DDrug%2520Delivery%26atitle%3DHSA-based%252Bmulti-target%252Bcombination%252Btherapy%25253A%252Bregulating%252Bdrugs%2525E2%252580%252599%252Brelease%252Bfrom%252BHSA%252Band%252Bovercoming%252Bsingle%252Bdrug%252Bresistance%252Bin%252Ba%252Bbreast%252Bcancer%252Bmodel%26aulast%3DGou%26aufirst%3DYi%26date%3D2018%26date%3D2018%26volume%3D25%26issue%3D1%26spage%3D321%26epage%3D329" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Jinxu  Qi</span>, <span class="hlFld-ContribAuthor ">Yunyun  Zheng</span>, <span class="hlFld-ContribAuthor ">Kun  Qian</span>, <span class="hlFld-ContribAuthor ">Liang  Tian</span>, <span class="hlFld-ContribAuthor ">Guo-Xin  Zhang</span>, <span class="hlFld-ContribAuthor ">Zhen  Cheng</span>, <span class="hlFld-ContribAuthor ">Yihong  Wang</span>. </span><span class="cited-content_cbyCitation_article-title">Synthesis, crystal structure and antiproliferative mechanisms of 2-acetylpyridine-thiosemicarbazones Ga(III) with a greater selectivity against tumor cells. </span><span class="cited-content_cbyCitation_journal-name">Journal of Inorganic Biochemistry</span><span> <strong>2017,</strong> <em>177 </em>, 110-117. <a href="https://doi.org/10.1016/j.jinorgbio.2017.09.012" title="DOI URL">https://doi.org/10.1016/j.jinorgbio.2017.09.012</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.jinorgbio.2017.09.012&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.jinorgbio.2017.09.012%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Inorganic%2520Biochemistry%26atitle%3DSynthesis%25252C%252Bcrystal%252Bstructure%252Band%252Bantiproliferative%252Bmechanisms%252Bof%252B2-acetylpyridine-thiosemicarbazones%252BGa%252528III%252529%252Bwith%252Ba%252Bgreater%252Bselectivity%252Bagainst%252Btumor%252Bcells%26aulast%3DQi%26aufirst%3DJinxu%26date%3D2017%26volume%3D177%26spage%3D110%26epage%3D117" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ritu R.  Kudarha</span>, <span class="hlFld-ContribAuthor ">Krutika K.  Sawant</span>. </span><span class="cited-content_cbyCitation_article-title">Albumin based versatile multifunctional nanocarriers for cancer therapy: Fabrication, surface modification, multimodal therapeutics and imaging approaches. </span><span class="cited-content_cbyCitation_journal-name">Materials Science and Engineering: C</span><span> <strong>2017,</strong> <em>81 </em>, 607-626. <a href="https://doi.org/10.1016/j.msec.2017.08.004" title="DOI URL">https://doi.org/10.1016/j.msec.2017.08.004</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.msec.2017.08.004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.msec.2017.08.004%26sid%3Dliteratum%253Aachs%26jtitle%3DMaterials%2520Science%2520and%2520Engineering%253A%2520C%26atitle%3DAlbumin%252Bbased%252Bversatile%252Bmultifunctional%252Bnanocarriers%252Bfor%252Bcancer%252Btherapy%25253A%252BFabrication%25252C%252Bsurface%252Bmodification%25252C%252Bmultimodal%252Btherapeutics%252Band%252Bimaging%252Bapproaches%26aulast%3DKudarha%26aufirst%3DRitu%2BR.%26date%3D2017%26volume%3D81%26spage%3D607%26epage%3D626" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Miljan N. M.  Milunović</span>, <span class="hlFld-ContribAuthor ">Aliona  Dobrova</span>, <span class="hlFld-ContribAuthor ">Ghenadie  Novitchi</span>, <span class="hlFld-ContribAuthor ">Nevenka  Gligorijević</span>, <span class="hlFld-ContribAuthor ">Siniša  Radulović</span>, <span class="hlFld-ContribAuthor ">Jozef  Kožišek</span>, <span class="hlFld-ContribAuthor ">Peter  Rapta</span>, <span class="hlFld-ContribAuthor ">Eva A.  Enyedy</span>, <span class="hlFld-ContribAuthor ">Vladimir B.  Arion</span>. </span><span class="cited-content_cbyCitation_article-title">Effects of Terminal Substitution and Iron Coordination on Antiproliferative Activity of
              l
              -Proline-salicylaldehyde-Thiosemicarbazone Hybrids. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Inorganic Chemistry</span><span> <strong>2017,</strong> <em>2017 </em>
                                    (40)
                                     , 4773-4783. <a href="https://doi.org/10.1002/ejic.201700962" title="DOI URL">https://doi.org/10.1002/ejic.201700962</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/ejic.201700962&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fejic.201700962%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Inorganic%2520Chemistry%26atitle%3DEffects%252Bof%252BTerminal%252BSubstitution%252Band%252BIron%252BCoordination%252Bon%252BAntiproliferative%252BActivity%252Bof%252Bl%252B-Proline-salicylaldehyde-Thiosemicarbazone%252BHybrids%26aulast%3DMilunovi%25C4%2587%26aufirst%3DMiljan%2BN.%2BM.%26date%3D2017%26date%3D2017%26volume%3D2017%26issue%3D40%26spage%3D4773%26epage%3D4783" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">S. Yousef  Ebrahimipour</span>, <span class="hlFld-ContribAuthor ">Maryam  Mohamadi</span>, <span class="hlFld-ContribAuthor ">Masoud  Torkzadeh Mahani</span>, <span class="hlFld-ContribAuthor ">Jim  Simpson</span>, <span class="hlFld-ContribAuthor ">Joel T.  Mague</span>, <span class="hlFld-ContribAuthor ">Iran  Sheikhshoaei</span>. </span><span class="cited-content_cbyCitation_article-title">Synthesis and structure elucidation of novel salophen-based dioxo-uranium(VI) complexes: In-vitro and in-silico studies of their DNA/BSA-binding properties and anticancer activity. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2017,</strong> <em>140 </em>, 172-186. <a href="https://doi.org/10.1016/j.ejmech.2017.08.068" title="DOI URL">https://doi.org/10.1016/j.ejmech.2017.08.068</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2017.08.068&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2017.08.068%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DSynthesis%252Band%252Bstructure%252Belucidation%252Bof%252Bnovel%252Bsalophen-based%252Bdioxo-uranium%252528VI%252529%252Bcomplexes%25253A%252BIn-vitro%252Band%252Bin-silico%252Bstudies%252Bof%252Btheir%252BDNA%25252FBSA-binding%252Bproperties%252Band%252Banticancer%252Bactivity%26aulast%3DEbrahimipour%26aufirst%3DS.%2BYousef%26date%3D2017%26volume%3D140%26spage%3D172%26epage%3D186" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Jinxu  Qi</span>, <span class="hlFld-ContribAuthor ">Jungang  Deng</span>, <span class="hlFld-ContribAuthor ">Kun  Qian</span>, <span class="hlFld-ContribAuthor ">Liang  Tian</span>, <span class="hlFld-ContribAuthor ">Jiaming  Li</span>, <span class="hlFld-ContribAuthor ">Kunhuan  He</span>, <span class="hlFld-ContribAuthor ">Xueren  Huang</span>, <span class="hlFld-ContribAuthor ">Zhen  Cheng</span>, <span class="hlFld-ContribAuthor ">Yunyun  Zheng</span>, <span class="hlFld-ContribAuthor ">Yihong  Wang</span>. </span><span class="cited-content_cbyCitation_article-title">Novel 2-pyridinecarboxaldehyde thiosemicarbazones Ga(III) complexes with a high antiproliferative activity by promoting apoptosis and inhibiting cell cycle. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2017,</strong> <em>134 </em>, 34-42. <a href="https://doi.org/10.1016/j.ejmech.2017.04.009" title="DOI URL">https://doi.org/10.1016/j.ejmech.2017.04.009</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2017.04.009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2017.04.009%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DNovel%252B2-pyridinecarboxaldehyde%252Bthiosemicarbazones%252BGa%252528III%252529%252Bcomplexes%252Bwith%252Ba%252Bhigh%252Bantiproliferative%252Bactivity%252Bby%252Bpromoting%252Bapoptosis%252Band%252Binhibiting%252Bcell%252Bcycle%26aulast%3DQi%26aufirst%3DJinxu%26date%3D2017%26volume%3D134%26spage%3D34%26epage%3D42" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Yao  Zhang</span>, <span class="hlFld-ContribAuthor ">Zhenlei  Zhang</span>, <span class="hlFld-ContribAuthor ">Yi  Gou</span>, <span class="hlFld-ContribAuthor ">Ming  Jiang</span>, <span class="hlFld-ContribAuthor ">Hamid  Khan</span>, <span class="hlFld-ContribAuthor ">Zuping  Zhou</span>, <span class="hlFld-ContribAuthor ">Hong  Liang</span>, <span class="hlFld-ContribAuthor ">Feng  Yang</span>. </span><span class="cited-content_cbyCitation_article-title">Design an anticancer copper(II) pro-drug based on the flexible IIA subdomain of human serum albumin. </span><span class="cited-content_cbyCitation_journal-name">Journal of Inorganic Biochemistry</span><span> <strong>2017,</strong> <em>172 </em>, 1-8. <a href="https://doi.org/10.1016/j.jinorgbio.2017.04.002" title="DOI URL">https://doi.org/10.1016/j.jinorgbio.2017.04.002</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.jinorgbio.2017.04.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.jinorgbio.2017.04.002%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Inorganic%2520Biochemistry%26atitle%3DDesign%252Ban%252Banticancer%252Bcopper%252528II%252529%252Bpro-drug%252Bbased%252Bon%252Bthe%252Bflexible%252BIIA%252Bsubdomain%252Bof%252Bhuman%252Bserum%252Balbumin%26aulast%3DZhang%26aufirst%3DYao%26date%3D2017%26volume%3D172%26spage%3D1%26epage%3D8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Yu-Ting  Wang</span>, <span class="hlFld-ContribAuthor ">Yan  Fang</span>, <span class="hlFld-ContribAuthor ">Meng  Zhao</span>, <span class="hlFld-ContribAuthor ">Ming-Xue  Li</span>, <span class="hlFld-ContribAuthor ">Yu-Mei  Ji</span>, <span class="hlFld-ContribAuthor ">Qiu-Xia  Han</span>. </span><span class="cited-content_cbyCitation_article-title">Cu(
              ii
              ), Ga(
              iii
              ) and In(
              iii
              ) complexes of 2-acetylpyridine
              N
              (4)-phenylthiosemicarbazone: synthesis, spectral characterization and biological activities. </span><span class="cited-content_cbyCitation_journal-name">MedChemComm</span><span> <strong>2017,</strong> <em>8 </em>
                                    (11)
                                     , 2125-2132. <a href="https://doi.org/10.1039/C7MD00415J" title="DOI URL">https://doi.org/10.1039/C7MD00415J</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/C7MD00415J&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FC7MD00415J%26sid%3Dliteratum%253Aachs%26jtitle%3DMedChemComm%26atitle%3DCu%252528%252Bii%252B%252529%25252C%252BGa%252528%252Biii%252B%252529%252Band%252BIn%252528%252Biii%252B%252529%252Bcomplexes%252Bof%252B2-acetylpyridine%252BN%252B%2525284%252529-phenylthiosemicarbazone%25253A%252Bsynthesis%25252C%252Bspectral%252Bcharacterization%252Band%252Bbiological%252Bactivities%26aulast%3DWang%26aufirst%3DYu-Ting%26date%3D2017%26date%3D2017%26volume%3D8%26issue%3D11%26spage%3D2125%26epage%3D2132" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li></ol></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li><li role="presentation"><a id="pane-m3con" href="#pane-m3" aria-controls="pane-m3" role="tab" data-toggle="tab" title="Support Info" aria-selected="false" class="empty tab__nav-suppInfo"><i class="icon-supporting-info"></i><span>Support Info</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="f_tgr1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-16/acs.jmedchem.6b00509/20160819/images/medium/jm-2016-00509b_0013.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-16/acs.jmedchem.6b00509/20160819/images/large/jm-2016-00509b_0013.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00509&amp;id=f_tgr1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-16/acs.jmedchem.6b00509/20160819/images/medium/jm-2016-00509b_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-16/acs.jmedchem.6b00509/20160819/images/large/jm-2016-00509b_0002.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Hypothesis of developing Fe prodrug based on the N-donor residues of HSA IIA subdomain.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-16/acs.jmedchem.6b00509/20160819/images/large/jm-2016-00509b_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00509&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-16/acs.jmedchem.6b00509/20160819/images/medium/jm-2016-00509b_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-16/acs.jmedchem.6b00509/20160819/images/large/jm-2016-00509b_0003.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Structure of ligands and Fe compounds.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-16/acs.jmedchem.6b00509/20160819/images/large/jm-2016-00509b_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00509&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-16/acs.jmedchem.6b00509/20160819/images/medium/jm-2016-00509b_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-16/acs.jmedchem.6b00509/20160819/images/large/jm-2016-00509b_0004.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. (A) Experimental sigmaA weighted 2Fo–Fc electron density map of compound <b>12</b> at IIA subdomain. (B) Overall structure of the HSA complex. (C) Structural binding environment of compound <b>12</b> to IIA subdomain of HSA. Amino acid chains that are close to the drug molecules are shown as sticks.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-16/acs.jmedchem.6b00509/20160819/images/large/jm-2016-00509b_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00509&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig4" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-16/acs.jmedchem.6b00509/20160819/images/medium/jm-2016-00509b_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-16/acs.jmedchem.6b00509/20160819/images/large/jm-2016-00509b_0005.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. (A) Net tumor volume as a function of time on Bel-7402 xenografts after IV administration (tail vein) of vehicle control, compound <b>12</b>, and HSA-<b>12</b> complex. (B) Tumor weight (wet weight) (A) after killing the mice on Day 28. (C) Tumors were removed from the mice after 28 days of treatment and stained with the TUNEL assay (400×). Results are mean ± SD (<i>n</i> = 6–7 mice/condition). Results are mean ± SD (<i>n</i> = 6–7): (*) <i>p</i> < 0.05, (**) <i>p</i> < 0.01, (***) <i>p</i> < 0.001.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-16/acs.jmedchem.6b00509/20160819/images/large/jm-2016-00509b_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00509&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig5" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-16/acs.jmedchem.6b00509/20160819/images/medium/jm-2016-00509b_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-16/acs.jmedchem.6b00509/20160819/images/large/jm-2016-00509b_0006.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. (A) Average body weight of treated nude mice was measured and recorded for 28 days. (B) After 28 days of treatment, the major organs (heart, liver, and kidney) were harvested from mice and then stained with H&E (400×).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-16/acs.jmedchem.6b00509/20160819/images/large/jm-2016-00509b_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00509&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig6" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-16/acs.jmedchem.6b00509/20160819/images/medium/jm-2016-00509b_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-16/acs.jmedchem.6b00509/20160819/images/large/jm-2016-00509b_0007.jpeg" id="rightTab-gr6" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. (A) Fe content in tumor of mice treated with compound <b>12</b> and HSA-<b>12</b> complex after 28 days. (B) Fe content released from HSA complex in pH 4.7 and pH 7.4 buffers, 0–48 h, respectively.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-16/acs.jmedchem.6b00509/20160819/images/large/jm-2016-00509b_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00509&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig7" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-16/acs.jmedchem.6b00509/20160819/images/medium/jm-2016-00509b_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-16/acs.jmedchem.6b00509/20160819/images/large/jm-2016-00509b_0008.jpeg" id="rightTab-gr7" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. (A) Western blot analysis of HSA in Bel-7402 cells treated with HSA-<b>12</b> complex; β-actin was used as the internal control. (B) Percentage levels of HSA; the values are relative to 0 mM of methyl-β-cyclodextrin-incubated. (C) Intracellular Fe concentration in Bel-7402 cells treated with HSA-<b>12</b> complex relative to 0 mM of methyl-β-cyclodextrin-incubated.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-16/acs.jmedchem.6b00509/20160819/images/large/jm-2016-00509b_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00509&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig8" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-16/acs.jmedchem.6b00509/20160819/images/medium/jm-2016-00509b_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-16/acs.jmedchem.6b00509/20160819/images/large/jm-2016-00509b_0009.jpeg" id="rightTab-gr8" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. (A) Agarose gel assay for Topo-IIα inhibition by compound <b>12</b>. (B) Effect of the cell cycle of Bel-7402 treated with compound <b>12</b> and HSA-<b>12</b> complex for 24 h compared with untreated cells. (C) Western blot analysis of E2F-1, Cyc A, Cyc E, and Cdk 2 in Bel-7402 cells treated with compound <b>12</b> and HSA-<b>12</b> complex for 24 h; β-actin was used as the internal control. (D) Expression levels of (C) shown as percentages. The values are relative to the control.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-16/acs.jmedchem.6b00509/20160819/images/large/jm-2016-00509b_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00509&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig9" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 9</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-16/acs.jmedchem.6b00509/20160819/images/medium/jm-2016-00509b_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-16/acs.jmedchem.6b00509/20160819/images/large/jm-2016-00509b_0010.jpeg" id="rightTab-gr9" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 9. (A) Intracellular production of reactive oxygen species by FeCl<sub>3</sub>, compound <b>6</b>, compound <b>12</b>, and HSA-<b>12</b> complex following a 24 h incubation determined by flow cytotometric. (B) Cyclic voltammograms of 1 mM solutions of compound <b>12</b> show the impact of a halogen atom on the Fe<sup>III/II</sup> redox potential. (C) The percentage of green fluorescence cells treated with FeCl<sub>3</sub>, compound <b>6</b>, compound <b>12</b>, and HSA-<b>12</b> complex for 24 h and control determined by flow cytometry.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-16/acs.jmedchem.6b00509/20160819/images/large/jm-2016-00509b_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00509&amp;id=fig9"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig10" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Figure 10</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-16/acs.jmedchem.6b00509/20160819/images/medium/jm-2016-00509b_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-16/acs.jmedchem.6b00509/20160819/images/large/jm-2016-00509b_0011.jpeg" id="rightTab-gr10" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 10. (A) Western blot analysis of p53, Bcl-2, Bcl-xl, Bax, Cyt C, caspase-3, and caspase-9 in Bel-7402 cells treated with compound <b>12</b> and HSA-<b>12</b> complex for 24 h; β-actin was used as the internal control. (B) Expression levels of p53, Bcl-2, Bcl-xl, Bax, Cyt C, caspase-3, and caspase-9 shown as percentages; the values are relative to the control. (C) The effect of cell apoptosis from Bel-7402 treated with compound <b>12</b> and HSA-<b>12</b> complex for 12 h compared with the untreated cells.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-16/acs.jmedchem.6b00509/20160819/images/large/jm-2016-00509b_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00509&amp;id=fig10"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig11" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Figure 11</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-16/acs.jmedchem.6b00509/20160819/images/medium/jm-2016-00509b_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-16/acs.jmedchem.6b00509/20160819/images/large/jm-2016-00509b_0012.jpeg" id="rightTab-gr11" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 11. Possible delivery and anticancer mechanism of HSA-<b>12</b> complex.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-16/acs.jmedchem.6b00509/20160819/images/large/jm-2016-00509b_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00509&amp;id=fig11"><span>Download MS PowerPoint Slide</span></a></div></div></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i63">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_30663" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_30663" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 61 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span><span class="NLM_contrib-group">Lainé, A. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Passirani, C.</span><span> </span><span class="NLM_article-title">Novel metal-based anticancer drugs: a new challenge in drug delivery</span> <span class="citation_source-journal">Curr. Opin. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">12</span><span class="NLM_x">, </span> <span class="NLM_fpage">420</span><span class="NLM_x">–</span> <span class="NLM_lpage">426</span><span class="refDoi"> DOI: 10.1016/j.coph.2012.04.006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00509&amp;key=10.1016%2Fj.coph.2012.04.006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00509&amp;key=22609113" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00509&amp;key=1%3ACAS%3A528%3ADC%252BC38XntlSrtLo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2012&pages=420-426&author=A.+L.+Lain%C3%A9author=C.+Passirani&title=Novel+metal-based+anticancer+drugs%3A+a+new+challenge+in+drug+delivery&doi=10.1016%2Fj.coph.2012.04.006"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Novel metal-based anticancer drugs: a new challenge in drug delivery</span></div><div class="casAuthors">Laine, Anne-Laure; Passirani, Catherine</div><div class="citationInfo"><span class="NLM_cas:title">Current Opinion in Pharmacology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">420-426</span>CODEN:
                <span class="NLM_cas:coden">COPUBK</span>;
        ISSN:<span class="NLM_cas:issn">1471-4892</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  Since the serependitous discovery of the cisplatin antiproliferative activity, many efforts have focused on the design of potent metal-based drugs for oncol. therapies.  A large no. of these complexes were evaluated in vitro and in vivo and some have reached clin. trials.  However, while metallodrug chem. has developed to an advanced level, these emerging therapeutics have encountered new hurdles including poor water soly. and pharmacol. deficiencies.  Today, solns. to overcome these issues do not lie in synthesizing new anticancer drugs but in finding suitable drug delivery strategies.  Over the past decades, various delivery systems were developed including prodrug, ligand design and nanocarriers aimed at enhancing the performance profile of these novel metallodrugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo0rPnLyzMlFrVg90H21EOLACvtfcHk0ljhunTr_2N-Fg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XntlSrtLo%253D&md5=6f7b911a7cdf6d20980badfd5aa94c8c</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1016%2Fj.coph.2012.04.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.coph.2012.04.006%26sid%3Dliteratum%253Aachs%26aulast%3DLain%25C3%25A9%26aufirst%3DA.%2BL.%26aulast%3DPassirani%26aufirst%3DC.%26atitle%3DNovel%2520metal-based%2520anticancer%2520drugs%253A%2520a%2520new%2520challenge%2520in%2520drug%2520delivery%26jtitle%3DCurr.%2520Opin.%2520Pharmacol.%26date%3D2012%26volume%3D12%26spage%3D420%26epage%3D426%26doi%3D10.1016%2Fj.coph.2012.04.006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span><span class="NLM_contrib-group">Yang, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liang, H.</span><span> </span><span class="NLM_article-title">HSA IIA subdomain-based developing anticancer metal prodrug: a new and improved approach</span> <span class="citation_source-journal">Future Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">8</span><span class="NLM_x">, </span> <span class="NLM_fpage">89</span><span class="NLM_x">–</span> <span class="NLM_lpage">91</span><span class="refDoi"> DOI: 10.4155/fmc.15.179</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00509&amp;key=10.4155%2Ffmc.15.179" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00509&amp;key=26824398" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00509&amp;key=1%3ACAS%3A528%3ADC%252BC28Xit1Wms7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2016&pages=89-91&author=F.+Yangauthor=H.+Liang&title=HSA+IIA+subdomain-based+developing+anticancer+metal+prodrug%3A+a+new+and+improved+approach&doi=10.4155%2Ffmc.15.179"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">HSA IIA subdomain-based developing anticancer metal prodrug: a new and improved approach</span></div><div class="casAuthors">Yang, Feng; Liang, Hong</div><div class="citationInfo"><span class="NLM_cas:title">Future Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">89-91</span>CODEN:
                <span class="NLM_cas:coden">FMCUA7</span>;
        ISSN:<span class="NLM_cas:issn">1756-8919</span>.
    
            (<span class="NLM_cas:orgname">Future Science Ltd.</span>)
        </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo_zsI4PaxkdbVg90H21EOLACvtfcHk0ljhunTr_2N-Fg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xit1Wms7g%253D&md5=b36af3e0527593991e3665bdd5fdc128</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.4155%2Ffmc.15.179&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4155%252Ffmc.15.179%26sid%3Dliteratum%253Aachs%26aulast%3DYang%26aufirst%3DF.%26aulast%3DLiang%26aufirst%3DH.%26atitle%3DHSA%2520IIA%2520subdomain-based%2520developing%2520anticancer%2520metal%2520prodrug%253A%2520a%2520new%2520and%2520improved%2520approach%26jtitle%3DFuture%2520Med.%2520Chem.%26date%3D2016%26volume%3D8%26spage%3D89%26epage%3D91%26doi%3D10.4155%2Ffmc.15.179" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group">Jansson, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sharpe, P. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bernhardt, P. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Richardson, D. R.</span><span> </span><span class="NLM_article-title">Novel Thiosemicarbazones of the ApT and DpT series and their copper complexes: identification of pronounced redox activity and characterization of their antitumor activity</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">53</span><span class="NLM_x">, </span> <span class="NLM_fpage">5759</span><span class="NLM_x">–</span> <span class="NLM_lpage">5769</span><span class="refDoi"> DOI: 10.1021/jm100561b</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm100561b" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00509&amp;key=1%3ACAS%3A528%3ADC%252BC3cXotlSnsr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2010&pages=5759-5769&author=P.+J.+Janssonauthor=P.+C.+Sharpeauthor=P.+V.+Bernhardtauthor=D.+R.+Richardson&title=Novel+Thiosemicarbazones+of+the+ApT+and+DpT+series+and+their+copper+complexes%3A+identification+of+pronounced+redox+activity+and+characterization+of+their+antitumor+activity&doi=10.1021%2Fjm100561b"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Novel Thiosemicarbazones of the ApT and DpT Series and Their Copper Complexes: Identification of Pronounced Redox Activity and Characterization of Their Antitumor Activity</span></div><div class="casAuthors">Jansson, Patric J.; Sharpe, Philip C.; Bernhardt, Paul V.; Richardson, Des R.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">5759-5769</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The novel chelators 2-acetylpyridine-4,4-dimethyl-3-thiosemicarbazone (HAp44mT) and di-2-pyridylketone-4,4-dimethyl-3-thiosemicarbazone (HDp44mT) have been examd. to elucidate the structure-activity relationships necessary to form copper (Cu) complexes with pronounced antitumor activity.  Electrochem. studies demonstrated that the Cu complexes of these ligands had lower redox potentials than their iron complexes.  Moreover, the Cu complexes where the ligand/metal ratio was 1:1 rather than 2:1 had significantly higher intracellular oxidative properties and antitumor efficacy.  Interestingly, the 2:1 complex was shown to dissoc. to give significant amts. of the 1:1 complex that could be the major cytotoxic effector.  Both types of Cu complex showed significantly more antiproliferative activity than the ligand alone.  We also demonstrate the importance of the inductive effects of substituents on the carbonyl group of the parent ketone, which influence the CuII/I redox potentials because of their proximity to the metal center.  The structure-activity relationships described are important for the design of potent thiosemicarbazone Cu complexes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqhryQ9dAB5CLVg90H21EOLACvtfcHk0lgtAL9u-03A6w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXotlSnsr4%253D&md5=7417f8c18eed7edddd542da369ecb5ab</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1021%2Fjm100561b&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm100561b%26sid%3Dliteratum%253Aachs%26aulast%3DJansson%26aufirst%3DP.%2BJ.%26aulast%3DSharpe%26aufirst%3DP.%2BC.%26aulast%3DBernhardt%26aufirst%3DP.%2BV.%26aulast%3DRichardson%26aufirst%3DD.%2BR.%26atitle%3DNovel%2520Thiosemicarbazones%2520of%2520the%2520ApT%2520and%2520DpT%2520series%2520and%2520their%2520copper%2520complexes%253A%2520identification%2520of%2520pronounced%2520redox%2520activity%2520and%2520characterization%2520of%2520their%2520antitumor%2520activity%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2010%26volume%3D53%26spage%3D5759%26epage%3D5769%26doi%3D10.1021%2Fjm100561b" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group">Qi, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liang, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gou, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhou, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liang, H.</span><span> </span><span class="NLM_article-title">Synthesis of four binuclear copper(II) complexes: structure, anticancer properties and anticancer mechanism</span> <span class="citation_source-journal">Eur. J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">96</span><span class="NLM_x">, </span> <span class="NLM_fpage">360</span><span class="NLM_x">–</span> <span class="NLM_lpage">368</span><span class="refDoi"> DOI: 10.1016/j.ejmech.2015.04.031</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00509&amp;key=10.1016%2Fj.ejmech.2015.04.031" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=96&publication_year=2015&pages=360-368&author=J.+Qiauthor=S.+Liangauthor=Y.+Gouauthor=Z.+Zhangauthor=Z.+Zhouauthor=F.+Yangauthor=H.+Liang&title=Synthesis+of+four+binuclear+copper%28II%29+complexes%3A+structure%2C+anticancer+properties+and+anticancer+mechanism&doi=10.1016%2Fj.ejmech.2015.04.031"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2015.04.031&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2015.04.031%26sid%3Dliteratum%253Aachs%26aulast%3DQi%26aufirst%3DJ.%26aulast%3DLiang%26aufirst%3DS.%26aulast%3DGou%26aufirst%3DY.%26aulast%3DZhang%26aufirst%3DZ.%26aulast%3DZhou%26aufirst%3DZ.%26aulast%3DYang%26aufirst%3DF.%26aulast%3DLiang%26aufirst%3DH.%26atitle%3DSynthesis%2520of%2520four%2520binuclear%2520copper%2528II%2529%2520complexes%253A%2520structure%252C%2520anticancer%2520properties%2520and%2520anticancer%2520mechanism%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2015%26volume%3D96%26spage%3D360%26epage%3D368%26doi%3D10.1016%2Fj.ejmech.2015.04.031" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group">van Rijt, S. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sadler, P. J.</span><span> </span><span class="NLM_article-title">Current applications and future potential for bioinorganic chemistry in the development of anticancer drugs</span> <span class="citation_source-journal">Drug Discovery Today</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">14</span><span class="NLM_x">, </span> <span class="NLM_fpage">1089</span><span class="NLM_x">–</span> <span class="NLM_lpage">1097</span><span class="refDoi"> DOI: 10.1016/j.drudis.2009.09.003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00509&amp;key=10.1016%2Fj.drudis.2009.09.003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00509&amp;key=19782150" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00509&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhsV2murvE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2009&pages=1089-1097&author=S.+H.+van+Rijtauthor=P.+J.+Sadler&title=Current+applications+and+future+potential+for+bioinorganic+chemistry+in+the+development+of+anticancer+drugs&doi=10.1016%2Fj.drudis.2009.09.003"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Current applications and future potential for bioinorganic chemistry in the development of anticancer drugs</span></div><div class="casAuthors">van Rijt, Sabine H.; Sadler, Peter J.</div><div class="citationInfo"><span class="NLM_cas:title">Drug Discovery Today</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">23/24</span>),
    <span class="NLM_cas:pages">1089-1097</span>CODEN:
                <span class="NLM_cas:coden">DDTOFS</span>;
        ISSN:<span class="NLM_cas:issn">1359-6446</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  This review illustrates notable recent progress in the field of medicinal bioinorg. chem. as many new approaches to the design of innovative metal-based anticancer drugs are emerging.  Current research addressing the problems assocd. with platinum drugs has focused on other metal-based therapeutics that have different modes of action and on prodrug and targeting strategies in an effort to diminish the side-effects of cisplatin chemotherapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqojVDzugGUJ7Vg90H21EOLACvtfcHk0lgtAL9u-03A6w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhsV2murvE&md5=37e89d98dc15aac0adbd3f9fc0fd0f74</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1016%2Fj.drudis.2009.09.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.drudis.2009.09.003%26sid%3Dliteratum%253Aachs%26aulast%3Dvan%2BRijt%26aufirst%3DS.%2BH.%26aulast%3DSadler%26aufirst%3DP.%2BJ.%26atitle%3DCurrent%2520applications%2520and%2520future%2520potential%2520for%2520bioinorganic%2520chemistry%2520in%2520the%2520development%2520of%2520anticancer%2520drugs%26jtitle%3DDrug%2520Discovery%2520Today%26date%3D2009%26volume%3D14%26spage%3D1089%26epage%3D1097%26doi%3D10.1016%2Fj.drudis.2009.09.003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span><span class="NLM_contrib-group">Kowol, C. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Trondl, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heffeter, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Arion, V. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jakupec, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roller, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Galanski, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Berger, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Keppler, B. K.</span><span> </span><span class="NLM_article-title">Impact of metal coordination on cytotoxicity of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (triapine) and novel insights into terminal dimethylation</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">52</span><span class="NLM_x">, </span> <span class="NLM_fpage">5032</span><span class="NLM_x">–</span> <span class="NLM_lpage">5043</span><span class="refDoi"> DOI: 10.1021/jm900528d</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm900528d" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00509&amp;key=1%3ACAS%3A528%3ADC%252BD1MXptFCht7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2009&pages=5032-5043&author=C.+R.+Kowolauthor=R.+Trondlauthor=P.+Heffeterauthor=V.+B.+Arionauthor=M.+A.+Jakupecauthor=A.+Rollerauthor=M.+Galanskiauthor=W.+Bergerauthor=B.+K.+Keppler&title=Impact+of+metal+coordination+on+cytotoxicity+of+3-aminopyridine-2-carboxaldehyde+thiosemicarbazone+%28triapine%29+and+novel+insights+into+terminal+dimethylation&doi=10.1021%2Fjm900528d"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Impact of Metal Coordination on Cytotoxicity of 3-Aminopyridine-2-carboxaldehyde Thiosemicarbazone (Triapine) and Novel Insights into Terminal Dimethylation</span></div><div class="casAuthors">Kowol, Christian R.; Trondl, Robert; Heffeter, Petra; Arion, Vladimir B.; Jakupec, Michael A.; Roller, Alexander; Galanski, Markus; Berger, Walter; Keppler, Bernhard K.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">52</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">5032-5043</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The 1st metal complexes of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (Triapine) were synthesized.  Triapine was prepd. by a novel three-step procedure in 64% overall yield.  Related ligands, namely, 2-formylpyridine thiosemicarbazone, 2-acetylpyridine thiosemicarbazone, 2-pyridineformamide thiosemicarbazone, and their N4-dimethylated derivs. (including the N4-dimethylated analog of Triapine) were prepd., along with their corresponding Ga(III) and Fe(III) complexes [M(L)2]+, where HL is the resp. thiosemicarbazone.  The compds. were characterized by elemental anal., 1H and 13C NMR, IR and UV-visible spectroscopies, mass spectrometry, and cyclic voltammetry.  Triapine and its Fe(III) and Ga(III) complexes were studied by x-ray crystallog.  All ligands and complexes were tested for their in vitro antiproliferative activity in two human cancer cell lines (41M and SK-BR-3), and structure-activity relations were established.  In general, the coordination to Ga(III) increased the cytotoxicity while the Fe(III) complexes show reduced cytotoxic activity compared to the metal-free thiosemicarbazones.  Selected compds. were studied for the capacity of inhibiting ribonucleotide reductase by incorporation of 3H-cytidine into DNA.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo5oU-NYorlKLVg90H21EOLACvtfcHk0lgAYNTWaV31kA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXptFCht7k%253D&md5=7b805ef6e229f3b30eddc9acb0931945</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1021%2Fjm900528d&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm900528d%26sid%3Dliteratum%253Aachs%26aulast%3DKowol%26aufirst%3DC.%2BR.%26aulast%3DTrondl%26aufirst%3DR.%26aulast%3DHeffeter%26aufirst%3DP.%26aulast%3DArion%26aufirst%3DV.%2BB.%26aulast%3DJakupec%26aufirst%3DM.%2BA.%26aulast%3DRoller%26aufirst%3DA.%26aulast%3DGalanski%26aufirst%3DM.%26aulast%3DBerger%26aufirst%3DW.%26aulast%3DKeppler%26aufirst%3DB.%2BK.%26atitle%3DImpact%2520of%2520metal%2520coordination%2520on%2520cytotoxicity%2520of%25203-aminopyridine-2-carboxaldehyde%2520thiosemicarbazone%2520%2528triapine%2529%2520and%2520novel%2520insights%2520into%2520terminal%2520dimethylation%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2009%26volume%3D52%26spage%3D5032%26epage%3D5043%26doi%3D10.1021%2Fjm900528d" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span><span class="NLM_contrib-group">Lainé, A. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Passirani, C.</span><span> </span><span class="NLM_article-title">Novel metal-based anticancer drugs: a new challenge in drug delivery</span> <span class="citation_source-journal">Curr. Opin. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">12</span><span class="NLM_x">, </span> <span class="NLM_fpage">420</span><span class="NLM_x">–</span> <span class="NLM_lpage">426</span><span class="refDoi"> DOI: 10.1016/j.coph.2012.04.006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00509&amp;key=10.1016%2Fj.coph.2012.04.006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00509&amp;key=22609113" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00509&amp;key=1%3ACAS%3A528%3ADC%252BC38XntlSrtLo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2012&pages=420-426&author=A.+L.+Lain%C3%A9author=C.+Passirani&title=Novel+metal-based+anticancer+drugs%3A+a+new+challenge+in+drug+delivery&doi=10.1016%2Fj.coph.2012.04.006"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Novel metal-based anticancer drugs: a new challenge in drug delivery</span></div><div class="casAuthors">Laine, Anne-Laure; Passirani, Catherine</div><div class="citationInfo"><span class="NLM_cas:title">Current Opinion in Pharmacology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">420-426</span>CODEN:
                <span class="NLM_cas:coden">COPUBK</span>;
        ISSN:<span class="NLM_cas:issn">1471-4892</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  Since the serependitous discovery of the cisplatin antiproliferative activity, many efforts have focused on the design of potent metal-based drugs for oncol. therapies.  A large no. of these complexes were evaluated in vitro and in vivo and some have reached clin. trials.  However, while metallodrug chem. has developed to an advanced level, these emerging therapeutics have encountered new hurdles including poor water soly. and pharmacol. deficiencies.  Today, solns. to overcome these issues do not lie in synthesizing new anticancer drugs but in finding suitable drug delivery strategies.  Over the past decades, various delivery systems were developed including prodrug, ligand design and nanocarriers aimed at enhancing the performance profile of these novel metallodrugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo0rPnLyzMlFrVg90H21EOLACvtfcHk0lgAYNTWaV31kA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XntlSrtLo%253D&md5=6f7b911a7cdf6d20980badfd5aa94c8c</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1016%2Fj.coph.2012.04.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.coph.2012.04.006%26sid%3Dliteratum%253Aachs%26aulast%3DLain%25C3%25A9%26aufirst%3DA.%2BL.%26aulast%3DPassirani%26aufirst%3DC.%26atitle%3DNovel%2520metal-based%2520anticancer%2520drugs%253A%2520a%2520new%2520challenge%2520in%2520drug%2520delivery%26jtitle%3DCurr.%2520Opin.%2520Pharmacol.%26date%3D2012%26volume%3D12%26spage%3D420%26epage%3D426%26doi%3D10.1016%2Fj.coph.2012.04.006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_contrib-group">Whitnall, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Howard, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ponka, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Richardson, D. R.</span><span> </span><span class="NLM_article-title">A class of iron chelators with a wide spectrum of potent antitumor activity that overcomes resistance to chemotherapeutics</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U. S. A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">103</span><span class="NLM_x">, </span> <span class="NLM_fpage">14901</span><span class="NLM_x">–</span> <span class="NLM_lpage">14906</span><span class="refDoi"> DOI: 10.1073/pnas.0604979103</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00509&amp;key=10.1073%2Fpnas.0604979103" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=103&publication_year=2006&pages=14901-14906&author=M.+Whitnallauthor=J.+Howardauthor=P.+Ponkaauthor=D.+R.+Richardson&title=A+class+of+iron+chelators+with+a+wide+spectrum+of+potent+antitumor+activity+that+overcomes+resistance+to+chemotherapeutics&doi=10.1073%2Fpnas.0604979103"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1073%2Fpnas.0604979103&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.0604979103%26sid%3Dliteratum%253Aachs%26aulast%3DWhitnall%26aufirst%3DM.%26aulast%3DHoward%26aufirst%3DJ.%26aulast%3DPonka%26aufirst%3DP.%26aulast%3DRichardson%26aufirst%3DD.%2BR.%26atitle%3DA%2520class%2520of%2520iron%2520chelators%2520with%2520a%2520wide%2520spectrum%2520of%2520potent%2520antitumor%2520activity%2520that%2520overcomes%2520resistance%2520to%2520chemotherapeutics%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2006%26volume%3D103%26spage%3D14901%26epage%3D14906%26doi%3D10.1073%2Fpnas.0604979103" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span><span class="NLM_contrib-group">Lovejoy, D. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jansson, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brunk, U. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wong, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ponka, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Richardson, D. R.</span><span> </span><span class="NLM_article-title">Antitumor activity of metal-chelating compound Dp44mT is mediated by formation of a redox-active copper complex that accumulates in lysosomes</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">71</span><span class="NLM_x">, </span> <span class="NLM_fpage">5871</span><span class="NLM_x">–</span> <span class="NLM_lpage">5880</span><span class="refDoi"> DOI: 10.1158/0008-5472.CAN-11-1218</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00509&amp;key=10.1158%2F0008-5472.CAN-11-1218" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00509&amp;key=21750178" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00509&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtFSmtbvL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=71&publication_year=2011&pages=5871-5880&author=D.+B.+Lovejoyauthor=P.+J.+Janssonauthor=U.+T.+Brunkauthor=J.+Wongauthor=P.+Ponkaauthor=D.+R.+Richardson&title=Antitumor+activity+of+metal-chelating+compound+Dp44mT+is+mediated+by+formation+of+a+redox-active+copper+complex+that+accumulates+in+lysosomes&doi=10.1158%2F0008-5472.CAN-11-1218"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Antitumor Activity of Metal-Chelating Compound Dp44mT Is Mediated by Formation of a Redox-Active Copper Complex That Accumulates in Lysosomes</span></div><div class="casAuthors">Lovejoy, David B.; Jansson, Patric J.; Brunk, Ulf T.; Wong, Jacky; Ponka, Prem; Richardson, Des R.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">71</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">5871-5880</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">The metal-chelating compd. Dp44mT is a di-2-pyridylketone thiosemicarbazone (DpT) which displays potent and selective antitumor activity.  This compd. is receiving translational attention, but its mechanism is poorly understood.  Here, we report that Dp44mT targets lysosome integrity through copper binding.  Studies using the lysosomotropic fluorochrome acridine orange established that the copper-Dp44mT complex (Cu[Dp44mT]) disrupted lysosomes.  This targeting was confirmed with pepstatin A-BODIPY FL, which showed redistribution of cathepsin D to the cytosol with ensuing cleavage of the proapoptotic BH3 protein Bid.  Redox activity of Cu[Dp44mT] caused cellular depletion of glutathione, and lysosomal damage was prevented by cotreatment with the glutathione precursor N-acetylcysteine.  Copper binding was essential for the potent antitumor activity of Dp44mT, as coincubation with nontoxic copper chelators markedly attenuated its cytotoxicity.  Taken together, our studies show how the lysosomal apoptotic pathway can be selectively activated in cancer cells by sequestration of redox-active copper.  Our findings define a novel generalized strategy to selectively target lysosome function for chemotherapeutic intervention against cancer.  Cancer Res; 71(17); 5871-80.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqT2ClJjP1OF7Vg90H21EOLACvtfcHk0lgAYNTWaV31kA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtFSmtbvL&md5=e6e8e99034c780e75b410784fd774103</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-11-1218&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-11-1218%26sid%3Dliteratum%253Aachs%26aulast%3DLovejoy%26aufirst%3DD.%2BB.%26aulast%3DJansson%26aufirst%3DP.%2BJ.%26aulast%3DBrunk%26aufirst%3DU.%2BT.%26aulast%3DWong%26aufirst%3DJ.%26aulast%3DPonka%26aufirst%3DP.%26aulast%3DRichardson%26aufirst%3DD.%2BR.%26atitle%3DAntitumor%2520activity%2520of%2520metal-chelating%2520compound%2520Dp44mT%2520is%2520mediated%2520by%2520formation%2520of%2520a%2520redox-active%2520copper%2520complex%2520that%2520accumulates%2520in%2520lysosomes%26jtitle%3DCancer%2520Res.%26date%3D2011%26volume%3D71%26spage%3D5871%26epage%3D5880%26doi%3D10.1158%2F0008-5472.CAN-11-1218" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group">Kalinowski, D. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Richardson, D. R.</span><span> </span><span class="NLM_article-title">The evolution of iron chelators for the treatment of iron overload disease and cancer</span> <span class="citation_source-journal">Pharmacol. Rev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">57</span><span class="NLM_x">, </span> <span class="NLM_fpage">547</span><span class="NLM_x">–</span> <span class="NLM_lpage">583</span><span class="refDoi"> DOI: 10.1124/pr.57.4.2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00509&amp;key=10.1124%2Fpr.57.4.2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00509&amp;key=16382108" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00509&amp;key=1%3ACAS%3A528%3ADC%252BD28XhtFWnsrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2005&pages=547-583&author=D.+S.+Kalinowskiauthor=D.+R.+Richardson&title=The+evolution+of+iron+chelators+for+the+treatment+of+iron+overload+disease+and+cancer&doi=10.1124%2Fpr.57.4.2"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">The evolution of iron chelators for the treatment of iron overload disease and cancer</span></div><div class="casAuthors">Kalinowski, Danuta S.; Richardson, Des. R.</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacological Reviews</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">547-583</span>CODEN:
                <span class="NLM_cas:coden">PAREAQ</span>;
        ISSN:<span class="NLM_cas:issn">0031-6997</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">A review.  The evolution of iron chelators from a range of primordial siderophores and arom. heterocyclic ligands has lead to the formation of a new generation of potent and efficient iron chelators.  For example, various siderophore analogs and synthetic ligands, including ICL670A [4-[3,5-bis-(hydroxyphenyl)-1,2,4-triazol-1-yl]-benzoic acid], 4'-hydroxydesazadesferrithiocin, and Triapine, have been developed from predecessors and illustrate potent iron-mobilizing or antineoplastic activities.  This review focuses on the evolution of iron chelators from initial lead compds. through to the development of novel chelating agents, many of which show great potential to be clin. applied in the treatment of iron overload disease and cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqYJXHJqhQ0U7Vg90H21EOLACvtfcHk0lhEZtlNzl6y_g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XhtFWnsrY%253D&md5=2983bf140d7da93242b64c25bd79211d</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1124%2Fpr.57.4.2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fpr.57.4.2%26sid%3Dliteratum%253Aachs%26aulast%3DKalinowski%26aufirst%3DD.%2BS.%26aulast%3DRichardson%26aufirst%3DD.%2BR.%26atitle%3DThe%2520evolution%2520of%2520iron%2520chelators%2520for%2520the%2520treatment%2520of%2520iron%2520overload%2520disease%2520and%2520cancer%26jtitle%3DPharmacol.%2520Rev.%26date%3D2005%26volume%3D57%26spage%3D547%26epage%3D583%26doi%3D10.1124%2Fpr.57.4.2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group">Ma, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goh, B. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tan, E. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lam, K. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Soo, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leong, S. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, L. Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mo, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chan, A. T. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zee, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mok, T.</span><span> </span><span class="NLM_article-title">A multicenter phase II trial of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP, Triapine (R)) and gemcitabine in advanced non-small-cell lung cancer with pharmacokinetic evaluation using peripheral blood mononuclear cells</span> <span class="citation_source-journal">Invest. New Drugs</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">26</span><span class="NLM_x">, </span> <span class="NLM_fpage">169</span><span class="NLM_x">–</span> <span class="NLM_lpage">173</span><span class="refDoi"> DOI: 10.1007/s10637-007-9085-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00509&amp;key=10.1007%2Fs10637-007-9085-0" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2008&pages=169-173&author=B.+Maauthor=B.+C.+Gohauthor=E.+H.+Tanauthor=K.+C.+Lamauthor=R.+Sooauthor=S.+S.+Leongauthor=L.+Z.+Wangauthor=F.+Moauthor=A.+T.+C.+Chanauthor=B.+Zeeauthor=T.+Mok&title=A+multicenter+phase+II+trial+of+3-aminopyridine-2-carboxaldehyde+thiosemicarbazone+%283-AP%2C+Triapine+%28R%29%29+and+gemcitabine+in+advanced+non-small-cell+lung+cancer+with+pharmacokinetic+evaluation+using+peripheral+blood+mononuclear+cells&doi=10.1007%2Fs10637-007-9085-0"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1007%2Fs10637-007-9085-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs10637-007-9085-0%26sid%3Dliteratum%253Aachs%26aulast%3DMa%26aufirst%3DB.%26aulast%3DGoh%26aufirst%3DB.%2BC.%26aulast%3DTan%26aufirst%3DE.%2BH.%26aulast%3DLam%26aufirst%3DK.%2BC.%26aulast%3DSoo%26aufirst%3DR.%26aulast%3DLeong%26aufirst%3DS.%2BS.%26aulast%3DWang%26aufirst%3DL.%2BZ.%26aulast%3DMo%26aufirst%3DF.%26aulast%3DChan%26aufirst%3DA.%2BT.%2BC.%26aulast%3DZee%26aufirst%3DB.%26aulast%3DMok%26aufirst%3DT.%26atitle%3DA%2520multicenter%2520phase%2520II%2520trial%2520of%25203-aminopyridine-2-carboxaldehyde%2520thiosemicarbazone%2520%25283-AP%252C%2520Triapine%2520%2528R%2529%2529%2520and%2520gemcitabine%2520in%2520advanced%2520non-small-cell%2520lung%2520cancer%2520with%2520pharmacokinetic%2520evaluation%2520using%2520peripheral%2520blood%2520mononuclear%2520cells%26jtitle%3DInvest.%2520New%2520Drugs%26date%3D2008%26volume%3D26%26spage%3D169%26epage%3D173%26doi%3D10.1007%2Fs10637-007-9085-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group">Lovejoy, D. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sharp, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Seebacher, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Obeidy, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Prichard, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stefani, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Basha, M. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sharpe, P. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jansson, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kalinowski, D. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bernhardt, P. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Richardson, D. R.</span><span> </span><span class="NLM_article-title">Novel second-generation di-2-pyridylketone thiosemicarbazones show synergism with standard chemotherapeutics and demonstrate potent activity against lung cancer xenografts after oral and intravenous administration in vivo</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">55</span><span class="NLM_x">, </span> <span class="NLM_fpage">7230</span><span class="NLM_x">–</span> <span class="NLM_lpage">7244</span><span class="refDoi"> DOI: 10.1021/jm300768u</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm300768u" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00509&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtFClurbK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=7230-7244&author=D.+B.+Lovejoyauthor=D.+M.+Sharpauthor=N.+Seebacherauthor=P.+Obeidyauthor=T.+Prichardauthor=C.+Stefaniauthor=M.+T.+Bashaauthor=P.+C.+Sharpeauthor=P.+J.+Janssonauthor=D.+S.+Kalinowskiauthor=P.+V.+Bernhardtauthor=D.+R.+Richardson&title=Novel+second-generation+di-2-pyridylketone+thiosemicarbazones+show+synergism+with+standard+chemotherapeutics+and+demonstrate+potent+activity+against+lung+cancer+xenografts+after+oral+and+intravenous+administration+in+vivo&doi=10.1021%2Fjm300768u"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Novel Second-Generation Di-2-Pyridylketone Thiosemicarbazones Show Synergism with Standard Chemotherapeutics and Demonstrate Potent Activity against Lung Cancer Xenografts after Oral and Intravenous Administration in Vivo</span></div><div class="casAuthors">Lovejoy, David B.; Sharp, Danae M.; Seebacher, Nicole; Obeidy, Peyman; Prichard, Thomas; Stefani, Christian; Basha, Maram T.; Sharpe, Philip C.; Jansson, Patric J.; Kalinowski, Danuta S.; Bernhardt, Paul V.; Richardson, Des R.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">7230-7244</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">We developed a series of second-generation di-2-pyridyl ketone thiosemicarbazone (DpT) and 2-benzoylpyridine thiosemicarbazone (BpT) ligands to improve the efficacy and safety profile of these potential antitumor agents.  Two novel DpT analogs, Dp4e4mT and DpC, exhibited pronounced and selective activity against human lung cancer xenografts in vivo via the i.v. and oral routes.  Importantly, these analogs did not induce the cardiotoxicity obsd. at high nonoptimal doses of the first-generation DpT analog, Dp44mT.  The Cu(II) complexes of these ligands exhibited potent antiproliferative activity having redox potentials in a range accessible to biol. reductants.  The activity of the copper complexes of Dp4e4mT and DpC against lung cancer cells was synergistic in combination with gemcitabine or cisplatin.  It was demonstrated by EPR spectroscopy that dimeric copper compds. of the type [CuLCl]2, identified crystallog., dissoc. in soln. to give monomeric 1:1 Cu:ligand complexes.  These monomers represent the biol. active form of the complex.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo75KAO0Ooc6bVg90H21EOLACvtfcHk0lhEZtlNzl6y_g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtFClurbK&md5=ce94f696851fc28cde48fc91bb38d132</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1021%2Fjm300768u&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm300768u%26sid%3Dliteratum%253Aachs%26aulast%3DLovejoy%26aufirst%3DD.%2BB.%26aulast%3DSharp%26aufirst%3DD.%2BM.%26aulast%3DSeebacher%26aufirst%3DN.%26aulast%3DObeidy%26aufirst%3DP.%26aulast%3DPrichard%26aufirst%3DT.%26aulast%3DStefani%26aufirst%3DC.%26aulast%3DBasha%26aufirst%3DM.%2BT.%26aulast%3DSharpe%26aufirst%3DP.%2BC.%26aulast%3DJansson%26aufirst%3DP.%2BJ.%26aulast%3DKalinowski%26aufirst%3DD.%2BS.%26aulast%3DBernhardt%26aufirst%3DP.%2BV.%26aulast%3DRichardson%26aufirst%3DD.%2BR.%26atitle%3DNovel%2520second-generation%2520di-2-pyridylketone%2520thiosemicarbazones%2520show%2520synergism%2520with%2520standard%2520chemotherapeutics%2520and%2520demonstrate%2520potent%2520activity%2520against%2520lung%2520cancer%2520xenografts%2520after%2520oral%2520and%2520intravenous%2520administration%2520in%2520vivo%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26spage%3D7230%26epage%3D7244%26doi%3D10.1021%2Fjm300768u" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13"><span><span class="NLM_contrib-group">Knox, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hotte, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kollmannsberger, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Winquist, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fisher, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eisenhauer, E. A.</span><span> </span><span class="NLM_article-title">Phase II study of triapine in patients with metastatic renal cell carcinoma: a trial of the national cancer institute of Canada clinical trials group (NCIC IND.161)</span> <span class="citation_source-journal">Invest. New Drugs</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">25</span><span class="NLM_x">, </span> <span class="NLM_fpage">471</span><span class="NLM_x">–</span> <span class="NLM_lpage">477</span><span class="refDoi"> DOI: 10.1007/s10637-007-9044-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00509&amp;key=10.1007%2Fs10637-007-9044-9" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2007&pages=471-477&author=J.+J.+Knoxauthor=S.+J.+Hotteauthor=C.+Kollmannsbergerauthor=E.+Winquistauthor=B.+Fisherauthor=E.+A.+Eisenhauer&title=Phase+II+study+of+triapine+in+patients+with+metastatic+renal+cell+carcinoma%3A+a+trial+of+the+national+cancer+institute+of+Canada+clinical+trials+group+%28NCIC+IND.161%29&doi=10.1007%2Fs10637-007-9044-9"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1007%2Fs10637-007-9044-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs10637-007-9044-9%26sid%3Dliteratum%253Aachs%26aulast%3DKnox%26aufirst%3DJ.%2BJ.%26aulast%3DHotte%26aufirst%3DS.%2BJ.%26aulast%3DKollmannsberger%26aufirst%3DC.%26aulast%3DWinquist%26aufirst%3DE.%26aulast%3DFisher%26aufirst%3DB.%26aulast%3DEisenhauer%26aufirst%3DE.%2BA.%26atitle%3DPhase%2520II%2520study%2520of%2520triapine%2520in%2520patients%2520with%2520metastatic%2520renal%2520cell%2520carcinoma%253A%2520a%2520trial%2520of%2520the%2520national%2520cancer%2520institute%2520of%2520Canada%2520clinical%2520trials%2520group%2520%2528NCIC%2520IND.161%2529%26jtitle%3DInvest.%2520New%2520Drugs%26date%3D2007%26volume%3D25%26spage%3D471%26epage%3D477%26doi%3D10.1007%2Fs10637-007-9044-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group">Ma, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goh, B. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tan, E. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lam, K. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Soo, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leong, S. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, L. Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mo, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chan, A. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zee, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mok, T.</span><span> </span><span class="NLM_article-title">A Multicenter phase II trial of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP, Triapine) and gemcitabine in advanced non-small-cell lung cancer with pharmacokinetic evaluation using peripheral blood mononuclear cells</span> <span class="citation_source-journal">Invest. New Drugs</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">26</span><span class="NLM_x">, </span> <span class="NLM_fpage">169</span><span class="NLM_x">–</span> <span class="NLM_lpage">173</span><span class="refDoi"> DOI: 10.1007/s10637-007-9085-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00509&amp;key=10.1007%2Fs10637-007-9085-0" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2008&pages=169-173&author=B.+Maauthor=B.+C.+Gohauthor=E.+H.+Tanauthor=K.+C.+Lamauthor=R.+Sooauthor=S.+S.+Leongauthor=L.+Z.+Wangauthor=F.+Moauthor=A.+T.+Chanauthor=B.+Zeeauthor=T.+Mok&title=A+Multicenter+phase+II+trial+of+3-aminopyridine-2-carboxaldehyde+thiosemicarbazone+%283-AP%2C+Triapine%29+and+gemcitabine+in+advanced+non-small-cell+lung+cancer+with+pharmacokinetic+evaluation+using+peripheral+blood+mononuclear+cells&doi=10.1007%2Fs10637-007-9085-0"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1007%2Fs10637-007-9085-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs10637-007-9085-0%26sid%3Dliteratum%253Aachs%26aulast%3DMa%26aufirst%3DB.%26aulast%3DGoh%26aufirst%3DB.%2BC.%26aulast%3DTan%26aufirst%3DE.%2BH.%26aulast%3DLam%26aufirst%3DK.%2BC.%26aulast%3DSoo%26aufirst%3DR.%26aulast%3DLeong%26aufirst%3DS.%2BS.%26aulast%3DWang%26aufirst%3DL.%2BZ.%26aulast%3DMo%26aufirst%3DF.%26aulast%3DChan%26aufirst%3DA.%2BT.%26aulast%3DZee%26aufirst%3DB.%26aulast%3DMok%26aufirst%3DT.%26atitle%3DA%2520Multicenter%2520phase%2520II%2520trial%2520of%25203-aminopyridine-2-carboxaldehyde%2520thiosemicarbazone%2520%25283-AP%252C%2520Triapine%2529%2520and%2520gemcitabine%2520in%2520advanced%2520non-small-cell%2520lung%2520cancer%2520with%2520pharmacokinetic%2520evaluation%2520using%2520peripheral%2520blood%2520mononuclear%2520cells%26jtitle%3DInvest.%2520New%2520Drugs%26date%3D2008%26volume%3D26%26spage%3D169%26epage%3D173%26doi%3D10.1007%2Fs10637-007-9085-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><span class="NLM_contrib-group">Yu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kalinowski, D. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kovacevic, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Siafakas, A. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jansson, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stefani, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lovejoy, D. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sharpe, P. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bernhardt, P. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Richardson, D. R.</span><span> </span><span class="NLM_article-title">Thiosemicarbazones from the old to new: Iron chelators that are more than just ribonucleotide reductase inhibitors</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">52</span><span class="NLM_x">, </span> <span class="NLM_fpage">5271</span><span class="NLM_x">–</span> <span class="NLM_lpage">5294</span><span class="refDoi"> DOI: 10.1021/jm900552r</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm900552r" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00509&amp;key=1%3ACAS%3A528%3ADC%252BD1MXosVGjs7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2009&pages=5271-5294&author=Y.+Yuauthor=D.+S.+Kalinowskiauthor=Z.+Kovacevicauthor=A.+R.+Siafakasauthor=P.+J.+Janssonauthor=C.+Stefaniauthor=D.+B.+Lovejoyauthor=P.+C.+Sharpeauthor=P.+V.+Bernhardtauthor=D.+R.+Richardson&title=Thiosemicarbazones+from+the+old+to+new%3A+Iron+chelators+that+are+more+than+just+ribonucleotide+reductase+inhibitors&doi=10.1021%2Fjm900552r"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Thiosemicarbazones from the Old to New: Iron Chelators That Are More Than Just Ribonucleotide Reductase Inhibitors</span></div><div class="casAuthors">Yu, Yu; Kalinowski, Danuta S.; Kovacevic, Zaklina; Siafakas, Aritee R.; Jansson, Patric J.; Stefani, Christian; Lovejoy, David B.; Sharpe, Philip C.; Bernhardt, Paul V.; Richardson, Des R.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">52</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">5271-5294</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  The chem. and biol. effects of thiosemicarbazones have received considerable interest from medicinal chemists for many years.  This is attributed to first, their wide pharmacol. utility that includes antineoplastic, antibacterial, antiviral, and antifungal activity, and second, their versatility as ligands that allows them to give rise to a great variety of coordination modes.  The antineoplastic activity of thiosemicarbazones has been continually examd. since the 1950s, where some compds. of this general class were found to have antileukemic activity.  The pronounced anti-neoplastic efficacy of these ligands has been widely attributed to their inhibition of the mammalian enzyme ribonucleotide reductase (RR).  The ability to inhibit RR is of particular importance owing to the role of RR in the de novo synthesis of deoxyribonucleotides required for DNA replication and repair.  Considering this, these compds. have often been described as RR inhibitors without mention of the property that actually leads to this effect, namely, metal chelation.  Apart from the inhibition of RR, it is also known that thiosemicarbazones are typically excellent chelators of transition metals such as iron (Fe), copper (Cu), and zinc (Zn).  Such ability for metal chelation is also an attractive strategy in developing anticancer drugs because of the high requirement of neoplastic cells for essential metals needed in growth and proliferation.  In fact, thiosemicarbazones were the first class of chelators to be comprehensively assessed as antineoplastic agents against cancer cells in vitro and in clin. trials.  This Perspective will focus on understanding the anti-neoplastic activity of thiosemicarbazones from the point of view of chelation.  To do this effectively, introduction to the roles of metals in cellular proliferation is required in addn. to an evaluation of the development of chelators for the treatment of cancer and other diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqx7tH0WVefYrVg90H21EOLACvtfcHk0lgqFSltL45n3A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXosVGjs7g%253D&md5=f0faee975954e0dfa7fbf5dd83829421</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1021%2Fjm900552r&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm900552r%26sid%3Dliteratum%253Aachs%26aulast%3DYu%26aufirst%3DY.%26aulast%3DKalinowski%26aufirst%3DD.%2BS.%26aulast%3DKovacevic%26aufirst%3DZ.%26aulast%3DSiafakas%26aufirst%3DA.%2BR.%26aulast%3DJansson%26aufirst%3DP.%2BJ.%26aulast%3DStefani%26aufirst%3DC.%26aulast%3DLovejoy%26aufirst%3DD.%2BB.%26aulast%3DSharpe%26aufirst%3DP.%2BC.%26aulast%3DBernhardt%26aufirst%3DP.%2BV.%26aulast%3DRichardson%26aufirst%3DD.%2BR.%26atitle%3DThiosemicarbazones%2520from%2520the%2520old%2520to%2520new%253A%2520Iron%2520chelators%2520that%2520are%2520more%2520than%2520just%2520ribonucleotide%2520reductase%2520inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2009%26volume%3D52%26spage%3D5271%26epage%3D5294%26doi%3D10.1021%2Fjm900552r" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span class="NLM_contrib-group">Richardson, D. R.</span><span> </span><span class="NLM_article-title">Molecular mechanisms of iron uptake by cells and the use of iron chelators for the treatment of cancer</span> <span class="citation_source-journal">Curr. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">12</span><span class="NLM_x">, </span> <span class="NLM_fpage">2711</span><span class="NLM_x">–</span> <span class="NLM_lpage">2729</span><span class="refDoi"> DOI: 10.2174/092986705774462996</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00509&amp;key=10.2174%2F092986705774462996" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00509&amp;key=16305467" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00509&amp;key=1%3ACAS%3A528%3ADC%252BD2MXht1ShsrrL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2005&pages=2711-2729&author=D.+R.+Richardson&title=Molecular+mechanisms+of+iron+uptake+by+cells+and+the+use+of+iron+chelators+for+the+treatment+of+cancer&doi=10.2174%2F092986705774462996"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Molecular mechanisms of iron uptake by cells and the use of iron chelators for the treatment of cancer</span></div><div class="casAuthors">Richardson, Des R.</div><div class="citationInfo"><span class="NLM_cas:title">Current Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">2711-2729</span>CODEN:
                <span class="NLM_cas:coden">CMCHE7</span>;
        ISSN:<span class="NLM_cas:issn">0929-8673</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  The field of Fe metab. has been invigorated in the past 10 years with the discovery of a variety of new mols. involved in the homeostatic control of this crit. nutrient.  These proteins include the transferrin receptor 2, Frataxin, Hephaestin, Hepcidin, Hemojuvelin, and others.  Basic understanding of the metab. of Fe in cells is vital in order to develop Fe chelators for the treatment of a variety of disease states.  In addn., examn. of the role of Fe in the regulation of cell cycle progression and angiogenesis has led to investigations of the use of novel Fe chelators as antiproliferative agents.  These studies have resulted in the identification of new ligands that show selective and potent antitumor activity in vitro and in vivo.  Moreover, the ability of these chelators to inhibit growth is not only limited to the inhibition of DNA synthesis.  In fact, there is a range of targets that are affected by Fe depletion, such as mols. involved in cell cycle control, angiogenesis, and metastasis suppression.  These include hypoxia-inducible factor-1α (HIF-1α), vascular endothelial growth factor-1 (VEGF1), p21CIP1/WAF1, cyclin D1, and the protein product of the N-myc downstream regulated gene-1 (Ndrg1).  As such, Fe chelators can now be designed to target mols. to induce specific effects, for instance, angiogenesis or metastasis suppression.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrwOqPiuDevOrVg90H21EOLACvtfcHk0lgqFSltL45n3A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXht1ShsrrL&md5=434a4239bfa1952f45679d3cc9bf7ccf</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.2174%2F092986705774462996&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F092986705774462996%26sid%3Dliteratum%253Aachs%26aulast%3DRichardson%26aufirst%3DD.%2BR.%26atitle%3DMolecular%2520mechanisms%2520of%2520iron%2520uptake%2520by%2520cells%2520and%2520the%2520use%2520of%2520iron%2520chelators%2520for%2520the%2520treatment%2520of%2520cancer%26jtitle%3DCurr.%2520Med.%2520Chem.%26date%3D2005%26volume%3D12%26spage%3D2711%26epage%3D2729%26doi%3D10.2174%2F092986705774462996" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span class="NLM_contrib-group">Liu, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mu, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xing, B.</span><span> </span><span class="NLM_article-title">Recent advances on the development of pharmacotherapeutic agents on the basis of human serum albumin</span> <span class="citation_source-journal">Curr. Pharm. Des.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">21</span><span class="NLM_x">, </span> <span class="NLM_fpage">1866</span><span class="NLM_x">–</span> <span class="NLM_lpage">1888</span><span class="refDoi"> DOI: 10.2174/1381612821666150302115411</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00509&amp;key=10.2174%2F1381612821666150302115411" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00509&amp;key=25732552" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00509&amp;key=1%3ACAS%3A528%3ADC%252BC2MXls1als7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2015&pages=1866-1888&author=F.+Liuauthor=J.+Muauthor=B.+Xing&title=Recent+advances+on+the+development+of+pharmacotherapeutic+agents+on+the+basis+of+human+serum+albumin&doi=10.2174%2F1381612821666150302115411"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Recent Advances on the Development of Pharmacotherapeutic Agents on the Basis of Human Serum Albumin</span></div><div class="casAuthors">Liu, Fang; Mu, Jing; Xing, Bengang</div><div class="citationInfo"><span class="NLM_cas:title">Current Pharmaceutical Design</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">1866-1888</span>CODEN:
                <span class="NLM_cas:coden">CPDEFP</span>;
        ISSN:<span class="NLM_cas:issn">1381-6128</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">Human serum albumin (HSA), a major transport protein component in blood plasma, has been reported recently to play many important roles in pharmacotherapeutics development.  Owing to its promising intrinsic binding capability of drug mols., HSA offers favorable characteristics and can be directly used as its monomeric formula or can be fabricated into protein based nanoparticle platforms to realize the effective delivery of therapeutic mols. into targeted diseases areas.  In addn., HSA can also serve as a protein stabilizer or environment-responsive moieties to hybridize with the functional materials including polymers or inorg. nanoparticles through the covalent reactions or electrostatic interactions, and can thus greatly alter the relevant biol. distribution and pharmacokinetic behavior to improve their therapeutic efficacy.  By right, extensive studies have been conducted to develop HSA-conjugated pharmacotherapeutic agents toward effective in vitro and in vivo diseases diagnosis and treatment.  The current review gives an in-detail account of the latest progresses of HSA-based carriers as functional protein materials, mainly with respect to its conjugation types, formulation aspects, and importantly their promising applications towards enhanced drug delivery and medical diagnosis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrm8KeYtnh2ybVg90H21EOLACvtfcHk0lggBlcWo-Sjqw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXls1als7g%253D&md5=ae9fb179bed5d22e48a6cc620f1196a1</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.2174%2F1381612821666150302115411&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F1381612821666150302115411%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DF.%26aulast%3DMu%26aufirst%3DJ.%26aulast%3DXing%26aufirst%3DB.%26atitle%3DRecent%2520advances%2520on%2520the%2520development%2520of%2520pharmacotherapeutic%2520agents%2520on%2520the%2520basis%2520of%2520human%2520serum%2520albumin%26jtitle%3DCurr.%2520Pharm.%2520Des.%26date%3D2015%26volume%3D21%26spage%3D1866%26epage%3D1888%26doi%3D10.2174%2F1381612821666150302115411" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><span class="NLM_contrib-group">Fanali, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">di Masi, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Trezza, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marino, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fasano, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ascenzi, P.</span><span> </span><span class="NLM_article-title">Human serum albumin: from bench to bedside</span> <span class="citation_source-journal">Mol. Aspects Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">33</span><span class="NLM_x">, </span> <span class="NLM_fpage">209</span><span class="NLM_x">–</span> <span class="NLM_lpage">90</span><span class="refDoi"> DOI: 10.1016/j.mam.2011.12.002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00509&amp;key=10.1016%2Fj.mam.2011.12.002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00509&amp;key=22230555" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00509&amp;key=1%3ACAS%3A528%3ADC%252BC38Xls12hu7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=33&publication_year=2012&pages=209-90&author=G.+Fanaliauthor=A.+di+Masiauthor=V.+Trezzaauthor=M.+Marinoauthor=M.+Fasanoauthor=P.+Ascenzi&title=Human+serum+albumin%3A+from+bench+to+bedside&doi=10.1016%2Fj.mam.2011.12.002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Human serum albumin: From bench to bedside</span></div><div class="casAuthors">Fanali, Gabriella; di Masi, Alessandra; Trezza, Viviana; Marino, Maria; Fasano, Mauro; Ascenzi, Paolo</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Aspects of Medicine</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">33</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">209-290</span>CODEN:
                <span class="NLM_cas:coden">MAMED5</span>;
        ISSN:<span class="NLM_cas:issn">0098-2997</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  Human serum albumin (HSA), the most abundant protein in plasma, is a monomeric multi-domain macromol., representing the main determinant of plasma oncotic pressure and the main modulator of fluid distribution between body compartments.  HSA displays an extraordinary ligand binding capacity, providing a depot and carrier for many endogenous and exogenous compds.  Indeed, HSA represents the main carrier for fatty acids, affects pharmacokinetics of many drugs, provides the metabolic modification of some ligands, renders potential toxins harmless, accounts for most of the anti-oxidant capacity of human plasma, and displays (pseudo-)enzymic properties.  HSA is a valuable biomarker of many diseases, including cancer, rheumatoid arthritis, ischemia, post-menopausal obesity, severe acute graft-vs.-host disease, and diseases that need monitoring of the glycemic control.  Moreover, HSA is widely used clin. to treat several diseases, including hypovolemia, shock, burns, surgical blood loss, trauma, hemorrhage, cardiopulmonary bypass, acute respiratory distress syndrome, hemodialysis, acute liver failure, chronic liver disease, nutrition support, resuscitation, and hypoalbuminemia.  Recently, biotechnol. applications of HSA, including implantable biomaterials, surgical adhesives and sealants, biochromatog., ligand trapping, and fusion proteins, have been reported.  Here, genetic, biochem., biomedical, and biotechnol. aspects of HSA are reviewed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoxjvB_5YQuerVg90H21EOLACvtfcHk0lggBlcWo-Sjqw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xls12hu7w%253D&md5=976cbd0c53b93f77bc172f909ba6682a</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1016%2Fj.mam.2011.12.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.mam.2011.12.002%26sid%3Dliteratum%253Aachs%26aulast%3DFanali%26aufirst%3DG.%26aulast%3Ddi%2BMasi%26aufirst%3DA.%26aulast%3DTrezza%26aufirst%3DV.%26aulast%3DMarino%26aufirst%3DM.%26aulast%3DFasano%26aufirst%3DM.%26aulast%3DAscenzi%26aufirst%3DP.%26atitle%3DHuman%2520serum%2520albumin%253A%2520from%2520bench%2520to%2520bedside%26jtitle%3DMol.%2520Aspects%2520Med.%26date%3D2012%26volume%3D33%26spage%3D209%26epage%3D90%26doi%3D10.1016%2Fj.mam.2011.12.002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group">Peters, T.</span> <span class="citation_source-book">All about Albumin: Biochemistry, Genetics, and Medical Applications</span>; <span class="NLM_publisher-name">Academic Press</span>: <span class="NLM_publisher-loc">San Diego</span>,<span class="NLM_x"> </span><span class="NLM_year">1996</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=1996&author=T.+Peters&title=All+about+Albumin%3A+Biochemistry%2C+Genetics%2C+and+Medical+Applications"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26aulast%3DPeters%26aufirst%3DT.%26btitle%3DAll%2520about%2520Albumin%253A%2520Biochemistry%252C%2520Genetics%252C%2520and%2520Medical%2520Applications%26pub%3DAcademic%2520Press%26date%3D1996" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20"><span><span class="NLM_contrib-group">Ghuman, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zunszain, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Petitpas, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bhattacharya, A. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Otagiri, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Curry, S.</span><span> </span><span class="NLM_article-title">Structural basis of the drug-binding specificity of human serum albumin</span> <span class="citation_source-journal">J. Mol. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">353</span><span class="NLM_x">, </span> <span class="NLM_fpage">38</span><span class="NLM_x">–</span> <span class="NLM_lpage">52</span><span class="refDoi"> DOI: 10.1016/j.jmb.2005.07.075</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00509&amp;key=10.1016%2Fj.jmb.2005.07.075" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00509&amp;key=16169013" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00509&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhtVensrbJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=353&publication_year=2005&pages=38-52&author=J.+Ghumanauthor=P.+A.+Zunszainauthor=I.+Petitpasauthor=A.+A.+Bhattacharyaauthor=M.+Otagiriauthor=S.+Curry&title=Structural+basis+of+the+drug-binding+specificity+of+human+serum+albumin&doi=10.1016%2Fj.jmb.2005.07.075"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Structural Basis of the Drug-binding Specificity of Human Serum Albumin</span></div><div class="casAuthors">Ghuman, Jamie; Zunszain, Patricia A.; Petitpas, Isabelle; Bhattacharya, Ananyo A.; Otagiri, Masaki; Curry, Stephen</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Molecular Biology</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">353</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">38-52</span>CODEN:
                <span class="NLM_cas:coden">JMOBAK</span>;
        ISSN:<span class="NLM_cas:issn">0022-2836</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Human serum albumin (HSA) is an abundant plasma protein that binds a remarkably wide range of drugs, thereby restricting their free, active concns.  The problem of overcoming the binding affinity of lead compds. for HSA represents a major challenge in drug development.  Crystallog. anal. of 17 different complexes of HSA with a wide variety of drugs and small-mol. toxins reveals the precise architecture of the two primary drug-binding sites on the protein, identifying residues that are key determinants of binding specificity and illuminating the capacity of both pockets for flexible accommodation.  Numerous secondary binding sites for drugs distributed across the protein have also been identified.  The binding of fatty acids, the primary physiol. ligand for the protein, is shown to alter the polarity and increase the vol. of drug site 1.  These results clarify the interpretation of accumulated drug binding data and provide a valuable template for design efforts to modulate the interaction with HSA.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpyKWUfReJZ-bVg90H21EOLACvtfcHk0lggBlcWo-Sjqw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhtVensrbJ&md5=d82105920c360292329bf509667df42f</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1016%2Fj.jmb.2005.07.075&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jmb.2005.07.075%26sid%3Dliteratum%253Aachs%26aulast%3DGhuman%26aufirst%3DJ.%26aulast%3DZunszain%26aufirst%3DP.%2BA.%26aulast%3DPetitpas%26aufirst%3DI.%26aulast%3DBhattacharya%26aufirst%3DA.%2BA.%26aulast%3DOtagiri%26aufirst%3DM.%26aulast%3DCurry%26aufirst%3DS.%26atitle%3DStructural%2520basis%2520of%2520the%2520drug-binding%2520specificity%2520of%2520human%2520serum%2520albumin%26jtitle%3DJ.%2520Mol.%2520Biol.%26date%3D2005%26volume%3D353%26spage%3D38%26epage%3D52%26doi%3D10.1016%2Fj.jmb.2005.07.075" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21"><span><span class="NLM_contrib-group">Zsila, F.</span><span> </span><span class="NLM_article-title">Subdomain IB is the third major drug binding region of human serum albumin: toward the three-sites model</span> <span class="citation_source-journal">Mol. Pharmaceutics</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x">, </span> <span class="NLM_fpage">1668</span><span class="NLM_x">–</span> <span class="NLM_lpage">1682</span><span class="refDoi"> DOI: 10.1021/mp400027q</span> </span><div class="citationLinks">[<a href="/doi/10.1021/mp400027q" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00509&amp;key=1%3ACAS%3A528%3ADC%252BC3sXjslSgurs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2013&pages=1668-1682&author=F.+Zsila&title=Subdomain+IB+is+the+third+major+drug+binding+region+of+human+serum+albumin%3A+toward+the+three-sites+model&doi=10.1021%2Fmp400027q"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Subdomain IB Is the Third Major Drug Binding Region of Human Serum Albumin: Toward the Three-Sites Model</span></div><div class="casAuthors">Zsila, Ferenc</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Pharmaceutics</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1668-1682</span>CODEN:
                <span class="NLM_cas:coden">MPOHBP</span>;
        ISSN:<span class="NLM_cas:issn">1543-8384</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">According to the conventional view, noncovalent assocn. of small mols. with human serum albumin (HSA) occurs principally at the so-called Sudlow's sites located in subdomain IIA and IIIA.  By employing a CD spectroscopic approach, it is shown that biliverdin is the specific CD label of an addnl. drug binding area in subdomain IB.  CD competition expts. disclosed the entrapment of a diverse assortment of acidic, neutral, and basic mols. within subdomain IB including anticancer agents (camptothecin, doxorubicin, daunorubicin, teniposide, suramin, tyrosine kinase inhibitors), anticoagulants (dicoumarol), various steroids (bile acids, carbenoxolone), nonsteroidal antiinflammatory drugs, natural substances (aristolochic acid, glycyrrhetinic acid), and synthetic dyes (methyl orange, azocarmine B).  These finding imply that subdomain IB can be considered as the third major drug binding region of HSA featured with promiscuous ligand recognition ability.  Addnl., subdomain IB is allosterically coupled with the Sudlow's sites, the ligand binding of which is shown to alter the HSA binding mode and affinity of biliverdin and hemin.  Brief case studies are presented to illustrate how the evaluation of spectral changes of tetrapyrrole CD probes gains new insight into the HSA binding properties of endogenous as well as pharmaceutical compds.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGru_3GyTZnyF7Vg90H21EOLACvtfcHk0lgFDV60wZ3O6Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXjslSgurs%253D&md5=0244eaa1f7bb00e7d1038b3bffaa10ba</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1021%2Fmp400027q&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fmp400027q%26sid%3Dliteratum%253Aachs%26aulast%3DZsila%26aufirst%3DF.%26atitle%3DSubdomain%2520IB%2520is%2520the%2520third%2520major%2520drug%2520binding%2520region%2520of%2520human%2520serum%2520albumin%253A%2520toward%2520the%2520three-sites%2520model%26jtitle%3DMol.%2520Pharmaceutics%26date%3D2013%26volume%3D10%26spage%3D1668%26epage%3D1682%26doi%3D10.1021%2Fmp400027q" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22"><span><span class="NLM_contrib-group">Lambrinidis, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vallianatou, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsantili-Kakoulidou, A.</span><span> </span><span class="NLM_article-title">In vitro, in silico and integrated strategies for the estimation of plasma protein binding. A review</span> <span class="citation_source-journal">Adv. Drug Delivery Rev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">86</span><span class="NLM_x">, </span> <span class="NLM_fpage">27</span><span class="NLM_x">–</span> <span class="NLM_lpage">45</span><span class="refDoi"> DOI: 10.1016/j.addr.2015.03.011</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00509&amp;key=10.1016%2Fj.addr.2015.03.011" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00509&amp;key=25819487" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00509&amp;key=1%3ACAS%3A528%3ADC%252BC2MXlslCltbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=86&publication_year=2015&pages=27-45&author=G.+Lambrinidisauthor=T.+Vallianatouauthor=A.+Tsantili-Kakoulidou&title=In+vitro%2C+in+silico+and+integrated+strategies+for+the+estimation+of+plasma+protein+binding.+A+review&doi=10.1016%2Fj.addr.2015.03.011"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">In vitro, in silico and integrated strategies for the estimation of plasma protein binding. A review</span></div><div class="casAuthors">Lambrinidis, George; Vallianatou, Theodosia; Tsantili-Kakoulidou, Anna</div><div class="citationInfo"><span class="NLM_cas:title">Advanced Drug Delivery Reviews</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">86</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">27-45</span>CODEN:
                <span class="NLM_cas:coden">ADDREP</span>;
        ISSN:<span class="NLM_cas:issn">0169-409X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Plasma protein binding (PPB) strongly affects drug distribution and pharmacokinetic behavior with consequences in overall pharmacol. action.  Extended plasma protein binding may be assocd. with drug safety issues and several adverse effects, like low clearance, low brain penetration, drug-drug interactions, loss of efficacy, while influencing the fate of enantiomers and diastereoisomers by stereoselective binding within the body.  Therefore in holistic drug design approaches, where ADME(T) properties are considered in parallel with target affinity, considerable efforts are focused in early estn. of PPB mainly in regard to human serum albumin (HSA), which is the most abundant and most important plasma protein.  The second crit. serum protein α1-acid glycoprotein (AGP), although often underscored, plays also an important and complicated role in clin. therapy and thus the last years it has been studied thoroughly too.In the present review, after an overview of the principles of HSA and AGP binding as well as the structure topol. of the proteins, the current trends and perspectives in the field of PPB predictions are presented and discussed considering both HSA and AGP binding.  Since however for the latter protein systematic studies have started only the last years, the review focuses mainly to HSA.  One part of the review highlights the challenge to develop rapid techniques for HSA and AGP binding simulation and their performance in assessment of PPB.  The second part focuses on in silico approaches to predict HSA and AGP binding, analyzing and evaluating structure-based and ligand-based methods, as well as combination of both methods in the aim to exploit the different information and overcome the limitations of each individual approach.  Ligand-based methods use the Quant. Structure-Activity Relationships (QSAR) methodol. to establish quantitate models for the prediction of binding consts. from mol. descriptors, while they provide only indirect information on binding mechanism.  Efforts for the establishment of global models, automated workflows and web-based platforms for PPB predictions are presented and discussed.  Structure-based methods relying on the crystal structures of drug-protein complexes provide detailed information on the underlying mechanism but are usually restricted to specific compds.  They are useful to identify the specific binding site while they may be important in investigating drug-drug interactions, related to PPB.  Moreover, chemometrics or structure-based modeling may be supported by exptl. data a promising integrated alternative strategy for ADME(T) properties optimization.  In the case of PPB the use of mol. modeling combined with bioanal. techniques is frequently used for the investigation of AGP binding.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrO5Jya4dWQ6LVg90H21EOLACvtfcHk0lgFDV60wZ3O6Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXlslCltbo%253D&md5=06b12cb016d725b42c3f59af08919f4e</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1016%2Fj.addr.2015.03.011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.addr.2015.03.011%26sid%3Dliteratum%253Aachs%26aulast%3DLambrinidis%26aufirst%3DG.%26aulast%3DVallianatou%26aufirst%3DT.%26aulast%3DTsantili-Kakoulidou%26aufirst%3DA.%26atitle%3DIn%2520vitro%252C%2520in%2520silico%2520and%2520integrated%2520strategies%2520for%2520the%2520estimation%2520of%2520plasma%2520protein%2520binding.%2520A%2520review%26jtitle%3DAdv.%2520Drug%2520Delivery%2520Rev.%26date%3D2015%26volume%3D86%26spage%3D27%26epage%3D45%26doi%3D10.1016%2Fj.addr.2015.03.011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23"><span><span class="NLM_contrib-group">Kragh-Hansen, U.</span><span> </span><span class="NLM_article-title">Molecular and practical aspects of the enzymatic properties of human serum albumin and of albumin-ligand complexes</span> <span class="citation_source-journal">Biochim. Biophys. Acta, Gen. Subj.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">1830</span><span class="NLM_x">, </span> <span class="NLM_fpage">5535</span><span class="NLM_x">–</span> <span class="NLM_lpage">5544</span><span class="refDoi"> DOI: 10.1016/j.bbagen.2013.03.015</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00509&amp;key=10.1016%2Fj.bbagen.2013.03.015" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00509&amp;key=23528895" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00509&amp;key=1%3ACAS%3A528%3ADC%252BC3sXlvVWgs78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1830&publication_year=2013&pages=5535-5544&author=U.+Kragh-Hansen&title=Molecular+and+practical+aspects+of+the+enzymatic+properties+of+human+serum+albumin+and+of+albumin-ligand+complexes&doi=10.1016%2Fj.bbagen.2013.03.015"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Molecular and practical aspects of the enzymatic properties of human serum albumin and of albumin-ligand complexes</span></div><div class="casAuthors">Kragh-Hansen, Ulrich</div><div class="citationInfo"><span class="NLM_cas:title">Biochimica et Biophysica Acta, General Subjects</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">1830</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">5535-5544</span>CODEN:
                <span class="NLM_cas:coden">BBGSB3</span>;
        ISSN:<span class="NLM_cas:issn">0304-4165</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Human serum albumin (HSA) and some of its ligand complexes possess enzymic properties which are useful both in vivo and in vitro.  Here, the author summarizes present knowledge about mol. aspects, practical applications, and potentials of these properties.  The most pronounced activities of HSA are different types of hydrolysis.  Key examples are esterase-like activities involving Tyr-411 or Lys-199 and the thioesterase activity of Cys-34.  In the 1st case, hydrolysis involves water and both products are released, whereas in the latter cases one of the products is set free, and the other stays covalently bound to the protein.  However, the modified Cys-34 can be converted back to its reduced form by another compd./enzymic system.  Among the other activities are glucuronidase, phosphatase, and amidase as well as isomerase and dehydration properties.  HSA has great impact on the metab. of, e.g., eicosanoids and xenobiotics.  HSA with a metal ion-contg. complex is capable of facilitating reactions involving reactive O and reactive N species.  HSA is useful in detoxification reactions, for activating prodrugs, and for binding and activating drug conjugates.  HSA can be used to construct smart nanotubes with enzymic properties useful for biomedical applications.  The binding of org. compds. with a metal ion often results in metalloenzymes or can be used for nanoparticle formation.  Because any compd. acting as cofactor and/or the protein can be modified, enzymes can be constructed which are not naturally found and therefore can increase, often stereospecifically, the no. of catalytic reactions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrri2FcKt6EX7Vg90H21EOLACvtfcHk0lgFDV60wZ3O6Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXlvVWgs78%253D&md5=226207b69070320146e3fcf70b8af508</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1016%2Fj.bbagen.2013.03.015&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bbagen.2013.03.015%26sid%3Dliteratum%253Aachs%26aulast%3DKragh-Hansen%26aufirst%3DU.%26atitle%3DMolecular%2520and%2520practical%2520aspects%2520of%2520the%2520enzymatic%2520properties%2520of%2520human%2520serum%2520albumin%2520and%2520of%2520albumin-ligand%2520complexes%26jtitle%3DBiochim.%2520Biophys.%2520Acta%252C%2520Gen.%2520Subj.%26date%3D2013%26volume%3D1830%26spage%3D5535%26epage%3D5544%26doi%3D10.1016%2Fj.bbagen.2013.03.015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24"><span><span class="NLM_contrib-group">He, X. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carter, D. C.</span><span> </span><span class="NLM_article-title">Atomic structure and chemistry of human serum albumin</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1992</span><span class="NLM_x">, </span> <span class="NLM_volume">358</span><span class="NLM_x">, </span> <span class="NLM_fpage">209</span><span class="NLM_x">–</span> <span class="NLM_lpage">215</span><span class="refDoi"> DOI: 10.1038/358209a0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00509&amp;key=10.1038%2F358209a0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00509&amp;key=1630489" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00509&amp;key=1%3ACAS%3A528%3ADyaK38XlsVGmurg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=358&publication_year=1992&pages=209-215&author=X.+M.+Heauthor=D.+C.+Carter&title=Atomic+structure+and+chemistry+of+human+serum+albumin&doi=10.1038%2F358209a0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Atomic structure and chemistry of human serum albumin</span></div><div class="casAuthors">He, Xiao Min; Carter, Daniel C.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">1992</span>),
    <span class="NLM_cas:volume">358</span>
        (<span class="NLM_cas:issue">6383</span>),
    <span class="NLM_cas:pages">209-15</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    </div><div class="casAbstract">The three-dimensional structure of human serum albumin has been detd. crystallog. to a resoln. of 2.8 Å.  It comprises three homologous domains that assemble to form a heart-shaped mol.  Each domain is a product of two subdomains that possess common structural motifs.  The principal regions of ligand binding to human serum albumin are located in hydrophobic cavities in subdomains IIA and IIIA, which exhibit similar chem.  The structure explains numerous phys. phenomena and should provide insight into future pharmacokinetic and genetically engineered therapeutic applications of serum albumin.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqxk19HsvWbsbVg90H21EOLACvtfcHk0lgFDV60wZ3O6Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK38XlsVGmurg%253D&md5=19bf8b69b15e16b6cde6486a230431c8</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1038%2F358209a0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252F358209a0%26sid%3Dliteratum%253Aachs%26aulast%3DHe%26aufirst%3DX.%2BM.%26aulast%3DCarter%26aufirst%3DD.%2BC.%26atitle%3DAtomic%2520structure%2520and%2520chemistry%2520of%2520human%2520serum%2520albumin%26jtitle%3DNature%26date%3D1992%26volume%3D358%26spage%3D209%26epage%3D215%26doi%3D10.1038%2F358209a0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit25"><span><span class="NLM_contrib-group">Yang, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ma, Z. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, G. Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Qin, J. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lockridge, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liang, H.</span><span> </span><span class="NLM_article-title">Human serum albumin-based design of a diflunisal prodrug</span> <span class="citation_source-journal">Eur. J. Pharm. Biopharm.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">84</span><span class="NLM_x">, </span> <span class="NLM_fpage">549</span><span class="NLM_x">–</span> <span class="NLM_lpage">554</span><span class="refDoi"> DOI: 10.1016/j.ejpb.2013.01.013</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00509&amp;key=10.1016%2Fj.ejpb.2013.01.013" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00509&amp;key=23416065" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00509&amp;key=1%3ACAS%3A528%3ADC%252BC3sXns1Kgs7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=84&publication_year=2013&pages=549-554&author=F.+Yangauthor=Z.+Y.+Maauthor=Y.+Zhangauthor=G.+Q.+Liauthor=M.+Liauthor=J.+K.+Qinauthor=O.+Lockridgeauthor=H.+Liang&title=Human+serum+albumin-based+design+of+a+diflunisal+prodrug&doi=10.1016%2Fj.ejpb.2013.01.013"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Human serum albumin-based design of a diflunisal prodrug</span></div><div class="casAuthors">Yang, Feng; Ma, Zhi Yuan; Zhang, Yao; Li, Guo Qing; Li, Mei; Qin, Jiang Ke; Lockridge, Oksana; Liang, Hong</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Pharmaceutics and Biopharmaceutics</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">84</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">549-554</span>CODEN:
                <span class="NLM_cas:coden">EJPBEL</span>;
        ISSN:<span class="NLM_cas:issn">0939-6411</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The cyclooxygenase-2 inhibitor, diflunisal, is used in the clinic for its anti-inflammatory activity.  About 99% of a dose of diflunisal is unavailable for reaction with the target enzyme, because diflunisal strongly binds to human serum albumin (HSA).  To reduce the binding affinity of diflunisal to albumin, we designed and synthesized the prodrug acetyldiflunisal.  The crystal structure of HSA complexed with fatty acid and acetyldiflunisal revealed that acetyldiflunisal binds to the IIA subdomain and that upon binding, it acetylates lysine 199.  Mass spectrometry confirmed that acetyldiflunisal acetylates Lys199.  The acetylated albumin had twofold weaker binding affinity for diflunisal as demonstrated by fluorescence quenching.  Reduced binding affinity means that diflunisal is more easily released from acetylated albumin into the circulation.  Therefore, lower doses of acetyldiflunisal compared to diflunisal will be required.  Taken together, our results not only provide a template for design of HSA-based prodrugs, but also pave the way toward more effective use of diflunisal in the clinic.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo_hwUREiEoJLVg90H21EOLACvtfcHk0lhWL9FZK_jIDw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXns1Kgs7k%253D&md5=f815912af39a7214fb73944d292c178a</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1016%2Fj.ejpb.2013.01.013&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejpb.2013.01.013%26sid%3Dliteratum%253Aachs%26aulast%3DYang%26aufirst%3DF.%26aulast%3DMa%26aufirst%3DZ.%2BY.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DLi%26aufirst%3DG.%2BQ.%26aulast%3DLi%26aufirst%3DM.%26aulast%3DQin%26aufirst%3DJ.%2BK.%26aulast%3DLockridge%26aufirst%3DO.%26aulast%3DLiang%26aufirst%3DH.%26atitle%3DHuman%2520serum%2520albumin-based%2520design%2520of%2520a%2520diflunisal%2520prodrug%26jtitle%3DEur.%2520J.%2520Pharm.%2520Biopharm.%26date%3D2013%26volume%3D84%26spage%3D549%26epage%3D554%26doi%3D10.1016%2Fj.ejpb.2013.01.013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">26</a></strong><div class="NLM_citation" id="rightTab-cit26"><span><span class="NLM_contrib-group">Yang, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yue, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ma, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ma, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liang, H.</span><span> </span><span class="NLM_article-title">Interactive associations of drug-drug and drug-drug-drug with IIA subdomain of human serum albumin</span> <span class="citation_source-journal">Mol. Pharmaceutics</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x">, </span> <span class="NLM_fpage">3259</span><span class="NLM_x">–</span> <span class="NLM_lpage">3265</span><span class="refDoi"> DOI: 10.1021/mp300322y</span> </span><div class="citationLinks">[<a href="/doi/10.1021/mp300322y" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00509&amp;key=1%3ACAS%3A528%3ADC%252BC38Xhtl2rtrnM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2012&pages=3259-3265&author=F.+Yangauthor=J.+Yueauthor=L.+Maauthor=Z.+Maauthor=M.+Liauthor=X.+Wuauthor=H.+Liang&title=Interactive+associations+of+drug-drug+and+drug-drug-drug+with+IIA+subdomain+of+human+serum+albumin&doi=10.1021%2Fmp300322y"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">Interactive Associations of Drug-Drug and Drug-Drug-Drug with IIA Subdomain of Human Serum Albumin</span></div><div class="casAuthors">Yang, Feng; Yue, Jiping; Ma, Li; Ma, Zhiyuan; Li, Mei; Wu, Xiaoyang; Liang, Hong</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Pharmaceutics</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">3259-3265</span>CODEN:
                <span class="NLM_cas:coden">MPOHBP</span>;
        ISSN:<span class="NLM_cas:issn">1543-8384</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Owing to advantageous biochem. and pharmacol. properties of human serum albumin (HSA), HSA-based drug carrier is playing an increasing role in the clin. setting.  Since the IIA subdomain of HSA is a big hydrophobic cavity, we proposed that HSA delivers multiple drugs simultaneously docking on the IIA subdomain and that drugs may influence each other's binding affinity to albumin when cobinding the HSA IIA subdomain.  Therefore, we studied the interactive assocn. of drugs with the IIA subdomain of HSA by fluorescence spectroscopy and X-ray crystallog., in order to elucidate the mol. mechanism and behavior of drugs cobinding the IIA subdomain of HSA, and develop a universal structure-based model for HSA carrier design.  We solved HSA-fatty acid-cinnamic acid, HSA-fatty acid-cinnamic acid-indomethacin and HSA-fatty acid-cinnamic acid-indomethacin-lamivudine complex structures, resp.  HSA complex structures and fluorescence quenching of HSA revealed that different drugs can regulate binding sites, binding mode and binding affinity of each other.  For example, indomethacin renders cinnamic acid to make reposition, and decreases binding affinity of HSA for cinnamic acid, but increases binding affinity of itself to HSA.  Lamivudine makes cinnamic acid and indomethacin to bind new subsites.  Cinnamic acid-indomethacin enhances binding affinity of lamivudine, and cinnamic acid-lamivudine increases binding affinity of indomethacin, but indomethacin-lamivudine decreases binding affinity of cinnamic acid to HSA.  The study provided a biochem. basis for structure-guided development of HSA delivery system.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqgnqaryPC5-7Vg90H21EOLACvtfcHk0lhWL9FZK_jIDw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xhtl2rtrnM&md5=a5e8ae79b334ddaec4ce1041ac771cac</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1021%2Fmp300322y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fmp300322y%26sid%3Dliteratum%253Aachs%26aulast%3DYang%26aufirst%3DF.%26aulast%3DYue%26aufirst%3DJ.%26aulast%3DMa%26aufirst%3DL.%26aulast%3DMa%26aufirst%3DZ.%26aulast%3DLi%26aufirst%3DM.%26aulast%3DWu%26aufirst%3DX.%26aulast%3DLiang%26aufirst%3DH.%26atitle%3DInteractive%2520associations%2520of%2520drug-drug%2520and%2520drug-drug-drug%2520with%2520IIA%2520subdomain%2520of%2520human%2520serum%2520albumin%26jtitle%3DMol.%2520Pharmaceutics%26date%3D2012%26volume%3D9%26spage%3D3259%26epage%3D3265%26doi%3D10.1021%2Fmp300322y" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref27"><div class="reference"><strong class="refLabel"><a href="#ref27" class="rightTabRefNumLink">27</a></strong><div class="NLM_citation" id="rightTab-cit27"><span><span class="NLM_contrib-group">Durante, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Orienti, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Teti, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Salvatore, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Focaroli, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tesei, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pignatta, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Falconi, M.</span><span> </span><span class="NLM_article-title">Anti-tumor activity of fenretinide complexed with human serum albumin in lung cancer xenograft mouse model</span> <span class="citation_source-journal">Oncotarget.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">5</span><span class="NLM_x">, </span> <span class="NLM_fpage">4811</span><span class="NLM_x">–</span> <span class="NLM_lpage">4820</span><span class="refDoi"> DOI: 10.18632/oncotarget.2038</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00509&amp;key=10.18632%2Foncotarget.2038" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00509&amp;key=25015569" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00509&amp;key=1%3ACAS%3A280%3ADC%252BC2cbhsFarug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2014&pages=4811-4820&author=S.+Duranteauthor=I.+Orientiauthor=G.+Tetiauthor=V.+Salvatoreauthor=S.+Focaroliauthor=A.+Teseiauthor=S.+Pignattaauthor=M.+Falconi&title=Anti-tumor+activity+of+fenretinide+complexed+with+human+serum+albumin+in+lung+cancer+xenograft+mouse+model&doi=10.18632%2Foncotarget.2038"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Anti-tumor activity of fenretinide complexed with human serum albumin in lung cancer xenograft mouse model</span></div><div class="casAuthors">Durante Sandra; Falconi Mirella; Orienti Isabella; Teti Gabriella; Salvatore Viviana; Focaroli Stefano; Tesei Anna; Pignatta Sara</div><div class="citationInfo"><span class="NLM_cas:title">Oncotarget</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">4811-20</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Sufficient knowledge regarding cellular and molecular basis of lung cancer progression and metastasis would help in the development of novel and effective strategies for the treatment of lung cancer. 4HPR is a synthetic retinoid with potential anti-tumor activity but is still limited because of its poor bioavailability.  The use of albumin as a complexing agent for a hydrophobic drug is expected to improve the water solubility and consequently their bioavailability.This study investigated the antitumor activity of a novel complex between albumin and 4-HPR in a mouse model of human lung cancer and focuses on role and mechanism of Cav-1 mainly involved in regulating cancer and ACSVL3 mainly connected with tumor growth.  Their expressions were assayed by immunohistochemistry and qRT-PCR, to demonstrate the reduction of the tumor growth following the drug treatment.  Our results showed a high antitumor activity of 4HPR-HSA by reduction of the volume of tumor mass and the presence of a high level of apoptotic cell by TUNEL assay.  The downregulation of Cav-1 and ACSVL3 suggested a reduction of tumor growth.  In conclusion, we demonstrated the great potential of 4HPR-HSA in the treatment of lung cancer.  More data about the mechanism of drug delivery the 4HPR-HSA are necessary.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRQAYuurzxHUeWhZTslLrfffW6udTcc2eYO_JfNBi607rntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2cbhsFarug%253D%253D&md5=b8179db2db32c1aafd302a7da6fdc5b7</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.18632%2Foncotarget.2038&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.18632%252Foncotarget.2038%26sid%3Dliteratum%253Aachs%26aulast%3DDurante%26aufirst%3DS.%26aulast%3DOrienti%26aufirst%3DI.%26aulast%3DTeti%26aufirst%3DG.%26aulast%3DSalvatore%26aufirst%3DV.%26aulast%3DFocaroli%26aufirst%3DS.%26aulast%3DTesei%26aufirst%3DA.%26aulast%3DPignatta%26aufirst%3DS.%26aulast%3DFalconi%26aufirst%3DM.%26atitle%3DAnti-tumor%2520activity%2520of%2520fenretinide%2520complexed%2520with%2520human%2520serum%2520albumin%2520in%2520lung%2520cancer%2520xenograft%2520mouse%2520model%26jtitle%3DOncotarget.%26date%3D2014%26volume%3D5%26spage%3D4811%26epage%3D4820%26doi%3D10.18632%2Foncotarget.2038" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref28"><div class="reference"><strong class="refLabel"><a href="#ref28" class="rightTabRefNumLink">28</a></strong><div class="NLM_citation" id="rightTab-cit28"><span><span class="NLM_contrib-group">Sasson, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marcus, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lev-Goldman, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rubinraut, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fridkin, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shechter, Y.</span><span> </span><span class="NLM_article-title">Engineering prolonged-acting prodrugs employing an albumin-binding probe that undergoes slow hydrolysis at physiological conditions</span> <span class="citation_source-journal">J. Controlled Release</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">142</span><span class="NLM_x">, </span> <span class="NLM_fpage">214</span><span class="NLM_x">–</span> <span class="NLM_lpage">220</span><span class="refDoi"> DOI: 10.1016/j.jconrel.2009.10.028</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00509&amp;key=10.1016%2Fj.jconrel.2009.10.028" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00509&amp;key=19883707" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00509&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhvFehurk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=142&publication_year=2010&pages=214-220&author=K.+Sassonauthor=Y.+Marcusauthor=V.+Lev-Goldmanauthor=S.+Rubinrautauthor=M.+Fridkinauthor=Y.+Shechter&title=Engineering+prolonged-acting+prodrugs+employing+an+albumin-binding+probe+that+undergoes+slow+hydrolysis+at+physiological+conditions&doi=10.1016%2Fj.jconrel.2009.10.028"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">Engineering prolonged-acting prodrugs employing an albumin-binding probe that undergoes slow hydrolysis at physiological conditions</span></div><div class="casAuthors">Sasson, K.; Marcus, Y.; Lev-Goldman, V.; Rubinraut, S.; Fridkin, M.; Shechter, Y.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Controlled Release</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">142</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">214-220</span>CODEN:
                <span class="NLM_cas:coden">JCREEC</span>;
        ISSN:<span class="NLM_cas:issn">0168-3659</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Here we describe the design and application of OSu-FMS-MAL-S-(CH2)15-COOH, an agent that assocs. with albumin while linked to a peptide or a protein with sufficient affinity (Ka = 2 to 2.6 × 105 M- 1) to protract the action of short- lived peptides and proteins in vivo.  Under physiol. conditions this probe undergoes spontaneous hydrolysis with the concomitant reactivation of inactive conjugates.  I.v. administered 125I-labeled-Insulin-FMS-MAL-S-(CH2)15-COOH to rats shows half-life of 17 ± 2 h, exceeding 5.2 times that obtained with i.v. administered 125I-labeled Insulin.  In mice this deriv. facilitates glucose-lowering effect over a period of 24 h, yielding AUC five times greater than that obtained by a similar dose of insulin-detemir.  Similarly, s.c. administration of Exendin-4-FMS-MAL-S-(CH2)15-COOH into mice facilitated prolonged and stable redn. in glucose level, yielding a t1/2 value of 28 ± 2 h, exceeding the effect of exendin-4 4.7 folds.  The inactive deriv. gentamicin-FMS-MAL-S-(CH2)15-COOH regained its full antibacterial potency upon incubation at physiol. conditions yielding a t1/2 value of 7.1 ± 0.2 h.  In conclusion, the albumin-binding probe we introduced enables to prolong the action of any amino contg. mol. in vivo, without the drawback of inactivation that often occurs upon such derivatization.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGovYJ3iL1DddbVg90H21EOLACvtfcHk0ljDazGX0u2Afw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhvFehurk%253D&md5=2daf59c742b023abd376af6a4d24487f</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1016%2Fj.jconrel.2009.10.028&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jconrel.2009.10.028%26sid%3Dliteratum%253Aachs%26aulast%3DSasson%26aufirst%3DK.%26aulast%3DMarcus%26aufirst%3DY.%26aulast%3DLev-Goldman%26aufirst%3DV.%26aulast%3DRubinraut%26aufirst%3DS.%26aulast%3DFridkin%26aufirst%3DM.%26aulast%3DShechter%26aufirst%3DY.%26atitle%3DEngineering%2520prolonged-acting%2520prodrugs%2520employing%2520an%2520albumin-binding%2520probe%2520that%2520undergoes%2520slow%2520hydrolysis%2520at%2520physiological%2520conditions%26jtitle%3DJ.%2520Controlled%2520Release%26date%3D2010%26volume%3D142%26spage%3D214%26epage%3D220%26doi%3D10.1016%2Fj.jconrel.2009.10.028" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref29"><div class="reference"><strong class="refLabel"><a href="#ref29" class="rightTabRefNumLink">29</a></strong><div class="NLM_citation" id="rightTab-cit29"><span><span class="NLM_contrib-group">Kratz, F.</span><span> </span><span class="NLM_article-title">Albumin as a drug carrier: design of prodrugs, drug conjugates and nanoparticles</span> <span class="citation_source-journal">J. Controlled Release</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">132</span><span class="NLM_x">, </span> <span class="NLM_fpage">171</span><span class="NLM_x">–</span> <span class="NLM_lpage">183</span><span class="refDoi"> DOI: 10.1016/j.jconrel.2008.05.010</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00509&amp;key=10.1016%2Fj.jconrel.2008.05.010" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00509&amp;key=18582981" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00509&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhsVensLvP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=132&publication_year=2008&pages=171-183&author=F.+Kratz&title=Albumin+as+a+drug+carrier%3A+design+of+prodrugs%2C+drug+conjugates+and+nanoparticles&doi=10.1016%2Fj.jconrel.2008.05.010"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Albumin as a drug carrier: Design of prodrugs, drug conjugates and nanoparticles</span></div><div class="casAuthors">Kratz, Felix</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Controlled Release</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">132</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">171-183</span>CODEN:
                <span class="NLM_cas:coden">JCREEC</span>;
        ISSN:<span class="NLM_cas:issn">0168-3659</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Albumin is playing an increasing role as a drug carrier in the clin. setting.  Principally, three drug delivery technologies can be distinguished: coupling of low-mol. wt. drugs to exogenous or endogenous albumin, conjugation with bioactive proteins and encapsulation of drugs into albumin nanoparticles.  The accumulation of albumin in solid tumors forms the rationale for developing albumin-based drug delivery systems for tumor targeting.  Clin., a methotrexate-albumin conjugate, an albumin-binding prodrug of doxorubicin, i.e. the (6-maleimido)caproylhydrazone deriv. of doxorubicin (DOXO-EMCH), and an albumin paclitaxel nanoparticle (Abraxane) have been evaluated clin.  Abraxane has been approved for treating metastatic breast cancer.  An alternative strategy is to bind a therapeutic peptide or protein covalently or phys. to albumin to enhance its stability and half-life.  This approach has been applied to peptides with antinociceptive, antidiabetes, antitumor or antiviral activity: Levemir, a myristic acid deriv. of insulin that binds to the fatty acid binding sites of circulating albumin, has been approved for the treatment of diabetes.  Furthermore, Albuferon, a fusion protein of albumin and interferon, is currently being assessed in phase III clin. trials for the treatment of hepatitis C and could become an alternative to pegylated interferon.  This review gives an account of the different drug delivery systems which make use of albumin as a drug carrier with a focus on those systems that have reached an advanced stage of preclin. evaluation or that have entered clin. trials.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoPSwOkIFOBr7Vg90H21EOLACvtfcHk0ljDazGX0u2Afw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhsVensLvP&md5=32729be05d7227de8b6a5c8d8d890e38</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1016%2Fj.jconrel.2008.05.010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jconrel.2008.05.010%26sid%3Dliteratum%253Aachs%26aulast%3DKratz%26aufirst%3DF.%26atitle%3DAlbumin%2520as%2520a%2520drug%2520carrier%253A%2520design%2520of%2520prodrugs%252C%2520drug%2520conjugates%2520and%2520nanoparticles%26jtitle%3DJ.%2520Controlled%2520Release%26date%3D2008%26volume%3D132%26spage%3D171%26epage%3D183%26doi%3D10.1016%2Fj.jconrel.2008.05.010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref30"><div class="reference"><strong class="refLabel"><a href="#ref30" class="rightTabRefNumLink">30</a></strong><div class="NLM_citation" id="rightTab-cit30"><span><span class="NLM_contrib-group">Gou, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liang, H.</span><span> </span><span class="NLM_article-title">Designing prodrugs based on special residues of human serum albumin</span> <span class="citation_source-journal">Curr. Top. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">16</span><span class="NLM_x">, </span> <span class="NLM_fpage">996</span><span class="NLM_x">–</span> <span class="NLM_lpage">1008</span><span class="refDoi"> DOI: 10.2174/1568026615666150825142908</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00509&amp;key=10.2174%2F1568026615666150825142908" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00509&amp;key=26303424" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00509&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhvFGkurjJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2016&pages=996-1008&author=Y.+Gouauthor=F.+Yangauthor=H.+Liang&title=Designing+prodrugs+based+on+special+residues+of+human+serum+albumin&doi=10.2174%2F1568026615666150825142908"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Designing Prodrugs Based on Special Residues of Human Serum Albumin</span></div><div class="casAuthors">Gou, Yi; Yang, Feng; Liang, Hong</div><div class="citationInfo"><span class="NLM_cas:title">Current Topics in Medicinal Chemistry (Sharjah, United Arab Emirates)</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">996-1008</span>CODEN:
                <span class="NLM_cas:coden">CTMCCL</span>;
        ISSN:<span class="NLM_cas:issn">1568-0266</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">Human serum albumin (HSA) is the most abundant protein in the plasma.  HSA plays a central role in drug pharmacokinetics because most drugs bound to HSA are delivered to their target organ/tissues.  The prodrug strategies have shown great promise for improving the activity and selectivity of drugs.  Designing prodrugs based on special HSA residues, such as Cys34 and Lys residues, has been extensively studied.  Therefore, this review provides an overview of the development of nonsteroidal anti-inflammatory and anticancer prodrugs based on these special residues.  In conclusion, this review may guide the rational design and development of new prodrugs for future clin. applications.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrUircGh2an-7Vg90H21EOLACvtfcHk0ljDazGX0u2Afw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhvFGkurjJ&md5=9a9401879ba2d7ec9e9b2acb12714eed</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.2174%2F1568026615666150825142908&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F1568026615666150825142908%26sid%3Dliteratum%253Aachs%26aulast%3DGou%26aufirst%3DY.%26aulast%3DYang%26aufirst%3DF.%26aulast%3DLiang%26aufirst%3DH.%26atitle%3DDesigning%2520prodrugs%2520based%2520on%2520special%2520residues%2520of%2520human%2520serum%2520albumin%26jtitle%3DCurr.%2520Top.%2520Med.%2520Chem.%26date%3D2016%26volume%3D16%26spage%3D996%26epage%3D1008%26doi%3D10.2174%2F1568026615666150825142908" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref31"><div class="reference"><strong class="refLabel"><a href="#ref31" class="rightTabRefNumLink">31</a></strong><div class="NLM_citation" id="rightTab-cit31"><span><span class="NLM_contrib-group">Elsadek, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kratz, F.</span><span> </span><span class="NLM_article-title">Impact of albumin on drug delivery—New applications on the horizon</span> <span class="citation_source-journal">J. Controlled Release</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">157</span><span class="NLM_x">, </span> <span class="NLM_fpage">4</span><span class="NLM_x">–</span> <span class="NLM_lpage">28</span><span class="refDoi"> DOI: 10.1016/j.jconrel.2011.09.069</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00509&amp;key=10.1016%2Fj.jconrel.2011.09.069" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00509&amp;key=21959118" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00509&amp;key=1%3ACAS%3A528%3ADC%252BC38XntFyguw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=157&publication_year=2012&pages=4-28&author=B.+Elsadekauthor=F.+Kratz&title=Impact+of+albumin+on+drug+delivery%E2%80%94New+applications+on+the+horizon&doi=10.1016%2Fj.jconrel.2011.09.069"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">Impact of albumin on drug delivery - New applications on the horizon</span></div><div class="casAuthors">Elsadek, Bakheet; Kratz, Felix</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Controlled Release</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">157</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">4-28</span>CODEN:
                <span class="NLM_cas:coden">JCREEC</span>;
        ISSN:<span class="NLM_cas:issn">0168-3659</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Over the past decades, albumin has emerged as a versatile carrier for therapeutic and diagnostic agents, primarily for diagnosing and treating diabetes, cancer, rheumatoid arthritis and infectious diseases.  Market approved products include fatty acid derivs. of human insulin or the glucagon-like-1 peptide (Levemir and Victoza) for treating diabetes, the taxol albumin nanoparticle Abraxane for treating metastatic breast cancer which is also under clin. investigation in further tumor indications, and 99mTc-aggregated albumin (Nanocoll and Albures) for diagnosing cancer and rheumatoid arthritis as well as for lymphoscintigraphy.  In addn., an increasing no. of albumin-based or albumin-binding drugs are in clin. trials such as antibody fusion proteins (MM-111) for treating HER2/neu pos. breast cancer (phase I), a camelid albumin-binding nanobody anti-HSA-anti-TNF-α (ATN-103) in phase II studies for treating rheumatoid arthritis, an antidiabetic Exendin-4 analog bound to recombinant human albumin (phase I/II), a fluorescein-labeled albumin conjugate (AFL)-human serum albumin for visualizing the malignant borders of brain tumors for improved surgical resection, and finally an albumin-binding prodrug of doxorubicin (INNO-206) entering phase II studies against sarcoma and gastric cancer.  In the preclin. setting, novel approaches include attaching peptides with high-affinity for albumin to antibody fragments, the exploitation of albumin-binding gadolinium contrast agents for magnetic resonance imaging, and phys. or covalent attachment of antiviral, antibacterial, and anticancer drugs to albumin that are permanently or transiently attached to human serum albumin (HSA) or act as albumin-binding prodrugs.  This review gives an overview of the expanding field of preclin. and clin. drug applications and developments that use albumin as a protein carrier to improve the pharmacokinetic profile of the drug or to target the drug to the pathogenic site addressing diseases with unmet medical needs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq-TUARuO_GX7Vg90H21EOLACvtfcHk0ljDazGX0u2Afw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XntFyguw%253D%253D&md5=04108fb5645788a1d61484df344a47a5</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1016%2Fj.jconrel.2011.09.069&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jconrel.2011.09.069%26sid%3Dliteratum%253Aachs%26aulast%3DElsadek%26aufirst%3DB.%26aulast%3DKratz%26aufirst%3DF.%26atitle%3DImpact%2520of%2520albumin%2520on%2520drug%2520delivery%25E2%2580%2594New%2520applications%2520on%2520the%2520horizon%26jtitle%3DJ.%2520Controlled%2520Release%26date%3D2012%26volume%3D157%26spage%3D4%26epage%3D28%26doi%3D10.1016%2Fj.jconrel.2011.09.069" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref32"><div class="reference"><strong class="refLabel"><a href="#ref32" class="rightTabRefNumLink">32</a></strong><div class="NLM_citation" id="rightTab-cit32"><span><span class="NLM_contrib-group">Zhang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ho, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yue, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kong, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhou, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liang, H.</span><span> </span><span class="NLM_article-title">Structural basis and anticancer properties of ruthenium-based drug complexed with human serum albumin</span> <span class="citation_source-journal">Eur. J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">86</span><span class="NLM_x">, </span> <span class="NLM_fpage">449</span><span class="NLM_x">–</span> <span class="NLM_lpage">455</span><span class="refDoi"> DOI: 10.1016/j.ejmech.2014.08.071</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00509&amp;key=10.1016%2Fj.ejmech.2014.08.071" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00509&amp;key=25200980" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00509&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhsFSjt7vE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=86&publication_year=2014&pages=449-455&author=Y.+Zhangauthor=A.+Hoauthor=J.+Yueauthor=L.+Kongauthor=Z.+Zhouauthor=X.+Wuauthor=F.+Yangauthor=H.+Liang&title=Structural+basis+and+anticancer+properties+of+ruthenium-based+drug+complexed+with+human+serum+albumin&doi=10.1016%2Fj.ejmech.2014.08.071"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">Structural basis and anticancer properties of ruthenium-based drug complexed with human serum albumin</span></div><div class="casAuthors">Zhang, Yao; Ho, Andy; Yue, Jiping; Kong, Linlin; Zhou, Zuping; Wu, Xiaoyang; Yang, Feng; Liang, Hong</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">86</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">449-455</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">Ruthenium-based anticancer complexes have become increasingly popular for study over the last two decades.  Although ruthenium complexes are currently being investigated in clin. trials, there are still some difficulties with their delivery and assocd. side effects.  Human serum albumin (HSA)-based delivery systems are promising for improving anticancer drug targeting and reducing neg. side effects.  However, there have been few studies regarding the HSA delivery system for metal-based anticancer compds. and no mention of its structural mechanism.  Therefore, we studied the structure and anticancer properties of the ruthenium-based compd. [RuCl5(ind)]2- in complex with HSA.  The structure revealed that [RuCl5(ind)]2- has two binding sites in HSA.  In the IB subdomain, [RuCl5(ind)]2- binds to a new sub-site by coordinating with His-146.  In the IIA subdomain, ruthenium (III) of [RuCl5(ind)]2- binds to the hydrophobic cavity and forms coordination bonds by replacing chlorine atoms with the His-242 and Lys-199 residues of HSA.  Interestingly, [RuCl5(ind)]2-, together with HSA, can enhance cytotoxicity by two to five times in cancer cells but has no effect on normal cells in vitro.  Compared with unbound drug, the HSA-[RuCl5(ind)]2- complex promotes MGC-803 cell apoptosis and also has a stronger capacity for cell cycle arrest at the G2 phase in MGC-803.  In conclusion, this study will guide the rational design and development of ruthenium-contg. or ruthenium-centered drugs and an HSA delivery system for ruthenium-based drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoyudavla2evbVg90H21EOLACvtfcHk0lhxT66znuR2jQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhsFSjt7vE&md5=b2bf15b76c83ea83e8327f626bafc60a</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2014.08.071&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2014.08.071%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DHo%26aufirst%3DA.%26aulast%3DYue%26aufirst%3DJ.%26aulast%3DKong%26aufirst%3DL.%26aulast%3DZhou%26aufirst%3DZ.%26aulast%3DWu%26aufirst%3DX.%26aulast%3DYang%26aufirst%3DF.%26aulast%3DLiang%26aufirst%3DH.%26atitle%3DStructural%2520basis%2520and%2520anticancer%2520properties%2520of%2520ruthenium-based%2520drug%2520complexed%2520with%2520human%2520serum%2520albumin%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2014%26volume%3D86%26spage%3D449%26epage%3D455%26doi%3D10.1016%2Fj.ejmech.2014.08.071" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref33"><div class="reference"><strong class="refLabel"><a href="#ref33" class="rightTabRefNumLink">33</a></strong><div class="NLM_citation" id="rightTab-cit33"><span><span class="NLM_contrib-group">Gou, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Qi, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ajayi, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhou, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liang, H.</span><span> </span><span class="NLM_article-title">Developing anticancer copper(II) prodrugs based on the nature of cancer cells and the human serum albumin carrier IIA subdomain</span> <span class="citation_source-journal">Mol. Pharmaceutics</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">12</span><span class="NLM_x">, </span> <span class="NLM_fpage">3597</span><span class="NLM_x">–</span> <span class="NLM_lpage">3609</span><span class="refDoi"> DOI: 10.1021/acs.molpharmaceut.5b00314</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.molpharmaceut.5b00314" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00509&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhsVOnsrbE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2015&pages=3597-3609&author=Y.+Gouauthor=J.+Qiauthor=J.+P.+Ajayiauthor=Y.+Zhangauthor=Z.+Zhouauthor=F.+Yangauthor=H.+Liang&title=Developing+anticancer+copper%28II%29+prodrugs+based+on+the+nature+of+cancer+cells+and+the+human+serum+albumin+carrier+IIA+subdomain&doi=10.1021%2Facs.molpharmaceut.5b00314"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">Developing Anticancer Copper(II) Pro-drugs Based on the Nature of Cancer Cells and the Human Serum Albumin Carrier IIA Subdomain</span></div><div class="casAuthors">Gou, Yi; Qi, Jinxu; Ajayi, Joshua-Paul; Zhang, Yao; Zhou, Zuping; Wu, Xiaoyang; Yang, Feng; Liang, Hong</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Pharmaceutics</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">3597-3609</span>CODEN:
                <span class="NLM_cas:coden">MPOHBP</span>;
        ISSN:<span class="NLM_cas:issn">1543-8384</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">To synergistically enhance the selectivity and efficiency of anticancer copper drugs, we proposed and built a model to develop anticancer copper pro-drugs based on the nature of human serum albumin (HSA) IIA subdomain and cancer cells.  Three copper(II) compds. of a 2-hydroxy-1-naphthaldehyde benzoyl hydrazone Schiff-base ligand in the presence pyridine, imidazole, or indazole ligands were synthesized (C1-C3).  The structures of three HSA complexes revealed that the Cu compds. bind to the hydrophobic cavity in the HSA IIA subdomain.  Among them, the pyridine and imidazole ligands of C1 and C2 are replaced by Lys199, and His242 directly coordinates with Cu(II).  The indazole and Br ligands of C3 are replaced by Lys199 and His242, resp.  Compared with the Cu(II) compds. alone, the HSA complexes enhance cytotoxicity in MCF-7 cells approx. 3-5-fold, but do not raise cytotoxicity levels in normal cells in vitro through selectively accumulating in cancer cells to some extent.  We find that the HSA complex has a stronger capacity for cell cycle arrest in the G2/M phase of MCF-7 by targeting cyclin-dependent kinase 1 (CDK1) and down-regulating the expression of CDK1 and cyclin B1.  Moreover, the HSA complex promotes MCF-7 cell apoptosis possibly through the intrinsic reactive oxygen species (ROS) mediated mitochondrial pathway, accompanied by the regulation of Bcl-2 family proteins.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoQC67vwTNSRLVg90H21EOLACvtfcHk0lhxT66znuR2jQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhsVOnsrbE&md5=c1977caff60b0d3a7ca3f47ce443c886</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1021%2Facs.molpharmaceut.5b00314&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.molpharmaceut.5b00314%26sid%3Dliteratum%253Aachs%26aulast%3DGou%26aufirst%3DY.%26aulast%3DQi%26aufirst%3DJ.%26aulast%3DAjayi%26aufirst%3DJ.%2BP.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DZhou%26aufirst%3DZ.%26aulast%3DYang%26aufirst%3DF.%26aulast%3DLiang%26aufirst%3DH.%26atitle%3DDeveloping%2520anticancer%2520copper%2528II%2529%2520prodrugs%2520based%2520on%2520the%2520nature%2520of%2520cancer%2520cells%2520and%2520the%2520human%2520serum%2520albumin%2520carrier%2520IIA%2520subdomain%26jtitle%3DMol.%2520Pharmaceutics%26date%3D2015%26volume%3D12%26spage%3D3597%26epage%3D3609%26doi%3D10.1021%2Facs.molpharmaceut.5b00314" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref34"><div class="reference"><strong class="refLabel"><a href="#ref34" class="rightTabRefNumLink">34</a></strong><div class="NLM_citation" id="rightTab-cit34"><span><span class="NLM_contrib-group">Qi, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gou, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhou, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liang, H.</span><span> </span><span class="NLM_article-title">Developing an anticancer copper(II) prodrug based on the His242 residue of the human serum albumin carrier IIA subdomain</span> <span class="citation_source-journal">Mol. Pharmaceutics</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">13</span><span class="NLM_x">, </span> <span class="NLM_fpage">1501</span><span class="NLM_x">–</span> <span class="NLM_lpage">1507</span><span class="refDoi"> DOI: 10.1021/acs.molpharmaceut.5b00938</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.molpharmaceut.5b00938" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00509&amp;key=1%3ACAS%3A528%3ADC%252BC28XkvVahurg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2016&pages=1501-1507&author=J.+Qiauthor=Y.+Zhangauthor=Y.+Gouauthor=Z.+Zhangauthor=Z.+Zhouauthor=X.+Wuauthor=F.+Yangauthor=H.+Liang&title=Developing+an+anticancer+copper%28II%29+prodrug+based+on+the+His242+residue+of+the+human+serum+albumin+carrier+IIA+subdomain&doi=10.1021%2Facs.molpharmaceut.5b00938"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">Developing an Anticancer Copper(II) Pro-Drug Based on the His242 Residue of the Human Serum Albumin Carrier IIA Subdomain</span></div><div class="casAuthors">Qi, Jinxu; Zhang, Yao; Gou, Yi; Zhang, Zhenlei; Zhou, Zuping; Wu, Xiaoyang; Yang, Feng; Liang, Hong</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Pharmaceutics</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1501-1507</span>CODEN:
                <span class="NLM_cas:coden">MPOHBP</span>;
        ISSN:<span class="NLM_cas:issn">1543-8384</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">To increase delivery efficiency, anticancer activity, and selectivity of anticancer metal agents in vivo, we proposed to develop the anticancer metal pro-drug based on His242 residue of the human serum albumin (HSA) carrier IIA subdomain.  To confirm our hypothesis, we prepd. two Cu(II) compds. [Cu(P4 mT)Cl and Cu(Bp44 mT)Cl] by modifying Cu(II) compd. ligand structure.  Studies with two HSA complex structures revealed that Cu(P4 mT)Cl bound to the HSA subdomain IIA via hydrophobic interactions, but Cu(Bp44 mT)Cl bound to the HSA subdomain IIA via His242 replacement of a Cl atom of Cu(Bp44 mT)Cl, and a coordination to Cu2+.  Furthermore, Cu(II) compds. released from HSA could be regulated at different pHs.  In vivo data revealed that the HSA-Cu(Bp44 mT) complex increased copper's selectivity and capacity of inhibiting tumor growth compared to Cu(Bp44 mT)Cl alone.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqHVA5oWe9GUbVg90H21EOLACvtfcHk0lhxT66znuR2jQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XkvVahurg%253D&md5=590fcfb50f0478829e3435277c6e8fd3</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1021%2Facs.molpharmaceut.5b00938&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.molpharmaceut.5b00938%26sid%3Dliteratum%253Aachs%26aulast%3DQi%26aufirst%3DJ.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DGou%26aufirst%3DY.%26aulast%3DZhang%26aufirst%3DZ.%26aulast%3DZhou%26aufirst%3DZ.%26aulast%3DWu%26aufirst%3DX.%26aulast%3DYang%26aufirst%3DF.%26aulast%3DLiang%26aufirst%3DH.%26atitle%3DDeveloping%2520an%2520anticancer%2520copper%2528II%2529%2520prodrug%2520based%2520on%2520the%2520His242%2520residue%2520of%2520the%2520human%2520serum%2520albumin%2520carrier%2520IIA%2520subdomain%26jtitle%3DMol.%2520Pharmaceutics%26date%3D2016%26volume%3D13%26spage%3D1501%26epage%3D1507%26doi%3D10.1021%2Facs.molpharmaceut.5b00938" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref35"><div class="reference"><strong class="refLabel"><a href="#ref35" class="rightTabRefNumLink">35</a></strong><div class="NLM_citation" id="rightTab-cit35"><span><span class="NLM_contrib-group">Torre, L. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bray, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Siegel, R. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ferlay, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lortet-Tieulent, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jemal, A.</span><span> </span><span class="NLM_article-title">Global cancer statistics, 2012</span> <span class="citation_source-journal">Ca-Cancer J. Clin.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">65</span><span class="NLM_x">, </span> <span class="NLM_fpage">87</span><span class="NLM_x">–</span> <span class="NLM_lpage">108</span><span class="refDoi"> DOI: 10.3322/caac.21262</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00509&amp;key=10.3322%2Fcaac.21262" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00509&amp;key=25651787" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00509&amp;key=1%3ACAS%3A280%3ADC%252BC2Mris1Ggsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=65&publication_year=2015&pages=87-108&author=L.+A.+Torreauthor=F.+Brayauthor=R.+L.+Siegelauthor=J.+Ferlayauthor=J.+Lortet-Tieulentauthor=A.+Jemal&title=Global+cancer+statistics%2C+2012&doi=10.3322%2Fcaac.21262"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">Global cancer statistics, 2012</span></div><div class="casAuthors">Torre Lindsey A; Bray Freddie; Siegel Rebecca L; Ferlay Jacques; Lortet-Tieulent Joannie; Jemal Ahmedin</div><div class="citationInfo"><span class="NLM_cas:title">CA: a cancer journal for clinicians</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">65</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">87-108</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Cancer constitutes an enormous burden on society in more and less economically developed countries alike.  The occurrence of cancer is increasing because of the growth and aging of the population, as well as an increasing prevalence of established risk factors such as smoking, overweight, physical inactivity, and changing reproductive patterns associated with urbanization and economic development.  Based on GLOBOCAN estimates, about 14.1 million new cancer cases and 8.2 million deaths occurred in 2012 worldwide.  Over the years, the burden has shifted to less developed countries, which currently account for about 57% of cases and 65% of cancer deaths worldwide.  Lung cancer is the leading cause of cancer death among males in both more and less developed countries, and has surpassed breast cancer as the leading cause of cancer death among females in more developed countries; breast cancer remains the leading cause of cancer death among females in less developed countries.  Other leading causes of cancer death in more developed countries include colorectal cancer among males and females and prostate cancer among males.  In less developed countries, liver and stomach cancer among males and cervical cancer among females are also leading causes of cancer death.  Although incidence rates for all cancers combined are nearly twice as high in more developed than in less developed countries in both males and females, mortality rates are only 8% to 15% higher in more developed countries.  This disparity reflects regional differences in the mix of cancers, which is affected by risk factors and detection practices, and/or the availability of treatment.  Risk factors associated with the leading causes of cancer death include tobacco use (lung, colorectal, stomach, and liver cancer), overweight/obesity and physical inactivity (breast and colorectal cancer), and infection (liver, stomach, and cervical cancer).  A substantial portion of cancer cases and deaths could be prevented by broadly applying effective prevention measures, such as tobacco control, vaccination, and the use of early detection tests.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcS93OidvnAA79ts4TFFB11gfW6udTcc2eZ26tVPI7rS-rntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2Mris1Ggsg%253D%253D&md5=f008b208320b129e10c7c383193ff772</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.3322%2Fcaac.21262&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3322%252Fcaac.21262%26sid%3Dliteratum%253Aachs%26aulast%3DTorre%26aufirst%3DL.%2BA.%26aulast%3DBray%26aufirst%3DF.%26aulast%3DSiegel%26aufirst%3DR.%2BL.%26aulast%3DFerlay%26aufirst%3DJ.%26aulast%3DLortet-Tieulent%26aufirst%3DJ.%26aulast%3DJemal%26aufirst%3DA.%26atitle%3DGlobal%2520cancer%2520statistics%252C%25202012%26jtitle%3DCa-Cancer%2520J.%2520Clin.%26date%3D2015%26volume%3D65%26spage%3D87%26epage%3D108%26doi%3D10.3322%2Fcaac.21262" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref36"><div class="reference"><strong class="refLabel"><a href="#ref36" class="rightTabRefNumLink">36</a></strong><div class="NLM_citation" id="rightTab-cit36"><span><span class="NLM_contrib-group">Lovejoy, D. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Richardson, D. R.</span><span> </span><span class="NLM_article-title">Novel ″hybrid″ iron chelators derived from aroylhydrazones and thiosemicarbazones demonstrate selective antiproliferative activity against tumor cells</span> <span class="citation_source-journal">Blood</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">100</span><span class="NLM_x">, </span> <span class="NLM_fpage">666</span><span class="NLM_x">–</span> <span class="NLM_lpage">676</span><span class="refDoi"> DOI: 10.1182/blood.V100.2.666</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00509&amp;key=10.1182%2Fblood.V100.2.666" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=100&publication_year=2002&pages=666-676&author=D.+B.+Lovejoyauthor=D.+R.+Richardson&title=Novel+%E2%80%B3hybrid%E2%80%B3+iron+chelators+derived+from+aroylhydrazones+and+thiosemicarbazones+demonstrate+selective+antiproliferative+activity+against+tumor+cells&doi=10.1182%2Fblood.V100.2.666"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1182%2Fblood.V100.2.666&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood.V100.2.666%26sid%3Dliteratum%253Aachs%26aulast%3DLovejoy%26aufirst%3DD.%2BB.%26aulast%3DRichardson%26aufirst%3DD.%2BR.%26atitle%3DNovel%2520%25E2%2580%25B3hybrid%25E2%2580%25B3%2520iron%2520chelators%2520derived%2520from%2520aroylhydrazones%2520and%2520thiosemicarbazones%2520demonstrate%2520selective%2520antiproliferative%2520activity%2520against%2520tumor%2520cells%26jtitle%3DBlood%26date%3D2002%26volume%3D100%26spage%3D666%26epage%3D676%26doi%3D10.1182%2Fblood.V100.2.666" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref37"><div class="reference"><strong class="refLabel"><a href="#ref37" class="rightTabRefNumLink">37</a></strong><div class="NLM_citation" id="rightTab-cit37"><span><span class="NLM_contrib-group">Ferraro, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Massai, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Messori, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Merlino, A.</span><span> </span><span class="NLM_article-title">Cisplatin binding to human serum albumin: a structural study</span> <span class="citation_source-journal">Chem. Commun.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">51</span><span class="NLM_x">, </span> <span class="NLM_fpage">9436</span><span class="NLM_x">–</span> <span class="NLM_lpage">9439</span><span class="refDoi"> DOI: 10.1039/C5CC01751C</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00509&amp;key=10.1039%2FC5CC01751C" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00509&amp;key=25873085" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00509&amp;key=1%3ACAS%3A528%3ADC%252BC2MXmt1WlsL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2015&pages=9436-9439&author=G.+Ferraroauthor=L.+Massaiauthor=L.+Messoriauthor=A.+Merlino&title=Cisplatin+binding+to+human+serum+albumin%3A+a+structural+study&doi=10.1039%2FC5CC01751C"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">Cisplatin binding to human serum albumin: a structural study</span></div><div class="casAuthors">Ferraro, Giarita; Massai, Lara; Messori, Luigi; Merlino, Antonello</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Communications (Cambridge, United Kingdom)</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">51</span>
        (<span class="NLM_cas:issue">46</span>),
    <span class="NLM_cas:pages">9436-9439</span>CODEN:
                <span class="NLM_cas:coden">CHCOFS</span>;
        ISSN:<span class="NLM_cas:issn">1359-7345</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">The reaction between cisplatin and human serum albumin (HSA) was investigated by X-ray crystallog. and crystal structures of the cisplatin/HSA adduct were eventually solved for the first time.  Structural data unambiguously prove that cisplatin mainly binds to His105 and Met329 side chains; addnl. binding sites are detected at His288, Met298, and Met548 and at His535, His67 and His247.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrsyb8t3PkHAbVg90H21EOLACvtfcHk0lhJE1anFIdlAQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXmt1WlsL8%253D&md5=f33fc82894330a0397afc82c4a45e3d8</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1039%2FC5CC01751C&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252FC5CC01751C%26sid%3Dliteratum%253Aachs%26aulast%3DFerraro%26aufirst%3DG.%26aulast%3DMassai%26aufirst%3DL.%26aulast%3DMessori%26aufirst%3DL.%26aulast%3DMerlino%26aufirst%3DA.%26atitle%3DCisplatin%2520binding%2520to%2520human%2520serum%2520albumin%253A%2520a%2520structural%2520study%26jtitle%3DChem.%2520Commun.%26date%3D2015%26volume%3D51%26spage%3D9436%26epage%3D9439%26doi%3D10.1039%2FC5CC01751C" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref38"><div class="reference"><strong class="refLabel"><a href="#ref38" class="rightTabRefNumLink">38</a></strong><div class="NLM_citation" id="rightTab-cit38"><span><span class="NLM_contrib-group">Desai, N.</span><span> </span><span class="NLM_article-title">Nab Technology: A drug delivery platform utilizing endothelial gp60 receptor-based transport and tumor derived SPARC for targeting</span>.  <span class="citation_source-book">Drug Delivery Report Winter 2007/008</span>,<span class="NLM_x"> </span><span class="NLM_year">2007</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2007&author=N.+Desai&title=Drug+Delivery+Report+Winter+2007%2F008"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26aulast%3DDesai%26aufirst%3DN.%26atitle%3DNab%2520Technology%253A%2520A%2520drug%2520delivery%2520platform%2520utilizing%2520endothelial%2520gp60%2520receptor-based%2520transport%2520and%2520tumor%2520derived%2520SPARC%2520for%2520targeting%26btitle%3DDrug%2520Delivery%2520Report%2520Winter%25202007%252F008%26date%3D2007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref39"><div class="reference"><strong class="refLabel"><a href="#ref39" class="rightTabRefNumLink">39</a></strong><div class="NLM_citation" id="rightTab-cit39"><span><span class="NLM_contrib-group">Atorrasagasti, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Malvicini, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aquino, J. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alaniz, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Garcia, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bolontrade, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rizzo, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Podhajcer, O. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mazzolini, G.</span><span> </span><span class="NLM_article-title">Overexpression of SPARC obliterates the in vivo tumorigenicity of human hepatocellular carcinoma cells</span> <span class="citation_source-journal">Int. J. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">126</span><span class="NLM_x">, </span> <span class="NLM_fpage">2726</span><span class="NLM_x">–</span> <span class="NLM_lpage">2740</span><span class="refDoi"> DOI: 10.1002/ijc.24966</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00509&amp;key=10.1002%2Fijc.24966" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00509&amp;key=19830689" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00509&amp;key=1%3ACAS%3A528%3ADC%252BC3cXjvFKlsb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=126&publication_year=2010&pages=2726-2740&author=C.+Atorrasagastiauthor=M.+Malviciniauthor=J.+B.+Aquinoauthor=L.+Alanizauthor=M.+Garciaauthor=M.+Bolontradeauthor=M.+Rizzoauthor=O.+L.+Podhajcerauthor=G.+Mazzolini&title=Overexpression+of+SPARC+obliterates+the+in+vivo+tumorigenicity+of+human+hepatocellular+carcinoma+cells&doi=10.1002%2Fijc.24966"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">Overexpression of SPARC obliterates the in vivo tumorigenicity of human hepatocellular carcinoma cells</span></div><div class="casAuthors">Atorrasagasti, Catalina; Malvicini, Mariana; Aquino, Jorge B.; Alaniz, Laura; Garcia, Mariana; Bolontrade, Marcela; Rizzo, Manglio; Podhajcer, Osvaldo L.; Mazzolini, Guillermo</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Cancer</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">126</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">2726-2740</span>CODEN:
                <span class="NLM_cas:coden">IJCNAW</span>;
        ISSN:<span class="NLM_cas:issn">0020-7136</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Liss, Inc.</span>)
        </div><div class="casAbstract">Hepatocellular carcinoma (HCC) is the sixth most common cancer and the third leading cause of cancer-related death worldwide.  Current treatments are extremely disappointing.  SPARC (Secreted protein, acidic and rich in cysteine) is a matricellular glycoprotein with differential expression in several tumors, including HCC, which significance remains unclear.  We infected HCC cells (HepG2, Hep3B and Huh7) with an adenovirus expressing SPARC (AdsSPARC) to examine the role of SPARC expression on HCC cells and its effect on tumor aggressiveness.  The in vitro HCC cells substrate-dependent proliferation and cell cycle profile were unaffected; however, SPARC overexpression reduced HCC proliferation when cells were grown in spheroids.  A mild induction of cellular apoptosis was obsd. upon SPARC overexpression.  SPARC overexpression resulted in spheroid growth inhibition in vitro while no effects were found when recombinant SPARC was exogenously applied.  Moreover, the clonogenic and migratory capabilities were largely decreased in SPARC-overexpressing HCC cells, altogether suggesting a less aggressive HCC cell phenotype.  Consistently, AdsSPARC-transduced cells showed increased E-cadherin expression and a concomitant decrease in N-cadherin expression.  Furthermore, SPARC overexpression was found to reduce HCC cell viability in response to 5-FU-based chemotherapy in vitro, partially through induction of apoptosis.  In vivo expts. revealed that SPARC overexpression in HCC cells inhibited their tumorigenic capacity and increased animal survival through a mechanism that partially involves host macrophages.  Our data suggest that SPARC overexpression in HCC cells results in a reduced tumorigenicity partially through the induction of mesenchymal-to-epithelial transition (MET).  These evidences point to SPARC as a novel target for HCC treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqh5waYevKpQLVg90H21EOLACvtfcHk0lhJE1anFIdlAQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXjvFKlsb0%253D&md5=e4247112eb4f96badc4e0798525bc8ff</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1002%2Fijc.24966&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fijc.24966%26sid%3Dliteratum%253Aachs%26aulast%3DAtorrasagasti%26aufirst%3DC.%26aulast%3DMalvicini%26aufirst%3DM.%26aulast%3DAquino%26aufirst%3DJ.%2BB.%26aulast%3DAlaniz%26aufirst%3DL.%26aulast%3DGarcia%26aufirst%3DM.%26aulast%3DBolontrade%26aufirst%3DM.%26aulast%3DRizzo%26aufirst%3DM.%26aulast%3DPodhajcer%26aufirst%3DO.%2BL.%26aulast%3DMazzolini%26aufirst%3DG.%26atitle%3DOverexpression%2520of%2520SPARC%2520obliterates%2520the%2520in%2520vivo%2520tumorigenicity%2520of%2520human%2520hepatocellular%2520carcinoma%2520cells%26jtitle%3DInt.%2520J.%2520Cancer%26date%3D2010%26volume%3D126%26spage%3D2726%26epage%3D2740%26doi%3D10.1002%2Fijc.24966" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref40"><div class="reference"><strong class="refLabel"><a href="#ref40" class="rightTabRefNumLink">40</a></strong><div class="NLM_citation" id="rightTab-cit40"><span><span class="NLM_contrib-group">Tiruppathi, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Naqvi, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vogel, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Minshall, R. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Malik, A. B.</span><span> </span><span class="NLM_article-title">Albumin mediates the transcytosis of myeloperoxidase by means of caveolae in endothelial cells</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U. S. A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">101</span><span class="NLM_x">, </span> <span class="NLM_fpage">7699</span><span class="NLM_x">–</span> <span class="NLM_lpage">7704</span><span class="refDoi"> DOI: 10.1073/pnas.0401712101</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00509&amp;key=10.1073%2Fpnas.0401712101" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=101&publication_year=2004&pages=7699-7704&author=C.+Tiruppathiauthor=T.+Naqviauthor=Y.+Wuauthor=S.+M.+Vogelauthor=R.+D.+Minshallauthor=A.+B.+Malik&title=Albumin+mediates+the+transcytosis+of+myeloperoxidase+by+means+of+caveolae+in+endothelial+cells&doi=10.1073%2Fpnas.0401712101"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1073%2Fpnas.0401712101&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.0401712101%26sid%3Dliteratum%253Aachs%26aulast%3DTiruppathi%26aufirst%3DC.%26aulast%3DNaqvi%26aufirst%3DT.%26aulast%3DWu%26aufirst%3DY.%26aulast%3DVogel%26aufirst%3DS.%2BM.%26aulast%3DMinshall%26aufirst%3DR.%2BD.%26aulast%3DMalik%26aufirst%3DA.%2BB.%26atitle%3DAlbumin%2520mediates%2520the%2520transcytosis%2520of%2520myeloperoxidase%2520by%2520means%2520of%2520caveolae%2520in%2520endothelial%2520cells%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2004%26volume%3D101%26spage%3D7699%26epage%3D7704%26doi%3D10.1073%2Fpnas.0401712101" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref41"><div class="reference"><strong class="refLabel"><a href="#ref41" class="rightTabRefNumLink">41</a></strong><div class="NLM_citation" id="rightTab-cit41"><span><span class="NLM_contrib-group">Larsen, A. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Escargueil, A. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Skladanowski, A.</span><span> </span><span class="NLM_article-title">Catalytic topoisomerase II inhibitors in cancer therapy</span> <span class="citation_source-journal">Pharmacol. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">99</span><span class="NLM_x">, </span> <span class="NLM_fpage">167</span><span class="NLM_x">–</span> <span class="NLM_lpage">181</span><span class="refDoi"> DOI: 10.1016/S0163-7258(03)00058-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00509&amp;key=10.1016%2FS0163-7258%2803%2900058-5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00509&amp;key=12888111" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00509&amp;key=1%3ACAS%3A528%3ADC%252BD3sXlvVWhtL0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=99&publication_year=2003&pages=167-181&author=A.+K.+Larsenauthor=A.+E.+Escargueilauthor=A.+Skladanowski&title=Catalytic+topoisomerase+II+inhibitors+in+cancer+therapy&doi=10.1016%2FS0163-7258%2803%2900058-5"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit41R"><div class="casContent"><span class="casTitleNuber">41</span><div class="casTitle"><span class="NLM_cas:atitle">Catalytic topoisomerase II inhibitors in cancer therapy</span></div><div class="casAuthors">Larsen, Annette K.; Escargueil, Alexandre E.; Skladanowski, Andrzej</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacology & Therapeutics</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">99</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">167-181</span>CODEN:
                <span class="NLM_cas:coden">PHTHDT</span>;
        ISSN:<span class="NLM_cas:issn">0163-7258</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science B.V.</span>)
        </div><div class="casAbstract">A review.  The nuclear enzyme DNA topoisomerase II is a major target for antineoplastic agents.  All topoisomerase II-directed agents are able to interfere with at least one step of the catalytic cycle.  Agents able to stabilize the covalent DNA topoisomerase II complex (also known as the cleavable complex) are traditionally called topoisomerase II poisons, while agents acting on any of the other steps in the catalytic cycle are called catalytic inhibitors.  Thus, catalytic topoisomerase II inhibitors are a heterogeneous group of compds. that might interfere with the binding between DNA and topoisomerase II (aclarubicin and suramin), stabilize noncovalent DNA topoisomerase II complexes (merbarone, ICRF-187, and structurally related bisdioxopiperazine derivs.), or inhibit ATP binding (novobiocin).  Some, such as fostriecin, may also have alternative biol. targets.  Whereas topoisomerase II poisons are used solely for their antitumor activities, catalytic inhibitors are utilized for a variety of reasons, including their activity as antineoplastic agents (aclarubicin and MST-16), cardioprotectors (ICRF-187), or modulators in order to increase the efficacy of other agents (suramin and novobiocin).  In this review, the mechanism and biol. activity of different catalytic inhibitors is described, with emphasis on therapeutically used compds.  We will then discuss future development and applications of this interesting class of compds.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGote2bOTWP17bVg90H21EOLACvtfcHk0ljVIatJnLqRMA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXlvVWhtL0%253D&md5=4207fb899e2b98345f97e91983514913</span></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1016%2FS0163-7258%2803%2900058-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0163-7258%252803%252900058-5%26sid%3Dliteratum%253Aachs%26aulast%3DLarsen%26aufirst%3DA.%2BK.%26aulast%3DEscargueil%26aufirst%3DA.%2BE.%26aulast%3DSkladanowski%26aufirst%3DA.%26atitle%3DCatalytic%2520topoisomerase%2520II%2520inhibitors%2520in%2520cancer%2520therapy%26jtitle%3DPharmacol.%2520Ther.%26date%3D2003%26volume%3D99%26spage%3D167%26epage%3D181%26doi%3D10.1016%2FS0163-7258%2803%2900058-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref42"><div class="reference"><strong class="refLabel"><a href="#ref42" class="rightTabRefNumLink">42</a></strong><div class="NLM_citation" id="rightTab-cit42"><span><span class="NLM_contrib-group">Zeglis, B. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Divilov, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lewis, J. S.</span><span> </span><span class="NLM_article-title">Role of metalation in the topoisomerase IIα inhibition and antiproliferation activity of a series of α-heterocyclic-N4-substituted thiosemicarbazones and their Cu(II) complexes</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">54</span><span class="NLM_x">, </span> <span class="NLM_fpage">2391</span><span class="NLM_x">–</span> <span class="NLM_lpage">2398</span><span class="refDoi"> DOI: 10.1021/jm101532u</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm101532u" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00509&amp;key=1%3ACAS%3A528%3ADC%252BC3MXivFygsLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2011&pages=2391-2398&author=B.+M.+Zeglisauthor=V.+Divilovauthor=J.+S.+Lewis&title=Role+of+metalation+in+the+topoisomerase+II%CE%B1+inhibition+and+antiproliferation+activity+of+a+series+of+%CE%B1-heterocyclic-N4-substituted+thiosemicarbazones+and+their+Cu%28II%29+complexes&doi=10.1021%2Fjm101532u"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit42R"><div class="casContent"><span class="casTitleNuber">42</span><div class="casTitle"><span class="NLM_cas:atitle">Role of metalation in the topoisomerase IIα inhibition and antiproliferation activity of a series of α-heterocyclic-N4-substituted thiosemicarbazones and their Cu(II) complexes</span></div><div class="casAuthors">Zeglis, Brian M.; Divilov, Vadim; Lewis, Jason S.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">2391-2398</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The topoisomerase-IIα inhibition and antiproliferative activity of α-heterocyclic thiosemicarbazones and their corresponding copper(II) complexes have been investigated.  The CuII(thiosemicarbazonato)Cl complexes were shown to catalytically inhibit topoisomerase-IIα at concns. (0.3-7.2 μM) over an order of magnitude lower than their corresponding thiosemicarbazone ligands alone.  The copper complexes were also shown to inhibit the proliferation of breast cancer cells expressing high levels of topoisomerase-IIα (SK-BR-3) at lower concns. than cells expressing lower levels of the enzyme (MCF-7).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo59ej6iFerf7Vg90H21EOLACvtfcHk0ljVIatJnLqRMA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXivFygsLk%253D&md5=9f6215d0b0fbfd470b24d777122658db</span></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1021%2Fjm101532u&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm101532u%26sid%3Dliteratum%253Aachs%26aulast%3DZeglis%26aufirst%3DB.%2BM.%26aulast%3DDivilov%26aufirst%3DV.%26aulast%3DLewis%26aufirst%3DJ.%2BS.%26atitle%3DRole%2520of%2520metalation%2520in%2520the%2520topoisomerase%2520II%25CE%25B1%2520inhibition%2520and%2520antiproliferation%2520activity%2520of%2520a%2520series%2520of%2520%25CE%25B1-heterocyclic-N4-substituted%2520thiosemicarbazones%2520and%2520their%2520Cu%2528II%2529%2520complexes%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2011%26volume%3D54%26spage%3D2391%26epage%3D2398%26doi%3D10.1021%2Fjm101532u" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref43"><div class="reference"><strong class="refLabel"><a href="#ref43" class="rightTabRefNumLink">43</a></strong><div class="NLM_citation" id="rightTab-cit43"><span><span class="NLM_contrib-group">Miller, M. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bastow, K. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stineman, C. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vance, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Song, S. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">West, D. X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hall, I. H.</span><span> </span><span class="NLM_article-title">The cytotoxicity of 2-formyl and 2-acetyl-(6-picolyl)-4N-substituted thiosemicarbazones and their copper(II) complexes</span> <span class="citation_source-journal">Arch. Pharm.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1998</span><span class="NLM_x">, </span> <span class="NLM_volume">331</span><span class="NLM_x">, </span> <span class="NLM_fpage">121</span><span class="NLM_x">–</span> <span class="NLM_lpage">127</span><span class="refDoi"> DOI: 10.1002/(SICI)1521-4184(199804)331:4<121::AID-ARDP121>3.3.CO;2-K</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00509&amp;key=10.1002%2F%28SICI%291521-4184%28199804%29331%3A4%3C121%3A%3AAID-ARDP121%3E3.3.CO%3B2-K" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00509&amp;key=9648520" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00509&amp;key=1%3ACAS%3A528%3ADyaK1cXjs1Ghtr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=331&publication_year=1998&pages=121-127&author=M.+C.+Millerauthor=K.+F.+Bastowauthor=C.+N.+Stinemanauthor=J.+R.+Vanceauthor=S.+C.+Songauthor=D.+X.+Westauthor=I.+H.+Hall&title=The+cytotoxicity+of+2-formyl+and+2-acetyl-%286-picolyl%29-4N-substituted+thiosemicarbazones+and+their+copper%28II%29+complexes&doi=10.1002%2F%28SICI%291521-4184%28199804%29331%3A4%3C121%3A%3AAID-ARDP121%3E3.3.CO%3B2-K"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit43R"><div class="casContent"><span class="casTitleNuber">43</span><div class="casTitle"><span class="NLM_cas:atitle">The cytotoxicity of 2-formyl and 2-acetyl-(6-picolyl)-4N-substituted thiosemicarbazones and their copper(II) complexes</span></div><div class="casAuthors">Miller, Merrill C.; Bastow, Kenneth F., III; Stineman, Christa N.; Vance, John R.; Song, Sun C.; West, Douglas X.; Hall, Iris H.</div><div class="citationInfo"><span class="NLM_cas:title">Archiv der Pharmazie (Weinheim, Germany)</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">331</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">121-127</span>CODEN:
                <span class="NLM_cas:coden">ARPMAS</span>;
        ISSN:<span class="NLM_cas:issn">0365-6233</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH</span>)
        </div><div class="casAbstract">2-Acetyl-(6-picolyl)-4N-substituted thiosemicarbazones and their Cu(II) complexes were shown to be potent antineoplastic and cytotoxic agents against murine and human cultured cells.  Numerous derivs. were as active against solid tumor growth as clin. useful agents.  The agents inhibited L1210 DNA and RNA syntheses with inhibition of key regulatory enzyme activities of the purine pathway as well as nucleoside kinase activities.  D[NTP] pools were reduced and DNA strand scission occurred.  These agents were DNA topoisomerase II inhibitors with lower IC50 values than that of VP-16.  However, they did not cause L1210 DNA protein linked breaks and actually protected against those breaks afforded by VP-16.  The agents were not synergistic with VP-16 in reducing cell growth or DNA synthesis although they did reduce growth of L1210 cells in agar suspended media.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqnDY-qmYHwS7Vg90H21EOLACvtfcHk0ljVIatJnLqRMA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXjs1Ghtr0%253D&md5=bbe6bb5147cf27395e83f1d3a8cee20b</span></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.1002%2F%28SICI%291521-4184%28199804%29331%3A4%3C121%3A%3AAID-ARDP121%3E3.3.CO%3B2-K&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252F%2528SICI%25291521-4184%2528199804%2529331%253A4%253C121%253A%253AAID-ARDP121%253E3.3.CO%253B2-K%26sid%3Dliteratum%253Aachs%26aulast%3DMiller%26aufirst%3DM.%2BC.%26aulast%3DBastow%26aufirst%3DK.%2BF.%26aulast%3DStineman%26aufirst%3DC.%2BN.%26aulast%3DVance%26aufirst%3DJ.%2BR.%26aulast%3DSong%26aufirst%3DS.%2BC.%26aulast%3DWest%26aufirst%3DD.%2BX.%26aulast%3DHall%26aufirst%3DI.%2BH.%26atitle%3DThe%2520cytotoxicity%2520of%25202-formyl%2520and%25202-acetyl-%25286-picolyl%2529-4N-substituted%2520thiosemicarbazones%2520and%2520their%2520copper%2528II%2529%2520complexes%26jtitle%3DArch.%2520Pharm.%26date%3D1998%26volume%3D331%26spage%3D121%26epage%3D127%26doi%3D10.1002%2F%28SICI%291521-4184%28199804%29331%3A4%3C121%3A%3AAID-ARDP121%3E3.3.CO%3B2-K" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref44"><div class="reference"><strong class="refLabel"><a href="#ref44" class="rightTabRefNumLink">44</a></strong><div class="NLM_citation" id="rightTab-cit44"><span><span class="NLM_contrib-group">Huang, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ku, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meng, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhu, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jiang, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ding, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, H.</span><span> </span><span class="NLM_article-title">A series of alpha-heterocyclic carboxaldehyde thiosemicarbazones inhibit topoisomerase-II catalytic activity</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">53</span><span class="NLM_x">, </span> <span class="NLM_fpage">3048</span><span class="NLM_x">–</span> <span class="NLM_lpage">3064</span><span class="refDoi"> DOI: 10.1021/jm9014394</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm9014394" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2010&pages=3048-3064&author=H.+Huangauthor=W.+Chenauthor=X.+Kuauthor=L.+Mengauthor=L.+Linauthor=X.+Wangauthor=C.+Zhuauthor=Y.+Wangauthor=Z.+Chenauthor=M.+Liauthor=H.+Jiangauthor=K.+Chenauthor=J.+Dingauthor=H.+Liu&title=A+series+of+alpha-heterocyclic+carboxaldehyde+thiosemicarbazones+inhibit+topoisomerase-II+catalytic+activity&doi=10.1021%2Fjm9014394"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.1021%2Fjm9014394&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm9014394%26sid%3Dliteratum%253Aachs%26aulast%3DHuang%26aufirst%3DH.%26aulast%3DChen%26aufirst%3DW.%26aulast%3DKu%26aufirst%3DX.%26aulast%3DMeng%26aufirst%3DL.%26aulast%3DLin%26aufirst%3DL.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DZhu%26aufirst%3DC.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DChen%26aufirst%3DZ.%26aulast%3DLi%26aufirst%3DM.%26aulast%3DJiang%26aufirst%3DH.%26aulast%3DChen%26aufirst%3DK.%26aulast%3DDing%26aufirst%3DJ.%26aulast%3DLiu%26aufirst%3DH.%26atitle%3DA%2520series%2520of%2520alpha-heterocyclic%2520carboxaldehyde%2520thiosemicarbazones%2520inhibit%2520topoisomerase-II%2520catalytic%2520activity%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2010%26volume%3D53%26spage%3D3048%26epage%3D3064%26doi%3D10.1021%2Fjm9014394" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref45"><div class="reference"><strong class="refLabel"><a href="#ref45" class="rightTabRefNumLink">45</a></strong><div class="NLM_citation" id="rightTab-cit45"><span><span class="NLM_contrib-group">Rao, V. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Klein, S. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Agama, K. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Toyoda, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Adachi, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pommier, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shacter, E. B.</span><span> </span><span class="NLM_article-title">The iron chelator Dp44mT causes DNA damage and selective inhibition of topoisomerase-II in breast cancer cells</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">69</span><span class="NLM_x">, </span> <span class="NLM_fpage">948</span><span class="NLM_x">–</span> <span class="NLM_lpage">957</span><span class="refDoi"> DOI: 10.1158/0008-5472.CAN-08-1437</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00509&amp;key=10.1158%2F0008-5472.CAN-08-1437" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=69&publication_year=2009&pages=948-957&author=V.+A.+Raoauthor=S.+R.+Kleinauthor=K.+K.+Agamaauthor=E.+Toyodaauthor=N.+Adachiauthor=Y.+Pommierauthor=E.+B.+Shacter&title=The+iron+chelator+Dp44mT+causes+DNA+damage+and+selective+inhibition+of+topoisomerase-II+in+breast+cancer+cells&doi=10.1158%2F0008-5472.CAN-08-1437"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-08-1437&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-08-1437%26sid%3Dliteratum%253Aachs%26aulast%3DRao%26aufirst%3DV.%2BA.%26aulast%3DKlein%26aufirst%3DS.%2BR.%26aulast%3DAgama%26aufirst%3DK.%2BK.%26aulast%3DToyoda%26aufirst%3DE.%26aulast%3DAdachi%26aufirst%3DN.%26aulast%3DPommier%26aufirst%3DY.%26aulast%3DShacter%26aufirst%3DE.%2BB.%26atitle%3DThe%2520iron%2520chelator%2520Dp44mT%2520causes%2520DNA%2520damage%2520and%2520selective%2520inhibition%2520of%2520topoisomerase-II%2520in%2520breast%2520cancer%2520cells%26jtitle%3DCancer%2520Res.%26date%3D2009%26volume%3D69%26spage%3D948%26epage%3D957%26doi%3D10.1158%2F0008-5472.CAN-08-1437" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref46"><div class="reference"><strong class="refLabel"><a href="#ref46" class="rightTabRefNumLink">46</a></strong><div class="NLM_citation" id="rightTab-cit46"><span><span class="NLM_contrib-group">Eastman, A.</span><span> </span><span class="NLM_article-title">Cell cycle checkpoints and their impact on anticancer therapeutic strategies</span> <span class="citation_source-journal">J. Cell. Biochem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">91</span><span class="NLM_x">, </span> <span class="NLM_fpage">223</span><span class="NLM_x">–</span> <span class="NLM_lpage">231</span><span class="refDoi"> DOI: 10.1002/jcb.10699</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00509&amp;key=10.1002%2Fjcb.10699" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=91&publication_year=2004&pages=223-231&author=A.+Eastman&title=Cell+cycle+checkpoints+and+their+impact+on+anticancer+therapeutic+strategies&doi=10.1002%2Fjcb.10699"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.1002%2Fjcb.10699&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fjcb.10699%26sid%3Dliteratum%253Aachs%26aulast%3DEastman%26aufirst%3DA.%26atitle%3DCell%2520cycle%2520checkpoints%2520and%2520their%2520impact%2520on%2520anticancer%2520therapeutic%2520strategies%26jtitle%3DJ.%2520Cell.%2520Biochem.%26date%3D2004%26volume%3D91%26spage%3D223%26epage%3D231%26doi%3D10.1002%2Fjcb.10699" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref47"><div class="reference"><strong class="refLabel"><a href="#ref47" class="rightTabRefNumLink">47</a></strong><div class="NLM_citation" id="rightTab-cit47"><span><span class="NLM_contrib-group">Masai, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Matsumoto, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">You, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yoshizawa-Sugata, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oda, M.</span><span> </span><span class="NLM_article-title">Eukaryotic chromosome DNA replication: where, when, and how?</span> <span class="citation_source-journal">Annu. Rev. Biochem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">79</span><span class="NLM_x">, </span> <span class="NLM_fpage">89</span><span class="NLM_x">–</span> <span class="NLM_lpage">130</span><span class="refDoi"> DOI: 10.1146/annurev.biochem.052308.103205</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00509&amp;key=10.1146%2Fannurev.biochem.052308.103205" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00509&amp;key=20373915" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00509&amp;key=1%3ACAS%3A528%3ADC%252BC3cXpslShsbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=79&publication_year=2010&pages=89-130&author=H.+Masaiauthor=S.+Matsumotoauthor=Z.+Youauthor=N.+Yoshizawa-Sugataauthor=M.+Oda&title=Eukaryotic+chromosome+DNA+replication%3A+where%2C+when%2C+and+how%3F&doi=10.1146%2Fannurev.biochem.052308.103205"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit47R"><div class="casContent"><span class="casTitleNuber">47</span><div class="casTitle"><span class="NLM_cas:atitle">Eukaryotic chromosome DNA replication: where, when, and how?</span></div><div class="casAuthors">Masai, Hisao; Matsumoto, Seiji; You, Zhiying; Yoshizawa-Sugata, Naoko; Oda, Masako</div><div class="citationInfo"><span class="NLM_cas:title">Annual Review of Biochemistry</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">79</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">89-130</span>CODEN:
                <span class="NLM_cas:coden">ARBOAW</span>;
        ISSN:<span class="NLM_cas:issn">0066-4154</span>.
    
            (<span class="NLM_cas:orgname">Annual Reviews Inc.</span>)
        </div><div class="casAbstract">A review.  DNA replication is central to cell proliferation.  Studies in the past six decades since the proposal of a semiconservative mode of DNA replication have confirmed the high degree of conservation of the basic machinery of DNA replication from prokaryotes to eukaryotes.  However, the need for replication of a substantially longer segment of DNA in coordination with various internal and external signals in eukaryotic cells has led to more complex and versatile regulatory strategies.  The replication program in higher eukaryotes is under a dynamic and plastic regulation within a single cell, or within the cell population, or during development.  We review here various regulatory mechanisms that control the replication program in eukaryotes and discuss future directions in this dynamic field.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoSQqhVEPZuJLVg90H21EOLACvtfcHk0li4A_VLm4SjKg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXpslShsbs%253D&md5=c8a0dfe38359a7eb2fe724d0693116b2</span></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=10.1146%2Fannurev.biochem.052308.103205&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1146%252Fannurev.biochem.052308.103205%26sid%3Dliteratum%253Aachs%26aulast%3DMasai%26aufirst%3DH.%26aulast%3DMatsumoto%26aufirst%3DS.%26aulast%3DYou%26aufirst%3DZ.%26aulast%3DYoshizawa-Sugata%26aufirst%3DN.%26aulast%3DOda%26aufirst%3DM.%26atitle%3DEukaryotic%2520chromosome%2520DNA%2520replication%253A%2520where%252C%2520when%252C%2520and%2520how%253F%26jtitle%3DAnnu.%2520Rev.%2520Biochem.%26date%3D2010%26volume%3D79%26spage%3D89%26epage%3D130%26doi%3D10.1146%2Fannurev.biochem.052308.103205" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref48"><div class="reference"><strong class="refLabel"><a href="#ref48" class="rightTabRefNumLink">48</a></strong><div class="NLM_citation" id="rightTab-cit48"><span><span class="NLM_contrib-group">Kang, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nho, C. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, N. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Song, D. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Park, Y. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pan, C. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shin, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oh, S. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oh, H. S.</span><span> </span><span class="NLM_article-title">Daurinol, a catalytic inhibitor of topoisomerase IIα, suppresses SNU-840 ovarian cancer cell proliferation through cell cycle arrest in S phase</span> <span class="citation_source-journal">Int. J. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">45</span><span class="NLM_x">, </span> <span class="NLM_fpage">558</span><span class="NLM_x">–</span> <span class="NLM_lpage">566</span><span class="refDoi"> DOI: 10.3892/ijo.2014.2442</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00509&amp;key=10.3892%2Fijo.2014.2442" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00509&amp;key=24841075" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00509&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhsVShsb7J" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=45&publication_year=2014&pages=558-566&author=K.+Kangauthor=C.+W.+Nhoauthor=N.+D.+Kimauthor=D.+G.+Songauthor=Y.+G.+Parkauthor=M.+Kimauthor=C.+H.+Panauthor=D.+Shinauthor=S.+H.+Ohauthor=H.+S.+Oh&title=Daurinol%2C+a+catalytic+inhibitor+of+topoisomerase+II%CE%B1%2C+suppresses+SNU-840+ovarian+cancer+cell+proliferation+through+cell+cycle+arrest+in+S+phase&doi=10.3892%2Fijo.2014.2442"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit48R"><div class="casContent"><span class="casTitleNuber">48</span><div class="casTitle"><span class="NLM_cas:atitle">Daurinol, a catalytic inhibitor of topoisomerase IIα, suppresses SNU-840 ovarian cancer cell proliferation through cell cycle arrest in S phase</span></div><div class="casAuthors">Kang, Kyungsu; Nho, Chu Won; Kim, Nam Doo; Song, Dae-Geun; Park, Young Gyun; Kim, Minkyun; Pan, Cheol-Ho; Shin, Dongyun; Oh, Seung Hyun; Oh, Ho-Suk</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Oncology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">45</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">558-566</span>CODEN:
                <span class="NLM_cas:coden">IJONES</span>;
        ISSN:<span class="NLM_cas:issn">1019-6439</span>.
    
            (<span class="NLM_cas:orgname">Spandidos Publications Ltd.</span>)
        </div><div class="casAbstract">Daurinol, a lignan from the ethnopharmacol. plant Haplophyllum dauricum, was recently reported to be a novel topoisomerase II inhibitor and an alternative to the clin. anticancer agent etoposide based on a colorectal cancer model.  In the present study, we elucidated the detailed biochem. mechanism underlying the inhibition of human topoisomerase IIα by daurinol based on a mol. docking study and in vitro biochem. expts.  The computational simulation predicted that daurinol binds to the ATP-binding pocket of topoisomerase IIα.  In a biochem. assay, daurinol (10-100 μM) inhibited the catalytic activity of topoisomerase IIα in an ATP concn.-dependent manner and suppressed the ATP hydrolysis activity of the enzyme.  However, daurinol did not inhibit topoisomerase I activity, most likely because topoisomerase I does not contain an ATP-binding domain.  We also evaluated the anti-proliferative activity of daurinol in ovarian, small cell lung and testicular cancer cells, common target cancers treated with etoposide.  Daurinol potently inhibited SNU-840 human ovarian cancer cell proliferation through cell cycle arrest in S phase, while etoposide induced G2/M phase arrest.  Daurinol induced the increased expression of cyclin E, cyclin A and E2F-1, which are important proteins regulating S phase initiation and progression.  Daurinol did not induce abnormal cell and nuclear enlargement in SNU-840 cells, in contrast to etoposide.  Based on these data, we suggest that daurinol is a potential anticancer drug candidate for the treatment of human ovarian cancer with few side effects.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpUi5IaNQeJ3rVg90H21EOLACvtfcHk0li4A_VLm4SjKg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhsVShsb7J&md5=553c732910df583645be9a6791ee0244</span></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=10.3892%2Fijo.2014.2442&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3892%252Fijo.2014.2442%26sid%3Dliteratum%253Aachs%26aulast%3DKang%26aufirst%3DK.%26aulast%3DNho%26aufirst%3DC.%2BW.%26aulast%3DKim%26aufirst%3DN.%2BD.%26aulast%3DSong%26aufirst%3DD.%2BG.%26aulast%3DPark%26aufirst%3DY.%2BG.%26aulast%3DKim%26aufirst%3DM.%26aulast%3DPan%26aufirst%3DC.%2BH.%26aulast%3DShin%26aufirst%3DD.%26aulast%3DOh%26aufirst%3DS.%2BH.%26aulast%3DOh%26aufirst%3DH.%2BS.%26atitle%3DDaurinol%252C%2520a%2520catalytic%2520inhibitor%2520of%2520topoisomerase%2520II%25CE%25B1%252C%2520suppresses%2520SNU-840%2520ovarian%2520cancer%2520cell%2520proliferation%2520through%2520cell%2520cycle%2520arrest%2520in%2520S%2520phase%26jtitle%3DInt.%2520J.%2520Oncol.%26date%3D2014%26volume%3D45%26spage%3D558%26epage%3D566%26doi%3D10.3892%2Fijo.2014.2442" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref49"><div class="reference"><strong class="refLabel"><a href="#ref49" class="rightTabRefNumLink">49</a></strong><div class="NLM_citation" id="rightTab-cit49"><span><span class="NLM_contrib-group">Stefani, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jansson, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gutierrez, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bernhardt, P. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Richardson, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kalinowski, D. S.</span><span> </span><span class="NLM_article-title">Alkyl substituted 2′-benzoylpyridine thiosemicarbazone chelators with potent and selective anti-neoplastic activity: novel ligands that limit methemoglobin formation</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">56</span><span class="NLM_x">, </span> <span class="NLM_fpage">357</span><span class="NLM_x">–</span> <span class="NLM_lpage">370</span><span class="refDoi"> DOI: 10.1021/jm301691s</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm301691s" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2013&pages=357-370&author=C.+Stefaniauthor=P.+J.+Janssonauthor=E.+Gutierrezauthor=P.+V.+Bernhardtauthor=D.+R.+Richardsonauthor=D.+S.+Kalinowski&title=Alkyl+substituted+2%E2%80%B2-benzoylpyridine+thiosemicarbazone+chelators+with+potent+and+selective+anti-neoplastic+activity%3A+novel+ligands+that+limit+methemoglobin+formation&doi=10.1021%2Fjm301691s"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=10.1021%2Fjm301691s&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm301691s%26sid%3Dliteratum%253Aachs%26aulast%3DStefani%26aufirst%3DC.%26aulast%3DJansson%26aufirst%3DP.%2BJ.%26aulast%3DGutierrez%26aufirst%3DE.%26aulast%3DBernhardt%26aufirst%3DP.%2BV.%26aulast%3DRichardson%26aufirst%3DD.%2BR.%26aulast%3DKalinowski%26aufirst%3DD.%2BS.%26atitle%3DAlkyl%2520substituted%25202%25E2%2580%25B2-benzoylpyridine%2520thiosemicarbazone%2520chelators%2520with%2520potent%2520and%2520selective%2520anti-neoplastic%2520activity%253A%2520novel%2520ligands%2520that%2520limit%2520methemoglobin%2520formation%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2013%26volume%3D56%26spage%3D357%26epage%3D370%26doi%3D10.1021%2Fjm301691s" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref50"><div class="reference"><strong class="refLabel"><a href="#ref50" class="rightTabRefNumLink">50</a></strong><div class="NLM_citation" id="rightTab-cit50"><span><span class="NLM_contrib-group">Jiang, G. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zheng, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yao, J. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Han, B. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huang, H. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, Y. J.</span><span> </span><span class="NLM_article-title">Ruthenium(II) polypyridyl complexes induce BEL-7402 cell apoptosis by ROS-mediated mitochondrial pathway</span> <span class="citation_source-journal">J. Inorg. Biochem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">141</span><span class="NLM_x">, </span> <span class="NLM_fpage">170</span><span class="NLM_x">–</span> <span class="NLM_lpage">179</span><span class="refDoi"> DOI: 10.1016/j.jinorgbio.2014.09.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00509&amp;key=10.1016%2Fj.jinorgbio.2014.09.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00509&amp;key=25268891" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00509&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhsFOqsL3N" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=141&publication_year=2014&pages=170-179&author=G.+B.+Jiangauthor=X.+Zhengauthor=J.+H.+Yaoauthor=B.+J.+Hanauthor=W.+Liauthor=J.+Wangauthor=H.+L.+Huangauthor=Y.+J.+Liu&title=Ruthenium%28II%29+polypyridyl+complexes+induce+BEL-7402+cell+apoptosis+by+ROS-mediated+mitochondrial+pathway&doi=10.1016%2Fj.jinorgbio.2014.09.001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit50R"><div class="casContent"><span class="casTitleNuber">50</span><div class="casTitle"><span class="NLM_cas:atitle">Ruthenium(II) polypyridyl complexes induce BEL-7402 cell apoptosis by ROS-mediated mitochondrial pathway</span></div><div class="casAuthors">Jiang, Guang-Bin; Zheng, Xiang; Yao, Jun-Hua; Han, Bing-Jie; Li, Wei; Wang, Ji; Huang, Hong-Liang; Liu, Yun-Jun</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Inorganic Biochemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">141</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">170-179</span>CODEN:
                <span class="NLM_cas:coden">JIBIDJ</span>;
        ISSN:<span class="NLM_cas:issn">0162-0134</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">A new ligand dmdppz and its four ruthenium(II) polypyridyl complexes [Ru(dmb)2(dmdppz)](ClO4)2 (1), [Ru(bpy)2(dmdppz)](ClO4)2 (2), [Ru(phen)2(dmdppz)](ClO4)2 (3) and [Ru(dmp)2(dmdppz)](ClO4)2 (4) (where dmb, bpy, phen, dmp and dmdppz stand for 4,4'-dimethyl-2,2'-bipyridine, 2,2'-bipyridine, 1,10-phenanthroline, 2,9-dimethyl-1,10-phenanthroline and 5,8-dimethoxylpyrido[3,2-a:2',3'-c]phenazine, resp.) have been synthesized and characterized.  Their DNA binding behaviors show that the complexes bind to calf thymus DNA by intercalation.  The complexes exhibit efficient photocleavage of pBR322 DNA on irradn.  The cytotoxicity of the ligand and the complexes toward HepG-2, HeLa, MG-63, A549 and BEL-7402 were assayed by MTT ((3-(4,5-dimethylthiazo-2-yl)-2,5-diphenyltetrazolium bromide)) method.  The IC50 values of the complexes 1, 2, 3 and 4 toward BEL-7402 cells are 14.6, 16.8, 18.0 and 16.7 μM, resp.  Dmdppz shows no cytotoxic activity against selected cell lines.  The cellular uptake, apoptosis, comet assay, reactive oxygen species (ROS), mitochondrial membrane potential and western blot anal. were investigated.  These results indicate that complexes 1-4 exert their toxicity through the intrinsic ROS-mediated mitochondrial pathway, which is accompanied by the regulation of Bcl-2 family proteins.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrOidPqyTc7eLVg90H21EOLACvtfcHk0ljiL5FT3MXA1w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhsFOqsL3N&md5=cf025ba89250d70c28809f92dd04d0c3</span></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=10.1016%2Fj.jinorgbio.2014.09.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jinorgbio.2014.09.001%26sid%3Dliteratum%253Aachs%26aulast%3DJiang%26aufirst%3DG.%2BB.%26aulast%3DZheng%26aufirst%3DX.%26aulast%3DYao%26aufirst%3DJ.%2BH.%26aulast%3DHan%26aufirst%3DB.%2BJ.%26aulast%3DLi%26aufirst%3DW.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DHuang%26aufirst%3DH.%2BL.%26aulast%3DLiu%26aufirst%3DY.%2BJ.%26atitle%3DRuthenium%2528II%2529%2520polypyridyl%2520complexes%2520induce%2520BEL-7402%2520cell%2520apoptosis%2520by%2520ROS-mediated%2520mitochondrial%2520pathway%26jtitle%3DJ.%2520Inorg.%2520Biochem.%26date%3D2014%26volume%3D141%26spage%3D170%26epage%3D179%26doi%3D10.1016%2Fj.jinorgbio.2014.09.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref51"><div class="reference"><strong class="refLabel"><a href="#ref51" class="rightTabRefNumLink">51</a></strong><div class="NLM_citation" id="rightTab-cit51"><span><span class="NLM_contrib-group">Trachootham, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alexandre, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huang, P.</span><span> </span><span class="NLM_article-title">Targeting cancer cells by ROS-mediated mechanisms: a radical therapeutic approach?</span> <span class="citation_source-journal">Nat. Rev. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">8</span><span class="NLM_x">, </span> <span class="NLM_fpage">579</span><span class="NLM_x">–</span> <span class="NLM_lpage">591</span><span class="refDoi"> DOI: 10.1038/nrd2803</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00509&amp;key=10.1038%2Fnrd2803" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00509&amp;key=19478820" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00509&amp;key=1%3ACAS%3A528%3ADC%252BD1MXmsFWqsLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2009&pages=579-591&author=D.+Trachoothamauthor=J.+Alexandreauthor=P.+Huang&title=Targeting+cancer+cells+by+ROS-mediated+mechanisms%3A+a+radical+therapeutic+approach%3F&doi=10.1038%2Fnrd2803"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit51R"><div class="casContent"><span class="casTitleNuber">51</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting cancer cells by ROS-mediated mechanisms: a radical therapeutic approach?</span></div><div class="casAuthors">Trachootham, Dunyaporn; Alexandre, Jerome; Huang, Peng</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">579-591</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Increased generation of reactive oxygen species (ROS) and an altered redox status have long been obsd. in cancer cells, and recent studies suggest that this biochem. property of cancer cells can be exploited for therapeutic benefits.  Cancer cells in advanced stage tumors frequently exhibit multiple genetic alterations and high oxidative stress, suggesting that it might be possible to preferentially eliminate these cells by pharmacol. ROS insults.  However, the upregulation of antioxidant capacity in adaptation to intrinsic oxidative stress in cancer cells can confer drug resistance.  Abrogation of such drug-resistant mechanisms by redox modulation could have significant therapeutic implications.  We argue that modulating the unique redox regulatory mechanisms of cancer cells might be an effective strategy to eliminate these cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGobgIa2fgBPBrVg90H21EOLACvtfcHk0ljiL5FT3MXA1w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXmsFWqsLk%253D&md5=d50931b8de8bcab62d376becc768a71c</span></div><a href="/servlet/linkout?suffix=cit51&amp;dbid=16384&amp;doi=10.1038%2Fnrd2803&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd2803%26sid%3Dliteratum%253Aachs%26aulast%3DTrachootham%26aufirst%3DD.%26aulast%3DAlexandre%26aufirst%3DJ.%26aulast%3DHuang%26aufirst%3DP.%26atitle%3DTargeting%2520cancer%2520cells%2520by%2520ROS-mediated%2520mechanisms%253A%2520a%2520radical%2520therapeutic%2520approach%253F%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2009%26volume%3D8%26spage%3D579%26epage%3D591%26doi%3D10.1038%2Fnrd2803" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref52"><div class="reference"><strong class="refLabel"><a href="#ref52" class="rightTabRefNumLink">52</a></strong><div class="NLM_citation" id="rightTab-cit52"><span><span class="NLM_contrib-group">Han, C. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jun do, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, Y. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, J. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, Y. H.</span><span> </span><span class="NLM_article-title">Prometaphase arrest-dependent phosphorylation of Bcl-2 family proteins and activation of mitochondrial apoptotic pathway are associated with 17α-estradiol-induced apoptosis in human Jurkat T cells</span> <span class="citation_source-journal">Biochim. Biophys. Acta, Mol. Cell Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">1833</span><span class="NLM_x">, </span> <span class="NLM_fpage">2220</span><span class="NLM_x">–</span> <span class="NLM_lpage">2232</span><span class="refDoi"> DOI: 10.1016/j.bbamcr.2013.05.016</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00509&amp;key=10.1016%2Fj.bbamcr.2013.05.016" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00509&amp;key=23707954" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00509&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtFSlsL7N" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1833&publication_year=2013&pages=2220-2232&author=C.+R.+Hanauthor=Y.+Jun+doauthor=Y.+H.+Kimauthor=J.+Y.+Leeauthor=Y.+H.+Kim&title=Prometaphase+arrest-dependent+phosphorylation+of+Bcl-2+family+proteins+and+activation+of+mitochondrial+apoptotic+pathway+are+associated+with+17%CE%B1-estradiol-induced+apoptosis+in+human+Jurkat+T+cells&doi=10.1016%2Fj.bbamcr.2013.05.016"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit52R"><div class="casContent"><span class="casTitleNuber">52</span><div class="casTitle"><span class="NLM_cas:atitle">Prometaphase arrest-dependent phosphorylation of Bcl-2 family proteins and activation of mitochondrial apoptotic pathway are associated with 17α-estradiol-induced apoptosis in human Jurkat T cells</span></div><div class="casAuthors">Han, Cho Rong; Jun, Do Youn; Kim, Yoon Hee; Lee, Ji Young; Kim, Young Ho</div><div class="citationInfo"><span class="NLM_cas:title">Biochimica et Biophysica Acta, Molecular Cell Research</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">1833</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">2220-2232</span>CODEN:
                <span class="NLM_cas:coden">BBAMCO</span>;
        ISSN:<span class="NLM_cas:issn">0167-4889</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">In Jurkat T cell clone (JT/Neo), G2/M arrest, apoptotic sub-G1 peak, mitochondrial membrane potential (Δψm) loss, and TUNEL-pos. DNA fragmentation were induced following exposure to 17α-estradiol (17α-E2), whereas none of these events (except for G2/M arrest) were induced in Jurkat cells overexpressing Bcl-2 (JT/Bcl-2).  Under these conditions, phosphorylation at Thr161 and dephosphorylation at Tyr15 of Cdk1, upregulation of cyclin B1 level, histone H1 phosphorylation, Cdc25C phosphorylation at , Bcl-2 phosphorylation at Thr-56 and Ser-70, Mcl-1 phosphorylation, and Bim phosphorylation were detected in the presence of Bcl-2 overexpression.  However, the 17α-E2-induced upregulation of Bak levels, activation of Bak, activation of caspase-3, and PARP degrdn. were abrogated by Bcl-2 overexpression.  In the presence of the G1/S blocking agent hydroxyurea, 17α-E2 failed to induce G2/M arrest and all apoptotic events including Cdk1 activation and phosphorylation of Bcl-2, Mcl-1 and Bim.  The 17α-E2-induced phosphorylation of Bcl-2 family proteins and mitochondrial apoptotic events were suppressed by a Cdk1 inhibitor but not by aurora A and aurora B kinase inhibitors.  Immunofluorescence microscopic anal. showed that an aberrant bipolar microtubule array, incomplete chromosome congression at the metaphase plate, and prometaphase arrest, which was reversible, were the underlying factors for 17α-E2-induced mitotic arrest.  The in vitro microtubule polymn. assay showed that 17α-E2 could directly inhibit microtubule formation.  These results show that the apoptogenic activity of 17α-E2 was due to the impaired mitotic spindle assembly causing prometaphase arrest and prolonged Cdk1 activation, the phosphorylation of Bcl-2, Mcl-1 and Bim, and the activation of Bak and mitochondria-dependent caspase cascade.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoP8jSwpLEnErVg90H21EOLACvtfcHk0lhMB2SHULM0sQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtFSlsL7N&md5=5ea80b538dd35c2fa324ecf26a7e3973</span></div><a href="/servlet/linkout?suffix=cit52&amp;dbid=16384&amp;doi=10.1016%2Fj.bbamcr.2013.05.016&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bbamcr.2013.05.016%26sid%3Dliteratum%253Aachs%26aulast%3DHan%26aufirst%3DC.%2BR.%26aulast%3DJun%2Bdo%26aufirst%3DY.%26aulast%3DKim%26aufirst%3DY.%2BH.%26aulast%3DLee%26aufirst%3DJ.%2BY.%26aulast%3DKim%26aufirst%3DY.%2BH.%26atitle%3DPrometaphase%2520arrest-dependent%2520phosphorylation%2520of%2520Bcl-2%2520family%2520proteins%2520and%2520activation%2520of%2520mitochondrial%2520apoptotic%2520pathway%2520are%2520associated%2520with%252017%25CE%25B1-estradiol-induced%2520apoptosis%2520in%2520human%2520Jurkat%2520T%2520cells%26jtitle%3DBiochim.%2520Biophys.%2520Acta%252C%2520Mol.%2520Cell%2520Res.%26date%3D2013%26volume%3D1833%26spage%3D2220%26epage%3D2232%26doi%3D10.1016%2Fj.bbamcr.2013.05.016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref53"><div class="reference"><strong class="refLabel"><a href="#ref53" class="rightTabRefNumLink">53</a></strong><div class="NLM_citation" id="rightTab-cit53"><span><span class="NLM_contrib-group">He, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liao, S. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tan, C. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ye, R. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, Y. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhao, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ji, L. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mao, Z. W.</span><span> </span><span class="NLM_article-title">Ruthenium-Arene-β-Carboline complexes as potent inhibitors of cyclin-dependent kinase 1: synthesis, characterization and anticancer mechanism studies</span> <span class="citation_source-journal">Chem. - Eur. J.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">19</span><span class="NLM_x">, </span> <span class="NLM_fpage">12152</span><span class="NLM_x">–</span> <span class="NLM_lpage">12160</span><span class="refDoi"> DOI: 10.1002/chem.201301389</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00509&amp;key=10.1002%2Fchem.201301389" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00509&amp;key=23878093" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00509&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtFCjtbnK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2013&pages=12152-12160&author=L.+Heauthor=S.+Y.+Liaoauthor=C.+P.+Tanauthor=R.+R.+Yeauthor=Y.+W.+Xuauthor=M.+Zhaoauthor=L.+N.+Jiauthor=Z.+W.+Mao&title=Ruthenium-Arene-%CE%B2-Carboline+complexes+as+potent+inhibitors+of+cyclin-dependent+kinase+1%3A+synthesis%2C+characterization+and+anticancer+mechanism+studies&doi=10.1002%2Fchem.201301389"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit53R"><div class="casContent"><span class="casTitleNuber">53</span><div class="casTitle"><span class="NLM_cas:atitle">Ruthenium-Arene-β-Carboline Complexes as Potent Inhibitors of Cyclin-Dependent Kinase 1: Synthesis, Characterization and Anticancer Mechanism Studies</span></div><div class="casAuthors">He, Liang; Liao, Si-Yan; Tan, Cai-Ping; Ye, Rui-Rong; Xu, Yu-Wen; Zhao, Meng; Ji, Liang-Nian; Mao, Zong-Wan</div><div class="citationInfo"><span class="NLM_cas:title">Chemistry - A European Journal</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">36</span>),
    <span class="NLM_cas:pages">12152-12160</span>CODEN:
                <span class="NLM_cas:coden">CEUJED</span>;
        ISSN:<span class="NLM_cas:issn">0947-6539</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">Ru(II)-arene complexes, [(η6-arene)Ru(L)Cl]PF6 (1-6, arene = benzene or p-cymene; L = bidentate β-carboline deriv., an indole alkaloid with potential cyclin-dependent kinases (CDKs) inhibitory activities), are prepd. from [(η6-arene)RuCl2]2 and L.  All the complexes were fully characterized by classical anal. methods, and three were characterized by x-ray crystallog.  Hydrolytic studies show that β-carboline ligands play a vital role in their aq. behavior.  These complexes are highly active in vitro, with the most active complex 6 displaying a 3-12-fold higher anticancer activity than cisplatin against several cancer cell lines.  The complexes are able to overcome cross-resistance to cisplatin, and show much lower cytotoxicity against normal cells.  Complexes 1-6 may directly target CDK1, because they can block cells in the G2M phase, down-regulate the expression of CDK1 and cyclin B1, and inhibit CDK1/cyclin B in vitro.  Further mechanism studies show that the complexes can effectively induce apoptosis through mitochondrial-related pathways and intracellular reactive O species (ROS) elevation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo6h10BlYuFK7Vg90H21EOLACvtfcHk0lhMB2SHULM0sQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtFCjtbnK&md5=fb2b63894c4f96209d60c1b4e8266e9a</span></div><a href="/servlet/linkout?suffix=cit53&amp;dbid=16384&amp;doi=10.1002%2Fchem.201301389&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fchem.201301389%26sid%3Dliteratum%253Aachs%26aulast%3DHe%26aufirst%3DL.%26aulast%3DLiao%26aufirst%3DS.%2BY.%26aulast%3DTan%26aufirst%3DC.%2BP.%26aulast%3DYe%26aufirst%3DR.%2BR.%26aulast%3DXu%26aufirst%3DY.%2BW.%26aulast%3DZhao%26aufirst%3DM.%26aulast%3DJi%26aufirst%3DL.%2BN.%26aulast%3DMao%26aufirst%3DZ.%2BW.%26atitle%3DRuthenium-Arene-%25CE%25B2-Carboline%2520complexes%2520as%2520potent%2520inhibitors%2520of%2520cyclin-dependent%2520kinase%25201%253A%2520synthesis%252C%2520characterization%2520and%2520anticancer%2520mechanism%2520studies%26jtitle%3DChem.%2520-%2520Eur.%2520J.%26date%3D2013%26volume%3D19%26spage%3D12152%26epage%3D12160%26doi%3D10.1002%2Fchem.201301389" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref54"><div class="reference"><strong class="refLabel"><a href="#ref54" class="rightTabRefNumLink">54</a></strong><div class="NLM_citation" id="rightTab-cit54"><span><span class="NLM_contrib-group">Marzec, K. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, M. Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martin, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baxter, R. C.</span><span> </span><span class="NLM_article-title">Involvement of p53 in insulin-like growth factor binding protein-3 regulation in the breast cancer cell response to DNA damage</span> <span class="citation_source-journal">Oncotarget.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">26583</span><span class="NLM_x">–</span> <span class="NLM_lpage">26598</span><span class="refDoi"> DOI: 10.18632/oncotarget.5612</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00509&amp;key=10.18632%2Foncotarget.5612" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2015&pages=26583-26598&author=K.+A.+Marzecauthor=M.+Z.+Linauthor=J.+L.+Martinauthor=R.+C.+Baxter&title=Involvement+of+p53+in+insulin-like+growth+factor+binding+protein-3+regulation+in+the+breast+cancer+cell+response+to+DNA+damage&doi=10.18632%2Foncotarget.5612"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit54&amp;dbid=16384&amp;doi=10.18632%2Foncotarget.5612&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.18632%252Foncotarget.5612%26sid%3Dliteratum%253Aachs%26aulast%3DMarzec%26aufirst%3DK.%2BA.%26aulast%3DLin%26aufirst%3DM.%2BZ.%26aulast%3DMartin%26aufirst%3DJ.%2BL.%26aulast%3DBaxter%26aufirst%3DR.%2BC.%26atitle%3DInvolvement%2520of%2520p53%2520in%2520insulin-like%2520growth%2520factor%2520binding%2520protein-3%2520regulation%2520in%2520the%2520breast%2520cancer%2520cell%2520response%2520to%2520DNA%2520damage%26jtitle%3DOncotarget.%26date%3D2015%26volume%3D6%26spage%3D26583%26epage%3D26598%26doi%3D10.18632%2Foncotarget.5612" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref55"><div class="reference"><strong class="refLabel"><a href="#ref55" class="rightTabRefNumLink">55</a></strong><div class="NLM_citation" id="rightTab-cit55"><span><span class="NLM_contrib-group">Sheldrick, G. M.</span> <span class="citation_source-book">SHELXTL</span> V5.1; <span class="NLM_publisher-name">Bruker AXS. Inc.</span>: <span class="NLM_publisher-loc">Madison, WI</span>,<span class="NLM_x"> </span><span class="NLM_year">1997</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=1997&author=G.+M.+Sheldrick&title=SHELXTL"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit55&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26aulast%3DSheldrick%26aufirst%3DG.%2BM.%26btitle%3DSHELXTL%26pub%3DBruker%2520AXS.%2520Inc%26date%3D1997" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref56"><div class="reference"><strong class="refLabel"><a href="#ref56" class="rightTabRefNumLink">56</a></strong><div class="NLM_citation" id="rightTab-cit56"><span><span class="NLM_contrib-group">Curry, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mandelkow, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brick, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Franks, N.</span><span> </span><span class="NLM_article-title">Crystal structure of human serum albumin complexed with fatty acid reveals an asymmetric distribution of binding sites</span> <span class="citation_source-journal">Nat. Struct. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1998</span><span class="NLM_x">, </span> <span class="NLM_volume">5</span><span class="NLM_x">, </span> <span class="NLM_fpage">827</span><span class="NLM_x">–</span> <span class="NLM_lpage">835</span><span class="refDoi"> DOI: 10.1038/1869</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00509&amp;key=10.1038%2F1869" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00509&amp;key=9731778" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00509&amp;key=1%3ACAS%3A528%3ADyaK1cXlvVyhs7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=1998&pages=827-835&author=S.+Curryauthor=H.+Mandelkowauthor=P.+Brickauthor=N.+Franks&title=Crystal+structure+of+human+serum+albumin+complexed+with+fatty+acid+reveals+an+asymmetric+distribution+of+binding+sites&doi=10.1038%2F1869"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit56R"><div class="casContent"><span class="casTitleNuber">56</span><div class="casTitle"><span class="NLM_cas:atitle">Crystal structure of human serum albumin complexed with fatty acid reveals an asymmetric distribution of binding sites</span></div><div class="casAuthors">Curry, Stephen; Mandelkow, Hendrik; Brick, Peter; Franks, Nick</div><div class="citationInfo"><span class="NLM_cas:title">Nature Structural Biology</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">827-835</span>CODEN:
                <span class="NLM_cas:coden">NSBIEW</span>;
        ISSN:<span class="NLM_cas:issn">1072-8368</span>.
    
            (<span class="NLM_cas:orgname">Nature America</span>)
        </div><div class="casAbstract">Human serum albumin (HSA) is the most abundant protein in the circulatory system.  Its principal function is to transport fatty acids, but it is also capable of binding a great variety of metabolites and drugs.  Despite intensive efforts, the detailed structural basis of fatty acid binding to HSA has remained elusive.  Here, the crystal structure of HSA complexed with 5 mols. of myristate at 2.5 Å resoln. is reported.  The fatty acid mols. were found to bind in long, hydrophobic pockets capped by polar side chains, many of which were basic.  These pockets were distributed asym. throughout the HSA mol., despite its sym. repeating domain structure.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrjkf-Ylc5g_7Vg90H21EOLACvtfcHk0lhMB2SHULM0sQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXlvVyhs7w%253D&md5=6df17724b7dac4c5aa99e71bf41f5849</span></div><a href="/servlet/linkout?suffix=cit56&amp;dbid=16384&amp;doi=10.1038%2F1869&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252F1869%26sid%3Dliteratum%253Aachs%26aulast%3DCurry%26aufirst%3DS.%26aulast%3DMandelkow%26aufirst%3DH.%26aulast%3DBrick%26aufirst%3DP.%26aulast%3DFranks%26aufirst%3DN.%26atitle%3DCrystal%2520structure%2520of%2520human%2520serum%2520albumin%2520complexed%2520with%2520fatty%2520acid%2520reveals%2520an%2520asymmetric%2520distribution%2520of%2520binding%2520sites%26jtitle%3DNat.%2520Struct.%2520Biol.%26date%3D1998%26volume%3D5%26spage%3D827%26epage%3D835%26doi%3D10.1038%2F1869" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref57"><div class="reference"><strong class="refLabel"><a href="#ref57" class="rightTabRefNumLink">57</a></strong><div class="NLM_citation" id="rightTab-cit57"><span><span class="NLM_contrib-group">Otwinowski, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Minor, W.</span><span> </span><span class="NLM_article-title">Processing of X-ray diffraction data collected in oscillation mode</span> <span class="citation_source-journal">Methods Enzymol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1997</span><span class="NLM_x">, </span> <span class="NLM_volume">276</span><span class="NLM_x">, </span> <span class="NLM_fpage">307</span><span class="NLM_x">–</span> <span class="NLM_lpage">326</span><span class="refDoi"> DOI: 10.1016/S0076-6879(97)76066-X</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00509&amp;key=10.1016%2FS0076-6879%2897%2976066-X" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00509&amp;key=27754618" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00509&amp;key=1%3ACAS%3A528%3ADyaK2sXivFehsbw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=276&publication_year=1997&pages=307-326&author=Z.+Otwinowskiauthor=W.+Minor&title=Processing+of+X-ray+diffraction+data+collected+in+oscillation+mode&doi=10.1016%2FS0076-6879%2897%2976066-X"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit57R"><div class="casContent"><span class="casTitleNuber">57</span><div class="casTitle"><span class="NLM_cas:atitle">Processing of x-ray diffraction data collected in oscillation mode</span></div><div class="casAuthors">Otwinowski, Zbyszek; Minor, Wladek</div><div class="citationInfo"><span class="NLM_cas:title">Methods in Enzymology</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">276</span>
        (<span class="NLM_cas:issue">Macromolecular Crystallography, Part A</span>),
    <span class="NLM_cas:pages">307-326</span>CODEN:
                <span class="NLM_cas:coden">MENZAU</span>;
        ISSN:<span class="NLM_cas:issn">0076-6879</span>.
    
            (<span class="NLM_cas:orgname">Academic</span>)
        </div><div class="casAbstract">Macromol. crystallog. is an iterative process.  Rarely do the first crystals provide all the necessary data to solve the biol. problem being studied.  Each step benefits from experience learned in previous steps.  To monitor the progress, the HKL package provides 2 tools: (1) statistics, both weighted (χ2) and unweighted (R-merge), are provided, and the Bayesian reasoning and multicomponent error model facilitates obtaining the proper error ests. and (2) visualization of the process plays a double role by helping the operator to confirm that the process of data redn., including the resulting statistics, is correct, and allowing one to evaluate problems for which there are no good statistical criteria.  Visualization also provides confidence that the point of diminishing returns in data collection and redn. has been reached.  At that point, the effort should be directed to solving the structure.  The methods presented here have been applied to solve a large variety of problems, from inorg. mols. with 5 Å unit cell to rotavirus of 700 Å diam. crystd. in 700 × 1000 × 1400 Å cell.  Overall quality of the method was tested by many researchers by successful application of the programs to MAD structure detns.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrA3fvBOHqhhrVg90H21EOLACvtfcHk0li2iabdQS1I6w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXivFehsbw%253D&md5=c9536971d4e32cc35352c40fb9368131</span></div><a href="/servlet/linkout?suffix=cit57&amp;dbid=16384&amp;doi=10.1016%2FS0076-6879%2897%2976066-X&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0076-6879%252897%252976066-X%26sid%3Dliteratum%253Aachs%26aulast%3DOtwinowski%26aufirst%3DZ.%26aulast%3DMinor%26aufirst%3DW.%26atitle%3DProcessing%2520of%2520X-ray%2520diffraction%2520data%2520collected%2520in%2520oscillation%2520mode%26jtitle%3DMethods%2520Enzymol.%26date%3D1997%26volume%3D276%26spage%3D307%26epage%3D326%26doi%3D10.1016%2FS0076-6879%2897%2976066-X" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref58"><div class="reference"><strong class="refLabel"><a href="#ref58" class="rightTabRefNumLink">58</a></strong><div class="NLM_citation" id="rightTab-cit58"><span><span class="NLM_contrib-group">Adams, P. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Afonine, P. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bunkóczi, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, V. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Davis, I. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Echols, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Headd, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hung, L. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kapral, G. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grosse-Kunstleve, R. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McCoy, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moriarty, N. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oeffner, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Read, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Richardson, D. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Richardson, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Terwilliger, T. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zwart, P. H.</span><span> </span><span class="NLM_article-title">PHENIX: a comprehensive Python-based system for macromolecular structure solution</span> <span class="citation_source-journal">Acta Crystallogr., Sect. D: Biol. Crystallogr.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">66</span><span class="NLM_x">, </span> <span class="NLM_fpage">213</span><span class="NLM_x">–</span> <span class="NLM_lpage">221</span><span class="refDoi"> DOI: 10.1107/S0907444909052925</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00509&amp;key=10.1107%2FS0907444909052925" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00509&amp;key=20124702" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00509&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhs1Sisbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=66&publication_year=2010&pages=213-221&author=P.+D.+Adamsauthor=P.+V.+Afonineauthor=G.+Bunk%C3%B3cziauthor=V.+B.+Chenauthor=I.+W.+Davisauthor=N.+Echolsauthor=J.+J.+Headdauthor=L.+W.+Hungauthor=G.+J.+Kapralauthor=R.+W.+Grosse-Kunstleveauthor=A.+J.+McCoyauthor=N.+W.+Moriartyauthor=R.+Oeffnerauthor=R.+J.+Readauthor=D.+C.+Richardsonauthor=J.+S.+Richardsonauthor=T.+C.+Terwilligerauthor=P.+H.+Zwart&title=PHENIX%3A+a+comprehensive+Python-based+system+for+macromolecular+structure+solution&doi=10.1107%2FS0907444909052925"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit58R"><div class="casContent"><span class="casTitleNuber">58</span><div class="casTitle"><span class="NLM_cas:atitle">PHENIX: a comprehensive Python-based system for macromolecular structure solution</span></div><div class="casAuthors">Adams, Paul D.; Afonine, Pavel V.; Bunkoczi, Gabor; Chen, Vincent B.; Davis, Ian W.; Echols, Nathaniel; Headd, Jeffrey J.; Hung, Li Wei; Kapral, Gary J.; Grosse-Kunstleve, Ralf W.; McCoy, Airlie J.; Moriarty, Nigel W.; Oeffner, Robert; Read, Randy J.; Richardson, David C.; Richardson, Jane S.; Terwilliger, Thomas C.; Zwart, Peter H.</div><div class="citationInfo"><span class="NLM_cas:title">Acta Crystallographica, Section D: Biological Crystallography</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">66</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">213-221</span>CODEN:
                <span class="NLM_cas:coden">ABCRE6</span>;
        ISSN:<span class="NLM_cas:issn">0907-4449</span>.
    
            (<span class="NLM_cas:orgname">International Union of Crystallography</span>)
        </div><div class="casAbstract">A review.  Macromol. X-ray crystallog. is routinely applied to understand biol. processes at a mol. level.  However, significant time and effort are still required to solve and complete many of these structures because of the need for manual interpretation of complex numerical data using many software packages and the repeated use of interactive three-dimensional graphics.  PHENIX has been developed to provide a comprehensive system for macromol. crystallog. structure soln. with an emphasis on the automation of all procedures.  This has relied on the development of algorithms that minimize or eliminate subjective input, the development of algorithms that automate procedures that are traditionally performed by hand and, finally, the development of a framework that allows a tight integration between the algorithms.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpm_HgKRpa-ObVg90H21EOLACvtfcHk0li2iabdQS1I6w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhs1Sisbc%253D&md5=67b439ff4bd61c659cae37ca4209b7bc</span></div><a href="/servlet/linkout?suffix=cit58&amp;dbid=16384&amp;doi=10.1107%2FS0907444909052925&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1107%252FS0907444909052925%26sid%3Dliteratum%253Aachs%26aulast%3DAdams%26aufirst%3DP.%2BD.%26aulast%3DAfonine%26aufirst%3DP.%2BV.%26aulast%3DBunk%25C3%25B3czi%26aufirst%3DG.%26aulast%3DChen%26aufirst%3DV.%2BB.%26aulast%3DDavis%26aufirst%3DI.%2BW.%26aulast%3DEchols%26aufirst%3DN.%26aulast%3DHeadd%26aufirst%3DJ.%2BJ.%26aulast%3DHung%26aufirst%3DL.%2BW.%26aulast%3DKapral%26aufirst%3DG.%2BJ.%26aulast%3DGrosse-Kunstleve%26aufirst%3DR.%2BW.%26aulast%3DMcCoy%26aufirst%3DA.%2BJ.%26aulast%3DMoriarty%26aufirst%3DN.%2BW.%26aulast%3DOeffner%26aufirst%3DR.%26aulast%3DRead%26aufirst%3DR.%2BJ.%26aulast%3DRichardson%26aufirst%3DD.%2BC.%26aulast%3DRichardson%26aufirst%3DJ.%2BS.%26aulast%3DTerwilliger%26aufirst%3DT.%2BC.%26aulast%3DZwart%26aufirst%3DP.%2BH.%26atitle%3DPHENIX%253A%2520a%2520comprehensive%2520Python-based%2520system%2520for%2520macromolecular%2520structure%2520solution%26jtitle%3DActa%2520Crystallogr.%252C%2520Sect.%2520D%253A%2520Biol.%2520Crystallogr.%26date%3D2010%26volume%3D66%26spage%3D213%26epage%3D221%26doi%3D10.1107%2FS0907444909052925" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref59"><div class="reference"><strong class="refLabel"><a href="#ref59" class="rightTabRefNumLink">59</a></strong><div class="NLM_citation" id="rightTab-cit59"><span><span class="NLM_contrib-group">Emsley, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cowtan, K.</span><span> </span><span class="NLM_article-title">Coot: model-building tools for molecular graphics</span> <span class="citation_source-journal">Acta Crystallogr., Sect. D: Biol. Crystallogr.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">60</span><span class="NLM_x">, </span> <span class="NLM_fpage">2126</span><span class="NLM_x">–</span> <span class="NLM_lpage">2132</span><span class="refDoi"> DOI: 10.1107/S0907444904019158</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00509&amp;key=10.1107%2FS0907444904019158" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00509&amp;key=15572765" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00509&amp;key=1%3ACAS%3A528%3ADC%252BD2cXhtVars73P" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2004&pages=2126-2132&author=P.+Emsleyauthor=K.+Cowtan&title=Coot%3A+model-building+tools+for+molecular+graphics&doi=10.1107%2FS0907444904019158"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit59R"><div class="casContent"><span class="casTitleNuber">59</span><div class="casTitle"><span class="NLM_cas:atitle">Coot: model-building tools for molecular graphics</span></div><div class="casAuthors">Emsley, Paul; Cowtan, Kevin</div><div class="citationInfo"><span class="NLM_cas:title">Acta Crystallographica, Section D: Biological Crystallography</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">D60</span>
        (<span class="NLM_cas:issue">12, Pt. 1</span>),
    <span class="NLM_cas:pages">2126-2132</span>CODEN:
                <span class="NLM_cas:coden">ABCRE6</span>;
        ISSN:<span class="NLM_cas:issn">0907-4449</span>.
    
            (<span class="NLM_cas:orgname">Blackwell Publishing Ltd.</span>)
        </div><div class="casAbstract">CCP4mg is a project that aims to provide a general-purpose tool for structural biologists, providing tools for x-ray structure soln., structure comparison and anal., and publication-quality graphics.  The map-fitting tools are available as a stand-alone package, distributed as 'Coot'.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoMisM42468k7Vg90H21EOLACvtfcHk0li2iabdQS1I6w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXhtVars73P&md5=1be390f3bb6fd584468499ad0921161e</span></div><a href="/servlet/linkout?suffix=cit59&amp;dbid=16384&amp;doi=10.1107%2FS0907444904019158&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1107%252FS0907444904019158%26sid%3Dliteratum%253Aachs%26aulast%3DEmsley%26aufirst%3DP.%26aulast%3DCowtan%26aufirst%3DK.%26atitle%3DCoot%253A%2520model-building%2520tools%2520for%2520molecular%2520graphics%26jtitle%3DActa%2520Crystallogr.%252C%2520Sect.%2520D%253A%2520Biol.%2520Crystallogr.%26date%3D2004%26volume%3D60%26spage%3D2126%26epage%3D2132%26doi%3D10.1107%2FS0907444904019158" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref60"><div class="reference"><strong class="refLabel"><a href="#ref60" class="rightTabRefNumLink">60</a></strong><div class="NLM_citation" id="rightTab-cit60"><span><span class="NLM_contrib-group">DeLano, W. L.</span> <span class="citation_source-book">The PyMol. Molecular Graphics System</span>; <span class="NLM_publisher-name">DeLano ScientiWc</span>: <span class="NLM_publisher-loc">San Carlos, CA</span>,<span class="NLM_x"> </span><span class="NLM_year">2004</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2004&author=W.+L.+DeLano&title=The+PyMol.+Molecular+Graphics+System"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit60&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26aulast%3DDeLano%26aufirst%3DW.%2BL.%26btitle%3DThe%2520PyMol.%2520Molecular%2520Graphics%2520System%26pub%3DDeLano%2520ScientiWc%26date%3D2004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref61"><div class="reference"><strong class="refLabel"><a href="#ref61" class="rightTabRefNumLink">61</a></strong><div class="NLM_citation" id="rightTab-cit61"><span><span class="NLM_contrib-group">Du, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Deng, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shan, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wan, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cao, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tian, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Achilefu, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gu, Y.</span><span> </span><span class="NLM_article-title">A pH-sensitive doxorubicin prodrug based on folate-conjugated BSA for tumor-targeted drug delivery</span> <span class="citation_source-journal">Biomaterials</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">34</span><span class="NLM_x">, </span> <span class="NLM_fpage">3087</span><span class="NLM_x">–</span> <span class="NLM_lpage">3097</span><span class="refDoi"> DOI: 10.1016/j.biomaterials.2013.01.041</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00509&amp;key=10.1016%2Fj.biomaterials.2013.01.041" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00509&amp;key=23374705" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00509&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhs1Cgtbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=34&publication_year=2013&pages=3087-3097&author=C.+Duauthor=D.+Dengauthor=L.+Shanauthor=S.+Wanauthor=J.+Caoauthor=J.+Tianauthor=S.+Achilefuauthor=Y.+Gu&title=A+pH-sensitive+doxorubicin+prodrug+based+on+folate-conjugated+BSA+for+tumor-targeted+drug+delivery&doi=10.1016%2Fj.biomaterials.2013.01.041"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit61R"><div class="casContent"><span class="casTitleNuber">61</span><div class="casTitle"><span class="NLM_cas:atitle">A pH-sensitive doxorubicin prodrug based on folate-conjugated BSA for tumor-targeted drug delivery</span></div><div class="casAuthors">Du, Changli; Deng, Dawei; Shan, Lingling; Wan, Shunan; Cao, Jie; Tian, Junmei; Achilefu, Samuel; Gu, Yueqing</div><div class="citationInfo"><span class="NLM_cas:title">Biomaterials</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">34</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">3087-3097</span>CODEN:
                <span class="NLM_cas:coden">BIMADU</span>;
        ISSN:<span class="NLM_cas:issn">0142-9612</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Doxorubicin (DOX) is one of the most effective anti-cancer drugs, but its therapeutic efficacy is greatly hampered by its non-specific delivery to the target tissue and the resultant cumulative cardiotoxicity and nephrotoxicity.  In order to overcome this limitation, we prepd. a folate-bovine serum albumin (BSA)-cis-aconitic anhydride-doxorubicin prodrug, denoted by FA-BSA-CAD.  A tumor-targeting agent, folic acid, was linked to BSA to increase the selective targeting ability of the conjugate.  BSA provided a large no. of reactive sites for multivalent coupling of bioactive mols. and improved the water-soly. of the prodrug.  DOX is attached to the BSA via a pH-sensitive linker, cis-aconitic anhydride, which hydrolyzes in the acidic lysosomal environment to allow pH-responsive release of DOX.  The in vitro results demonstrate a pH-responsive drug release under different pH conditions.  Furthermore, the targeting ability and therapeutic efficacy of the prodrug were assessed both in vitro and in vivo.  The results demonstrate that FA-BSA-CAD prodrug selectively targeted tumor cells and tissue, with assocd. redn. in non-specific toxicity to the normal cells.  More importantly, the therapeutic efficacy of the prodrug for FA-pos. tumors increased compared to the non-conjugated DOX.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr-GqVf-n7iAbVg90H21EOLACvtfcHk0lgMpGjtCuNa1A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhs1Cgtbk%253D&md5=440dafd9e6542b524cd933567f296f91</span></div><a href="/servlet/linkout?suffix=cit61&amp;dbid=16384&amp;doi=10.1016%2Fj.biomaterials.2013.01.041&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.biomaterials.2013.01.041%26sid%3Dliteratum%253Aachs%26aulast%3DDu%26aufirst%3DC.%26aulast%3DDeng%26aufirst%3DD.%26aulast%3DShan%26aufirst%3DL.%26aulast%3DWan%26aufirst%3DS.%26aulast%3DCao%26aufirst%3DJ.%26aulast%3DTian%26aufirst%3DJ.%26aulast%3DAchilefu%26aufirst%3DS.%26aulast%3DGu%26aufirst%3DY.%26atitle%3DA%2520pH-sensitive%2520doxorubicin%2520prodrug%2520based%2520on%2520folate-conjugated%2520BSA%2520for%2520tumor-targeted%2520drug%2520delivery%26jtitle%3DBiomaterials%26date%3D2013%26volume%3D34%26spage%3D3087%26epage%3D3097%26doi%3D10.1016%2Fj.biomaterials.2013.01.041" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li><li id="pane-m3" aria-labelledby="pane-m3" class="tab__pane tab__pane-suppInfo empty"><div class="accessionCode mb-5"><div class="toolbar-section accession-codes"><ul><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=1BJ5" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=1BJ5','PDB','1BJ5'); return false;">PDB: 1BJ5</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5GIX" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5GIX','PDB','5GIX'); return false;">PDB: 5GIX</a></li></ul></div></div><h2 class="supp-info-label">Supporting Information</h2><div class="article_supporting-info" id="rightTab-notes-1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-rightTab-_i58"><a href="/doi/suppl/10.1021/acs.jmedchem.6b00509">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a class="" href="#"><span>Jump To</span><i class="icon-angle-down"></i></a><div class="dropBlock__holder" data-db-target-of="sectionsDB_66651"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge on the <a class="ext-link" href="/">ACS Publications website</a> at DOI: <a class="ext-link" href="/doi/abs/10.1021/acs.jmedchem.6b00509">10.1021/acs.jmedchem.6b00509</a>.<ul id="rightTab-silist" class="NLM_list-list_type-label"><li><p class="inline">Determination of binding affinity of HSA for Fe compounds, MALDI-TOF-MS analyses, crystal data for Fe compounds, and selected bond lengths and angles for Fe compounds (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.6b00509/suppl_file/jm6b00509_si_001.pdf">PDF</a>)</p></li><li><p class="inline">SMILES (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.6b00509/suppl_file/jm6b00509_si_002.csv">CSV</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.6b00509/suppl_file/jm6b00509_si_001.pdf">jm6b00509_si_001.pdf (360.36 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.6b00509/suppl_file/jm6b00509_si_002.csv">jm6b00509_si_002.csv (0.77 kb)</a></li></ul></div></div><span class="author-information-subsection-header">Accession Codes</span><p class="last">PDB code: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5GIX">5GIX</a>, HSA-PA-<b>12</b> complex.</p><div id="rightTab-figshare-widget"></div><br /></br><div class="TermsAndConditionsDropzoneRight" data-pb-dropzone="TermsAndConditionsDropzoneRight"><div data-widget-def="UX3HTMLWidget" data-widget-id="b84e6b6c-b4d0-4427-b286-3cf14d52d013" class="mb-4">
        



        
        <h2 style="font-size: 1rem;margin-bottom: 10px;">Terms & Conditions</h2>
<p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system:
<a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div></div></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Facs.jmedchem.6b00509&amp;pbContext=%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Bwgroup%3Astring%3AACHS+website+Group%3Bwebsite%3Awebsite%3Aacspubs%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2016.59.issue-16%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text%3Barticle%3Aarticle%3A10.1021%2Facs.jmedchem.6b00509" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Supporting Information" data-slide-target=".tab__pane-suppInfo" class="w-slide__btn slide-active"><i class="icon-supporting-info"></i><span>Supporting Information</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/acs.jmedchem.6b00509" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                10MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright © 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">You’ve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-191cb5c7d88ed9894acd.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-524acd43b3dccf6df3df.js"></script>

<script type="text/javascript" src="/wro/kfa7~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"679abac98f933cc4","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.7.0","si":10}'></script>
</body>
</html>
